

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 200012322 B2**
(10) Patent No. **767725**

(54) Title
Modified peptides as therapeutic agents

(51)⁷ International Patent Classification(s)
C07K 019/00 C12N 015/62
C12N 001/21 C12N 015/70

(21) Application No: **200012322**

(22) Application Date: **1999.10.25**

(87) WIPO No: **WO00/24782**

(30) Priority Data

(31) Number	(32) Date	(33) Country
60/105371	1998.10.23	US
09/428082	1999.10.22	US

(43) Publication Date : **2000.05.15**

(43) Publication Journal Date : **2000.07.13**

(44) Accepted Journal Date : **2003.11.20**

(71) Applicant(s)
Amgen Inc.

(72) Inventor(s)
Ulrich Feige; Chuan-Fa Liu; Janet Cheetham; Thomas Charles Boone

(74) Agent/Attorney
Baldwin Shelston Waters, Level 21, 60 Margaret Street, SYDNEY NSW 2000

(56) Related Art
WO 96/18412
WO 96/32478
WO 94/04689



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K 19/00, C12N 15/62, 15/70, 1/21	A2	(11) International Publication Number: WO 00/24782 (43) International Publication Date: 4 May 2000 (04.05.00)
(21) International Application Number: PCT/US99/25044 (22) International Filing Date: 25 October 1999 (25.10.99) (30) Priority Data: 60/105,371 23 October 1998 (23.10.98) US 09/428,082 22 October 1999 (22.10.99) US (71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US). (72) Inventors: FEIGE, Ulrich; 3117 Deer Valley Avenue, Newbury Park, CA 91320 (US). LIU, Chuan-Fa; 1425 Clover Creek Drive, Longmont, CO 80503 (US). CHEETHAM, Janet; 1695 East Valley Road, Montecito, CA 93108 (US). BOONE, Thomas, Charles; 3010 Deer Valley Avenue, Newbury Park, CA 91320 (US). (74) Agents: ODRE, Steven, M. et al.; Amgen, Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: MODIFIED PEPTIDES AS THERAPEUTIC AGENTS (57) Abstract The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides. In this invention, pharmacologically active compounds are prepared by a process comprising: a) selecting at least one peptide that modulates the activity of a protein of interest; and b) preparing a pharmacologic agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded <i>in vivo</i>. The preferred vehicle is an Fc domain. The peptide is preferably selected by phage display, <i>E. coli</i> display, ribosome display, RNA-peptide screening, or chemical-peptide screening.		

Modified Peptides as Therapeutic Agents

Background of the Invention

Any discussion of the prior art throughout the specification should in no way be
5 considered as an admission that such prior art is widely known or forms part of common
general knowledge in the field.

Recombinant proteins are an emerging class of therapeutic agents. Such
recombinant therapeutics have engendered advances in protein formulation and chemical
modification. Such modifications can protect therapeutic proteins, primarily by blocking
10 their exposure to proteolytic enzymes. Protein modifications may also increase the
therapeutic protein's stability, circulation time, and biological activity. A review article
describing protein modification and fusion protein is Francis (1992), Focus on Growth
Factors 3:4-10 (Mediscript, London), which is hereby incorporated by reference.

One useful modification is combination with the "Fc" domain of an antibody.
15 Antibodies comprise two functionally independent parts, a variable domain known as
"Fab", which binds antigen, and a constant domain known as "Fc", which links to such
effector functions as complement activation and attack by phagocytic cells. An Fc has a
long serum half-life, whereas an Fab is short-lived. Capon et al. (1989), Nature
337:525-31. When constructed together with a therapeutic protein, an Fc domain can
20 provide longer half-life or incorporate such functions as Fc receptor binding, protein A
binding, complement fixation and perhaps even placental transfer. Id. Table 1
summarizes use of Fc fusions known in the art.




Table 1—Fc fusion with therapeutic proteins

Form of Fc	Fusion partner	Therapeutic implications	Reference
IgG1	N-terminus of CD30-L	Hodgkin's disease; anaplastic lymphoma; T-cell leukemia	U.S. Patent No. 5,480,981
Murine Fcγ2a	IL-10	anti-inflammatory; transplant rejection	Zheng <i>et al.</i> (1995), <i>J. Immunol.</i> 154: 5590-600
IgG1	TNF receptor	septic shock	Fisher <i>et al.</i> (1996), <i>N. Engl. J. Med.</i> 334: 1697-1702; Van Zee, K. <i>et al.</i> (1996), <i>J. Immunol.</i> 156: 2221-30
IgG, IgA, IgM, or IgE (excluding the first domain)	TNF receptor	inflammation, autoimmune disorders	U.S. Pat. No. 5,808,029, issued September 15, 1998
IgG1	CD4 receptor	AIDS	Capon <i>et al.</i> (1989), <i>Nature</i> 337: 525-31
IgG1, IgG3	N-terminus of IL-2	anti-cancer, antiviral	Harvill <i>et al.</i> (1995), <i>Immunotech.</i> 1: 95-105
IgG1	C-terminus of OPG	osteoarthritis; bone density	WO 97/23614, published July 3, 1997
IgG1	N-terminus of leptin	anti-obesity	PCT/US 97/23183, filed December 11, 1997
Human Ig Cy1	CTLA-4	autoimmune disorders	Linsley (1991), <i>J. Exp. Med.</i> 174:561-9

A much different approach to development of therapeutic agents is peptide library screening. The interaction of a protein ligand with its receptor often takes place at a relatively large interface. However, as demonstrated for human growth hormone and its receptor, only a few key residues at the interface contribute to most of the binding energy. Clackson *et al.* (1995), *Science* 267: 383-6. The bulk of the protein ligand merely displays the binding epitopes in the right topology or serves functions unrelated to binding. Thus, molecules of only "peptide" length (2 to 40 amino acids) can bind to the receptor protein of a given large protein ligand. Such peptides may mimic the bioactivity of the large protein ligand ("peptide agonists") or, through competitive binding, inhibit the bioactivity of the large protein ligand ("peptide antagonists").

Phage display peptide libraries have emerged as a powerful method in identifying such peptide agonists and antagonists. See, for example, Scott *et al.* (1990), *Science* 249: 386; Devlin *et al.* (1990), *Science* 249: 404; U.S. Pat. No. 5,223,409, issued June 29, 1993; U.S. Pat. No. 5,733,731, issued March 31, 1998; U.S. Pat. No. 5,498,530, issued March 12, 1996; U.S. Pat. No. 5,432,018, issued July 11, 1995; U.S. Pat. No. 5,338,665, issued August 16, 1994; U.S. Pat. No. 5,922,545, issued July 13, 1999; WO 96/40987, published December 19, 1996; and WO 98/15833, published April 16, 1998 (each of which is incorporated by reference). In such libraries, random peptide sequences are displayed by fusion with coat proteins of filamentous phage. Typically, the displayed peptides are affinity-eluted against an antibody-immobilized extracellular domain of a receptor. The retained phages may be enriched by successive rounds of affinity purification and repropagation. The best binding peptides may be sequenced to identify key residues within one or more structurally related families of peptides. See, e.g., Cwirla *et al.* (1997), *Science* 276: 1696-9, in which two distinct families were identified. The peptide sequences may also suggest which residues may be safely replaced by alanine scanning or by mutagenesis at the DNA level. Mutagenesis libraries may be created and screened to further optimize the sequence of the best binders. Lowman (1997), *Ann. Rev. Biophys. Biomol. Struct.* 26: 401-24.

Structural analysis of protein-protein interaction may also be used to suggest peptides that mimic the binding activity of large protein ligands. In such an analysis, the crystal structure may suggest the identity and relative orientation of critical residues of the large protein ligand, from which a peptide may be designed. See, e.g., Takasaki *et al.* (1997), *Nature Biotech.* 15: 1266-70. These analytical methods may also be used to investigate the interaction between a receptor protein and peptides

selected by phage display, which may suggest further modification of the peptides to increase binding affinity.

Other methods compete with phage display in peptide research. A peptide library can be fused to the carboxyl terminus of the lac repressor and expressed in E. coli. Another E. coli-based method allows display on the cell's outer membrane by fusion with a peptidoglycan-associated lipoprotein (PAL). Hereinafter, these and related methods are collectively referred to as "E. coli display." In another method, translation of random RNA is halted prior to ribosome release, resulting in a library of polypeptides with their associated RNA still attached. Hereinafter, this and related methods are collectively referred to as "ribosome display." Other methods employ chemical linkage of peptides to RNA; see, for example, Roberts & Szostak (1997), Proc. Natl. Acad. Sci. USA, 94: 12297-303. Hereinafter, this and related methods are collectively referred to as "RNA-peptide screening." Chemically derived peptide libraries have been developed in which peptides are immobilized on stable, non-biological materials, such as polyethylene rods or solvent-permeable resins. Another chemically derived peptide library uses photolithography to scan peptides immobilized on glass slides. Hereinafter, these and related methods are collectively referred to as "chemical-peptide screening." Chemical-peptide screening may be advantageous in that it allows use of D-amino acids and other unnatural analogues, as well as non-peptide elements. Both biological and chemical methods are reviewed in Wells & Lowman (1992), Curr. Opin. Biotechnol. 3: 355-62.

Conceptually, one may discover peptide mimetics of any protein using phage display and the other methods mentioned above. These methods have been used for epitope mapping, for identification of critical amino acids in protein-protein interactions, and as leads for the discovery of new therapeutic agents. E.g., Cortese et al. (1996), Curr. Opin. Biotech. 7:

616-21. Peptide libraries are now being used most often in immunological studies, such as epitope mapping. Kreeger (1996), The Scientist 10(13): 19-20.

Of particular interest here is use of peptide libraries and other
5 techniques in the discovery of pharmacologically active peptides. A
number of such peptides identified in the art are summarized in Table 2.
The peptides are described in the listed publications, each of which is
hereby incorporated by reference. The pharmacologic activity of the
peptides is described, and in many instances is followed by a shorthand
10 term therefor in parentheses. Some of these peptides have been modified
(e.g., to form C-terminally cross-linked dimers). Typically, peptide
libraries were screened for binding to a receptor for a pharmacologically
active protein (e.g., EPO receptor). In at least one instance (CTLA4), the
peptide library was screened for binding to a monoclonal antibody.

Table 2—Pharmacologically active peptides

Form of peptide	Binding partner/ protein of interest ^a	Pharmacologic activity	Reference
intra-peptide disulfide-bonded	EPO receptor	EPO-mimetic	Wrighton <i>et al.</i> (1996), <i>Science</i> 273: 458-63; U.S. Pat. No. 5,773,569, issued June 30, 1998 to Wrighton <i>et al.</i>
C-terminally cross-linked dimer	EPO receptor	EPO-mimetic	Livnah <i>et al.</i> (1996), <i>Science</i> 273: 464-71; Wrighton <i>et al.</i> (1997), <i>Nature Biotechnology</i> 15: 1261-5; International patent application WO 96/40772, published Dec. 19, 1996
linear	EPO receptor	EPO-mimetic	Naranda <i>et al.</i> (1999), <i>Proc. Natl. Acad. Sci. USA</i> , 96: 7569-74
linear	c-Mpl	TPO-mimetic	Cwirla <i>et al.</i> (1997) <i>Science</i> 276: 1696-9; U.S. Pat. No. 5,869,451, issued Feb. 9, 1999; U.S. Pat. No. 5,932,946, issued Aug. 3, 1999
C-terminally cross-linked dimer	c-Mpl	TPO-mimetic	Cwirla <i>et al.</i> (1997), <i>Science</i> 276: 1696-9
disulfide-linked dimer		stimulation of hematopoiesis ("G-CSF-mimetic")	Paukovits <i>et al.</i> (1984), <i>Hoppe-Seyler's Z. Physiol. Chem.</i> 365: 303-11; Laerum <i>et al.</i> (1988), <i>Exp. Hemat.</i> 16: 274-80
alkylene-linked dimer		G-CSF-mimetic	Bhatnagar <i>et al.</i> (1996), <i>J. Med. Chem.</i> 39: 3814-9; Cuthbertson <i>et al.</i> (1997), <i>J. Med. Chem.</i> 40: 2876-82; King <i>et al.</i> (1991), <i>Exp. Hematol.</i> 19:481; King <i>et al.</i> (1995), <i>Blood</i> 86 (Suppl. 1): 309a
linear	IL-1 receptor	inflammatory and autoimmune diseases ("IL-1 antagonist" or "IL-1 ra-mimetic")	U.S. Pat. No. 5,608,035; U.S. Pat. No. 5,786,331; U.S. Pat. No. 5,880,096; Yanofsky <i>et al.</i> (1996),

^a The protein listed in this column may be bound by the associated peptide (e.g., EPO receptor, IL-1 receptor) or mimicked by the associated peptide. The references listed for each clarify whether the molecule is bound by or mimicked by the peptides.

			Proc. Natl. Acad. Sci. 93: 7381-6; Akeson <i>et al.</i> (1996), <i>J. Biol. Chem.</i> 271: 30517-23; Wiekzorek <i>et al.</i> (1997), <i>Pol. J. Pharmacol.</i> 49: 107-17; Yanofsky (1996), <i>PNAs</i> , 93:7381-7386.
linear	Facteur thymique serique (FTS)	stimulation of lymphocytes ("FTS-mimetic")	Inagaki-Ohara <i>et al.</i> (1996), <i>Cellular Immunol.</i> 171: 30-40; Yoshida (1984), <i>Int. J. Immunopharmacol.</i> 6:141-6.
intrapeptide disulfide bonded	CTLA4 MAb	CTLA4-mimetic	Fukumoto <i>et al.</i> (1998), <i>Nature Biotech.</i> 16: 267-70
exocyclic	TNF- α receptor	TNF- α antagonist	Takasaki <i>et al.</i> (1997), <i>Nature Biotech.</i> 15:1266-70; WO 98/53842, published December 3, 1998
linear	TNF- α receptor	TNF- α antagonist	Chirinos-Rojas (), <i>J. Imm.</i> , 5621-5626.
intrapeptide disulfide bonded	C3b	inhibition of complement activation; autoimmune diseases ("C3b-antagonist")	Sahu <i>et al.</i> (1996), <i>J. Immunol.</i> 157: 884-91; Morikis <i>et al.</i> (1998), <i>Protein Sci.</i> 7: 619-27
linear	vinculin	cell adhesion processes—cell growth, differentiation, wound healing, tumor metastasis ("vinculin binding")	Adey <i>et al.</i> (1997), <i>Biochem. J.</i> 324: 523-8
linear	C4 binding protein (C4BP)	anti-thrombotic	Linse <i>et al.</i> (1997), <i>J. Biol. Chem.</i> 272: 14658-65
linear	urokinase receptor	processes associated with urokinase interaction with its receptor (e.g., angiogenesis, tumor cell invasion and metastasis); ("UKR antagonist")	Goodson <i>et al.</i> (1994), <i>Proc. Natl. Acad. Sci.</i> 91: 7129-33; International application WO 97/35969, published October 2, 1997
linear	Mdm2, Hdm2	Inhibition of inactivation of p53 mediated by Mdm2 or hdm2; anti-tumor ("Mdm/hdm antagonist")	Picksley <i>et al.</i> (1994), <i>Oncogene</i> 9: 2523-9; Bottger <i>et al.</i> (1997) <i>J. Mol. Biol.</i> 269: 744-56; Bottger <i>et al.</i> (1996), <i>Oncogene</i> 13: 2141-7
linear	p21 ^{WAF1}	anti-tumor by mimicking the activity of p21 ^{WAF1}	Ball <i>et al.</i> (1997), <i>Curr. Biol.</i> 7: 71-80
linear	farnesyl	anti-cancer by preventing	Gibbs <i>et al.</i> (1994), <i>Cell</i>

^b FTS is a thymic hormone mimicked by the molecule of this invention rather than a receptor bound by the molecule of this invention.

	transferase	activation of ras oncogene	77:175-178
linear	Ras effector domain	anti-cancer by inhibiting biological function of the ras oncogene	Moodie et al. (1994), <u>Trends Genet</u> 10: 44-48 Rodriguez et al. (1994), <u>Nature</u> 370:527-532
linear	SH2/SH3 domains	anti-cancer by inhibiting tumor growth with activated tyrosine kinases	Pawson et al (1993), <u>Curr. Biol.</u> 3:434-432 Yu et al. (1994), <u>Cell</u> 76:933-945
linear	p16 ^{INK4}	anti-cancer by mimicking activity of p16; e.g., inhibiting cyclin D-Cdk complex ("p16-mimetic")	Fähræus et al. (1996), <u>Curr. Biol.</u> 6:84-91
linear	Src, Lyn	inhibition of Mast cell activation, IgE-related conditions, type I hypersensitivity ("Mast cell antagonist")	Stauffer et al. (1997), <u>Biochem.</u> 36: 9388-94
linear	Mast cell protease	treatment of inflammatory disorders mediated by release of tryptase-6 ("Mast cell protease inhibitors")	International application WO 98/33812, published August 6, 1998
linear	SH3 domains	treatment of SH3-mediated disease states ("SH3 antagonist")	Rickles et al. (1994), <u>EMBO J.</u> 13: 5598-5604; Sparks et al. (1994), <u>J. Biol. Chem.</u> 269: 23853-6; Sparks et al. (1996), <u>Proc. Natl. Acad. Sci.</u> 93: 1540-4
linear	HBV core antigen (HBcAg)	treatment of HBV viral infections ("anti-HBV")	Dyson & Muray (1995), <u>Proc. Natl. Acad. Sci.</u> 92: 2194-8
linear	selectins	neutrophil adhesion; inflammatory diseases ("selectin antagonist")	Martens et al. (1995), <u>J. Biol. Chem.</u> 270: 21129-36; European patent application EP 0 714 912, published June 5, 1996
linear, cyclized	calmodulin	calmodulin antagonist	Pierce et al. (1995), <u>Molec. Diversity</u> 1: 259-65; Dedman et al. (1993), <u>J. Biol. Chem.</u> 268: 23025-30; Adey & Kay (1996), <u>Gene</u> 169: 133-4
linear, cyclized-	integrins	tumor-homing; treatment for conditions related to integrin-mediated cellular events, including platelet aggregation, thrombosis, wound healing, osteoporosis, tissue repair, angiogenesis (e.g.,	International applications WO 95/14714, published June 1, 1995; WO 97/08203, published March 6, 1997; WO 98/10795, published March 19, 1998; WO 99/24462, published May

		for treatment of cancer), and tumor invasion ("integrin-binding")	20, 1999; Kraft <i>et al.</i> (1999), <i>J. Biol. Chem.</i> 274: 1979-1985
cyclic, linear	fibronectin and extracellular matrix components of T cells and macrophages	treatment of inflammatory and autoimmune conditions	WO 98/09985, published March 12, 1998
linear	somatostatin and cortistatin	treatment or prevention of hormone-producing tumors, acromegaly, giantism, dementia, gastric ulcer, tumor growth, inhibition of hormone secretion, modulation of sleep or neural activity	European patent application 0 911 393, published April 28, 1999
linear	bacterial lipopolysac- charide	antibiotic; septic shock; disorders modulatable by CAP37	U.S. Pat. No. 5,877,151, issued March 2, 1999
linear or cyclic, including D- amino acids	pardaxin, mellitin	antipathogenic	WO 97/31019, published 28 August 1997
linear, cyclic	VIP	impotence, neurodegenerative disorders	WO 97/40070, published October 30, 1997
linear	CTLs	cancer	EP 0 770 624, published May 2, 1997
linear	THF-gamma2		Burnstein (1988), <i>Biochem.</i> , 27:4066-71.
linear	Amylin		Cooper (1987), <i>Proc.</i> <i>Natl. Acad. Sci.</i> , 84:8628-32.
linear	Adrenomedullin		Kitamura (1993), <i>BBRC</i> , 192:553-60.
cyclic, linear	VEGF	anti-angiogenic; cancer, rheumatoid arthritis, diabetic retinopathy, psoriasis ("VEGF antagonist")	Fairbrother (1998), <i>Biochem.</i> , 37:17754- 17764.
cyclic	MMP	inflammation and autoimmune disorders; tumor growth ("MMP inhibitor")	Koivunen (1999), <i>Nature</i> <i>Biotech.</i> , 17:768-774.
	HGH fragment		U.S. Pat. No. 5,869,452
	Echistatin	inhibition of platelet aggregation	Gan (1988), <i>J. Biol.</i> <i>Chem.</i> , 263:19827-32.
linear	SLE autoantibody	SLE	WO 96/30057, published October 3, 1996
	GD1alpha	suppression of tumor metastasis	Ishikawa <i>et al.</i> (1998), <i>FEBS Lett.</i> 441 (1): 20-4
	antiphospholipid	endothelial cell activation	Blank <i>et al.</i> (1999), <i>Proc.</i>

	beta-2-glycoprotein-I (β 2GPI) antibodies	antiphospholipid syndrome (APS), thromboembolic phenomena, thrombocytopenia, and recurrent fetal loss	<u>Natl. Acad. Sci. USA 96: 5164-8</u>
linear	T Cell Receptor beta chain	diabetes	WO 96/11214, published April 18, 1996

Peptides identified by peptide library screening have been regarded as "leads" in development of therapeutic agents rather than as therapeutic agents themselves. Like other proteins and peptides, they would be rapidly removed in vivo either by renal filtration, cellular clearance mechanisms in the reticuloendothelial system, or proteolytic degradation. Francis (1992), Focus on Growth Factors 3: 4-11. As a result, the art presently uses the identified peptides to validate drug targets or as scaffolds for design of organic compounds that might not have been as easily or as quickly identified through chemical library screening. Lowman (1997), Ann. Rev. Biophys. Biomol. Struct. 26: 401-24; Kay et al. (1998), Drug Disc. Today 3: 370-8. The art would benefit from a process by which such peptides could more readily yield therapeutic agents.

Summary of the Invention

The present invention concerns a process by which the in vivo half-life of one or more biologically active peptides is increased by fusion with a vehicle. In this invention, pharmacologically active compounds are prepared by a process comprising:

- a) selecting at least one peptide that modulates the activity of a protein of interest; and
- b) preparing a pharmacologic agent comprising at least one vehicle covalently linked to at least one amino acid sequence of the selected peptide.

The preferred vehicle is an Fc domain. The peptides screened in step (a) are preferably expressed in a phage display library. The vehicle and the

peptide may be linked through the N- or C-terminus of the peptide or the vehicle, as described further below. Derivatives of the above compounds (described below) are also encompassed by this invention.

5 The compounds of this invention may be prepared by standard synthetic methods, recombinant DNA techniques, or any other methods of preparing peptides and fusion proteins. Compounds of this invention that encompass non-peptide portions may be synthesized by standard organic chemistry reactions, in addition to standard peptide chemistry reactions when applicable.


10 The primary use contemplated is as therapeutic or prophylactic agents. The vehicle-linked peptide may have activity comparable to—or even greater than—the natural ligand mimicked by the peptide. In addition, certain natural ligand-based therapeutic agents might induce antibodies against the patient's own endogenous ligand; the vehicle-linked
15 peptide avoids this pitfall by having little or typically no sequence identity with the natural ligand.

20 Although mostly contemplated as therapeutic agents, compounds of this invention may also be useful in screening for such agents. For example, one could use an Fc-peptide (e.g., Fc-SH2 domain peptide) in an assay employing anti-Fc coated plates. The vehicle, especially Fc, may make insoluble peptides soluble and thus useful in a number of assays.

25 The compounds of this invention may be used for therapeutic or prophylactic purposes by formulating them with appropriate pharmaceutical carrier materials and administering an effective amount to a patient, such as a human (or other mammal) in need thereof. Other related aspects are also included in the instant invention.

Numerous additional aspects and advantages of the present invention will become apparent upon consideration of the figures and detailed description of the invention.

According to a first aspect, the present invention provides a composition of matter of the formula



and multimers thereof, wherein:

5 F^1 is an Fc domain;

X^1 and X^2 are each independently selected from $-(L^1)_c-P^1$, $-(L^1)_c-P^1-(L^2)_d-P^2$, $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3$, and $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3-(L^4)_f-P^4$

P^1 , P^2 , P^3 , and P^4 are each independently sequences of pharmacologically active peptides;

10 L^1 , L^2 , L^3 , and L^4 are each independently linkers; and

a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1.

According to a second aspect, the present invention provides a DNA encoding a composition of matter according to the first aspect.

15 According to a third aspect, the present invention provides an expression vector comprising the DNA according to the second aspect.

According to a fourth aspect, the present invention provides a host cell comprising the expression vector according to the third aspect.

According to a fifth aspect, the present invention provides a process for preparing
20 a pharmacologically active compound, which comprises


- a) selecting at least one randomized peptide that modulates the activity of a protein of interest; and
- b) preparing a pharmacologic agent comprising at least one Fc domain covalently linked to at least one amino acid sequence of the selected
25 peptide or peptides.


According to a sixth aspect, the present invention provides a pharmacologically active compound when prepared by a process according to the fifth aspect.

According to a seventh aspect, the present invention provides a pharmaceutical composition comprising a composition according to the first aspect and a
30 pharmaceutically acceptable carrier.

According to an eighth aspect, the present invention provides a method of treatment comprising administering a therapeutically effective amount of a composition according to the first aspect to a subject in need thereof.

According to a ninth aspect, the present invention provides use of a composition according to the first aspect in the manufacture of a medicament.

- Unless the context clearly requires otherwise, throughout the description and the claims, the words ‘comprise’, ‘comprising’, and the like are to be construed in an
- 5 inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of “including, but not limited to”.
- 



Brief Description of the Figures

Figure 1 shows a schematic representation of an exemplary process of the invention. In this preferred process, the vehicle is an Fc domain, which is linked to the peptide covalently by expression from a DNA
5 construct encoding both the Fc domain and the peptide. As noted in Figure 1, the Fc domains spontaneously form a dimer in this process.

Figure 2 shows exemplary Fc dimers that may be derived from an IgG1 antibody. "Fc" in the figure represents any of the Fc variants within the meaning of "Fc domain" herein. "X¹" and "X²" represent peptides or
10 linker-peptide combinations as defined hereinafter. The specific dimers are as follows:

A, D: Single disulfide-bonded dimers. IgG1 antibodies typically have two disulfide bonds at the hinge region between the constant and variable domains. The Fc domain in Figures 2A and 2D may be formed by
15 truncation between the two disulfide bond sites or by substitution of a cysteinyl residue with an unreactive residue (e.g., alanyl). In Figure 2A, the Fc domain is linked at the amino terminus of the peptides; in 2D, at the carboxyl terminus.

B, E: Doubly disulfide-bonded dimers. This Fc domain may be
20 formed by truncation of the parent antibody to retain both cysteinyl residues in the Fc domain chains or by expression from a construct including a sequence encoding such an Fc domain. In Figure 2B, the Fc domain is linked at the amino terminus of the peptides; in 2E, at the carboxyl terminus.

25 C, F: Noncovalent dimers. This Fc domain may be formed by elimination of the cysteinyl residues by either truncation or substitution. One may desire to eliminate the cysteinyl residues to avoid impurities formed by reaction of the cysteinyl residue with cysteinyl residues of other

proteins present in the host cell. The noncovalent bonding of the Fc domains is sufficient to hold together the dimer.

Other dimers may be formed by using Fc domains derived from different types of antibodies (e.g., IgG2, IgM).

Figure 3 shows the structure of preferred compounds of the invention that feature tandem repeats of the pharmacologically active peptide. Figure 3A shows a single chain molecule and may also represent the DNA construct for the molecule. Figure 3B shows a dimer in which the linker-peptide portion is present on only one chain of the dimer. Figure 3C shows a dimer having a peptide portion on both chains. The dimer of Figure 3C will form spontaneously in certain host cells upon expression of a DNA construct encoding the single chain shown in Figure 3A. In other host cells, the cells could be placed in conditions favoring formation of dimers or the dimers can be formed in vitro.

Figure 4 shows exemplary nucleic acid and amino acid sequences (SEQ ID NOS: 1 and 2, respectively) of human IgG1 Fc that may be used in this invention.

Figure 5 shows a synthetic scheme for the preparation of PEGylated peptide 19 (SEQ ID NO: 3) as prepared through intermediates having SEQ ID NOS: 1128 through 1131, respectively.

Figure 6 shows a synthetic scheme for the preparation of PEGylated peptide 20 (SEQ ID NO: 4) as prepared through intermediates having SEQ ID NOS: 1132 and 1133, respectively.

Figure 7 shows the nucleotide and amino acid sequences (SEQ ID NOS: 5 and 6, respectively) of the molecule identified as "Fc-TMP" in Example 2 hereinafter.

Figure 8 shows the nucleotide and amino acid sequences (SEQ. ID. NOS: 7 and 8, respectively) of the molecule identified as "Fc-TMP-TMP" in Example 2 hereinafter.

Figure 9 shows the nucleotide and amino acid sequences (SEQ. ID. NOS: 9 and 10, respectively) of the molecule identified as "TMP-TMP-Fc" in Example 2 hereinafter.

Figure 10 shows the nucleotide and amino acid sequences (SEQ. ID. NOS: 11 and 12, respectively) of the molecule identified as "TMP-Fc" in Example 2 hereinafter.

Figure 11 shows the number of platelets generated in vivo in normal female BDF1 mice treated with one 100 µg/kg bolus injection of various compounds, with the terms defined as follows.

- 10 PEG-MGDF: 20 kD average molecular weight PEG attached by reductive amination to the N-terminal amino group of amino acids 1-163 of native human TPO, which is expressed in E. coli (so that it is not glycosylated);
- 15 TMP: the TPO-mimetic peptide having the amino acid sequence IEGPTLRQWLAARA (SEQ ID NO: 13);
- TMP-TMP: the TPO-mimetic peptide having the amino acid sequence IEGPTLRQWLAARA-GGGGGGGG-IEGPTLRQWLAARA (SEQ ID NO: 14);
- 20 PEG-TMP-TMP: the peptide of SEQ ID NO: 14, wherein the PEG group is a 5 kD average molecular weight PEG attached as shown in Figure 6;
- Fc-TMP-TMP: the compound of SEQ ID NO: 8 (Figure 8) dimerized with an identical second monomer (i.e., Cys residues 7 and 10 are bound to the corresponding Cys residues in the second monomer to form a dimer, as shown in Figure 2); and
- 25 TMP-TMP-Fc is the compound of SEQ ID NO: 10 (Figure 9) dimerized in the same way as TMP-TMP-Fc except that the Fc domain is attached at the C-terminal end rather than the N-terminal end of the TMP-TMP peptide.

Figure 12 shows the number of platelets generated in vivo in normal BDF1 mice treated with various compounds delivered via implanted osmotic pumps over a 7-day period. The compounds are as defined for Figure 7.

5 Figure 13 shows the nucleotide and amino acid sequences (SEQ. ID. NOS: 15 and 16, respectively) of the molecule identified as "Fc-EMP" in Example 3 hereinafter.

Figure 14 shows the nucleotide and amino acid sequences (SEQ ID NOS: 17 and 18, respectively) of the molecule identified as "EMP-Fc" in
10 Example 3 hereinafter.

Figure 15 shows the nucleotide and amino acid sequences (SEQ ID NOS: 19 and 20, respectively) of the molecule identified as "EMP-EMP-Fc" in Example 3 hereinafter.

Figure 16 shows the nucleotide and amino acid sequences (SEQ ID
15 NOS: 21 and 22, respectively) of the molecule identified as "Fc-EMP-EMP" in Example 3 hereinafter.

Figures 17A and 17B show the DNA sequence (SEQ ID NO: 23) inserted into pCFM1656 between the unique AatII (position #4364 in pCFM1656) and SacII (position #4585 in pCFM1656) restriction sites to
20 form expression plasmid pAMG21 (ATCC accession no. 98113).

Figure 18A shows the hemoglobin, red blood cells, and hematocrit generated in vivo in normal female BDF1 mice treated with one 100 µg/kg bolus injection of various compounds. Figure 18B shows the same results with mice treated with 100 µg/kg per day delivered ~~the same dose~~ by 7-
25 day micro-osmotic pump with the EMPs delivered at 100 µg/kg, rhEPO at 30U/mouse. (In both experiments, neutrophils, lymphocytes, and platelets were unaffected.) In these figures, the terms are defined as follows.

Fc-EMP: the compound of SEQ ID NO: 16 (Figure 13) dimerized with an identical second monomer (i.e., Cys residues 7 and 10 are

bound to the corresponding Cys residues in the second monomer to form a dimer, as shown in Figure 2);

EMP-Fc: the compound of SEQ ID NO: 18 (Figure 14) dimerized in the same way as Fc-EMP except that the Fc domain is attached at the C-terminal end rather than the N-terminal end of the EMP peptide.

"EMP-EMP-Fc" refers to a tandem repeat of the same peptide (SEQ ID NO: 20) attached to the same Fc domain by the carboxyl terminus of the peptides. "Fc-EMP-EMP" refers to the same tandem repeat of the peptide but with the same Fc domain attached at the amino terminus of the tandem repeat. All molecules are expressed in E. coli and so are not glycosylated.

Figures 19A and 19B show the nucleotide and amino acid sequences (SEQ ID NOS: 1055 and 1056) of the Fc-TNF- α inhibitor fusion molecule described in Example 4 hereinafter.

Figures 20A and 20B show the nucleotide and amino acid sequences (SEQ ID NOS: 1057 and 1058) of the TNF- α inhibitor-Fc fusion molecule described in Example 4 hereinafter.

Figures 21A and 21B show the nucleotide and amino acid sequences (SEQ ID NOS: 1059 and 1060) of the Fc-IL-1 antagonist fusion molecule described in Example 5 hereinafter.

Figures 22A and 22B show the nucleotide and amino acid sequences (SEQ ID NOS: 1061 and 1062) of the IL-1 antagonist-Fc fusion molecule described in Example 5 hereinafter.

Figures 23A, 23B, and 23C show the nucleotide and amino acid sequences (SEQ ID NOS: 1063 and 1064) of the Fc-VEGF antagonist fusion molecule described in Example 6 hereinafter.

Figures 24A and 24B show the nucleotide and amino acid sequences (SEQ ID NOS: 1065 and 1066) of the VEGF antagonist-Fc fusion molecule described in Example 6 hereinafter.

Figures 25A and 25B show the nucleotide and amino acid sequences (SEQ ID NOS: 1067 and 1068) of the Fc-MMP inhibitor fusion molecule described in Example 7 hereinafter.

Figures 26A and 26B show the nucleotide and amino acid sequences (SEQ ID NOS: 1069 and 1070) of the MMP inhibitor-Fc fusion molecule described in Example 7 hereinafter.

10 Detailed Description of the Invention

Definition of Terms

The terms used throughout this specification are defined as follows, unless otherwise limited in specific instances.

The term "comprising" means that a compound may include additional amino acids on either or both of the N- or C- termini of the given sequence. Of course, these additional amino acids should not significantly interfere with the activity of the compound.

The term "vehicle" refers to a molecule that prevents degradation and/or increases half-life, reduces toxicity, reduces immunogenicity, or increases biological activity of a therapeutic protein. Exemplary vehicles include an Fc domain (which is preferred) as well as a linear polymer (e.g., polyethylene glycol (PEG), polylysine, dextran, etc.); a branched-chain polymer (see, for example, U.S. Patent No. 4,289,872 to Denkenwalter et al., issued September 15, 1981; 5,229,490 to Tam, issued July 20, 1993; WO 93/21259 by Frechet et al., published 28 October 1993); a lipid; a cholesterol group (such as a steroid); a carbohydrate or oligosaccharide; or any natural or synthetic protein, polypeptide or peptide that binds to a salvage receptor. Vehicles are further described hereinafter.

The term "native Fc" refers to molecule or sequence comprising the sequence of a non-antigen-binding fragment resulting from digestion of whole antibody, whether in monomeric or multimeric form. The original immunoglobulin source of the native Fc is preferably of human origin and
5 may be any of the immunoglobulins, although IgG1 and IgG2 are preferred. Native Fc's are made up of monomeric polypeptides that may be linked into dimeric or multimeric forms by covalent (i.e., disulfide bonds) and non-covalent association. The number of intermolecular disulfide bonds between monomeric subunits of native Fc molecules
10 ranges from 1 to 4 depending on class (e.g., IgG, IgA, IgE) or subclass (e.g., IgG1, IgG2, IgG3, IgA1, IgGA2). One example of a native Fc is a disulfide-bonded dimer resulting from papain digestion of an IgG (see Ellison *et al.* (1982), Nucleic Acids Res. 10: 4071-9). The term "native Fc" as used herein is generic to the monomeric, dimeric, and multimeric forms.

15 The term "Fc variant" refers to a molecule or sequence that is modified from a native Fc but still comprises a binding site for the salvage receptor, FcRn. International applications WO 97/34631 (published 25 September 1997) and WO 96/32478 describe exemplary Fc variants, as well as interaction with the salvage receptor, and are hereby incorporated
20 by reference. Thus, the term "Fc variant" comprises a molecule or sequence that is humanized from a non-human native Fc. Furthermore, a native Fc comprises sites that may be removed because they provide structural features or biological activity that are not required for the fusion molecules of the present invention. Thus, the term "Fc variant" comprises
25 a molecule or sequence that lacks one or more native Fc sites or residues that affect or are involved in (1) disulfide bond formation, (2) incompatibility with a selected host cell (3) N-terminal heterogeneity upon expression in a selected host cell, (4) glycosylation, (5) interaction with complement, (6) binding to an Fc receptor other than a salvage receptor, or

(7) antibody-dependent cellular cytotoxicity (ADCC). Fc variants are described in further detail hereinafter.

The term "Fc domain" encompasses native Fc and Fc variant molecules and sequences as defined above. As with Fc variants and native
5 Fc's, the term "Fc domain" includes molecules in monomeric or multimeric form, whether digested from whole antibody or produced by other means.

The term "multimer" as applied to Fc domains or molecules comprising Fc domains refers to molecules having two or more
10 polypeptide chains associated covalently, noncovalently, or by both covalent and non-covalent interactions. IgG molecules typically form dimers; IgM, pentamers; IgD, dimers; and IgA, monomers, dimers, trimers, or tetramers. Multimers may be formed by exploiting the sequence and resulting activity of the native Ig source of the Fc or by
15 derivatizing (as defined below) such a native Fc.

The term "dimer" as applied to Fc domains or molecules comprising Fc domains refers to molecules having two polypeptide chains associated covalently or non-covalently. Thus, exemplary dimers within the scope of this invention are as shown in Figure 2.

20 The terms "derivatizing" and "derivative" or "derivatized" comprise processes and resulting compounds respectively in which (1) the compound has a cyclic portion; for example, cross-linking between cysteinyl residues within the compound; (2) the compound is cross-linked or has a cross-linking site; for example, the compound has a cysteinyl
25 residue and thus forms cross-linked dimers in culture or *in vivo*; (3) one or more peptidyl linkage is replaced by a non-peptidyl linkage; (4) the N-terminus is replaced by -NRR¹, NRC(O)R¹, -NRC(O)OR¹, -NRS(O)₂R¹, -NHC(O)NHR, a succinimide group, or substituted or unsubstituted benzyloxycarbonyl-NH-, wherein R and R¹ and the ring substituents are

as defined hereinafter; (5) the C-terminus is replaced by $-C(O)R^2$ or $-NR^3R^4$ wherein R^2 , R^3 and R^4 are as defined hereinafter; and (6) compounds in which individual amino acid moieties are modified through treatment with agents capable of reacting with selected side chains or terminal
5 residues. Derivatives are further described hereinafter.

The term "peptide" refers to molecules of 2 to 40 amino acids, with molecules of 3 to 20 amino acids preferred and those of 6 to 15 amino acids most preferred. Exemplary peptides may be randomly generated by any of the methods cited above, carried in a peptide library (e.g., a phage
10 display library), or derived by digestion of proteins.

The term "randomized" as used to refer to peptide sequences refers to fully random sequences (e.g., selected by phage display methods) and sequences in which one or more residues of a naturally occurring molecule is replaced by an amino acid residue not appearing in that position in the
15 naturally occurring molecule. Exemplary methods for identifying peptide sequences include phage display, *E. coli* display, ribosome display, RNA-peptide screening, chemical screening, and the like.

The term "pharmacologically active" means that a substance so described is determined to have activity that affects a medical parameter
20 (e.g., blood pressure, blood cell count, cholesterol level) or disease state (e.g., cancer, autoimmune disorders). Thus, pharmacologically active peptides comprise agonistic or mimetic and antagonistic peptides as defined below.

The terms "-mimetic peptide" and "-agonist peptide" refer to a
25 peptide having biological activity comparable to a protein (e.g., EPO, TPO, G-CSF) that interacts with a protein of interest. These terms further include peptides that indirectly mimic the activity of a protein of interest, such as by potentiating the effects of the natural ligand of the protein of interest; see, for example, the G-CSF-mimetic peptides listed in Tables 2

and 7. Thus, the term "EPO-mimetic peptide" comprises any peptides that can be identified or derived as described in Wrighton et al. (1996), Science 273: 458-63, Naranda et al. (1999), Proc. Natl. Acad. Sci. USA 96: 7569-74, or any other reference in Table 2 identified as having EPO-mimetic subject matter. Those of ordinary skill in the art appreciate that each of these references enables one to select different peptides than actually disclosed therein by following the disclosed procedures with different peptide libraries.

The term "TPO-mimetic peptide" comprises peptides that can be identified or derived as described in Cwirala et al. (1997), Science 276: 1696-9, U.S. Pat. Nos. 5,869,451 and 5,932,946 and any other reference in Table 2 identified as having TPO-mimetic subject matter, as well as the U.S. patent application, "Thrombopoietic Compounds," filed on even date herewith and hereby incorporated by reference. Those of ordinary skill in the art appreciate that each of these references enables one to select different peptides than actually disclosed therein by following the disclosed procedures with different peptide libraries.

The term "G-CSF-mimetic peptide" comprises any peptides that can be identified or described in Paukovits et al. (1984), Hoppe-Seylers Z. Physiol. Chem. 365: 303-11 or any of the references in Table 2 identified as having G-CSF-mimetic subject matter. Those of ordinary skill in the art appreciate that each of these references enables one to select different peptides than actually disclosed therein by following the disclosed procedures with different peptide libraries.

The term "CTLA4-mimetic peptide" comprises any peptides that can be identified or derived as described in Fukumoto et al. (1998), Nature Biotech. 16: 267-70. Those of ordinary skill in the art appreciate that each of these references enables one to select different peptides than actually

disclosed therein by following the disclosed procedures with different peptide libraries.

The term "-antagonist peptide" or "inhibitor peptide" refers to a peptide that blocks or in some way interferes with the biological activity of the associated protein of interest, or has biological activity comparable to a known antagonist or inhibitor of the associated protein of interest. Thus, the term "TNF-antagonist peptide" comprises peptides that can be identified or derived as described in Takasaki *et al.* (1997), *Nature Biotech.* 15: 1266-70 or any of the references in Table 2 identified as having TNF-antagonistic subject matter. Those of ordinary skill in the art appreciate that each of these references enables one to select different peptides than actually disclosed therein by following the disclosed procedures with different peptide libraries.

The terms "IL-1 antagonist" and "IL-1ra-mimetic peptide" comprises peptides that inhibit or down-regulate activation of the IL-1 receptor by IL-1. IL-1 receptor activation results from formation of a complex among IL-1, IL-1 receptor, and IL-1 receptor accessory protein. IL-1 antagonist or IL-1ra-mimetic peptides bind to IL-1, IL-1 receptor, or IL-1 receptor accessory protein and obstruct complex formation among any two or three components of the complex. Exemplary IL-1 antagonist or IL-1ra-mimetic peptides can be identified or derived as described in U.S. Pat. Nos. 5,608,035, 5,786,331, 5,880,096, or any of the references in Table 2 identified as having IL-1ra-mimetic or IL-1 antagonistic subject matter. Those of ordinary skill in the art appreciate that each of these references enables one to select different peptides than actually disclosed therein by following the disclosed procedures with different peptide libraries.

The term "VEGF-antagonist peptide" comprises peptides that can be identified or derived as described in Fairbrother (1998), *Biochem.* 37:

17754-64, and in any of the references in Table 2 identified as having VEGF-antagonistic subject matter. Those of ordinary skill in the art appreciate that each of these references enables one to select different peptides than actually disclosed therein by following the disclosed procedures with different peptide libraries.

The term "MMP inhibitor peptide" comprises peptides that can be identified or derived as described in Koivunen (1999), Nature Biotech. 17: 768-74 and in any of the references in Table 2 identified as having MMP inhibitory subject matter. Those of ordinary skill in the art appreciate that each of these references enables one to select different peptides than actually disclosed therein by following the disclosed procedures with different peptide libraries.

Additionally, physiologically acceptable salts of the compounds of this invention are also encompassed herein. By "physiologically acceptable salts" is meant any salts that are known or later discovered to be pharmaceutically acceptable. Some specific examples are: acetate; trifluoroacetate; hydrohalides, such as hydrochloride and hydrobromide; sulfate; citrate; tartrate; glycolate; and oxalate.

Structure of compounds

In General. In the compositions of matter prepared in accordance with this invention, the peptide may be attached to the vehicle through the peptide's N-terminus or C-terminus. Thus, the vehicle-peptide molecules of this invention may be described by the following formula I:

I



wherein:

F^1 is a vehicle (preferably an Fc domain);

X^1 and X^2 are each independently selected from $-(L^1)_c-P^1$, $-(L^1)_c-P^1-(L^2)_d-P^2$, $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3$, and $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3-(L^4)_f-P^4$

where

P^1 , P^2 , P^3 , and P^4 are each independently sequences of pharmacologically active peptides;

L^1 , L^2 , L^3 , and L^4 are each independently linkers; and

a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1.

Thus, compound I comprises preferred compounds of the formulae

II




and multimers thereof wherein F^1 is an Fc domain and is attached at the C-terminus of X^1 ;

III



and multimers thereof wherein F^1 is an Fc domain and is attached at the N-terminus of X^2 ;

IV



and multimers thereof wherein F^1 is an Fc domain and is attached at the N-terminus of $-(L^1)_c-P^1$; and

V



and multimers thereof wherein F^1 is an Fc domain and is attached at the N-terminus of $-L^1-P^1-L^2-P^2$.

Peptides. Any number of peptides may be used in conjunction with the present invention. Of particular interest are peptides that mimic the activity of EPO, TPO, growth hormone, G-CSF, GM-CSF, IL-1ra, leptin, CTLA4, TRAIL, TGF- α , and TGF- β . Peptide antagonists are also of interest, particularly those antagonistic to the activity of TNF, leptin, any of the interleukins (IL-1, 2, 3, ...), and proteins involved in complement activation (e.g., C3b). Targeting peptides are also of interest, including

tumor-homing peptides, membrane-transporting peptides, and the like. All of these classes of peptides may be discovered by methods described in the references cited in this specification and other references.

5 Phage display, in particular, is useful in generating peptides for use in the present invention. It has been stated that affinity selection from libraries of random peptides can be used to identify peptide ligands for any site of any gene product. Dedman et al. (1993), J. Biol. Chem. 268: 23025-30. Phage display is particularly well suited for identifying peptides that bind to such proteins of interest as cell surface receptors or any
10 proteins having linear epitopes. Wilson et al. (1998), Can. J. Microbiol. 44: 313-29; Kay et al. (1998), Drug Disc. Today 3: 370-8. Such proteins are extensively reviewed in Herz et al. (1997), J. Receptor & Signal Transduction Res. 17(5): 671-776, which is hereby incorporated by reference. Such proteins of interest are preferred for use in this invention.

15 A particularly preferred group of peptides are those that bind to cytokine receptors. Cytokines have recently been classified according to their receptor code. See Inglot (1997), Archivum Immunologiae et Therapiae Experimentalis 45: 353-7, which is hereby incorporated by reference. Among these receptors, most preferred are the CKRs (family I in
20 Table 3). The receptor classification appears in Table 3.

Table 3—Cytokine Receptors Classified by Receptor Code

Cytokines (ligands)		Receptor Type	
family	subfamily	family	subfamily
I. Hematopoietic cytokines	1. IL-2, IL-4, IL-7, IL-9, IL-13, IL-15 2. IL-3, IL-5, GM-CSF 3. IL-6, IL-11, IL-12, LIF, OSM, CNTF, leptin (OB) 4. G-CSF, EPO, TPO, PRL, GH 5. IL-17, HVS-IL-17	I. Cytokine R (CKR)	1. shared γ Cr 2. shared GP 140 β R 3. 3.shared RP 130 4. "single chain" R 5. other R ^c
II. IL-10 ligands	IL-10, BCRF-1, HSV-IL-10	II. IL-10 R	
III. Interferons	1. IFN- α , α 2, α 4, m, t, IFN- β ^d 2. IFN- γ	III. Interferon R	1. IFNAR 2. IFNGR
IV. IL-1 ligands	1. IL-1 α , IL-1 β , IL-1Ra	IV. IL-1R	
V. TNF ligands	1. TNF- α , TNF- β (LT), FAS1, CD40 L, CD30L, CD27 L	V. NGF/TNF R ^e	
VI. Chemokines	1. α chemokines: IL-8, GRO α , β , γ , IF-10, PF-4, SDF-1 2. β chemokines: MIP1 α , MIP1 β , MCP-1,2,3,4, RANTES, eotaxin 3. γ chemokines: lymphotactin	VI. Chemokine R	1. CXCR 2. CCR 3. CR 4. DARC ^f

^c IL-17R belongs to the CKR family but is not assigned to any of the 4 indicated subfamilies.

^d Other IFN type I subtypes remain unassigned. Hematopoietic cytokines, IL-10 ligands and interferons do not possess functional intrinsic protein kinases. The signaling molecules for the cytokines are JAK's, STATs and related non-receptor molecules. IL-14, IL-16 and IL-18 have been cloned but according to the receptor code they remain unassigned.

^e TNF receptors use multiple, distinct intracellular molecules for signal transduction including "death domain" of FAS R and 55 kDa TNF- α R that participates in their cytotoxic effects. NGF/TNF R can bind both NGF and related factors as well as TNF ligands. Chemokine receptors are G protein-coupled, seven transmembrane (7TM, serpentine) domain receptors.

^f The Duffy blood group antigen (DARC) is an erythrocyte receptor that can bind several different chemokines. It belongs to the immunoglobulin superfamily but characteristics of its signal transduction events remain unclear.

VII. Growth factors	VII. RKF	1. TK sub-family
1.1 SCF, M-CSF, PDGF-AA, AB, BB, FLT-3L, VEGF, SSV-PDGF		1.1 IgTK III R
1.2 FGF α , FGF β		1.2 IgTK IV R
1.3 EGF, TGF- α , VV-F19 (EGF-like)		1.3 Cysteine-rich TK-I
1.4 IGF-I, IGF-II, Insulin		1.4 Cysteine rich TK-II
1.5 NGF, BDNF, NT-3, NT-4 ⁹		1.5 Cysteine knot TK V
2. TGF- β 1, β 2, β 3		2. STK subfamily ⁿ

Exemplary peptides for this invention appear in Tables 4 through 20 below. These peptides may be prepared by methods disclosed in the art. Single letter amino acid abbreviations are used. The X in these sequences (and throughout this specification, unless specified otherwise in a particular instance) means that any of the 20 naturally occurring amino acid residues may be present. Any of these peptides may be linked in tandem (i.e., sequentially), with or without linkers, and a few tandem-linked examples are provided in the table. Linkers are listed as "Λ" and may be any of the linkers described herein. Tandem repeats and linkers are shown separated by dashes for clarity. Any peptide containing a cysteinyl residue may be cross-linked with another Cys-containing peptide, either or both of which may be linked to a vehicle. A few cross-linked examples are provided in the table. Any peptide having more than one Cys residue may form an intrapeptide disulfide bond, as well; see, for example, EPO-mimetic peptides in Table 5. A few examples of intrapeptide disulfide-bonded peptides are specified in the table. Any of these peptides may be derivatized as described herein, and a few derivatized examples are provided in the table. Derivatized peptides in

⁹ The neurotrophic cytokines can associate with NGF/TNF receptors also.

the tables are exemplary rather than limiting, as the associated underivatized peptides may be employed in this invention, as well. For derivatives in which the carboxyl terminus may be capped with an amino group, the capping amino group is shown as -NH₂. For derivatives in

5 which amino acid residues are substituted by moieties other than amino acid residues, the substitutions are denoted by σ , which signifies any of the moieties described in Bhatnagar *et al.* (1996), *J. Med. Chem.* 39: 3814-9 and Cuthbertson *et al.* (1997), *J. Med. Chem.* 40: 2876-82, which are incorporated by reference. The J substituent and the Z substituents (Z₅, Z₆,

10 ...Z₄₀) are as defined in U.S. Pat. Nos. 5,608,035, 5,786,331, and 5,880,096, which are incorporated by reference. For the EPO-mimetic sequences (Table 5), the substituents X₂ through X₁₁ and the integer "n" are as defined in WO 96/40772, which is incorporated by reference. The substituents " Ψ ," " Θ ," and "+" are as defined in Sparks *et al.* (1996), *Proc. Natl. Acad. Sci.* 93:

15 1540-4, which is hereby incorporated by reference. X₄, X₅, X₆, and X₇ are as defined in U.S. Pat. No. 5,773,569, which is hereby incorporated by reference, except that: for integrin-binding peptides, X₁, X₂, X₃, X₄, X₅, X₆, X₇, and X₈ are as defined in International applications WO 95/14714, published June 1, 1995 and WO 97/08203, published March 6, 1997, which

20 are also incorporated by reference; and for VIP-mimetic peptides, X₁, X₁', X₁", X₂, X₃, X₄, X₅, X₆ and Z and the integers m and n are as defined in WO 97/40070, published October 30, 1997, which is also incorporated by reference. Xaa and Yaa below are as defined in WO 98/09985, published March 12, 1998, which is incorporated by reference. AA₁, AA₂, AB₁, AB₂,

25 and AC are as defined in International application WO 98/53842, published December 3, 1998, which is incorporated by reference. X¹, X², X³, and X⁴ in Table 17 only are as defined in European application EP 0 911

ⁿ STKS may encompass many other TGF- β -related factors that remain unassigned. The protein kinases are intrinsic part of the intracellular domain of receptor kinase family (RKF). The enzymes participate in the signals transmission via the receptors.

- 393, published April 28, 1999. Residues appearing in boldface are D-amino acids. All peptides are linked through peptide bonds unless otherwise noted. Abbreviations are listed at the end of this specification. In the "SEQ ID NO." column, "NR" means that no sequence listing is required for the given sequence.

Table 4—IL-1 antagonist peptide sequences

Sequence/structure	SEQ ID NO:
<u>Z</u> ₁₁ <u>Z</u> ₇ <u>Z</u> ₈ <u>QZ</u> ₅ <u>YZ</u> ₆ <u>Z</u> ₉ <u>Z</u> ₁₀	212
<u>XXQZ</u> ₅ <u>YZ</u> ₆ <u>XX</u>	907
<u>Z</u> ₇ <u>XQZ</u> ₅ <u>YZ</u> ₆ <u>XX</u>	908
<u>Z</u> ₇ <u>Z</u> ₈ <u>QZ</u> ₅ <u>YZ</u> ₆ <u>Z</u> ₉ <u>Z</u> ₁₀	909
<u>Z</u> ₁₁ <u>Z</u> ₇ <u>Z</u> ₈ <u>QZ</u> ₅ <u>YZ</u> ₆ <u>Z</u> ₉ <u>Z</u> ₁₀	910
<u>Z</u> ₁₂ <u>Z</u> ₁₃ <u>Z</u> ₁₄ <u>Z</u> ₁₅ <u>Z</u> ₁₆ <u>Z</u> ₁₇ <u>Z</u> ₁₈ <u>Z</u> ₁₉ <u>Z</u> ₂₀ <u>Z</u> ₂₁ <u>Z</u> ₂₂ <u>Z</u> ₁₁ <u>Z</u> ₇ <u>Z</u> ₈ <u>QZ</u> ₅ <u>YZ</u> ₆ <u>Z</u> ₉ <u>Z</u> ₁₀ <u>L</u>	917
<u>Z</u> ₂₁ <u>NZ</u> ₂₄ <u>Z</u> ₂₃ <u>Z</u> ₂₅ <u>Z</u> ₂₆ <u>Z</u> ₂₇ <u>Z</u> ₂₈ <u>Z</u> ₂₉ <u>Z</u> ₃₀ <u>Z</u> ₄₀	979
TANVSSFEWTPYYWQPYALPL	213
SWTDYGYWQPYALPISGL	214
ETPFTWEESNAYYWQPYALPL	215
ENTYSPNWADSMYWQPYALPL	216
SVGEDHNFWTSEYWQPYALPL	217
DGYDRWRQSGERYWQPYALPL	218
FEWTPGYWQPY	219
FEWTPGYWQHY	220
FEWTPGWYQJY	221
AcFEWTPGWYQJY	222
FEWTPGWpYQJY	223
FAWTPGYWQJY	224
FEWAPGYWQJY	225
FEWVPGYWQJY	226
FEWTPGYWQJY	227
AcFEWTPGYWQJY	228
FEWTPaWYQJY	229
FEWTPSarWYQJY	230
FEWTPGYYPY	231
FEWTPGWWQPY	232
FEWTPNYWQPY	233
FEWTPvYWQJY	234
FEWTPecGYWQJY	235
FEWTPAibYWQJY	236
FEWTSarGYWQJY	237
FEWTPGYWQPY	238
FEWTPGYWQHY	239
FEWTPGWYQJY	240

AcFEWTPGWYQJY	241
FEWTPGW-pY-QJY	242
FAWTPGYWQJY	243
FEWAPGYWQJY	244
FEWVPGYWQJY	245
FEWTPGYWQJY	246
AcFEWTPGYWQJY	247
FEWTPAWYQJY	248
FEWTPSarWYQJY	249
FEWTPGYYQPY	250
FEWTPGWWQPY	251
FEWTPNYWQPY	252
FEWTPVYWQJY	253
FEWTPecGYWQJY	254
FEWTPAibYWQJY	255
FEWTSarGYWQJY	256
FEWTPGYWQPYALPL	257
1NapEWTPGYYQJY	258
YEWTPGYYQJY	259
FEWVPGYYQJY	260
FEWTPSYQJY	261
FEWTPNYYQJY	262
TKPR	263
RKSSK	264
RKQDK	265
NRKQDK	266
RKQDKR	267
ENRKQDKRF	268
VTKFYF	269
VTKFY	270
VTDFY	271
SHLYWQPYSVQ	671
TLVYWQPYSLQT	672
RGDYWQPYSVQS	673
VHVVWQPYSVQT	674
RLVYWQPYSVQT	675
SRVWFQPYSLQS	676
NMVYWQPYSIQT	677
SVVFWQPYSVQT	678
TFVYWQPYALPL	679
TLVYWQPYSIQR	680
RLVYWQPYSVQR	681
SPVFWQPYSIQI	682
WIEWWQPYSVQS	683
SLIYWQPYSLQM	684
TRLYWQPYSVQR	685
RCDYWQPYSVQT	686
MRVFWQPYSVQN	687
KIVYWQPYSVQT	688
RHLYWQPYSVQR	689

ALVWWQPYSEQI	690
SRVWFQPYSLQS	691
WEQPYALPLE	692
QLVWWQPYSVQR	693
DLRYWQPYSVQV	694
ELVWWQPYSLQL	695
DLVWWQPYSVQW	696
NGNYWQPYSFQV	697
ELVYWQPYSIQR	698
ELMYWQPYSVQE	699
NLLYWQPYSMQD	700
GYESWQPYSVQR	701
SRVWYQPYSVQR	702
LSEQYQPYSVQR	703
GGGWWQPYSVQR	704
VGRWYQPYSVQR	705
VHVVWQPYSVQR	706
QARWYQPYSVQR	707
VHVVWQPYSVQT	708
RSVWQPYSVQR	709
TRVWFQPYSVQR	710
GRIWFQPYSVQR	711
GRVWFQPYSVQR	712
ARTWYQPYSVQR	713
ARVWWQPYSVQM	714
RLMFYQPYSVQR	715
ESMWYQPYSVQR	716
HFGWWQPYSVHM	717
ARFWWQPYSVQR	718
RLVYWQ PYAPIY	719
RLVYWQ PYSYQT	720
RLVYWQ PYSLPI	721
RLVYWQ PYSVQA	722
SRVWYQ PYAKGL	723
SRVWYQ PYAQGL	724
SRVWYQ PYAMPL	725
SRVWYQ PYSVQA	726
SRVWYQ PYSLGL	727
SRVWYQ PYAREL	728
SRVWYQ PYSRQP	729
SRVWYQ PYFVQP	730
EYESWYQ PYALPL	731
IPEYWQ PYALPL	732
SRIWWQ PYALPL	733
DPLFWQ PYALPL	734
SRQWVQ PYALPL	735
IRSWWQ PYALPL	736
RGYWQ PYALPL	737
RLLWVQ PYALPL	738
EYRWFQ PYALPL	739

DAYWVQ PYALPL	740
WSGYFQ PYALPL	741
NIEFWQ PYALPL	742
TRDWVQ PYALPL	743
DSSWYQ PYALPL	744
IGNWYQ PYALPL	745
NLRWDQ PYALPL	746
LPEFWQ PYALPL	747
DSYWWQ PYALPL	748
RSQYYQ PYALPL	749
ARFWLQ PYALPL	750
NSYFWQ PYALPL	751
RFMYWQPYSVQR	752
AHLFWQPYSVQR	753
WWQPYALPL	754
YYQPYALPL	755
YFQPYALGL	756
YWYQPYALPL	757
RWWQPYATPL	758
GWYQPYALGF	759
YWYQPYALGL	760
IWYQPYAMPL	761
SNMQPYQRLS	762
TFVYWQPY AVGLPAAETACN	763
TFVYWQPY SVQMTITGKVTM	764
TFVYWQPY SSHXXVPXGFPL	765
TFVYWQPY YGNPQWAIHVRH	766
TFVYWQPY VLLELPEGAVRA	767
TFVYWQPY VDYVWPIPIAQV	768
GWYQPYVDGWR	769
RWEQPYVKDGWS	770
EWYQPYALGWAR	771
GWWQPYARGL	772
LFEQPYAKALGL	773
GWEQPYARGLAG	774
AWVQPYATPLDE	775
MWYQPYSSQPAE	776
GWTQPYSSQGEV	777
DWFQPYSIQSDE	778
PWIQPYARGFG	779
RPLYWQPYSVQV	780
TLIYWQPYSVQI	781
RFDYWQPYSDQT	782
WHQFVQPYALPL	783
EWDS VYWQPYSVQ TLLR	784
WEQN VYWQPYSVQ SFAD	785
SDV VYWQPYSVQ SLEM	786
YYDG VYWQPYSVQ VMPA	787
SDIWYQ PYALPL	788
QRIWWQ PYALPL	789

SRIWWQ PYALPL	790
RSLYWQ PYALPL	791
TIIWEQ PYALPL	792
WETWYQ PYALPL	793
SYDWEQ PYALPL	794
SRIWCQ PYALPL	795
EIMFWQ PYALPL	796
DYVWQQ PYALPL	797
MDLLVQ WYQPYALPL	798
GSKVIL WYQPYALPL	799
RQGANI WYQPYALPL	800
GGGDEP WYQPYALPL	801
SQLERT WYQPYALPL	802
ETWVRE WYQPYALPL	803
KKGSTQ WYQPYALPL	804
LQARMN WYQPYALPL	805
EPRSQK WYQPYALPL	806
VKQKWR WYQPYALPL	807
LRRHDV WYQPYALPL	808
RSTASI WYQPYALPL	809
ESKEDQ WYQPYALPL	810
EGLTMK WYQPYALPL	811
EGSREG WYQPYALPL	812
VIEWWQ PYALPL	813
VWYWEQ PYALPL	814
ASEWWQ PYALPL	815
FYEWVQ PYALPL	816
EGWWVQ PYALPL	817
WGEWLQ PYALPL	818
DYVWEQ PYALPL	819
AHTWWQ PYALPL	820
FIEWFQ PYALPL	821
WLAWEQ PYALPL	822
VMEWWQ PYALPL	823
ERMWQ PYALPL	824
NXXWXX PYALPL	825
WGNWYQ PYALPL	826
TLYWEQ PYALPL	827
VWRWEQ PYALPL	828
LLWTQ PYALPL	829
SRIWXX PYALPL	830
SDIWYQ PYALPL	831
WGYYXX PYALPL	832
TSGWYQ PYALPL	833
VHPYXX PYALPL	834
EHSYFQ PYALPL	835
XXIWYQ PYALPL	836
AQLHSQ PYALPL	837
WANWFQ PYALPL	838
SRLYSQ PYALPL	839




GVTFSQ PYALPL	840
SIVWSQ PYALPL	841
SRDLVQ PYALPL	842
HWGH VYWQPYSVQ DDLG	843
SWHS VYWQPYSVQ SVPE	844
WRDS VYWQPYSVQ PESA	845
TWDA VYWQPYSVQ KWLD	846
TPPW VYWQPYSVQ SLDP	847
YWSS VYWQPYSVQ SVHS	848
YWY QPY ALGL	849
YWY QPY ALPL	850
EWI QPY ATGL	851
NWE QPY AKPL	852
AFY QPY ALPL	853
FLY QPY ALPL	854
VCK QPY LEWC	855
ETPFTWEESNAYYWQPYALPL	856
QGWLTWQDSVDMYWQPYALPL	857
FSEAGYTWPEPTYWQPYALPL	858
TESPGGLDWAKIYWQPYALPL	859
DGYDRWRQSGERYWQPYALPL	860
TANVSSFEWTPGYWQPYALPL	861
SVGEDHNFWTSE YWQPYALPL	862
MNDQTSEVSTFP YWQPYALPL	863
SWSEAFEQPRNL YWQPYALPL	864
QYAEPSALNDWG YWQPYALPL	865
NGDWATADWSNY YWQPYALPL	866
THDEHI YWQPYALPL	867
MLEKTYTTWTPG YWQPYALPL	868
WSDPLTRDADL YWQPYALPL	869
SDAFTTQDSQAM YWQPYALPL	870
GDDAAWRDSDLT YWQPYALPL	871
AIIRQLYRWSEM YWQPYALPL	872
ENTYSPNWADSM YWQPYALPL	873
MNDQTSEVSTFP YWQPYALPL	874
SVGEDHNFWTSE YWQPYALPL	875
QTPFTWEESNAY YWQPYALPL	876
ENPFTWQESNAY YWQPYALPL	877
VTPFTWEDSNVF YWQPYALPL	878
QIPFTWEQSNAY YWQPYALPL	879
QAPLWQESAAY YWQPYALPL	880
EPTFTWEESKAT YWQPYALPL	881
TTTLTWEESNAY YWQPYALPL	882
ESPLTWEESAL YWQPYALPL	883
ETPLTWEESNAY YWQPYALPL	884
EATFTWAESNAY YWQPYALPL	885
EALFTWKESTAY YWQPYALPL	886
STP-TWEESNAY YWQPYALPL	887
ETPFTWEESNAY YWQPYALPL	888
KAPFTWEESQAY YWQPYALPL	889

STSFTWEESNAY YWQPYALPL	890
DSTFTWEESNAY YWQPYALPL	891
YIPFTWEESNAY YWQPYALPL	892
QTAFTWEESNAY YWQPYALPL	893
ETLFTWEESNAT YWQPYALPL	894
VSSFTWEESNAY YWQPYALPL	895
QPYALPL	896
Py-1-NapPYQJYALPL	897
TANVSSFEWTPG YWQPYALPL	898
FEWTPGYWQPYALPL	899
FEWTPGYWQJYALPL	900
FEWTPGYYQJYALPL	901
ETPFTWEESNAYYWQPYALPL	902
FTWEESNAYYWQJYALPL	903
ADVL YWQPYA PVTWV	904
GDVAE YWQPYA LPLTSL	905
SWTDYG YWQPYA LPISGL	906
FEWTPGYWQPYALPL	911
FEWTPGYWQJYALPL	912
FEWTPGWYQPYALPL	913
FEWTPGWYQJYALPL	914
FEWTPGYYQPYALPL	915
FEWTPGYYQJYALPL	916
TANVSSFEWTPGYWQPYALPL	918
SWTDYGYWQPYALPISGL	919
ETPFTWEESNAYYWQPYALPL	920
ENTYSPNWADSMYWQPYALPL	921
SVGEDHNFWTSEYWQPYALPL	922
DGYDRWRQSGERYWQPYALPL	923
FEWTPGYWQPYALPL	924
FEWTPGYWQPY	925
FEWTPGYWQJY	926
EWTPGYWQPY	927
FEWTPGWYQJY	928
AEWTPGYWQJY	929
FAWTPGYWQJY	930
FEATPGYWQJY	931
FEWAPGYWQJY	932
FEWTAGYWQJY	933
FEWTPAYWQJY	934
FEWTPGAWQJY	935
FEWTPGYAQJY	936
FEWTPGYWQJA	937
FEWTGGYWQJY	938
FEWTPGYWQJY	939
FEWTJGYWQJY	940
FEWTPecGYWQJY	941
FEWTPAibYWQJY	942
FEWTPSarWYQJY	943
FEWTSarGYWQJY	944

FEWTPNYWQJY	945
FEWTPVYWQJY	946
FEWTPYVWQJY	947
AcFEWTPGWYQJY	948
AcFEWTPGYWQJY	949
INap-EWTPGYYQJY	950
YEWTPGYYQJY	951
FEWVPGYYQJY	952
FEWTPGYYQJY	953
FEWTPsYYQJY	954
FEWTPnYYQJY	955
SHLY-Nap-QPYSVQM	956
TLVY-Nap-QPYSLQT	957
RGDY-Nap-QPYSVQS	958
NMVY-Nap-QPYSIQT	959
VYWQPYSVQ	960
VY-Nap-QPYSVQ	961
TFVYWQJYALPL	962
FEWTPGYYQJ-Bpa	963
XaaFEWTPGYYQJ-Bpa	964
FEWTPGY-Bpa-QJY	965
AcFEWTPGY-Bpa-QJY	966
FEWTPG-Bpa-YQJY	967
AcFEWTPG-Bpa-YQJY	968
AcFE-Bpa-TPGYYQJY	969
AcFE-Bpa-TPGYYQJY	970
Bpa-EWTPGYYQJY	971
AcBpa-EWTPGYYQJY	972
VYWQPYSVQ	973
RLVYWQPYSVQR	974
RLVY-Nap-QPYSVQR	975
RLDYWQPYSVQR	976
RLVWFQPYSVQR	977
RLVYWQPYSIQR	978
DNSSWYDSFLL	980
DNTAWYESFLA	981
DNTAWYENFLL	982
PARE DNTAWYDSFLI WC	983
TSEY DNTTWYKFLA SQ	984
SQIP DNTAWYQSFLL HG	985
SPFI DNTAWYENFLL TY	986
EQIY DNTAWYDHFL SY	987
TPFI DNTAWYENFLL TY	988
TYTY DNTAWYERFLM SY	989
TMTQ DNTAWYENFLL SY	990
TI DNTAWYANLVQ TYPQ	991
TI DNTAWYERFLA QYPD	992
HI DNTAWYENFLL TYTP	993
SQ DNTAWYENFLL SYKA	994
QI DNTAWYERFLL QYNA	995

NQ DNTAWYESFLL QYNT	996
TI DNTAWYENFLL NHNL	997
HY DNTAWYERFLQ QGWH	998
ETPFTWEESNAYYWQPYALPL	999
YIPFTWEESNAYYWQPYALPL	1000
DGYDRWRQSGERYWQPYALPL	1001
pY-INap-pY-QJYALPL	1002
TANVSSFEWTPGYWQPYALPL	1003
FEWTPGYWQJYALPL	1004
FEWTPGYWQPYALPLSD	1005
FEWTPGYYQJYALPL	1006
FEWTPGYWQJY	1007
AcFEWTPGYWQJY	1008
AcFEWTPGWYQJY	1009
AcFEWTPGYYQJY	1010
AcFEWTPaYWQJY	1011
AcFEWTPaWYQJY	1012
AcFEWTPaYYQJY	1013
FEWTPGYYQJYALPL	1014
FEWTPGYWQJYALPL	1015
FEWTPGWYQJYALPL	1016
TANVSSFEWTPGYWQPYALPL	1017
AcFEWTPGYWQJY	1018
AcFEWTPGWYQJY	1019
AcFEWTPGYYQJY	1020
AcFEWTPaYWQJY	1021
AcFEWTPaWYQJY	1022
AcFEWTPaYYQJY	1023

Table 5—EPO-mimetic peptide sequences

Sequence/structure	SEQ ID NO:
YXCXXGPXTWXCXP	83
YXCXXGPXTWXCXP-YXCXXGPXTWXCXP	84
YXCXXGPXTWXCXP- Λ -YXCXXGPXTWXCXP	85
YXCXXGPXTWXCXP- Λ - 	86
GGTYSCHFGPLTWVCKPQGG	87
GGDYHCRMGPLTWVCKPLGG	88
GGVYACRMGPITWVCSPLGG	89
VGNYMCHFGPITWVCRPGGG	90
GGLYLCRFGPVTWDCGYKGG	91
GGTYSCHFGPLTWVCKPQGG- GGTYSCHFGPLTWVCKPQGG	92
GGTYSCHFGPLTWVCKPQGG - Λ - GGTYSCHFGPLTWVCKPQGG	93
GGTYSCHFGPLTWVCKPQGGSSK	94
GGTYSCHFGPLTWVCKPQGGSSK- GGTYSCHFGPLTWVCKPQGGSSK	95
GGTYSCHFGPLTWVCKPQGGSSK- Λ - GGTYSCHFGPLTWVCKPQGGSSK	96
GGTYSCHFGPLTWVCKPQGGSS 	97
GGTYSCHFGPLTWVCKPQGGSS 	97
GGTYSCHFGPLTWVCKPQGGSSK(- Λ -biotin)	98
CX ₄ X ₅ GPX ₆ TWX ₇ C	421
GGTYSCHGPLTWVCKPQGG	422
VGNYMAHMGPIWVCRPGG	423
GGPHHVYACRMGPLTWIC	424
GGTYSCHFGPLTWVCKPQ	425
GGLYACHMGPMWVWCQPLRG	426
TIAQYICYMGPETWECRSPKA	427
YSCHFGPLTWVCK	428
YCHFGPLTWVC	429
X ₃ X ₄ X ₅ GPX ₆ TWX ₇ X ₈	124
YX ₂ X ₃ X ₄ X ₅ GPX ₆ TWX ₇ X ₈	461

$X_1 Y X_2 X_3 X_4 X_5 G P X_6 T W X_7 X_8 X_9 X_{10} X_{11}$	419
$X_1 Y X_2 C X_3 X_4 X_5 G P X_6 T W X_7 C X_8 X_9 X_{10} X_{11}$	420
GGLYLCRFGPVTWDCGYKGG	1024
GGTYSCHFGPLTWVCKPQGG	1025
GGDYHCRMGPLTWVCKPLGG	1026
VGNYMCHFGPITWVCRPGGG	1029
GGVYACRMGPITWVCSPGG	1030
VGNYPMAHMGPIWVCRPGG	1035
GGTYSCHFGPLTWVCKPQ	1036
GGLYACHMGPMPTWVCQPLRG	1037
TIAQYICYMGPETWECPSPKA	1038
YSCHFGPLTWVCK	1039
YCHFGPLTWVC	1040
SCHFGPLTWVCK	1041
$(A X_2) X_1 X_3 X_4 X_5 G P X_6 T W X_7 X_8$	1042

Table 6—TPO-mimetic peptide sequences

Sequence/structure	SEQ ID NO:
IEGPTLRQWLAARA	13
IEGPTLRQWLAACA	24
IEGPTLRQWLAARA	25
IEGPTLRQWLAARA- Δ -IEGPTLRQWLAARA	26
IEGPTLRQWLAACA- Δ -IEGPTLRQWLAACA	27
IEGPTLRQCLAARA- Δ -IEGPTLRQCLAARA	28
IEGPTLRQWLAARA- Δ -K(BrAc)- Δ -IEGPTLRQWLAARA	29
IEGPTLRQWLAARA- Δ -K(PEG)- Δ -IEGPTLRQWLAARA	30
IEGPTLRQCLAARA- Δ -IEGPTLRQWLAARA	31
IEGPTLRQCLAARA- Δ -IEGPTLRQWLAARA	31
IEGPTLRQWLAARA- Δ -IEGPTLRQCLAARA	32
IEGPTLRQWLAARA- Δ -IEGPTLRQCLAARA	32
VRDQIXXL	33
TLREWL	34
GRVRDQVAGW	35
GRVKDQIAQL	36
GVRDQVSWAL	37
ESVREQVMKY	38
SVRSQISASL	39
GVRETVYRHM	40
GVREVIVMHML	41
GRVRDQIWAAL	42
AGVRDQILIWL	43
GRVRDQIMLSL	44
GRVRDQI(X) ₁ L	45
CTLRQWLQGC	46
CTLQEFLEG	47
CTRTEWLHGC	48
CTLREWLHGGFC	49
CTLREWVFAGLC	50
CTLRQWLILLGMC	51
CTLAEFASGVEQC	52
CSLQEFSLHGGYVC	53
CTLREFLDPTTAVC	54
CTLKEWLVSHEVWC	55
CTLREWL(X) _{2,6} C	56-60
REGPTLRQWM	61
EGPTLRQWLA	62
ERGPFWAKAC	63
REGPRCVMWM	64
CGTEGPTLSTWLDC	65

CEQDGPTLLEWLKC	66
CELVGPSLMSWLTC	67
CLTGPFVTQWLYEC	68
CRAGPTLLEWLTL	69
CADGPTLREWISFC	70
$C(X)_{1,2}$ EGPTLREWL $(X)_{1,2}$ C	71-74
GGCTLREWLHGGFCGG	75
GGCADGPTLREWISFCGG	76
GNADGPTLRQWLEGRRPKN	77
LAIEGPTLRQWLHGNGRDT	78
HGRVGPTLREWKTQVATKK	79
TIKGPTLRQWLKSREHTS	80
ISDGPTLKEWLSVTRGAS	81
SIEGPTLREWLTSTRTPHS	82

Table 7—G-CSF-mimetic peptide sequences

Sequence/structure	SEQ ID NO:
EEDCK	99
EEDCK	99
EEDCK	99
EED σ K	100
EED σ K	100
EED σ K	100
pGluED σ K	101
pGluED σ K	101
pGluED σ K	101
PicSD σ K	102
PicSD σ K	102
PicSD σ K	102
EEDCK- Λ -EEDCK	103
EEDXK- Λ -EEDXK	104

Table 8—TNF-antagonist peptide sequences

Sequence/structure	SEQ ID NO:
YCFTASENHCY	106
YCFTNSENHCY	107
YCFTRSENHCY	108
FCASENHCY	109
YCASENHCY	110
FCNSENHCY	111
FCNSENRCY	112
FCNSVENRCY	113
YCSQSVSND CF	114
FCVSNDRCY	115
YCRKELGQVCY	116
YCKEPGQCY	117
YCRKEMGCY	118
FCRKEMGCY	119
YCWSQNLCY	120
YCELSQYLCY	121
YCWSQNYCY	122
YCWSQYLCY	123
DFLPHYKNTSLGHRP	1085
$ \begin{array}{c} \text{AA}_1\text{-AB}_1 \\ \quad \backslash \\ \quad \quad \text{AC} \\ \quad / \\ \text{AA}_2\text{-AB}_2 \end{array} $	NR

Table 9—Integrin-binding peptide sequences

Sequence/structure	SEQ ID NO:
RX ₁ ETX ₂ WX ₃	441
RX ₁ ETX ₂ WX ₃	442
RGDGX	443
CRGDGXC	444
CX ₁ X ₂ RLDX ₄ X ₅ C	445
CARRLDAPC	446
CPSRLDSPC	447
X ₁ X ₂ X ₃ RGDX ₄ X ₅ X ₆	448
CX ₂ CRGDCX ₅ C	449
CDCRGDCFC	450
CDCRGDCLC	451
CLCRGDCIC	452
X ₁ X ₂ DDX ₄ X ₅ X ₆	453
X ₁ X ₂ X ₃ DDX ₄ X ₅ X ₆ X ₇ X ₈	454
CWDDGWLC	455
CWDDLWWLC	456
CWDDGLMC	457
CWDDGWMC	458
CSWDDGWLC	459
CPDDLWWLC	460
NGR	NR
GSL	NR
RGD	NR
CGRECPRLCQSSC	1071
CNGRCVSGCAGRC	1072
CLSGSLSC	1073
RGD	NR
NGR	NR
GSL	NR
NGRAHA	1074
CNGRC	1075
CDCRGDCFC	1076
CGSLVRC	1077
DLXXL	1043
RTDLDSLRTYTL	1044
RTDLDSLRTY	1053
RTDLDSLRT	1054
RTDLDSLRL	1078
GDLDLLKLRLTL	1079
GDLHSLRQLLSR	1080
RDDLHMLRLQLW	1081
SSDLHALKKRYG	1082
RGDLKQLSELTW	1083
RGDLAALSAPPV	1084

Table 10—Selectin antagonist peptide sequences

Sequence/structure	SEQ ID NO:
DITWDQLWDLMK	147
DITWDELWKIMN	148
DYTWFEWDMMQ	149
QITWAQLWNMMK	150
DMTWHDLWTLMS	151
DYSWHDLWEMMS	152
EITWDQLWEVMN	153
HVSWEQLWDIMN	154
HITWDQLWRIMT	155
RNMSWLELWEHMK	156
AEWTWDQLWHVMNPAESQ	157
HRAEWLALWEQMSP	158
KKEDWLALWRIMSV	159
ITWDQLWDLMK	160
DITWDQLWDLMK	161
DITWDQLWDLMK	162
DITWDQLWDLMK	163
CQNRYTDLVAIQNKNE	462
AENWADNEPNNKRNNED	463
RKNNKTWTWVGTKKALTNE	464
KKALTNEAENWAD	465
CQXRYTDLVAIQNKXE	466
RKXNXXWTWVGTXKXLTEE	467
AENWADGEPNNKXNXED	468
CXXXYTXLVAIQNKXE	469
RKXXXXWXWVGTXKXLTXE	470
AXNWXXXEPNNXXXED	471
XKXKTXEAXNWXX	472

Table 11—Antipathogenic peptide sequences

Sequence/structure	SEQ ID NO:
GFFALIPKIISSPLFKTLLSAVGSALSSSGGQQ	503
GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE	504
GFFALIPKIISSPLFKTLLSAV	505
GFFALIPKIISSPLFKTLLSAV	506
KGFFALIPKIISSPLFKTLLSAV	507
KKGFFALIPKIISSPLFKTLLSAV	508
KKGFFALIPKIISSPLFKTLLSAV	509
GFFALIPKIISS	510
GIGAVLKVLTTGLPALISWIKRKRQQ	511
GIGAVLKVLTTGLPALISWIKRKRQQ	512
GIGAVLKVLTTGLPALISWIKRKRQQ	513
GIGAVLKVLTTGLPALISWIKR	514
AVLKVLTTGLPALISWIKR	515
KLLLLLKLLLLK	516
KLLLKLLLKLLK	517
KLLLKLLLKLLK	518
KLLLKLLLKLLK	519
KLLLKLLLKLLK	520
KLLLKLLLKLLK	521
KLLLLK	522
KLLLKLLK	523
KLLLKLLKLLK	524
KLLLKLLKLLK	525
KLLLKLLKLLK	526
KAAAKAAAKAAK	527
KVVVKVVVKVVK	528
KVVVKVVVKVVK	529
KVVVKVVVKVVK	530
KVVVKVVVKVVK	531
KLILKL	532
KVLHLL	533
LKLRL	534
KPLHLL	535
KLILKLVR	536
KVFHLLHL	537
HKFRILKL	538
KPFHILHL	539
KIIKIKIKIK	540
KIIKIKIKIK	541
KIIKIKIKIK	542
KIPIKIKIKIPK	543
KIPIKIKIKIVK	544
RIIRIRIRIR	545
RIIRIRIRIR	546
RIIRIRIRIR	547
RIVIRIRIRLIR	548

RIIVRIRLRIIR	549
RIGIRLRVRIIR	550
KIVIRIRIRLIR	551
RIAVKWRLRFIK	552
KIGWKLRVRIIR	553
KKIGWLIIRVRR	554
RIVIRIRIRLIRIR	555
RIIVRIRLRIIRVR	556
RIGIRLRVRIIRRV	557
KIVIRIRARLIRIRIR	558
RIIVKIRLRIKKIRL	559
KIGIKARVRIIRVKII	560
RIIVHIRLRIHHIRL	561
HIGIKAHVRIIRVHII	562
RIYVKIHLRYIKKIRL	563
KIGHKARVHIIRYKII	564
RIYVKPHPRYIKKIRL	565
KPGHKARPHIIRYKII	566
KIVIRIRIRLIRIRIRKIV	567
RIIVKIRLRIKKIRLIKK	568
KIGWKLRVRIIRVKIGRLR	569
KIVIRIRIRLIRIRIRKIVKVKRIR	570
RFAVKIRLRIKKIRLIKKIRKRVIK	571
KAGWKLRVRIIRVKIGRLRKIGWKRVRIK	572
RIYVKPHPRYIKKIRL	573
KPGHKARPHIIRYKII	574
KIVIRIRIRLIRIRIRKIV	575
RIIVKIRLRIKKIRLIKK	576
RIYVSKISYIKKIRL	577
KIVIFTRIRLTSIRIRSIV	578
KPIHKARPTIIRYKMI	579
cyclicCKGFFALIPKIISSPLFKTLLSAVC	580
CKKGFFALIPKIISSPLFKTLLSAVC	581
CKKKGFFALIPKIISSPLFKTLLSAVC	582
CyclicCRIVIRIRIRLIRIRC	583
CyclicCKPGHKARPHIIRYKIIIC	584
CyclicCRFAVKIRLRIKKIRLIKKIRKRVIKC	585
KLLLKLLL KLLKC	586
KLLLKLLLKLLK	587
KLLLKLKLKLLKC	588
KLLLKLLLKLLK	589

Table 12—VIP-mimetic peptide sequences

Sequence/structure	SEQ ID NO:
HSDAVFYDNYTR LRKQMAVKKYLN SILN	590
Nle HSDAVFYDNYTR LRKQMAVKKYLN SILN	591
X ₁ X ₁ ' X ₁ " X ₂	592
X ₂ S X ₁ LN	593
NH CH CO KKYX5 NH CH CO X6 (CH2)m Z (CH2)n	594
KKYL	595
NSILN	596
KKYL	597
KKYA	598
AVKKYL	599
NSILN	600
KKYV	601
SILauN	602
KKYLNle	603
NSYLN	604
NSIYN	605
KKYLPPNSILN	606
LauKKYL	607
CapKKYL	608
KYL	NR
KKYNle	609
VKKYL	610
LNSILN	611
YLNSILN	612
KKYLN	613
KKYLNS	614
KKYLNSI	615
KKYLNSIL	616
KKYL	617
KKYDA	618
AVKKYL	619
NSILN	620
KKYV	621
SILauN	622
NSYLN	623
NSIYN	624
KKYLNle	625
KKYLPPNSILN	626
KKYL	627
KKYDA	628
AVKKYL	629
NSILN	630
KKYV	631
SILauN	632

LauKKYL	633
CapKKYL	634
KYL	NR
KYL	NR
KKYNle	635
VKKYL	636
LNSILN	637
YLNSILN	638
KKYLNle	639
KKYLN	640
KKYLNS	641
KKYLNSI	642
KKYLNSIL	643
KKKYLD	644
cyclicCKKYLC	645
CKKYLK S-CH ₂ -CO	646
KKYA	647
WWTDTGLW	648
WWTDDGLW	649
WWDTRGLWVWTI	650
FWGNDGIWLESG	651
DWDQFGLWRGAA	652
RWDDNGLWVVVL	653
SGMWSHYGIWMG	654
GGRWDQAGLWVA	655
KLWSEQGIWMGE	656
CWSMHGLWLC	657
GCWDNTGIWVPC	658
DWDTRGLWVY	659
SLWDENGAWI	660
KWDDRGLWMH	661
QAWNERGLWT	662
QWDTRGLWVA	663
WNVHGIWQE	664
SWDTRGLWVE	665
DWDTRGLWVA	666
SWGRDGLWIE	667
EWTDNGLWAL	668
SWDEKGLWSA	669
SWDSSGLWMD	670

Table 13—Mdm/hdm antagonist peptide sequences

Sequence/structure	SEQ ID NO:
TFSDLW	130
QETFSDLWKLLP	131
QPTFSDLWKLLP	132
QETFSDYWKLLP	133
QPTFSDYWKLLP	134
MPRFMDYWEGLN	135
VQNFIDYWTQQF	136
TGPAFTHYWATF	137
IDRAPTFRDHWFALV	138
PRPALVFADYWETLY	139
PAFSRFWSDLSAGAH	140
PAFSRFWSKLSAGAH	141
PXFXDYWXXL	142
QETFSDLWKLLP	143
QPTFSDLWKLLP	144
QETFSDYWKLLP	145
QPTFSDYWKLLP	146

Table 14—Calmodulin antagonist peptide sequences

Sequence/structure	SEQ ID NO:
SCVKWKGKKEFCGS	164
SCWKYWGKECGS	165
SCYEWGKLRWCGS	166
SCLRWGKWSNCGS	167
SCWRWGKYQICGS	168
SCVSWGALKLCGS	169
SCIRWGQNTFCGS	170
SCWQWGNLKICGS	171
SCVRWGQLSICGS	172
LKKFNARRKLKGAILTTMLAK	173
RRWKKNFIAVSAANRFKK	174
RKWQKTGHAVRAIGRLSS	175
INLKALAALAKKIL	176
KIWSILAPLGTTLVKLVA	177
LKKLLKLLKKLLKL	178
LKWKKLLKLLKKLLKLL	179
AEWPSLTEIKTSLHFSV	180
AEWPSPTRVISTTYFGS	181
AELAHWPPVKTVLRSFT	182
AEGSWLQLLNLMKQMNN	183
AEWPSLTEIK	184

**Table 15—Mast cell antagonists/Mast cell protease inhibitor
peptide sequences**

Sequence/structure	SEQ ID NO:
SGSGVLKRPLPILPVTR	272
RWLSSRPLPPLPPRT	273
GSGSYDTLALPSLPLHPMSS	274
GSGSYDTRALPSLPLHPMSS	275
GSGSSGVTMYPKLPPHWSMA	276
GSGSSGVARMYPKLPPHWSMA	277
GSGSSSMRMVPTIPGSAKHG	278
RNR	NR
QT	NR
RQK	NR
NRQ	NR
RQK	NR
RNRQKT	436
RNRQ	437
RNRQK	438
NRQKT	439
RQKT	440

Table 16—SH3 antagonist peptide sequences

Sequence/structure	SEQ ID NO:
RPLPPLP	282
RELPPPLP	283
SPLPPLP	284
GPLPPLP	285
RPLPIPP	286
RPLPIPP	287
RRLPPTP	288
RQLPPTP	289
RPLPSRP	290
RPLPTRP	291
SRLPPLP	292
RALPSPP	293
RRLPRTT	294
RPVPPIT	295
ILAPPVP	296
RPLPMLP	297
RPLPILP	298
RPLPSLP	299
RPLPSLP	300
RPLPMIP	301
RPLPLIP	302
RPLPPTP	303
RSLPPLP	304
RPQPPPP	305
RQLPIPP	306
XXXRPLPPLXP	307
XXXRPLPIPXX	308
XXXRPLPPLPXX	309
RXXRPLPPLXP	310
RXXRPLPPLPPP	311
PPPYPPPIPX	312
PPPYPPPPVPXX	313
LXXRPLPXYP	314
YXXRPLPXL	315
PPXOXPPPYP	316
+PPYPXKXPWL	317
RPXYPYR+SXP	318
PPVPPRPXXTL	319
YPYLPYK	320
+OXPLPXL	321

Table 17—Somatostatin or cortistatin mimetic peptide sequences

Sequence/structure	SEQ ID NO:
X ¹ -X ² -Asn-Phe-Phe-Trp-Lys-Thr-Phe-X ³ -Ser-X ⁴	473
Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys	474
Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys	475
Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys	476
Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys	477
Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys	478
Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys	479
Asp Arg Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys	480
Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys	481
Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys	482
Asp Arg Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys	483
Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys	484
Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys	485
Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys Lys	486
Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys Lys	487
Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys Lys	488
Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys	489
Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys	490
Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys	491
Asp Arg Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys Lys	492
Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys Lys	493
Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys Lys	494
Asp Arg Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys	495
Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys	496
Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys	497

Table 18—UKR antagonist peptide sequences

Sequence/structure	SEQ ID NO:
AEPMPHSLNFSQYLWYT	196
AEHTYSSLWDTYSPLAF	197
AELDLWMRHYPLSFNR	198
AESSLWTRYAWPSMPSY	199
AEWHPGLSFGSYLWSKT	200
AEPALLNWSFFFNPGLH	201
AEWSFYNLHLPEPQTIF	202
AEPLDLWSLYSLPPLAM	203
AEPTLWQLYQFPLRLSG	204
AEISFSELMWLRSTPAF	205
AELSEADLWTTWFGMGS	206
AESSLWRIFSPSALMMS	207
AESLPTLTSILWGKESV	208
AETLFMDLWHDKHILLT	209
AEILNFPLWHEPLWSTE	210
AESQTGTLNTLFWNTLR	211
AEPVYQYELDSYLRSY	430
AELDLSTFYDIQYLLRT	431
AEFFKLGPNGYVYLHSA	432
FKLXXXGYVYL	433
AESTYHHLSLGYMYTLN	434
YHXLXXGYMYT	435

**Table 19—Macrophage and/or
T-cell inhibiting peptide sequences**

Sequence/structure	SEQ ID NO:
Xaa-Yaa-Arg	NR
Arg-Yaa-Xaa	NR
Xaa-Arg-Yaa	NR
Yaa-Arg-Xaa	NR
Ala-Arg	NR
Arg-Arg	NR
Asn-Arg	NR
Asp-Arg	NR
Cys-Arg	NR
Gln-Arg	NR
Glu-Arg	NR
Gly-Arg	NR
His-arg	NR
Ile-Arg	NR
Leu-Arg	NR
Lys-Arg	NR
Met-Arg	NR
Phe-Arg	NR
Ser-Arg	NR
Thr-Arg	NR
Trp-Arg	NR
Tyr-Arg	NR
Val-Arg	NR
Ala-Glu-Arg	NR
Arg-Glu-Arg	NR
Asn-Glu-Arg	NR
Asp-Glu-Arg	NR
Cys-Glu-Arg	NR
Gln-Glu-Arg	NR
Glu-Glu-Arg	NR
Gly-Glu-Arg	NR
His-Glu-Arg	NR
Ile-Glu-Arg	NR
Leu-Glu-Arg	NR
Lys-Glu-Arg	NR
Met-Glu-Arg	NR
Phe-Glu-Arg	NR
Pro-Glu-Arg	NR
Ser-Glu-Arg	NR
Thr-Glu-Arg	NR
Trp-Glu-Arg	NR
Tyr-Glu-Arg	NR
Val-Glu-Arg	NR

Arg-Ala	NR
Arg-Asp	NR
Arg-Cys	NR
Arg-Gln	NR
Arg-Glu	NR
Arg-Gly	NR
Arg-His	NR
Arg-Ile	NR
Arg-Leu	NR
Arg-Lys	NR
Arg-Met	NR
Arg-Phe	NR
Arg-Pro	NR
Arg-Ser	NR
Arg-Thr	NR
Arg-Trp	NR
Arg-Tyr	NR
Arg-Val	NR
Arg-Glu-Ala	NR
Arg-Glu-Asn	NR
Arg-Glu-Asp	NR
Arg-Glu-Cys	NR
Arg-Glu-Gln	NR
Arg-Glu-Glu	NR
Arg-Glu-Gly	NR
Arg-Glu-His	NR
Arg-Glu-Ile	NR
Arg-Glu-Leu	NR
Arg-Glu-Lys	NR
Arg-Glu-Met	NR
Arg-Glu-Phe	NR
Arg-Glu-Pro	NR
Arg-Glu-Ser	NR
Arg-Glu-Thr	NR
Arg-Glu-Trp	NR
Arg-Glu-Tyr	NR
Arg-Glu-Val	NR
Ala-Arg-Glu	NR
Arg-Arg-Glu	NR
Asn-Arg-Glu	NR
Asp-Arg-Glu	NR
Cys-Arg-Glu	NR
Gln-Arg-Glu	NR
Glu-Arg-Glu	NR
Gly-Arg-Glu	NR
His-Arg-Glu	NR
Ile-Arg-Glu	NR
Leu-Arg-Glu	NR
Lys-Arg-Glu	NR
Met-Arg-Glu	NR

Phe-Arg-Glu	NR
Pro-Arg-Glu	NR
Ser-Arg-Glu	NR
Thr-Arg-Glu	NR
Trp-Arg-Glu	NR
Tyr-Arg-Glu	NR
Val-Arg-Glu	NR
Glu-Arg-Ala,	NR
Glu-Arg-Arg	NR
Glu-Arg-Asn	NR
Glu-Arg-Asp	NR
Glu-Arg-Cys	NR
Glu-Arg-Gln	NR
Glu-Arg-Gly	NR
Glu-Arg-His	NR
Glu-Arg-Ile	NR
Glu-Arg-Leu .	NR
Glu-Arg-Lys	NR
Glu-Arg-Met	NR
Glu-Arg-Phe	NR
Glu-Arg-Pro	NR
Glu-Arg-Ser	NR
Glu-Arg-Thr	NR
Glu-Arg-Trp	NR
Glu-Arg-Tyr	NR
Glu-Arg-Val	NR

Table 20—Additional Exemplary Pharmacologically Active Peptides

Sequence/structure	SEQ ID NO:	Activity
VEPNCDIHVMWEWECFERL	1027	VEGF-antagonist
GERWCDFDGPLTWVCGEES	398	VEGF-antagonist
RGWVEICVADDNGMCVTEAQ	1085	VEGF-antagonist
GWDECDVARMWEWECFAGV	1086	VEGF-antagonist
GERWCDFGPRAWVCGWEI	501	VEGF-antagonist
EELWCDFGPRAWVCGYVK	502	VEGF-antagonist
RGWVEICAADDYGRCLTEAQ	1031	VEGF-antagonist
RGWVEICESDVWGRCL	1087	VEGF-antagonist
RGWVEICESDVWGRCL	1088	VEGF-antagonist
GGNECDIARMWEWECFERL	1089	VEGF-antagonist
RGWVEICAADDYGRCL	1090	VEGF-antagonist
CTTHWGFTLC	1028	MMP inhibitor
CLRSXGXC	1091	MMP inhibitor
CXXHWGFXXC	1092	MMP inhibitor
CXPXC	1093	MMP inhibitor
CRRHWGFEFC	1094	MMP inhibitor
STTHWGFTLS	1095	MMP inhibitor
CSLHWGFWWC	1096	CTLA4-mimetic
GFVCSGIFAVGVGRC	125	CTLA4-mimetic
APGVRLGCAVLGRYC	126	CTLA4-mimetic
LLGRMK	105	Antiviral (HBV)
ICVVQDWGHHRCTAGHMANLTSHASAI	127	C3b antagonist
ICVVQDWGHHRCT	128	C3b antagonist
CVVQDWGHHAC	129	C3b antagonist
STGGFDDVYDWARGVSSALTTTLVATR	185	Vinculin-binding
STGGFDDVYDWARRVSSALTTTLVATR	186	Vinculin-binding
SRGVNFSEWLYDMSAAMKEASNVFPSRRSR	187	Vinculin-binding
SSQNWDMEAGVEDLTAAMLGLLSTIHSSSR	188	Vinculin-binding
SSPSLYTQFLVNYESAATRIQDLLIASRPSR	189	Vinculin-binding
SSTGWVDLLGALQRAADATRTSIPPSLQNSR	190	Vinculin-binding
DVYTKKELIECARRVSEK	191	Vinculin-binding
EKGSYYPGSGIAQFHIDYNNVS	192	C4BP-binding
SGIAQFHIDYNNVSSAEGWHVN	193	C4BP-binding
LVTVEKGSYYPGSGIAQFHIDYNNVSSAEGWHVN	194	C4BP-binding
SGIAQFHIDYNNVS	195	C4BP-binding
LLGRMK	279	anti-HBV
ALLGRMKG	280	anti-HBV
LDPAFR	281	anti-HBV
CXXRGDC	322	Inhibition of platelet aggregation
RPLPPLP	323	Src antagonist
PPVPPR	324	Src antagonist
XFXDXWXXLXX	325	Anti-cancer (particularly for

		sarcomas)
KACRRLFGPVDSEQLSRDCD	326	p16-mimetic
RERWNFDVFTETPLEGDFAW	327	p16-mimetic
KRRQTSMTDFYHSKRRLIFS	328	p16-mimetic
TSMTDFYHSKRRLIFSKRKP	329	p16-mimetic
RRLIF	330	p16-mimetic
KRRQTSATDFYHSKRRLIFSRQIKIWFQNRMMKWKK	331	p16-mimetic
KRRLIFSKRQIKIWFQNRMMKWKK	332	p16-mimetic
Asn Gln Gly Arg His Phe Cys Gly Gly Ala Leu Ile His Ala Arg Phe Val Met Thr Ala Ala Ser Cys Phe Gln	498	CAP37 mimetic/LPS binding
Arg His Phe Cys Gly Gly Ala Leu Ile His Ala Arg Phe Val Met Thr Ala Ala Ser Cys	499	CAP37 mimetic/LPS binding
Gly Thr Arg Cys Gln Val Ala Gly Trp Gly Ser Gln Arg Ser Gly Gly Arg Leu Ser Arg Phe Pro Arg Phe Val Asn Val	500	CAP37 mimetic/LPS binding
WHWRHRIPLQLAAGR	1097	carbohydrate (GD1 alpha) mimetic
LKTPRV	1098	β 2GPI Ab binding
NTLKTPRV	1099	β 2GPI Ab binding
NTLKTPRVGGC	1100	β 2GPI Ab binding
KDKATF	1101	β 2GPI Ab binding
KDKATFGCHD	1102	β 2GPI Ab binding
KDKATFGCHDGC	1103	β 2GPI Ab binding
TLRVYK	1104	β 2GPI Ab binding
ATLRVYKGG	1105	β 2GPI Ab binding
CATLRVYKGG	1106	β 2GPI Ab binding
INLKALAALAKKIL	1107	Membrane- transporting
GWT	NR	Membrane- transporting
GWTLNSAGYLLG	1108	Membrane- transporting
GWTLNSAGYLLGKINLKALAALAKKIL	1109	Membrane- transporting

The present invention is also particularly useful with peptides having activity in treatment of:

- cancer, wherein the peptide is a VEGF-mimetic or a VEGF receptor antagonist, a HER2 agonist or antagonist, a CD20 antagonist and the like;
- asthma, wherein the protein of interest is a CKR3 antagonist, an IL-5 receptor antagonist, and the like;
- thrombosis, wherein the protein of interest is a GPIIb antagonist, a GPIIIa antagonist, and the like;

- autoimmune diseases and other conditions involving immune modulation, wherein the protein of interest is an IL-2 receptor antagonist, a CD40 agonist or antagonist, a CD40L agonist or antagonist, a thymopoietin mimetic and the like.

5 Vehicles. This invention requires the presence of at least one vehicle (F¹, F²) attached to a peptide through the N-terminus, C-terminus or a sidechain of one of the amino acid residues. Multiple vehicles may also be used; e.g., Fc's at each terminus or an Fc at a terminus and a PEG group at the other terminus or a sidechain.

10 An Fc domain is the preferred vehicle. The Fc domain may be fused to the N or C termini of the peptides or at both the N and C termini. For the TPO-mimetic peptides, molecules having the Fc domain fused to the N terminus of the peptide portion of the molecule are more bioactive than other such fusions, so fusion to the N terminus is preferred.

15 As noted above, Fc variants are suitable vehicles within the scope of this invention. A native Fc may be extensively modified to form an Fc variant in accordance with this invention, provided binding to the salvage receptor is maintained; see, for example WO 97/34631 and WO 96/32478. In such Fc variants, one may remove one or more sites of a native Fc that
20 provide structural features or functional activity not required by the fusion molecules of this invention. One may remove these sites by, for example, substituting or deleting residues, inserting residues into the site, or truncating portions containing the site. The inserted or substituted residues may also be altered amino acids, such as peptidomimetics or D-
25 amino acids. Fc variants may be desirable for a number of reasons, several of which are described below. Exemplary Fc variants include molecules and sequences in which:

1. Sites involved in disulfide bond formation are removed. Such removal may avoid reaction with other cysteine-containing proteins present in

- the host cell used to produce the molecules of the invention. For this purpose, the cysteine-containing segment at the N-terminus may be truncated or cysteine residues may be deleted or substituted with other amino acids (e.g., alanyl, seryl). In particular, one may truncate the N-terminal 20-amino acid segment of SEQ ID NO: 2 or delete or substitute the cysteine residues at positions 7 and 10 of SEQ ID NO: 2. Even when cysteine residues are removed, the single chain Fc domains can still form a dimeric Fc domain that is held together non-covalently.
2. A native Fc is modified to make it more compatible with a selected host cell. For example, one may remove the PA sequence near the N-terminus of a typical native Fc, which may be recognized by a digestive enzyme in E. coli such as proline iminopeptidase. One may also add an N-terminal methionine residue, especially when the molecule is expressed recombinantly in a bacterial cell such as E. coli. The Fc domain of SEQ ID NO: 2 (Figure 4) is one such Fc variant.
3. A portion of the N-terminus of a native Fc is removed to prevent N-terminal heterogeneity when expressed in a selected host cell. For this purpose, one may delete any of the first 20 amino acid residues at the N-terminus, particularly those at positions 1, 2, 3, 4 and 5.
4. One or more glycosylation sites are removed. Residues that are typically glycosylated (e.g., asparagine) may confer cytolytic response. Such residues may be deleted or substituted with unglycosylated residues (e.g., alanine).
5. Sites involved in interaction with complement, such as the C1q binding site, are removed. For example, one may delete or substitute the EKK sequence of human IgG1. Complement recruitment may not be advantageous for the molecules of this invention and so may be avoided with such an Fc variant.

6. Sites are removed that affect binding to Fc receptors other than a salvage receptor. A native Fc may have sites for interaction with certain white blood cells that are not required for the fusion molecules of the present invention and so may be removed.
- 5 7. The ADCC site is removed. ADCC sites are known in the art; see, for example, Molec. Immunol. 29 (5): 633-9 (1992) with regard to ADCC sites in IgG1. These sites, as well, are not required for the fusion molecules of the present invention and so may be removed.
8. When the native Fc is derived from a non-human antibody, the native
10 Fc may be humanized. Typically, to humanize a native Fc, one will substitute selected residues in the non-human native Fc with residues that are normally found in human native Fc. Techniques for antibody humanization are well known in the art.

Preferred Fc variants include the following. In SEQ ID NO: 2
15 (Figure 4) the leucine at position 15 may be substituted with glutamate; the glutamate at position 99, with alanine; and the lysines at positions 101 and 103, with alanines. In addition, one or more tyrosine residues can be replaced by phenylalanine residues.

An alternative vehicle would be a protein, polypeptide, peptide,
20 antibody, antibody fragment, , or small molecule (e.g., a peptidomimetic compound) capable of binding to a salvage receptor. For example, one could use as a vehicle a polypeptide as described in U.S. Pat. No. 5,739,277, issued April 14, 1998 to Presta et al. Peptides could also be selected by phage display for binding to the FcRn salvage receptor. Such salvage
25 receptor-binding compounds are also included within the meaning of "vehicle" and are within the scope of this invention. Such vehicles should be selected for increased half-life (e.g., by avoiding sequences recognized by proteases) and decreased immunogenicity (e.g., by favoring non-immunogenic sequences, as discovered in antibody humanization).

As noted above, polymer vehicles may also be used for F¹ and F². Various means for attaching chemical moieties useful as vehicles are currently available, see, e.g., Patent Cooperation Treaty ("PCT") International Publication No. WO 96/11953, entitled "N-Terminally
5 Chemically Modified Protein Compositions and Methods," herein incorporated by reference in its entirety. This PCT publication discloses, among other things, the selective attachment of water soluble polymers to the N-terminus of proteins.

A preferred polymer vehicle is polyethylene glycol (PEG). The PEG
10 group may be of any convenient molecular weight and may be linear or branched. The average molecular weight of the PEG will preferably range from about 2 kiloDalton ("kD") to about 100 kDa, more preferably from about 5 kDa to about 50 kDa, most preferably from about 5 kDa to about 10 kDa. The PEG groups will generally be attached to the compounds of
15 the invention via acylation or reductive alkylation through a reactive group on the PEG moiety (e.g., an aldehyde, amino, thiol, or ester group) to a reactive group on the inventive compound (e.g., an aldehyde, amino, or ester group).

A useful strategy for the PEGylation of synthetic peptides consists
20 of combining, through forming a conjugate linkage in solution, a peptide and a PEG moiety, each bearing a special functionality that is mutually reactive toward the other. The peptides can be easily prepared with conventional solid phase synthesis (see, for example, Figures 5 and 6 and the accompanying text herein). The peptides are "preactivated" with an
25 appropriate functional group at a specific site. The precursors are purified and fully characterized prior to reacting with the PEG moiety. Ligation of the peptide with PEG usually takes place in aqueous phase and can be easily monitored by reverse phase analytical HPLC. The PEGylated peptides can be easily purified by preparative HPLC and characterized by

analytical HPLC, amino acid analysis and laser desorption mass spectrometry.

Polysaccharide polymers are another type of water soluble polymer which may be used for protein modification. Dextran is polysaccharide polymers comprised of individual subunits of glucose predominantly linked by α 1-6 linkages. The dextran itself is available in many molecular weight ranges, and is readily available in molecular weights from about 1 kD to about 70 kD. Dextran is a suitable water soluble polymer for use in the present invention as a vehicle by itself or in combination with another vehicle (e.g., Fc). See, for example, WO 96/11953 and WO 96/05309. The use of dextran conjugated to therapeutic or diagnostic immunoglobulins has been reported; see, for example, European Patent Publication No. 0 315 456, which is hereby incorporated by reference. Dextran of about 1 kD to about 20 kD is preferred when dextran is used as a vehicle in accordance with the present invention.

Linkers. Any "linker" group is optional. When present, its chemical structure is not critical, since it serves primarily as a spacer. The linker is preferably made up of amino acids linked together by peptide bonds. Thus, in preferred embodiments, the linker is made up of from 1 to 20 amino acids linked by peptide bonds, wherein the amino acids are selected from the 20 naturally occurring amino acids. Some of these amino acids may be glycosylated, as is well understood by those in the art. In a more preferred embodiment, the 1 to 20 amino acids are selected from glycine, alanine, proline, asparagine, glutamine, and lysine. Even more preferably, a linker is made up of a majority of amino acids that are sterically unhindered, such as glycine and alanine. Thus, preferred linkers are polyglycines (particularly (Gly)₄, (Gly)₅), poly(Gly-Ala), and polyalanines. Other specific examples of linkers are:

(Gly)₃Lys(Gly)₄ (SEQ ID NO: 333);


(Gly)₃AsnGlySer(Gly)₂ (SEQ ID NO: 334);

(Gly)₃Cys(Gly)₄ (SEQ ID NO: 335); and

GlyProAsnGlyGly (SEQ ID NO: 336).

To explain the above nomenclature, for example, (Gly)₃Lys(Gly)₄ means
 5 Gly-Gly-Gly-Lys-Gly-Gly-Gly-Gly. Combinations of Gly and Ala are also preferred. The linkers shown here are exemplary; linkers within the scope of this invention may be much longer and may include other residues.

Non-peptide linkers are also possible. For example, alkyl linkers such as -NH-(CH₂)_s-C(O)-, wherein s = 2-20 could be used. These alkyl
 10 linkers may further be substituted by any non-sterically hindering group such as lower alkyl (e.g., C₁-C₆) lower acyl, halogen (e.g., Cl, Br), CN, NH₂, phenyl, etc. An exemplary non-peptide linker is a PEG linker,
 VI



15

wherein n is such that the linker has a molecular weight of 100 to 5000 kD, preferably 100 to 500 kD. The peptide linkers may be altered to form derivatives in the same manner as described above.


Derivatives. The inventors also contemplate derivatizing the
 20 peptide and/or vehicle portion of the compounds. Such derivatives may improve the solubility, absorption, biological half life, and the like of the compounds. The moieties may alternatively eliminate or attenuate any undesirable side-effect of the compounds and the like. Exemplary derivatives include compounds in which:

- 25 1. The compound or some portion thereof is cyclic. For example, the peptide portion may be modified to contain two or more Cys residues (e.g., in the linker), which could cyclize by disulfide bond formation.

For citations to references on preparation of cyclized derivatives, see Table 2.

2. The compound is cross-linked or is rendered capable of cross-linking between molecules. For example, the peptide portion may be modified to contain one Cys residue and thereby be able to form an intermolecular disulfide bond with a like molecule. The compound may also be cross-linked through its C-terminus, as in the molecule shown below.

VII



3. One or more peptidyl [-C(O)NR-] linkages (bonds) is replaced by a non-peptidyl linkage. Exemplary non-peptidyl linkages are -CH₂-carbamate [-CH₂-OC(O)NR-], phosphonate, -CH₂-sulfonamide [-CH₂-S(O)₂NR-], urea [-NHC(O)NH-], -CH₂-secondary amine, and alkylated peptide [-C(O)NR⁶- wherein R⁶ is lower alkyl].
5. The N-terminus is derivatized. Typically, the N-terminus may be acylated or modified to a substituted amine. Exemplary N-terminal derivative groups include -NRR¹ (other than -NH₂), -NRC(O)R¹, -NRC(O)OR¹, -NRS(O)₂R¹, -NHC(O)NHR¹, succinimide, or benzyloxycarbonyl-NH- (CBZ-NH-), wherein R and R¹ are each independently hydrogen or lower alkyl and wherein the phenyl ring may be substituted with 1 to 3 substituents selected from the group consisting of C₁-C₄ alkyl, C₁-C₄ alkoxy, chloro, and bromo.
6. The free C-terminus is derivatized. Typically, the C-terminus is esterified or amidated. For example, one may use methods described in the art to add (NH-CH₂-CH₂-NH₂)₂ to compounds of this invention

having any of SEQ ID NOS: 504 to 508 at the C-terminus. Likewise, one may use methods described in the art to add $-NH_2$ to compounds of this invention having any of SEQ ID NOS: 924 to 955, 963 to 972, 1005 to 1013, or 1018 to 1023 at the C-terminus. Exemplary C-terminal derivative groups include, for example, $-C(O)R^2$ wherein R^2 is lower alkoxy or $-NR^3R^4$ wherein R^3 and R^4 are independently hydrogen or C_1 - C_8 alkyl (preferably C_1 - C_4 alkyl).

7. A disulfide bond is replaced with another, preferably more stable, cross-linking moiety (e.g., an alkylene). See, e.g., Bhatnagar *et al.* (1996), *J. Med. Chem.* 39: 3814-9; Alberts *et al.* (1993) *Thirteenth Am. Pep. Symp.*, 357-9.

8. One or more individual amino acid residues is modified. Various derivatizing agents are known to react specifically with selected sidechains or terminal residues, as described in detail below.

Lysinyl residues and amino terminal residues may be reacted with succinic or other carboxylic acid anhydrides, which reverse the charge of the lysinyl residues. Other suitable reagents for derivatizing alpha-amino-containing residues include imidoesters such as methyl picolinimidate; pyridoxal phosphate; pyridoxal; chloroborohydride; trinitrobenzenesulfonic acid; O-methylisourea; 2,4 pentanedione; and transaminase-catalyzed reaction with glyoxylate.

Arginyl residues may be modified by reaction with any one or combination of several conventional reagents, including phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, and ninhydrin. Derivatization of arginyl residues requires that the reaction be performed in alkaline conditions because of the high pKa of the guanidine functional group. Furthermore, these reagents may react with the groups of lysine as well as the arginine epsilon-amino group.

Specific modification of tyrosyl residues has been studied extensively, with particular interest in introducing spectral labels into tyrosyl residues by reaction with aromatic diazonium compounds or tetranitromethane. Most commonly, N-acetylimidazole and tetranitromethane are used to form O-acetyl
5 tyrosyl species and 3-nitro derivatives, respectively.

Carboxyl sidechain groups (aspartyl or glutamyl) may be selectively modified by reaction with carbodiimides ($R'-N=C=N-R'$) such as 1-cyclohexyl-3-(2-morpholinyl-(4-ethyl) carbodiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl) carbodiimide. Furthermore, aspartyl and glutamyl residues
10 may be converted to asparaginyl and glutaminyl residues by reaction with ammonium ions.

Glutaminyl and asparaginyl residues may be deamidated to the corresponding glutamyl and aspartyl residues. Alternatively, these residues are deamidated under mildly acidic conditions. Either form of these residues
15 falls within the scope of this invention.

Cysteinyl residues can be replaced by amino acid residues or other moieties either to eliminate disulfide bonding or, conversely, to stabilize cross-linking. See, e.g., Bhatnagar *et al.* (1996), *J. Med. Chem.* 39: 3814-9.

Derivatization with bifunctional agents is useful for cross-linking the
20 peptides or their functional derivatives to a water-insoluble support matrix or to other macromolecular vehicles. Commonly used cross-linking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-
25 dithiobis(succinimidylpropionate), and bifunctional maleimides such as bis-N-maleimido-1,8-octane. Derivatizing agents such as methyl-3-[(p-azidophenyl)dithio]propioimide yield photoactivatable intermediates that are capable of forming crosslinks in the presence of light. Alternatively, reactive water-insoluble matrices such as cyanogen bromide-activated carbohydrates

and the reactive substrates described in U.S. Pat. Nos. 3,969,287; 3,691,016; 4,195,128; 4,247,642; 4,229,537; and 4,330,440 are employed for protein immobilization.

Carbohydrate (oligosaccharide) groups may conveniently be
5 attached to sites that are known to be glycosylation sites in proteins. Generally, O-linked oligosaccharides are attached to serine (Ser) or threonine (Thr) residues while N-linked oligosaccharides are attached to asparagine (Asn) residues when they are part of the sequence Asn-X-Ser/Thr, where X can be any amino acid except proline. X is preferably
10 one of the 19 naturally occurring amino acids other than proline. The structures of N-linked and O-linked oligosaccharides and the sugar residues found in each type are different. One type of sugar that is commonly found on both is N-acetylneuraminic acid (referred to as sialic acid). Sialic acid is usually the terminal residue of both N-linked and O-
15 linked oligosaccharides and, by virtue of its negative charge, may confer acidic properties to the glycosylated compound. Such site(s) may be incorporated in the linker of the compounds of this invention and are preferably glycosylated by a cell during recombinant production of the polypeptide compounds (e.g., in mammalian cells such as CHO, BHK,
20 COS). However, such sites may further be glycosylated by synthetic or semi-synthetic procedures known in the art.

Other possible modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, oxidation of the sulfur atom in Cys, methylation of the alpha-amino
25 groups of lysine, arginine, and histidine side chains. Creighton, Proteins: Structure and Molecule Properties (W. H. Freeman & Co., San Francisco), pp. 79-86 (1983).

Compounds of the present invention may be changed at the DNA level, as well. The DNA sequence of any portion of the compound may be

changed to codons more compatible with the chosen host cell. For E. coli, which is the preferred host cell, optimized codons are known in the art. Codons may be substituted to eliminate restriction sites or to include silent restriction sites, which may aid in processing of the DNA in the selected
5 host cell. The vehicle, linker and peptide DNA sequences may be modified to include any of the foregoing sequence changes.

Methods of Making

The compounds of this invention largely may be made in transformed host cells using recombinant DNA techniques. To do so, a
10 recombinant DNA molecule coding for the peptide is prepared. Methods of preparing such DNA molecules are well known in the art. For instance, sequences coding for the peptides could be excised from DNA using suitable restriction enzymes. Alternatively, the DNA molecule could be synthesized using chemical synthesis techniques, such as the
15 phosphoramidate method. Also, a combination of these techniques could be used.

The invention also includes a vector capable of expressing the peptides in an appropriate host. The vector comprises the DNA molecule that codes for the peptides operatively linked to appropriate expression
20 control sequences. Methods of effecting this operative linking, either before or after the DNA molecule is inserted into the vector, are well known. Expression control sequences include promoters, activators, enhancers, operators, ribosomal binding sites, start signals, stop signals, cap signals, polyadenylation signals, and other signals involved with the
25 control of transcription or translation.

The resulting vector having the DNA molecule thereon is used to transform an appropriate host. This transformation may be performed using methods well known in the art.

Any of a large number of available and well-known host cells may be used in the practice of this invention. The selection of a particular host is dependent upon a number of factors recognized by the art. These include, for example, compatibility with the chosen expression vector, toxicity of the peptides encoded by the DNA molecule, rate of transformation, ease of recovery of the peptides, expression characteristics, bio-safety and costs. A balance of these factors must be struck with the understanding that not all hosts may be equally effective for the expression of a particular DNA sequence. Within these general guidelines, useful microbial hosts include bacteria (such as E. coli sp.), yeast (such as Saccharomyces sp.) and other fungi, insects, plants, mammalian (including human) cells in culture, or other hosts known in the art.

Next, the transformed host is cultured and purified. Host cells may be cultured under conventional fermentation conditions so that the desired compounds are expressed. Such fermentation conditions are well known in the art. Finally, the peptides are purified from culture by methods well known in the art.

The compounds may also be made by synthetic methods. For example, solid phase synthesis techniques may be used. Suitable techniques are well known in the art, and include those described in Merrifield (1973), Chem. Polypeptides, pp. 335-61 (Katsoyannis and Panayotis eds.); Merrifield (1963), J. Am. Chem. Soc. 85: 2149; Davis et al. (1985), Biochem. Intl. 10: 394-414; Stewart and Young (1969), Solid Phase Peptide Synthesis; U.S. Pat. No. 3,941,763; Finn et al. (1976), The Proteins (3rd ed.) 2: 105-253; and Erickson et al. (1976), The Proteins (3rd ed.) 2: 257-527. Solid phase synthesis is the preferred technique of making individual peptides since it is the most cost-effective method of making small peptides.

Compounds that contain derivatized peptides or which contain non-peptide groups may be synthesized by well-known organic chemistry techniques.

Uses of the Compounds

In general. The compounds of this invention have pharmacologic activity resulting from their ability to bind to proteins of interest as agonists, mimetics or antagonists of the native ligands of such proteins of interest. The utility of specific compounds is shown in Table 2. The activity of these compounds can be measured by assays known in the art. For the TPO-mimetic and EPO-mimetic compounds, in vivo assays are further described in the Examples section herein.

In addition to therapeutic uses, the compounds of the present invention are useful in diagnosing diseases characterized by dysfunction of their associated protein of interest. In one embodiment, a method of detecting in a biological sample a protein of interest (e.g., a receptor) that is capable of being activated comprising the steps of: (a) contacting the sample with a compound of this invention; and (b) detecting activation of the protein of interest by the compound. The biological samples include tissue specimens, intact cells, or extracts thereof. The compounds of this invention may be used as part of a diagnostic kit to detect the presence of their associated proteins of interest in a biological sample. Such kits employ the compounds of the invention having an attached label to allow for detection. The compounds are useful for identifying normal or abnormal proteins of interest. For the EPO-mimetic compounds, for example, presence of abnormal protein of interest in a biological sample may be indicative of such disorders as Diamond Blackfan anemia, where it is believed that the EPO receptor is dysfunctional.

Therapeutic uses of EPO-mimetic compounds. The EPO-mimetic compounds of the invention are useful for treating disorders characterized by low red blood cell levels. Included in the invention are methods of modulating the endogenous activity of an EPO receptor in a mammal, preferably methods of increasing the activity of an EPO receptor. In

general, any condition treatable by erythropoietin, such as anemia, may also be treated by the EPO-mimetic compounds of the invention. These compounds are administered by an amount and route of delivery that is appropriate for the nature and severity of the condition being treated and
5 may be ascertained by one skilled in the art. Preferably, administration is by injection, either subcutaneous, intramuscular, or intravenous.

Therapeutic uses of TPO-mimetic compounds. For the TPO-mimetic compounds, one can utilize such standard assays as those described in WO95/26746 entitled "Compositions and Methods for
10 Stimulating Megakaryocyte Growth and Differentiation". In vivo assays also appear in the Examples hereinafter.

The conditions to be treated are generally those that involve an existing megakaryocyte/platelet deficiency or an expected megakaryocyte/platelet deficiency (e.g., because of planned surgery or
15 platelet donation). Such conditions will usually be the result of a deficiency (temporary or permanent) of active Mpl ligand in vivo. The generic term for platelet deficiency is thrombocytopenia, and hence the methods and compositions of the present invention are generally available for treating thrombocytopenia in patients in need thereof.

20 Thrombocytopenia (platelet deficiencies) may be present for various reasons, including chemotherapy and other therapy with a variety of drugs, radiation therapy, surgery, accidental blood loss, and other specific disease conditions. Exemplary specific disease conditions that involve thrombocytopenia and may be treated in accordance with this
25 invention are: aplastic anemia, idiopathic thrombocytopenia, metastatic tumors which result in thrombocytopenia, systemic lupus erythematosus, splenomegaly, Fanconi's syndrome, vitamin B12 deficiency, folic acid deficiency, May-Hegglin anomaly, Wiskott-Aldrich syndrome, and paroxysmal nocturnal hemoglobinuria. Also, certain treatments for AIDS

result in thrombocytopenia (e.g., AZT). Certain wound healing disorders might also benefit from an increase in platelet numbers.

With regard to anticipated platelet deficiencies, e.g., due to future surgery, a compound of the present invention could be administered
5 several days to several hours prior to the need for platelets. With regard to acute situations, e.g., accidental and massive blood loss, a compound of this invention could be administered along with blood or purified platelets.

The TPO-mimetic compounds of this invention may also be useful in
10 stimulating certain cell types other than megakaryocytes if such cells are found to express Mpl receptor. Conditions associated with such cells that express the Mpl receptor, which are responsive to stimulation by the Mpl ligand, are also within the scope of this invention.

The TPO-mimetic compounds of this invention may be used in any
15 situation in which production of platelets or platelet precursor cells is desired, or in which stimulation of the c-Mpl receptor is desired. Thus, for example, the compounds of this invention may be used to treat any condition in a mammal wherein there is a need of platelets, megakaryocytes, and the like. Such conditions are described in detail in the following exemplary sources:
20 WO95/26746; WO95/21919; WO95/18858; WO95/21920 and are incorporated herein.

The TPO-mimetic compounds of this invention may also be useful in maintaining the viability or storage life of platelets and/or megakaryocytes and related cells. Accordingly, it could be useful to include an effective amount of
25 one or more such compounds in a composition containing such cells.

The therapeutic methods, compositions and compounds of the present invention may also be employed, alone or in combination with other cytokines, soluble Mpl receptor, hematopoietic factors, interleukins, growth factors or antibodies in the treatment of disease states

characterized by other symptoms as well as platelet deficiencies. It is anticipated that the inventive compound will prove useful in treating some forms of thrombocytopenia in combination with general stimulators of hematopoiesis, such as IL-3 or GM-CSF. Other megakaryocytic
5 stimulatory factors, i.e., meg-CSF, stem cell factor (SCF), leukemia inhibitory factor (LIF), oncostatin M (OSM), or other molecules with megakaryocyte stimulating activity may also be employed with Mpl ligand. Additional exemplary cytokines or hematopoietic factors for such co-administration include IL-1 alpha, IL-1 beta, IL-2, IL-3, IL-4, IL-5, IL-6,
10 IL-11, colony stimulating factor-1 (CSF-1), SCF, GM-CSF, granulocyte colony stimulating factor (G-CSF), EPO, interferon-alpha (IFN-alpha), consensus interferon, IFN-beta, or IFN-gamma. It may further be useful to administer, either simultaneously or sequentially, an effective amount of a soluble mammalian Mpl receptor, which appears to have an effect of
15 causing megakaryocytes to fragment into platelets once the megakaryocytes have reached mature form. Thus, administration of an inventive compound (to enhance the number of mature megakaryocytes) followed by administration of the soluble Mpl receptor (to inactivate the ligand and allow the mature megakaryocytes to produce platelets) is
20 expected to be a particularly effective means of stimulating platelet production. The dosage recited above would be adjusted to compensate for such additional components in the therapeutic composition. Progress of the treated patient can be monitored by conventional methods.

In cases where the inventive compounds are added to compositions
25 of platelets and/or megakaryocytes and related cells, the amount to be included will generally be ascertained experimentally by techniques and assays known in the art. An exemplary range of amounts is 0.1 μ g—1 mg inventive compound per 10^6 cells.

Pharmaceutical Compositions

In General. The present invention also provides methods of using pharmaceutical compositions of the inventive compounds. Such pharmaceutical compositions may be for administration for injection, or for oral, pulmonary, nasal, transdermal or other forms of administration. In general, the invention encompasses pharmaceutical compositions comprising effective amounts of a compound of the invention together with pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers. Such compositions include diluents of various buffer content (*e.g.*, Tris-HCl, acetate, phosphate), pH and ionic strength; additives such as detergents and solubilizing agents (*e.g.*, Tween 80, Polysorbate 80), anti-oxidants (*e.g.*, ascorbic acid, sodium metabisulfite), preservatives (*e.g.*, Thimersol, benzyl alcohol) and bulking substances (*e.g.*, lactose, mannitol); incorporation of the material into particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, etc. or into liposomes. Hyaluronic acid may also be used, and this may have the effect of promoting sustained duration in the circulation. Such compositions may influence the physical state, stability, rate of *in vivo* release, and rate of *in vivo* clearance of the present proteins and derivatives. See, *e.g.*, Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, PA 18042) pages 1435-1712 which are herein incorporated by reference. The compositions may be prepared in liquid form, or may be in dried powder, such as lyophilized form. Implantable sustained release formulations are also contemplated, as are transdermal formulations.

Oral dosage forms. Contemplated for use herein are oral solid dosage forms, which are described generally in Chapter 89 of Remington's Pharmaceutical Sciences (1990), 18th Ed., Mack Publishing Co. Easton PA 18042, which is herein incorporated by reference. Solid dosage forms include tablets, capsules, pills, troches or lozenges, cachets or pellets. Also,

liposomal or proteinoid encapsulation may be used to formulate the present compositions (as, for example, proteinoid microspheres reported in U.S. Patent No. 4,925,673). Liposomal encapsulation may be used and the liposomes may be derivatized with various polymers (e.g., U.S. Patent
5 No. 5,013,556). A description of possible solid dosage forms for the therapeutic is given in Chapter 10 of Marshall, K., Modern Pharmaceutics (1979), edited by G. S. Banker and C. T. Rhodes, herein incorporated by reference. In general, the formulation will include the inventive compound, and inert ingredients which allow for protection against the
10 stomach environment, and release of the biologically active material in the intestine.

Also specifically contemplated are oral dosage forms of the above inventive compounds. If necessary, the compounds may be chemically modified so that oral delivery is efficacious. Generally, the chemical
15 modification contemplated is the attachment of at least one moiety to the compound molecule itself, where said moiety permits (a) inhibition of proteolysis; and (b) uptake into the blood stream from the stomach or intestine. Also desired is the increase in overall stability of the compound and increase in circulation time in the body. Moieties useful as covalently
20 attached vehicles in this invention may also be used for this purpose. Examples of such moieties include: PEG, copolymers of ethylene glycol and propylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone and polyproline. See, for example, Abuchowski and Davis, Soluble Polymer-Enzyme Adducts, Enzymes as Drugs (1981),
25 Hocenberg and Roberts, eds., Wiley-Interscience, New York, NY, , pp 367-83; Newmark, et al. (1982), J. Appl. Biochem. 4:185-9. Other polymers that could be used are poly-1,3-dioxolane and poly-1,3,6-tioxocane. Preferred for pharmaceutical usage, as indicated above, are PEG moieties.

For oral delivery dosage forms, it is also possible to use a salt of a modified aliphatic amino acid, such as sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), as a carrier to enhance absorption of the therapeutic compounds of this invention. The clinical efficacy of a heparin
5 formulation using SNAC has been demonstrated in a Phase II trial conducted by Emisphere Technologies. See US Patent No. 5,792,451, "Oral drug delivery composition and methods".

The compounds of this invention can be included in the formulation as fine multiparticulates in the form of granules or pellets of
10 particle size about 1 mm. The formulation of the material for capsule administration could also be as a powder, lightly compressed plugs or even as tablets. The therapeutic could be prepared by compression.

Colorants and flavoring agents may all be included. For example, the protein (or derivative) may be formulated (such as by liposome or
15 microsphere encapsulation) and then further contained within an edible product, such as a refrigerated beverage containing colorants and flavoring agents.

One may dilute or increase the volume of the compound of the invention with an inert material. These diluents could include
20 carbohydrates, especially mannitol, α -lactose, anhydrous lactose, cellulose, sucrose, modified dextrans and starch. Certain inorganic salts may also be used as fillers including calcium triphosphate, magnesium carbonate and sodium chloride. Some commercially available diluents are Fast-Flo, Emdex, STA-Rx 1500, Emcompress and Avicell.

25 Disintegrants may be included in the formulation of the therapeutic into a solid dosage form. Materials used as disintegrants include but are not limited to starch including the commercial disintegrant based on starch, Explotab. Sodium starch glycolate, Amberlite, sodium carboxymethylcellulose, ultramylopectin, sodium alginate, gelatin, orange

peel, acid carboxymethyl cellulose, natural sponge and bentonite may all be used. Another form of the disintegrants are the insoluble cationic exchange resins. Powdered gums may be used as disintegrants and as binders and these can include powdered gums such as agar, Karaya or tragacanth. Alginic acid and its sodium salt are also useful as disintegrants.

Binders may be used to hold the therapeutic agent together to form a hard tablet and include materials from natural products such as acacia, tragacanth, starch and gelatin. Others include methyl cellulose (MC), ethyl cellulose (EC) and carboxymethyl cellulose (CMC). Polyvinyl pyrrolidone (PVP) and hydroxypropylmethyl cellulose (HPMC) could both be used in alcoholic solutions to granulate the therapeutic.

An antifrictional agent may be included in the formulation of the therapeutic to prevent sticking during the formulation process. Lubricants may be used as a layer between the therapeutic and the die wall, and these can include but are not limited to; stearic acid including its magnesium and calcium salts, polytetrafluoroethylene (PTFE), liquid paraffin, vegetable oils and waxes. Soluble lubricants may also be used such as sodium lauryl sulfate, magnesium lauryl sulfate, polyethylene glycol of various molecular weights, Carbowax 4000 and 6000.

Glidants that might improve the flow properties of the drug during formulation and to aid rearrangement during compression might be added. The glidants may include starch, talc, pyrogenic silica and hydrated silicoaluminate.

To aid dissolution of the compound of this invention into the aqueous environment a surfactant might be added as a wetting agent. Surfactants may include anionic detergents such as sodium lauryl sulfate, dioctyl sodium sulfosuccinate and dioctyl sodium sulfonate. Cationic detergents might be used and could include benzalkonium chloride or

benzethonium chloride. The list of potential nonionic detergents that could be included in the formulation as surfactants are lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 50 and 60, glycerol monostearate, polysorbate 40, 60, 65 and 80, sucrose fatty acid ester, methyl cellulose and carboxymethyl cellulose. These surfactants could be present in the formulation of the protein or derivative either alone or as a mixture in different ratios.

Additives may also be included in the formulation to enhance uptake of the compound. Additives potentially having this property are for instance the fatty acids oleic acid, linoleic acid and linolenic acid.

Controlled release formulation may be desirable. The compound of this invention could be incorporated into an inert matrix which permits release by either diffusion or leaching mechanisms e.g., gums. Slowly degenerating matrices may also be incorporated into the formulation, e.g., alginates, polysaccharides. Another form of a controlled release of the compounds of this invention is by a method based on the Oros therapeutic system (Alza Corp.), i.e., the drug is enclosed in a semipermeable membrane which allows water to enter and push drug out through a single small opening due to osmotic effects. Some enteric coatings also have a delayed release effect.

Other coatings may be used for the formulation. These include a variety of sugars which could be applied in a coating pan. The therapeutic agent could also be given in a film coated tablet and the materials used in this instance are divided into 2 groups. The first are the nonenteric materials and include methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, methylhydroxy-ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl-methyl cellulose, sodium carboxy-methyl cellulose, providone and the polyethylene glycols. The second group consists of the enteric materials that are commonly esters of phthalic acid.

A mix of materials might be used to provide the optimum film coating. Film coating may be carried out in a pan coater or in a fluidized bed or by compression coating.

Pulmonary delivery forms. Also contemplated herein is pulmonary
5 delivery of the present protein (or derivatives thereof). The protein (or
derivative) is delivered to the lungs of a mammal while inhaling and
traverses across the lung epithelial lining to the blood stream. (Other
reports of this include Adjei et al., Pharma. Res. (1990) 7: 565-9; Adjei et al.
(1990), Internatl. J. Pharmaceutics 63: 135-44 (leuprolide acetate); Braquet
10 et al. (1989), J. Cardiovasc. Pharmacol. 13 (suppl.5): s.143-146 (endothelin-
1); Hubbard et al. (1989), Annals Int. Med. 3: 206-12 (α 1-antitrypsin); Smith
et al. (1989), J. Clin. Invest. 84: 1145-6 (α 1-proteinase); Oswein et al. (March
1990), "Aerosolization of Proteins", Proc. Symp. Resp. Drug Delivery II,
Keystone, Colorado (recombinant human growth hormone); Debs et al.
15 (1988), J. Immunol. 140: 3482-8 (interferon- γ and tumor necrosis factor α)
and Platz et al., U.S. Patent No. 5,284,656 (granulocyte colony stimulating
factor).

Contemplated for use in the practice of this invention are a wide
range of mechanical devices designed for pulmonary delivery of
20 therapeutic products, including but not limited to nebulizers, metered
dose inhalers, and powder inhalers, all of which are familiar to those
skilled in the art. Some specific examples of commercially available
devices suitable for the practice of this invention are the Ultravent
nebulizer, manufactured by Mallinckrodt, Inc., St. Louis, Missouri; the
25 Acorn II nebulizer, manufactured by Marquest Medical Products,
Englewood, Colorado; the Ventolin metered dose inhaler, manufactured
by Glaxo Inc., Research Triangle Park, North Carolina; and the Spinhaler
powder inhaler, manufactured by Fisons Corp., Bedford, Massachusetts.

All such devices require the use of formulations suitable for the dispensing of the inventive compound. Typically, each formulation is specific to the type of device employed and may involve the use of an appropriate propellant material, in addition to diluents, adjuvants
5 and/or carriers useful in therapy.

The inventive compound should most advantageously be prepared in particulate form with an average particle size of less than 10 μm (or microns), most preferably 0.5 to 5 μm , for most effective delivery to the distal lung.

10 Pharmaceutically acceptable carriers include carbohydrates such as trehalose, mannitol, xylitol, sucrose, lactose, and sorbitol. Other ingredients for use in formulations may include DPPC, DOPE, DSPC and DOPC. Natural or synthetic surfactants may be used. PEG may be used (even apart from its use in derivatizing the protein or analog). Dextran,
15 such as cyclodextran, may be used. Bile salts and other related enhancers may be used. Cellulose and cellulose derivatives may be used. Amino acids may be used, such as use in a buffer formulation.

Also, the use of liposomes, microcapsules or microspheres, inclusion complexes, or other types of carriers is contemplated.

20 Formulations suitable for use with a nebulizer, either jet or ultrasonic, will typically comprise the inventive compound dissolved in water at a concentration of about 0.1 to 25 mg of biologically active protein per mL of solution. The formulation may also include a buffer and a simple sugar (e.g., for protein stabilization and regulation of osmotic
25 pressure). The nebulizer formulation may also contain a surfactant, to reduce or prevent surface induced aggregation of the protein caused by atomization of the solution in forming the aerosol.

Formulations for use with a metered-dose inhaler device will generally comprise a finely divided powder containing the inventive

compound suspended in a propellant with the aid of a surfactant. The propellant may be any conventional material employed for this purpose, such as a chlorofluorocarbon, a hydrochlorofluorocarbon, a hydrofluorocarbon, or a hydrocarbon, including trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol, and 1,1,1,2-tetrafluoroethane, or combinations thereof. Suitable surfactants include sorbitan trioleate and soya lecithin. Oleic acid may also be useful as a surfactant.

Formulations for dispensing from a powder inhaler device will comprise a finely divided dry powder containing the inventive compound and may also include a bulking agent, such as lactose, sorbitol, sucrose, mannitol, trehalose, or xylitol in amounts which facilitate dispersal of the powder from the device, e.g., 50 to 90% by weight of the formulation.

Nasal delivery forms. Nasal delivery of the inventive compound is also contemplated. Nasal delivery allows the passage of the protein to the blood stream directly after administering the therapeutic product to the nose, without the necessity for deposition of the product in the lung. Formulations for nasal delivery include those with dextran or cyclodextran. Delivery via transport across other mucous membranes is also contemplated.

Dosages. The dosage regimen involved in a method for treating the above-described conditions will be determined by the attending physician, considering various factors which modify the action of drugs, e.g. the age, condition, body weight, sex and diet of the patient, the severity of any infection, time of administration and other clinical factors. Generally, the daily regimen should be in the range of 0.1-1000 micrograms of the inventive compound per kilogram of body weight, preferably 0.1-150 micrograms per kilogram.

Specific preferred embodiments

The inventors have determined preferred peptide sequences for molecules having many different kinds of activity. The inventors have further determined preferred structures of these preferred peptides combined with preferred linkers and vehicles. Preferred structures for these preferred peptides listed in Table 21 below.

Table 21—Preferred embodiments

Sequence/structure	SEQ ID NO:	Activity
F ¹ -(G) ₅ -IEGPTLRQWLAARA-(G) ₈ -IEGPTLRQWLAARA	337	TPO-mimetic
IEGPTLRQWLAARA-(G) ₈ -IEGPTLRQWLAARA-(G) ₅ -F ¹	338	TPO-mimetic
F ¹ -(G) ₅ -IEGPTLRQWLAARA	1032	TPO-mimetic
IEGPTLRQWLAARA -(G) ₅ -F ¹	1033	TPO-mimetic
F ¹ -(G) ₅ -GGTYSCHFGPLTWVCKPQGG-(G) ₄ -GGTYSCHFGPLTWVCKPQGG	339	EPO-mimetic
GGTYSCHFGPLTWVCKPQGG-(G) ₄ -GGTYSCHFGPLTWVCKPQGG-(G) ₅ -F ¹	340	EPO-mimetic
GGTYSCHFGPLTWVCKPQGG-(G) ₅ -F ¹	1034	EPO-mimetic
F ¹ -(G) ₅ -DFLPHYKNTSLGHRP	1045	TNF- α inhibitor
DFLPHYKNTSLGHRP-(G) ₅ -F ¹	1046	TNF- α inhibitor
F ¹ -(G) ₅ -FEWTPGYWQPYALPL	1047	IL-1 R antagonist
FEWTPGYWQPYALPL-(G) ₅ -F ¹	1048	IL-1 R antagonist
F ¹ -(G) ₅ -VEPNCDIHVMWEWECFERL	1049	VEGF-antagonist
VEPNCDIHVMWEWECFERL-(G) ₅ -F ¹	1050	VEGF-antagonist
F ¹ -(G) ₅ -CTTHWGFTLC	1051	MMP inhibitor
CTTHWGFTLC-(G) ₅ -F ¹	1052	MMP inhibitor

"F¹" is an Fc domain as defined previously herein.

Working examples

The compounds described above may be prepared as described below. These examples comprise preferred embodiments of the invention and are illustrative rather than limiting.

Example 1

5

TPO-Mimetics

The following example uses peptides identified by the numbers appearing in Table A hereinafter.

Preparation of peptide 19. Peptide 17b (12 mg) and MeO-PEG-SH 5000 (30 mg, 2 equiv.) were dissolved in 1 ml aqueous buffer (pH 8). The
10 mixture was incubated at RT for about 30 minutes and the reaction was checked by analytical HPLC, which showed a > 80% completion of the reaction. The pegylated material was isolated by preparative HPLC.

Preparation of peptide 20. Peptide 18 (14 mg) and MeO-PEG-maleimide (25 mg) were dissolved in about 1.5 ml aqueous buffer (pH 8).
15 The mixture was incubated at RT for about 30 minutes, at which time about 70% transformation was complete as monitored with analytical HPLC by applying an aliquot of sample to the HPLC column. The pegylated material was purified by preparative HPLC.

Bioactivity assay. The TPO in vitro bioassay is a mitogenic assay
20 utilizing an IL-3 dependent clone of murine 32D cells that have been transfected with human mpl receptor. This assay is described in greater detail in WO 95/26746. Cells are maintained in MEM medium containing 10% Fetal Clone II and 1 ng/ml mIL-3. Prior to sample addition, cells are prepared by rinsing twice with growth medium lacking mIL-3. An
25 extended twelve point TPO standard curve is prepared, ranging from 33 to 39 pg/ml. Four dilutions, estimated to fall within the linear portion of the standard curve, (100 to 125 pg/ml), are prepared for each sample and run in triplicate. A volume of 100 μ l of each dilution of sample or standard is added to appropriate wells of a 96 well microtiter plate

containing 10,000 cells/well. After forty-four hours at 37 °C and 10% CO₂, MTS (a tetrazolium compound which is bio-reduced by cells to a formazan) is added to each well. Approximately six hours later, the optical density is read on a plate reader at 490 nm. A dose response curve (log TPO

5 concentration vs. O.D.- Background) is generated and linear regression analysis of points which fall in the linear portion of the standard curve is performed. Concentrations of unknown test samples are determined using the resulting linear equation and a correction for the dilution factor.

TMP tandem repeats with polyglycine linkers. Our design of
10 sequentially linked TMP repeats was based on the assumption that a dimeric form of TMP was required for its effective interaction with c-Mpl (the TPO receptor) and that depending on how they were wound up against each other in the receptor context, the two TMP molecules could be tethered together in the C- to N-terminus configuration in a way that
15 would not perturb the global dimeric conformation. Clearly, the success of the design of tandem linked repeats depends on proper selection of the length and composition of the linker that joins the C- and N-termini of the two sequentially aligned TMP monomers. Since no structural information of the TMP bound to c-Mpl was available, a series of repeated peptides
20 with linkers composed of 0 to 10 and 14 glycine residues (Table A) were synthesized. Glycine was chosen because of its simplicity and flexibility, based on the rationale that a flexible polyglycine peptide chain might allow for the free folding of the two tethered TMP repeats into the required conformation, while other amino acid sequences may adopt
25 undesired secondary structures whose rigidity might disrupt the correct packing of the repeated peptide in the receptor context.

The resulting peptides are readily accessible by conventional solid phase peptide synthesis methods (Merrifield (1963), J. Amer. Chem. Soc. 85: 2149) with either Fmoc or t-Boc chemistry. Unlike the synthesis of the

C-terminally linked parallel dimer which required the use of an orthogonally protected lysine residue as the initial branch point to build the two peptide chains in a pseudosymmetrical way (Cwirla et al. (1997), Science 276: 1696-9), the synthesis of these tandem repeats was a

5 straightforward, stepwise assembly of the continuous peptide chains from the C- to N-terminus. Since dimerization of TMP had a more dramatic effect on the proliferative activity than binding affinity as shown for the C-terminal dimer (Cwirla et al. (1997)), the synthetic peptides were tested directly for biological activity in a TPO-dependent cell-proliferation assay

10 using an IL-3 dependent clone of murine 32D cells transfected with the full-length c-Mpl (Palacios et al., Cell 41:727 (1985)). As the test results showed, all the polyglycine linked tandem repeats demonstrated >1000 fold increases in potency as compared to the monomer, and were even more potent than the C-terminal dimer in this cell proliferation assay. The

15 absolute activity of the C-terminal dimer in our assay was lower than that of the native TPO protein, which is different from the previously reported findings in which the C-terminal dimer was found to be as active as the natural ligand (Cwirla et al. (1997)). This might be due to differences in the conditions used in the two assays. Nevertheless, the difference in

20 activity between tandem (C terminal of first monomer linked to N terminal of second monomer) and C-terminal (C terminal of first monomer linked to C terminal of second monomer; also referred to as parallel) dimers in the same assay clearly demonstrated the superiority of tandem repeat strategy over parallel peptide dimerization. It is interesting to note

25 that a wide range of length is tolerated by the linker. The optimal linker between tandem peptides with the selected TMP monomers apparently is composed of 8 glycines.

Other tandem repeats. Subsequent to this first series of TMP tandem repeats, several other molecules were designed either with

different linkers or containing modifications within the monomer itself. The first of these molecules, peptide 13, has a linker composed of GPNG, a sequence known to have a high propensity to form a β -turn-type secondary structure. Although still about 100-fold more potent than the monomer, this peptide was found to be >10-fold less active than the equivalent GGGG-linked analog. Thus, introduction of a relatively rigid β -turn at the linker region seemed to have caused a slight distortion of the optimal agonist conformation in this short linker form.

The Trp9 in the TMP sequence is a highly conserved residue among the active peptides isolated from random peptide libraries. There is also a highly conserved Trp in the consensus sequences of EPO mimetic peptides and this Trp residue was found to be involved in the formation of a hydrophobic core between the two EMPs and contributed to hydrophobic interactions with the EPO receptor. Livnah *et al.* (1996), *Science* 273: 464-71). By analogy, the Trp9 residue in TMP might have a similar function in dimerization of the peptide ligand, and as an attempt to modulate and estimate the effects of noncovalent hydrophobic forces exerted by the two indole rings, several analogs were made resulting from mutations at the Trp. So in peptide 14, the Trp residue was replaced in each of the two TMP monomers with a Cys, and an intramolecular disulfide bond was formed between the two cysteines by oxidation which was envisioned to mimic the hydrophobic interactions between the two Trp residues in peptide dimerization. Peptide 15 is the reduced form of peptide 14. In peptide 16, the two Trp residues were replaced by Ala. As the assay data show, all three analogs were inactive. These data further demonstrated that Trp is critical for the activity of the TPO mimetic peptide, not just for dimer formation.

The next two peptides (peptide 17a, and 18) each contain in their 8-amino acid linker a Lys or Cys residue. These two compounds are

precursors to the two PEGylated peptides (peptide 19 and 20) in which the side chain of the Lys or Cys is modified by a PEG moiety. A PEG moiety was introduced at the middle of a relatively long linker, so that the large PEG component (5 kDa) is far enough away from the critical binding sites
5 in the peptide molecule. PEG is a known biocompatible polymer which is increasingly used as a covalent modifier to improve the pharmacokinetic profiles of peptide- and protein-based therapeutics.

A modular, solution-based method was devised for convenient PEGylation of synthetic or recombinant peptides. The method is based on
10 the now well established chemoselective ligation strategy which utilizes the specific reaction between a pair of mutually reactive functionalities. So, for pegylated peptide 19, the lysine side chain was preactivated with a bromoacetyl group to give peptide 17b to accommodate reaction with a thiol-derivatized PEG. To do that, an orthogonal protecting group, Dde,
15 was employed for the protection of the lysine ϵ -amine. Once the whole peptide chain was assembled, the N-terminal amine was reprotected with t-Boc. Dde was then removed to allow for the bromoacetylation. This strategy gave a high quality crude peptide which was easily purified using conventional reverse phase HPLC. Ligation of the peptide with the thiol-
20 modified PEG took place in aqueous buffer at pH 8 and the reaction completed within 30 minutes. MALDI-MS analysis of the purified, pegylated material revealed a characteristic, bell-shaped spectrum with an increment of 44 Da between the adjacent peaks. For PEG-peptide 20, a cysteine residue was placed in the linker region and its side chain thiol
25 group would serve as an attachment site for a maleimide-containing PEG. Similar conditions were used for the pegylation of this peptide. As the assay data revealed, these two pegylated peptides had even higher in vitro bioactivity as compared to their unpegylated counterparts.

Peptide 21 has in its 8-amino acid linker a potential glycosylation motif, NGS. Since our exemplary tandem repeats are made up of natural amino acids linked by peptide bonds, expression of such a molecule in an appropriate eukaryotic cell system should produce a glycopeptide with the carbohydrate moiety added on the side chain carboxamide of Asn. Glycosylation is a common post-translational modification process which can have many positive impacts on the biological activity of a given protein by increasing its aqueous solubility and *in vivo* stability. As the assay data show, incorporation of this glycosylation motif into the linker maintained high bioactivity. The synthetic precursor of the potential glycopeptide had in effect an activity comparable to that of the $-(G)_8$ -linked analog. Once glycosylated, this peptide is expected to have the same order of activity as the pegylated peptides, because of the similar chemophysical properties exhibited by a PEG and a carbohydrate moiety.

The last peptide is a dimer of a tandem repeat. It was prepared by oxidizing peptide 18, which formed an intermolecular disulfide bond between the two cysteine residues located at the linker. This peptide was designed to address the possibility that TMP was active as a tetramer. The assay data showed that this peptide was not more active than an average tandem repeat on an adjusted molar basis, which indirectly supports the idea that the active form of TMP is indeed a dimer, otherwise dimerization of a tandem repeat would have a further impact on the bioactivity.

In order to confirm the *in vitro* data in animals, one pegylated TMP tandem repeat (compound 20 in Table A) was delivered subcutaneously to normal mice via osmotic pumps. Time and dose-dependent increases were seen in platelet numbers for the duration of treatment. Peak platelet levels over 4-fold baseline were seen on day 8. A dose of $10\ \mu\text{g}/\text{kg}/\text{day}$ of the pegylated TMP repeat produced a similar response to rHuMGDF (non-pegylated) at $100\ \mu\text{g}/\text{kg}/\text{day}$ delivered by the same route.

Table A—TPO-mimetic Peptides

Peptide No.	Compound	SEQ ID NO:	Relative Potency
	TPO		++++
	TMP monomer	13	+
	TMP C-C dimer		+++-
TMP-(G) _n -TMP:			
1	n = 0	341	++++-
2	n = 1	342	++++
3	n = 2	343	++++
4	n = 3	344	++++
5	n = 4	345	++++
6	n = 5	346	++++
7	n = 6	347	++++
8	n = 7	348	++++
9	n = 8	349	++++-
10	n = 9	350	++++
11	n = 10	351	++++
12	n = 14	352	++++
13	TMP-GPNG-TMP	353	+++
14	IEGPTLRQCLAARA-GGGGGGGG-IEGPTLRQCLAARA ----- (cyclic)	354	-
15	IEGPTLRQCLAARA-GGGGGGGG- IEGPTLRQCLAARA (linear)	355	-
16	IEGPTLRQALAARA-GGGGGGGG- IEGPTLRQALAARA	356	-
17a	TMP-GGGKGGGG-TMP	357	++++
17b	TMP-GGGK(BrAc)GGGG-TMP	358	ND
18	TMP-GGGCGGGG-TMP	359	++++
19	TMP-GGGK(PEG)GGGG-TMP	360	+++++
20	TMP-GGGC(PEG)GGGG-TMP	361	+++++
21	TMP-GGGN*GSGG-TMP	362	++++
22	TMP-GGGCGGGG-TMP TMP-GGGCGGGG-TMP	363 363	++++ ++++

Discussion. It is well accepted that MGDF acts in a way similar to hGH, i.e., one molecule of the protein ligand binds two molecules of the receptor for its activation. Wells et al.(1996), Ann. Rev. Biochem. 65: 609-34. Now, this interaction is mimicked by the action of a much smaller peptide, TMP. However, the present studies suggest that this mimicry requires the concerted action of two TMP molecules, as covalent dimerization of TMP in either a C-C parallel or C-N sequential fashion increased the in vitro biological potency of the original monomer by a factor of greater than 10^3 . The relatively low biopotency of the monomer is probably due to inefficient formation of the noncovalent dimer. A preformed covalent repeat has the ability to eliminate the entropy barrier for the formation of a noncovalent dimer which is exclusively driven by weak, noncovalent interactions between two molecules of the small, 14-residue peptide.

It is intriguing that this tandem repeat approach had a similar effect on enhancing bioactivity as the reported C-C dimerization is intriguing. These two strategies brought about two very different molecular configurations. The C-C dimer is a quasi-symmetrical molecule, while the tandem repeats have no such symmetry in their linear structures. Despite this difference in their primary structures, these two types of molecules appeared able to fold effectively into a similar biologically active conformation and cause the dimerization and activation of c-Mpl. These experimental observations provide a number of insights into how the two TMP molecules may interact with one another in binding to c-Mpl. First, the two C-termini of the two bound TMP molecules must be in relatively close proximity with each other, as suggested by data on the C-terminal dimer. Second, the respective N- and C-termini of the two TMP molecules in the receptor complex must also be very closely aligned with each other, such that they can be directly tethered together with a single peptide bond

to realize the near maximum activity-enhancing effect brought about by the tandem repeat strategy. Insertion of one or more (up to 14) glycine residues at the junction did not increase (or decrease) significantly the activity any further. This may be due to the fact that a flexible polyglycine peptide chain is able to loop out easily from the junction without causing any significant changes in the overall conformation. This flexibility seems to provide the freedom of orientation for the TMP peptide chains to fold into the required conformation in interacting with the receptor and validate it as a site of modification. Indirect evidence supporting this came from the study on peptide 13, in which a much more rigid b-turn-forming sequence as the linker apparently forced a deviation of the backbone alignment around the linker which might have resulted in a slight distortion of the optimal conformation, thus resulting in a moderate (10-fold) decrease in activity as compared with the analogous compound with a 4-Gly linker. Third, Trp9 in TMP plays a similar role as Trp13 in EMP, which is involved not only in peptide:peptide interaction for the formation of dimers but also is important for contributing hydrophobic forces in peptide:receptor interaction. Results obtained with the W to C mutant analog, peptide 14, suggest that a covalent disulfide linkage is not sufficient to approximate the hydrophobic interactions provided by the Trp pair and that, being a short linkage, it might bring the two TMP monomers too close, therefore perturbing the overall conformation of the optimal dimeric structure.

An analysis of the possible secondary structure of the TMP peptide can provide further understanding on the interaction between TMP and c-Mpl. This can be facilitated by making reference to the reported structure of the EPO mimetic peptide. Livnah *et al.* (1996), *Science* 273:464-75 The receptor-bound EMP has a b-hairpin structure with a b-turn formed by the highly consensus Gly-Pro-Leu-Thr at the center of its sequence. Instead of

GPLT, TMP has a highly selected GPTL sequence which is likely to form a similar turn. However, this turn-like motif is located near the N-terminal part in TMP. Secondary structure prediction using Chau-Fasman method suggests that the C-terminal half of the peptide has a tendency to adopt a helical conformation. Together with the highly conserved Trp at position 9, this C-terminal helix may contribute to the stabilization of the dimeric structure. It is interesting to note that most of our tandem repeats are more potent than the C-terminal parallel dimer. Tandem repeats seem to give the molecule a better fit conformation than does the C-C parallel dimerization. The seemingly asymmetric feature of a tandem repeat might have brought it closer to the natural ligand which, as an asymmetric molecule, uses two different sites to bind two identical receptor molecules.

Introduction of a PEG moiety was envisaged to enhance the in vivo activity of the modified peptide by providing it a protection against proteolytic degradation and by slowing down its clearance through renal filtration. It was unexpected that pegylation could further increase the in vitro bioactivity of a tandem repeated TMP peptide in the cell-based proliferation assay.

Example 2

Fc-TMP fusions

TMPs (and EMPs as described in Example 3) were expressed in either monomeric or dimeric form as either N-terminal or C-terminal fusions to the Fc region of human IgG1. In all cases, the expression construct utilized the luxPR promoter promoter in the plasmid expression vector pAMG21.

Fc-TMP. A DNA sequence coding for the Fc region of human IgG1 fused in-frame to a monomer of the TPO-mimetic peptide was constructed using standard PCR technology. Templates for PCR reactions were the pFc-A3 vector and a synthetic TMP gene. The synthetic gene was

constructed from the 3 overlapping oligonucleotides (SEQ ID NOS: 364, 365, and 366, respectively) shown below:

5 1842-97 AAA AAA GGA TCC TCG AGA TTA AGC ACG AGC AGC CAG CCA
 CTG ACG CAG AGT CGG ACC

1842-98 AAA GGT GGA GGT GGT GGT ATC GAA GGT CCG ACT CTG CGT

1842-99 CAG TGG CTG GCT GCT CGT GCT TAA TCT CGA GGA TCC TTT
 TTT

10 These oligonucleotides were annealed to form the duplex encoding an amino acid sequence (SEQ ID NOS: 367 and 368, respectively) shown below:

15 AAAGGTGGAGGTGGTGGTATCGAAGGTCCGACTCTGCGTCAGTGGCTGGCTGCTCGTGCT
 1 +-----+-----+-----+-----+-----+-----+-----+-----+-----+ 60
 CCAGGCTGAGACGCAGTCACCGACCGACGAGCACGA
 a K G G G G G I E G P T L R Q W L A A R A -

20 TAATCTCGAGGATCCTTTTTT
 61 +-----+-----+-----+-----+ 81
 ATTAGAGCTCCTAGGAAAAAA
 a *

25 This duplex was amplified in a PCR reaction using 1842-98 and 1842-97 as the sense and antisense primers.

The Fc portion of the molecule was generated in a PCR reaction with pFc-A3 using the primers shown below (SEQ ID NOS: 369 and 370):

30 1216-52 AAC ATA AGT ACC TGT AGG ATC G

1830-51 TTCGATACCA CCACCTCCAC CTTTACCCGG AGACAGGGAG AGGCTCTTCTGC

35 The oligonucleotides 1830-51 and 1842-98 contain an overlap of 24 nucleotides, allowing the two genes to be fused together in the correct reading frame by combining the above PCR products in a third reaction using the outside primers, 1216-52 and 1842-97.

The final PCR gene product (the full length fusion gene) was digested with restriction endonucleases XbaI and BamHI, and then ligated
 40 into the vector pAMG21 and transformed into competent E. coli strain 2596 cells as described for EMP-Fc herein. Clones were screened for the ability to produce the recombinant protein product and to possess the

The nucleotide and amino acid sequences (SEQ ID NOS: 5 and 6) of the fusion protein are shown in Figure 7.

1830-52	AAA ACT	GGT CTG	GGA CGT	GGT CAG	GGT TGG	GGT CTG	ATC GCT	GAA GCT	GGT CGT	CCG GCT				
1830-53	ACC CCA	TCC CTG	ACC ACG	ACC CAG	AGC AGT	ACG CGG	AGC ACC	AGC	CAG					
1830-54	GGT CTT	GGT CGC	GGA CAA	GGT TGG	GGC CTT	GGC GCA	GGA GCA	GGT CGC	ATT GCA	GAG	GGC	CCA	ACC	
1830-55	AAA ATT	AAA GGC	AGG GAA	ATC GGG	CTC TTG	GAG GGC	ATT CCT	ATG CAA	CGC TAC	GTG CTC	CTG CGC	CAA CGC	GCC C	

```

1  AAAGGTGGAGGTGGTGGTATCGAAGGTCGCGACTCTGCGTCAGTGGCTGGCTGCTCGTGCT
a  1  -----+-----+-----+-----+-----+-----+-----+-----+ 60
    CCAGGCTGAGACGCAGTCACCGACCGACGAGCACGA
    K  G  G  G  G  G  I  E  G  P  T  L  R  Q  W  L  A  A  R  A  -
61  GGTGGTGGAGGTGGCGGCGGAGGTATTGAGGGCCCCAACCTTCGCCAATGGCTTGCAGCA
    -----+-----+-----+-----+-----+-----+-----+-----+ 120
    CCACCACCTCCACCGCCGCCTCCATAACTCCCGGGTTGGGAAGCGGTTACCGAACGTCGT
a  121  G  G  G  G  G  G  G  G  I  E  G  P  T  L  R  Q  W  L  A  A  -
    CGCGCA
    -----+-----+-----+-----+-----+-----+-----+-----+ 148
    GCGCGTATTAGAGCTCCTAGGAAAAAAA
a  149  R  A  * -

```

The Fc portion of the molecule was generated in a PCR reaction with pFc-A3 using the primers 1216-52 and 1830-51 as described above for

Fc-TMP. The full length fusion gene was obtained from a third PCR reaction using the outside primers 1216-52 and 1830-55.

The final PCR gene product (the full length fusion gene) was digested with restriction endonucleases XbaI and BamHI, and then ligated into the vector pAMG21 and transformed into competent E. coli strain 2596 cells as described in example 1. Clones were screened for the ability to produce the recombinant protein product and to possess the gene fusion having the correct nucleotide sequence. A single such clone was selected and designated Amgen strain #3727.

The nucleotide and amino acid sequences (SEQ ID NOS: 7 and 8) of the fusion protein are shown in Figure 8.

TMP-TMP-Fc. A DNA sequence coding for a tandem repeat of the TPO-mimetic peptide fused in-frame to the Fc region of human IgG1 was constructed using standard PCR technology. Templates for PCR reactions were the EMP-Fc plasmid from strain #3688 (see Example 3) and a synthetic gene encoding the TMP dimer. The synthetic gene for the tandem repeat was constructed from the 7 overlapping oligonucleotides shown below (SEQ ID NOS: 377 to 383, respectively):

20	1885-52	TTT TTT CAT ATG ATC GAA GGT CCG ACT CTG CGT CAG TGG
	1885-53	AGC ACG AGC AGC CAG CCA CTG ACG CAG AGT CGG ACC TTC GAT CAT ATG
25	1885-54	CTG GCT GCT CGT GCT GGT GGA GGC GGT GGG GAC AAA ACT CAC ACA
	1885-55	CTG GCT GCT CGT GCT GGC GGT GGT GGC GGA GGG GGT GGC ATT GAG GGC CCA
30	1885-56	AAG CCA TTG GCG AAG GGT TGG GCC CTC AAT GCC ACC CCC TCC GCC ACC ACC GCC
35	1885-57	ACC CTT CGC CAA TGG CTT GCA GCA CGC GCA GGG GGA GGC GGT GGG GAC AAA ACT
	1885-58	CCC ACC GCC TCC CCC TGC GCG TGC TGC

These oligonucleotides were annealed to form the duplex shown encoding an amino acid sequence shown below (SEQ ID NOS 384 and 385):

```

      TTTTTCATATGATCGAAGGTCCGACTCTGCGTCAGTGGCTGGCTGCTCGTGCTGGCGGT
1  -----+-----+-----+-----+-----+-----+-----+-----+ 60
      GTATACTAGCTTCCAGGCTGAGACGCAGTCACCGACCGACGAGCACGACCGCCA
a      M I E G P T L R Q W L A A R A G G -
5
      GGTGGCGGAGGGGTGGCATTGAGGGCCCAACCCCTCGCCAATGGCTGGCTGCTCGTGCT
61 -----+-----+-----+-----+-----+-----+-----+-----+ 120
a      CCACCGCCTCCCCACCGTAAC TCCCGGTTGGGAAGCGGTTACCGAACGTCGTGCGCGT
10      G G G G G G I E G P T L R Q W L A A R A -
      GGTGGAGGCGGTGGGGACAAAAC TCTGGCTGCTCGTGCTGGTGGAGGCGGTGGGGACAAA
121 -----+-----+-----+-----+-----+-----+-----+-----+ 180
a      CCCCCTCCGCCACCC
15      G G G G G D K T L A A R A G G G G G D K -
      ACTCACACA
181 ----- 189
20 a      T H T -

```

This duplex was amplified in a PCR reaction using 1885-52 and 1885-58 as the sense and antisense primers.

The Fc portion of the molecule was generated in a PCR reaction with DNA from the EMP-Fc fusion strain #3688 (see Example 3) using the primers 1885-54 and 1200-54. The full length fusion gene was obtained from a third PCR reaction using the outside primers 1885-52 and 1200-54.

The final PCR gene product (the full length fusion gene) was digested with restriction endonucleases XbaI and BamHI, and then ligated into the vector pAMG21 and transformed into competent E. coli strain 2596 cells as described for Fc-EMP herein. Clones were screened for the ability to produce the recombinant protein product and to possess the gene fusion having the correct nucleotide sequence. A single such clone was selected and designated Amgen strain #3798.

The nucleotide and amino acid sequences (SEQ ID NOS: 9 and 10) of the fusion protein are shown in Figure 9.

TMP-Fc. A DNA sequence coding for a monomer of the TPO-mimetic peptide fused in-frame to the Fc region of human IgG1 was obtained fortuitously in the ligation in TMP-TMP-Fc, presumably due to the ability of primer 1885-54 to anneal to 1885-53 as well as to 1885-58. A single clone having the correct nucleotide sequence for the TMP-Fc construct was selected and designated Amgen strain #3788.

The nucleotide and amino acid sequences (SEQ ID NOS: 11 and 12) of the fusion protein are shown in Figure 10.

Expression in E. coli. Cultures of each of the pAMG21-Fc-fusion constructs in E. coli GM221 were grown at 37 °C in Luria Broth medium containing 50 mg/ml kanamycin. Induction of gene product expression from the luxPR promoter was achieved following the addition of the synthetic autoinducer N-(3-oxohexanoyl)-DL-homoserine lactone to the culture media to a final concentration of 20 ng/ml. Cultures were incubated at 37 °C for a further 3 hours. After 3 hours, the bacterial cultures were examined by microscopy for the presence of inclusion bodies and were then collected by centrifugation. Refractile inclusion bodies were observed in induced cultures indicating that the Fc-fusions were most likely produced in the insoluble fraction in E. coli. Cell pellets were lysed directly by resuspension in Laemmli sample buffer containing 10% b-mercaptoethanol and were analyzed by SDS-PAGE. In each case, an intense coomassie-stained band of the appropriate molecular weight was observed on an SDS-PAGE gel.

pAMG21. The expression plasmid pAMG21 can be derived from the Amgen expression vector pCFM1656 (ATCC #69576) which in turn be derived from the Amgen expression vector system described in US Patent No. 4,710,473. The pCFM1656 plasmid can be derived from the described pCFM836 plasmid (Patent No. 4,710,473) by:

- (a) destroying the two endogenous NdeI restriction sites by end filling with T4 polymerase enzyme followed by blunt end ligation;
- (b) replacing the DNA sequence between the unique AatII and ClaI restriction sites containing the synthetic P_L promoter with a similar fragment obtained from pCFM636 (patent No. 4,710,473) containing the PL promoter (see SEQ ID NO: 386 below); and

SEQ ID NO: 386:

SEQ ID NO: 387:

20 The expression plasmid pAMG21 can then be derived from pCFM1656 by making a series of site-directed base changes by PCR overlapping oligo mutagenesis and DNA sequence substitutions. Starting with the BglIII site (plasmid bp # 180) immediately 5' to the plasmid replication promoter

25 P_{copB} and proceeding toward the plasmid replication genes, the base pair changes are as shown in Table B below.

Table B—Base pair changes resulting in pAMG21

	<u>pAMG21 bp #</u>	<u>bp in pCFM1656</u>	<u>bp changed to in pAMG21</u>
5	# 204	T/A	C/G
	# 428	A/T	G/C
	# 509	G/C	A/T
	# 617	--	insert two G/C bp
	# 679	G/C	T/A
10	# 980	T/A	C/G
	# 994	G/C	A/T
	# 1004	A/T	C/G
	# 1007	C/G	T/A
	# 1028	A/T	T/A
15	# 1047	C/G	T/A
	# 1178	G/C	T/A
	# 1466	G/C	T/A
	# 2028	G/C	bp deletion
	# 2187	C/G	T/A
20	# 2480	A/T	T/A
	# 2499-2502	<u>AGTG</u> TCAC	<u>GTCA</u> CAGT
25	# 2642	<u>TCCGAGC</u> AGGCTCG	7 bp deletion
	# 3435	G/C	A/T
30	# 3446	G/C	A/T
	# 3643	A/T	T/A

The DNA sequence between the unique AatII (position #4364 in pCFM1656) and SacII (position #4585 in pCFM1656) restriction sites is substituted with the DNA sequence (SEQ ID NO: 23) shown in Figures 17A and 17B. During the ligation of the sticky ends of this substitution DNA sequence, the outside AatII and SacII sites are destroyed. There are unique AatII and SacII sites in the substituted DNA.

GM221 (Amgen #2596). The Amgen host strain #2596 is an E.coli K-12 strain derived from Amgen strain #393. It has been modified to contain both the temperature sensitive lambda repressor cl857s7 in the early ebg region and the lacI^q repressor in the late ebg region (68 minutes). The presence of these two repressor genes allows the use of this host with a variety of expression systems, however both of these repressors are irrelevant to the expression from luxP_R. The untransformed host has no antibiotic resistances.

The ribosome binding site of the cl857s7 gene has been modified to include an enhanced RBS. It has been inserted into the ebg operon between nucleotide position 1170 and 1411 as numbered in Genbank accession number M64441Gb_Ba with deletion of the intervening ebg sequence. The sequence of the insert is shown below with lower case letters representing the ebg sequences flanking the insert shown below (SEQ ID NO: 388):

```

ttattttcgtgCGGCCGCACCATTATCACCGCCAGAGGTAAACTAGTCAACACGCACGGTGTAGATATTTAT
CCCTTGCGGTGATAGATTGAGCACATCGATTTGATTCTAGAAGGAGGGATAATATATGAGCACAAAAAGAAA
25 CCATTAACACAAGAGCAGCTTGAGGACGCACGTCGCCTTAAAGCAATTTATGAAAAAAGAAAAATGAACCTG
GCTTATCCCAGGAATCTGTTCGACACAAGATGGGGATGGGGCAGTCAGGCGTTGGTGTCTTATTTAATGGCAT
CAATGCATTAAATGCTTATAACGCCGCATTGCTTACAAAAATTCTCAAAGTTAGCGTTGAAGAATTTAGCCCT
TCAATCGCCAGAGAATCTACGAGATGTATGAAGCGTTAGTATGCAGCCGTCACCTAGAAGTGAGTATGAGTA
CCCTGTTTTTCTCATGTTTCAGGCAGGGATGTTCTCACCTAAGCTTAGAACCTTTACCAAAGGTGATGCGGAG
AGATGGGTAAGCACAACCAAAAAAGCCAGTGATTCTGCATTCTGGCTTGAGGTTGAAGGTAATTCCATGACCG
30 CACCAACAGGCTCCAAGCCAAGCTTTCCTGACGGAATGTTAATTCTCGTTGACCCTGAGCAGGCTGTTGAGCC
AGGTGATTTCTGCATAGCCAGACTTGGGGTGATGAGTTTACCTTCAAGAACTGATCAGGGATAGCGGTCAG
GTGTTTTTACAACCACTAAACCCACAGTACCCAATGATCCCATGCAATGAGAGTTGTTCCGTTGTGGGGAAG
TTATCGCTAGTCAGTGGCTGAAGAGACGTTGGCTGATAGACTAGTGGATCCACTAGTgtttctgccc

```

The construct was delivered to the chromosome using a recombinant phage called MMe_{ebg}-cl857s7enhanced RBS #4 into F'tet/393. After recombination and resolution only the chromosomal insert described

above remains in the cell. It was renamed F'tet/GM101. F'tet/GM101 was then modified by the delivery of a lacI^Q construct into the ebg operon between nucleotide position 2493 and 2937 as numbered in the Genbank accession number M64441Gb_Ba with the deletion of the intervening ebg sequence. The sequence of the insert is shown below with the lower case letters representing the ebg sequences flanking the insert (SEQ ID NO: 389) shown below:

```

10  ggcggaaccGACGTCCATCGAATGGTGCAAAACCTTTTCGCGGTATGGCATGATAGCGCCCGGAAGAGAGTCA
    ATTCAGGGTGGTGAATGTGAAACCAGTAACGTTATACGATGTCGCAGAGTATGCCGGTGTCTCTTATCAGACC
    GTTTCCTCCGCGTGGTGAACCAGGCCAGCCACGTTTCTGCGAAAACGCGGGAAAAAGTCGAAGCGGCGATGGCGG
    AGCTGAATTACATTCCCAACCGCGTGGCACAACAACCTGGCGGGCAAACAGTCGCTCCTGATTGGCGTTGCCAC
    CTCCAGTCTGGCCCTGCACGCGCCGTCGCAAAATTGTCGCGCGGATTAAATCTCGCGCCGATCAACTGGGTGCC
    AGCGTGGTGGTGTGATGGTAGAACGAAGCGCGCTCGAAGCCTGTAAAGCGGCGGTGCACAATCTTCTCGCGC
    AACGCGTCAGTGGGCTGATCATTAACTATCCGCTGGATGACCAGGATGCCATTGCTGTGGAAGCTGCCATGCAC
15  TAATGTTCCGGCGTTATTTCTTGATGTCTCTGACCAGACACCCATCAACAGTATTATTTCTCCCATGAAGAC
    GGTACGCGACTGGGCGTGGAGCATCTGGTCGCATTGGGTCACCAGCAAATCGCGCTGTAGCGGGCCCATTA
    GTTCTGTCTCGGCGCGTCTGCGTCTGGCTGGCTGGCATAAAATATCTCACTCGCAATCAAATTCAGCCGATAGC
    GGAACGGGAAGGCGACTGGAGTGCCATGTCGGTTTTCACAAACCATGCAAATGCTGAATGAGGGCATCGTT
    CCCACTGCGATGCTGGTTGCCAACGATCAGATGGCGCTGGGCGCAATGCGCGCCATTACCGAGTCCGGGCTGC
20  CCGTTGGTGCGGATATCTCGGTAGTGGGATACGACGATACCGAAGACAGCTCATGTTATATCCCGCCGTTAAC
    CACCATCAAACAGGATTTTCGCCTGCTGGGGCAAACAGCGTGGACCGCTTGTGCAACTCTCTCAGGGCCAG
    GCGGTGAAGGGCAATCAGCTGTTGCCCCTCTCACTGGTGAAAAAGAAAACCCCTGGCGCCCAATACGCAAA
    CCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAGCGGACA
25  GTAAGGTACCATAGGATCCaggcacagga

```

The construct was delivered to the chromosome using a recombinant phage called AGebg-LacIQ#5 into F'tet/GM101. After recombination and resolution only the chromosomal insert described above remains in the cell. It was renamed F'tet/GM221. The F'tet episome was cured from the strain using acridine orange at a concentration of 25 µg/ml in LB. The cured strain was identified as tetracycline sensitive and was stored as GM221.

Expression. Cultures of pAMG21-Fc-TMP-TMP in *E. coli* GM221 in Luria Broth medium containing 50 µg/ml kanamycin were incubated at 37°C prior to induction. Induction of Fc-TMP-TMP gene product expression from the luxPR promoter was achieved following the addition of the synthetic autoinducer N-(3-oxohexanoyl)-DL-homoserine lactone to the culture media to a final concentration of 20 ng/ml and cultures were incubated at 37°C for a further 3 hours. After 3 hours, the bacterial

cultures were examined by microscopy for the presence of inclusion bodies and were then collected by centrifugation. Refractile inclusion bodies were observed in induced cultures indicating that the Fc-TMP-TMP was most likely produced in the insoluble fraction in *E. coli*. Cell pellets
5 were lysed directly by resuspension in Laemmli sample buffer containing 10% β -mercaptoethanol and were analyzed by SDS-PAGE. An intense Coomassie stained band of approximately 30kDa was observed on an SDS-PAGE gel. The expected gene product would be 269 amino acids in length and have an expected molecular weight of about 29.5 kDa.
10 Fermentation was also carried out under standard batch conditions at the 10 L scale, resulting in similar expression levels of the Fc-TMP-TMP to those obtained at bench scale.

Purification of Fc-TMP-TMP. Cells are broken in water (1/10) by high pressure homogenization (2 passes at 14,000 PSI) and inclusion
15 bodies are harvested by centrifugation (4200 RPM in J-6B for 1 hour). Inclusion bodies are solubilized in 6M guanidine, 50mM Tris, 8mM DTT, pH 8.7 for 1 hour at a 1/10 ratio. The solubilized mixture is diluted 20 times into 2M urea, 50 mM tris, 160mM arginine, 3mM cysteine, pH 8.5. The mixture is stirred overnight in the cold and then concentrated about
20 10 fold by ultrafiltration. It is then diluted 3 fold with 10mM Tris, 1.5M urea, pH 9. The pH of this mixture is then adjusted to pH 5 with acetic acid. The precipitate is removed by centrifugation and the supernatant is loaded onto a SP-Sepharose Fast Flow column equilibrated in 20mM NaAc, 100 mM NaCl, pH 5(10mg/ml protein load, room temperature).
25 The protein is eluted off using a 20 column volume gradient in the same buffer ranging from 100mM NaCl to 500mM NaCl. The pool from the column is diluted 3 fold and loaded onto a SP-Sepharose HP column in 20 mM NaAc, 150 mM NaCl, pH 5(10 mg/ml protein load, room temperature). The protein is eluted off using a 20 column volume gradient

in the same buffer ranging from 150 mM NaCl to 400 mM NaCl. The peak is pooled and filtered.

Characterization of Fc-TMP activity. The following is a summary of in vivo data in mice with various compounds of this invention.

5 Mice: Normal female BDF1 approximately 10-12 weeks of age.

Bleed schedule: Ten mice per group treated on day 0, two groups started 4 days apart for a total of 20 mice per group. Five mice bled at each time point, mice were bled a minimum of three times a week. Mice were anesthetized with isoflurane and a total volume of 140-160 μ l of blood was
10 obtained by puncture of the orbital sinus. Blood was counted on a Technicon H1E blood analyzer running software for murine blood. Parameters measured were white blood cells, red blood cells, hematocrit, hemoglobin, platelets, neutrophils.

Treatments: Mice were either injected subcutaneously for a bolus
15 treatment or implanted with 7-day micro-osmotic pumps for continuous delivery. Subcutaneous injections were delivered in a volume of 0.2 ml. Osmotic pumps were inserted into a subcutaneous incision made in the skin between the scapulae of anesthetized mice. Compounds were diluted in PBS with 0.1% BSA. All experiments included one control group,
20 labeled "carrier" that were treated with this diluent only. The concentration of the test articles in the pumps was adjusted so that the calibrated flow rate from the pumps gave the treatment levels indicated in the graphs.

Compounds: A dose titration of the compound was delivered to
25 mice in 7 day micro-osmotic pumps. Mice were treated with various compounds at a single dose of 100 μ g/kg in 7 day osmotic pumps. Some of the same compounds were then given to mice as a single bolus injection.

Activity test results: The results of the activity experiments are shown in Figures 11 and 12. In dose response assays using 7-day micro-

osmotic pumps, the maximum effect was seen with the compound of SEQ ID NO: 18 was at 100 $\mu\text{g/kg/day}$; the 10 $\mu\text{g/kg/day}$ dose was about 50% maximally active and 1 $\mu\text{g/kg/day}$ was the lowest dose at which activity could be seen in this assay system. The compound at 10 $\mu\text{g/kg/day}$ dose
5 was about equally active as 100 $\mu\text{g/kg/day}$ unpegylated rHu-MGDF in the same experiment.

Example 3

Fc-EMP fusions

Fc-EMP. A DNA sequence coding for the Fc region of human IgG1 fused in-frame to a monomer of the EPO-mimetic peptide was constructed using standard PCR technology. Templates for PCR reactions were a vector containing the Fc sequence (pFc-A3, described in International application WO 97/23614, published July 3, 1997) and a synthetic gene encoding EPO monomer. The synthetic gene for the monomer was constructed from the 4 overlapping oligonucleotides (SEQ ID NOS: 390 to 393, respectively) shown below:

	1798-2	TAT	GAA	AGG	TGG	AGG	TGG	TGG	TGG	AGG	TAC	TTA	CTC	TTG
		CCA	CTT	CGG	CCC	GCT	GAC	TTG	G					
15	1798-3	CGG	TTT	GCA	AAC	CCA	AGT	CAG	CGG	GCC	GAA	GTG	GCA	AGA
		GTA	AGT	ACC	TCC	ACC	ACC	TCC	ACC	TTT	CAT			
	1798-4	GTT	TGC	AAA	CCG	CAG	GGT	GGC	GGC	GGC	GGC	GGC	GGT	GGT
20		ACC	TAT	TCC	TGT	CAT	TTT							
	1798-5	CCA	GGT	CAG	CGG	GCC	AAA	ATG	ACA	GGA	ATA	GGT	ACC	ACC
		GCC	GCC	GCC	GCC	GCC	ACC	CTG						

25 The 4 oligonucleotides were annealed to form the duplex encoding an amino acid sequence (SEQ ID NOS: 394 and 395, respectively) shown below:

30 1 TATGAAAGGTGGAGGTGGTGGTGGAGGTACTTACTCTTGCCACTTCCGCCCGCTGACTTG 60
b M K G G G G G G G T Y S C H F G P L T W -

35 61 GGTTTGCAAACCGCAGGTGGCGGCGGCGGCGGTGGTACCTATTCTGTCAATTTT 133
b CCAAACGTTTGCGCTGCCACCGCGCGCGGCCGCCACCATGGATAAGGACAGTAAACCGGGCGACTGGACC

This duplex was amplified in a PCR reaction using

40 1798-18 GCA GAA GAG CCT CTC CCT GTC TCC GGG TAA
AGG TGG AGG TGG TGG TGG AGG TAC TTA
CTC T

and

45 1798-19 CTA ATT GGA TCC ACG AGA TTA ACC ACC
CTG CGG TTT GCA A

as the sense and antisense primers (SEQ ID NOS: 396 and 397, respectively).

The Fc portion of the molecule was generated in a PCR reaction with pFc-A3 using the primers

5 1216-52 AAC ATA AGT ACC TGT AGG ATC G
1798-17 AGA GTA AGT ACC TCC ACC ACC ACC TCC ACC TTT ACC CGG
10 AGA CAG GGA GAG GCT CTT CTG C

which are SEQ ID NOS: 369 and 399, respectively. The oligonucleotides 1798-17 and 1798-18 contain an overlap of 61 nucleotides, allowing the two genes to be fused together in the correct reading frame by combining the above PCR products in a third reaction using the outside primers, 1216-52
15 and 1798-19.

The final PCR gene product (the full length fusion gene) was digested with restriction endonucleases XbaI and BamHI, and then ligated into the vector pAMC21 (described below), also digested with XbaI and BamHI. Ligated DNA was transformed into competent host cells of E. coli
20 strain 2596 (GM221, described herein). Clones were screened for the ability to produce the recombinant protein product and to possess the gene fusion having the correct nucleotide sequence. A single such clone was selected and designated Amgen strain #3718.

The nucleotide and amino acid sequence of the resulting fusion
25 protein (SEQ ID NOS: 15 and 16) are shown in Figure 13.

• EMP-Fc. A DNA sequence coding for a monomer of the EPO-mimetic peptide fused in-frame to the Fc region of human IgG1 was constructed using standard PCR technology. Templates for PCR reactions were the pFC-A3a vector and a synthetic gene encoding EPO monomer.

30 The synthetic gene for the monomer was constructed from the 4 overlapping oligonucleotides 1798-4 and 1798-5 (above) and 1798-6 and 1798-7 (SEQ ID NOS: 400 and 401, respectively) shown below:

1798-6 GGC CCG CTG ACC TGG GTA TGT AAG CCA CAA GGG GGT GGG
GGA GGC GGG GGG TAA TCT CGA G

5 1798-7 GAT CCT CGA GAT TAC CCC CCG CCT CCC CCA CCC CCT TGT
GGC TTA CAT AC

The 4 oligonucleotides were annealed to form the duplex encoding an amino acid sequence (SEQ ID NOS: 402 and 403, respectively) shown below:

```

      GTTTGCAAACCGCAGGGTGGCGGCGGCGGGCGGTGGTACCTATTCCTGTCATTTGGC
1  -----+-----+-----+-----+-----+-----+-----+-----+ 60
      GTCCCACCGCCGCCGCCGCCGCCACCATGGATAAGGACAGTAAAACCG
15 A      V C K P Q G G G G G G G G G T Y S C H F G -
      CCGCTGACCTGGGTATGTAAGCCACAAGGGGGTGGGGGAGGCGGGGGTAATCTCGAG
61 -----+-----+-----+-----+-----+-----+-----+-----+ 122
20 A      GCGACTGGACCATACATTCTGGTGTCCCCACCCCTCCGCCCCCATTAGAGCTCCTAG
      P L T W V C K P Q G G G G G G G G *

```

This duplex was amplified in a PCR reaction using

1798-21 TTA TTT CAT ATG AAA GGT GGT AAC TAT TCC TGT CAT TTT

25 and

1798-22 TGG ACA TGT GTG AGT TTT GTC CCC CCC GCC TCC CCC ACC
CCC T

30 as the sense and antisense primers (SEQ ID NOS: 404 and 405, respectively).

The Fc portion of the molecule was generated in a PCR reaction with pFc-A3 using the primers

1798-23 AGG GGG TGG GGG AGG CGG GGG GGA CAA AAC TCA CAC ATG
TCC A

and

40 1200-54 GTT ATT GCT CAG CGG TGG CA

which are SEQ ID NOS: 406 and 407, respectively. The oligonucleotides 1798-22 and 1798-23 contain an overlap of 43 nucleotides, allowing the two genes to be fused together in the correct reading frame by combining the above PCR products in a third reaction using the outside primers, 1787-21 and 1200-54.

The final PCR gene product (the full length fusion gene) was digested with restriction endonucleases XbaI and BamHI, and then ligated

into the vector pAMG21 and transformed into competent E. coli strain 2596 cells as described above. Clones were screened for the ability to produce the recombinant protein product and to possess the gene fusion having the correct nucleotide sequence. A single such clone was selected and designated Amgen strain #3688.

The nucleotide and amino acid sequences (SEQ ID NOS: 17 and 18) of the resulting fusion protein are shown in Figure 14.

EMP-EMP-Fc. A DNA sequence coding for a dimer of the EPO-mimetic peptide fused in-frame to the Fc region of human IgG1 was constructed using standard PCR technology. Templates for PCR reactions were the EMP-Fc plasmid from strain #3688 above and a synthetic gene encoding the EPO dimer. The synthetic gene for the dimer was constructed from the 8 overlapping oligonucleotides (SEQ ID NOS:408 to 415, respectively) shown below:

1869-23	TTT TAG	TTT AAG	ATC GAG	GAT GAA	TTG TAA	ATT AAT	CTA ATG	GAT	TTG	AGT	TTT	AAC	TTT
1869-48	TAA AA	AAG	TTA	AAA	CTC	AAA	TCT	AGA	ATC	AAA	TCG	ATA	AAA
1871-72	GGA GTT	GGT TGC	ACT AAA	TAC CCG	TCT	TGC	CAC	TTC	GGC	CCG	CTG	ACT	TGG
1871-73	AGT ATT	CAG TTA	CGG TTC	GCC CTC	GAA CTT	GTG C	GCA	AGA	GTA	AGT	ACC	TCC	CAT
1871-74	CAG CAT	GGT TTT	GGC GGC	GGC CCG	GGC CTG	GGC ACC	GGC TGG	GGT	GGT	ACC	TAT	TCC	TGT
1871-75	AAA ACC	ATG CTG	ACA CGG	GGA TTT	ATA GCA	GGT AAC	ACC CCA	ACC	GCC	GCC	GCC	GCC	GCC
1871-78	GTA AAA	TGT ACT	AAG CAC	CCA ACA	CAA TGT	GGG CCA	GGT	GGG	GGA	GGC	GGG	GGG	GAC
1871-79	AGT ACA	TTT TAC	GTC CCA	CCC GGT	CCC CAG	GCC CGG	TCC GCC	CCC	ACC	CCC	TTG	TGG	CTT

The 8 oligonucleotides were annealed to form the duplex encoding an amino acid sequence (SEQ ID NOS: 416 and 417, respectively) shown below:

a

```
TTTTTATCGATTGATTCTAGATTGAGTTTAACTTTTAGAAGGAGGAATAAAATATG  
-----+-----+-----+-----+-----+-----+-----+  
1 AAAAAATAGCTAAACTAAGATCTAAACTCAAAATTGAAAATCTTCCTCCTTATTTTATAC 60  
M
```

```

      GGAGGTACTTACTCTTGCCACTTCGGCCCCGCTGACTTGGGTTTGCAAACCGCAGGGTGGC
5   a  61  -----+-----+-----+-----+-----+-----+-----+-----+ 120
      CCTCCATGAATGAGAACGGTGAAGCCGGGCGACTGAACCCAAACGTTTGGCGTCCCACCG
      G G T Y S C H F G P L T W V C K P Q G G -
      GCGGCGGCGGCGGTGGTACCTATTCTGTCATTTTGGCCCGCTGACCTGGGTATGTAAG
10  a  121 -----+-----+-----+-----+-----+-----+-----+ 180
      CCGCCGCCGCGCCACCATGGATAAGGACAGTAAAACCGGCGACTGGACCCATACATTC
      G G G G G G T Y S C H F G P L T W V C K -
      CCACAAGGGGGTGGGGGAGGCGGGGGGGACAAACTCACACATGTCCA
15  a  181 -----+-----+-----+-----+-----+-----+ 228
      GGTGTTCCCCCACCCTCCGCCCCCTGTTTGA
      P Q G G G G G G G D K T H T C P -

```

This duplex was amplified in a PCR reaction using 1869-23 and 1871-79 (shown above) as the sense and antisense primers.

The Fc portion of the molecule was generated in a PCR reaction with strain 3688 DNA using the primers 1798-23 and 1200-54 (shown above).

The oligonucleotides 1871-79 and 1798-23 contain an overlap of 31 nucleotides, allowing the two genes to be fused together in the correct reading frame by combining the above PCR products in a third reaction using the outside primers, 1869-23 and 1200-54.

The final PCR gene product (the full length fusion gene) was digested with restriction endonucleases XbaI and BamHI, and then ligated into the vector pAMG21 and transformed into competent E. coli strain 2596 cells as described for Fc-EMP. Clones were screened for ability to produce the recombinant protein product and possession of the gene fusion having the correct nucleotide sequence. A single such clone was selected and designated Amgen strain #3813.

The nucleotide and amino acid sequences (SEQ ID NOS: 19 and 20, respectively) of the resulting fusion protein are shown in Figure 15. There is a silent mutation at position 145 (A to G, shown in boldface) such that the final construct has a different nucleotide sequence than the oligonucleotide 1871-72 from which it was derived.

Fc-EMP-EMP. A DNA sequence coding for the Fc region of human IgG1 fused in-frame to a dimer of the EPO-mimetic peptide was

constructed using standard PCR technology. Templates for PCR reactions were the plasmids from strains 3688 and 3813 above.

The Fc portion of the molecule was generated in a PCR reaction with strain 3688 DNA using the primers 1216-52 and 1798-17 (shown above). The EMP dimer portion of the molecule was the product of a second PCR reaction with strain 3813 DNA using the primers 1798-18 (also shown above) and SEQ ID NO: 418, shown below:

1798-20 CTA ATT GGA TCC TCG AGA TTA ACC CCC TTG TGG CTT ACAT

The oligonucleotides 1798-17 and 1798-18 contain an overlap of 61 nucleotides, allowing the two genes to be fused together in the correct reading frame by combining the above PCR products in a third reaction using the outside primers, 1216-52 and 1798-20.

The final PCR gene product (the full length fusion gene) was digested with restriction endonucleases XbaI and BamHI, and then ligated into the vector pAMG21 and transformed into competent E. coli strain 2596 cells as described for Fc-EMP. Clones were screened for the ability to produce the recombinant protein product and to possess the gene fusion having the correct nucleotide sequence. A single such clone was selected and designated Amgen strain #3822.

The nucleotide and amino acid sequences (SEQ ID NOS:21 and 22 respectively) of the fusion protein are shown in Figure 16.

Characterization of Fc-EMP activity. Characterization was carried out in vivo as follows.

Mice: Normal female BDF1 approximately 10-12 weeks of age.

Bleed schedule: Ten mice per group treated on day 0, two groups started 4 days apart for a total of 20 mice per group. Five mice bled at each time point, mice were bled a maximum of three times a week. Mice were anesthetized with isoflurane and a total volume of 140-160 ml of blood was obtained by puncture of the orbital sinus. Blood was counted

on a Technicon H1E blood analyzer running software for murine blood. Parameters measured were WBC, RBC, HCT, HGB, PLT, NEUT, LYMPH.

Treatments: Mice were either injected subcutaneously for a bolus treatment or implanted with 7 day micro-osmotic pumps for continuous delivery. Subcutaneous injections were delivered in a volume of 0.2 ml. Osmotic pumps were inserted into a subcutaneous incision made in the skin between the scapulae of anesthetized mice. Compounds were diluted in PBS with 0.1% BSA. All experiments included one control group, labeled "carrier" that were treated with this diluent only. The concentration of the test articles in the pumps was adjusted so that the calibrated flow rate from the pumps gave the treatment levels indicated in the graphs.

Experiments: Various Fc-conjugated EPO mimetic peptides (EMPs) were delivered to mice as a single bolus injection at a dose of 100 µg/kg. Fc-EMPs were delivered to mice in 7-day micro-osmotic pumps. The pumps were not replaced at the end of 7 days. Mice were bled until day 51 when HGB and HCT returned to baseline levels.

Example 4

TNF-α inhibitors

Fc-TNF-α inhibitors. A DNA sequence coding for the Fc region of human IgG1 fused in-frame to a monomer of the TNF-α inhibitory peptide was constructed using standard PCR technology. The Fc and 5 glycine linker portion of the molecule was generated in a PCR reaction with DNA from the Fc-EMP fusion strain #3718 (see Example 3) using the sense primer 1216-52 and the antisense primer 2295-89 (SEQ ID NOS: 369 and 1112, respectively). The nucleotides encoding the TNF-α inhibitory peptide were provided by the PCR primer 2295-89 shown below:

1216-52	AAC ATA AGT ACC TGT AGG ATC G
2295-89	CCG CGG ATC CAT TAC GGA CGG TGA CCC AGA GAG GTG TTT TTG TAG

TGC GGC AGG AAG TCA CCA CCA CCT CCA CCT TTA CCC

The oligonucleotide 2295-89 overlaps the glycine linker and Fc portion of the template by 22 nucleotides, with the PCR resulting in the two genes
5 being fused together in the correct reading frame.

The PCR gene product (the full length fusion gene) was digested with restriction endonucleases NdeI and BamHI, and then ligated into the vector pAMG21 and transformed into competent E. coli strain 2596 cells as described for EMP-Fc herein. Clones were screened for the ability to
10 produce the recombinant protein product and to possess the gene fusion having the correct nucleotide sequence. A single such clone was selected and designated Amgen strain #4544.

The nucleotide and amino acid sequences (SEQ ID NOS: 1055 and 1056) of the fusion protein are shown in Figures 19A and 19B.

15 TNF- α inhibitor-Fc. A DNA sequence coding for a TNF- α inhibitory peptide fused in-frame to the Fc region of human IgG1 was constructed using standard PCR technology. The template for the PCR reaction was a plasmid containing an unrelated peptide fused via a five glycine linker to Fc. The nucleotides encoding the TNF- α inhibitory peptide were
20 provided by the sense PCR primer 2295-88, with primer 1200-54 serving as the antisense primer (SEQ ID NOS: 1117 and 407, respectively). The primer sequences are shown below:

25 2295-88 GAA TAA CAT ATG GAC TTC CTG CCG CAC TAC AAA AAC ACC TCT CTG GGT
CAC CGT CCG GGT GGA GGC GGT GGG GAC AAA ACT

30 1200-54 GTT ATT GCT CAG CGG TGG CA

The oligonucleotide 2295-88 overlaps the glycine linker and Fc portion of the template by 24 nucleotides, with the PCR resulting in the two genes being fused together in the correct reading frame.

The PCR gene product (the full length fusion gene) was digested with restriction endonucleases NdeI and BamHI, and then ligated into the vector pAMG21 and transformed into competent E. coli strain 2596 cells as described for EMP-Fc herein. Clones were screened for the ability to
5 produce the recombinant protein product and to possess the gene fusion having the correct nucleotide sequence. A single such clone was selected and designated Amgen strain #4543.

The nucleotide and amino acid sequences (SEQ ID NOS: 1057 and 1058) of the fusion protein are shown in Figures 20A and 20B.

10 Expression in E. coli. Cultures of each of the pAMG21-Fc-fusion constructs in E. coli GM221 were grown at 37 °C in Luria Broth medium containing 50 mg/ml kanamycin. Induction of gene product expression from the luxPR promoter was achieved following the addition of the synthetic autoinducer N-(3-oxohexanoyl)-DL-homoserine lactone to the
15 culture media to a final concentration of 20 ng/ml. Cultures were incubated at 37 °C for a further 3 hours. After 3 hours, the bacterial cultures were examined by microscopy for the presence of inclusion bodies and were then collected by centrifugation. Refractile inclusion bodies were observed in induced cultures indicating that the Fc-fusions
20 were most likely produced in the insoluble fraction in E. coli. Cell pellets were lysed directly by resuspension in Laemmli sample buffer containing 10% β -mercaptoethanol and were analyzed by SDS-PAGE. In each case, an intense coomassie-stained band of the appropriate molecular weight was observed on an SDS-PAGE gel.

25 Purification of Fc-peptide fusion proteins. Cells are broken in water (1/10) by high pressure homogenization (2 passes at 14,000 PSI) and inclusion bodies are harvested by centrifugation (4200 RPM in J-6B for 1 hour). Inclusion bodies are solubilized in 6M guanidine, 50mM Tris, 8mM DTT, pH 8.7 for 1 hour at a 1/10 ratio. The solubilized mixture is diluted

20 times into 2M urea, 50 mM tris, 160mM arginine, 3mM cysteine, pH 8.5. The mixture is stirred overnight in the cold and then concentrated about 10 fold by ultrafiltration. It is then diluted 3 fold with 10mM Tris, 1.5M urea, pH 9. The pH of this mixture is then adjusted to pH 5 with acetic acid. The precipitate is removed by centrifugation and the supernatant is loaded onto a SP-Sepharose Fast Flow column equilibrated in 20mM NaAc, 100 mM NaCl, pH 5 (10mg/ml protein load, room temperature). The protein is eluted from the column using a 20 column volume gradient in the same buffer ranging from 100mM NaCl to 500mM NaCl. The pool from the column is diluted 3 fold and loaded onto a SP-Sepharose HP column in 20mM NaAc, 150mM NaCl, pH 5 (10mg/ml protein load, room temperature). The protein is eluted using a 20 column volume gradient in the same buffer ranging from 150mM NaCl to 400mM NaCl. The peak is pooled and filtered.

Characterization of activity of Fc-TNF- α inhibitor and TNF- α inhibitor -Fc. Binding of these peptide fusion proteins to TNF- α can be characterized by BIAcore by methods available to one of ordinary skill in the art who is armed with the teachings of the present specification.

Example 5

IL-1 Antagonists

Fc-IL-1 antagonist. A DNA sequence coding for the Fc region of human IgG1 fused in-frame to a monomer of an IL-1 antagonist peptide was constructed using standard PCR technology. The Fc and 5 glycine linker portion of the molecule was generated in a PCR reaction with DNA from the Fc-EMP fusion strain #3718 (see Example 3) using the sense primer 1216-52 and the antisense primer 2269-70 (SEQ ID NOS: 369 and 1118, respectively). The nucleotides encoding the IL-1 antagonist peptide were provided by the PCR primer 2269-70 shown below:

1216-52 AAC ATA AGT ACC TGT AGG ATC G
 2269-70 CCG CGG ATC CAT TAC AGC GGC AGA GCG TAC GGC TGC CAG TAA CCC
 GGG GTC CAT TCG AAA CCA CCA CCT CCA CCT TTA CCC

5

The oligonucleotide 2269-70 overlaps the glycine linker and Fc portion of the template by 22 nucleotides, with the PCR resulting in the two genes being fused together in the correct reading frame.

10 The PCR gene product (the full length fusion gene) was digested with restriction endonucleases NdeI and BamHI, and then ligated into the vector pAMG21 and transformed into competent E. coli strain 2596 cells as described for EMP-Fc herein. Clones were screened for the ability to produce the recombinant protein product and to possess the gene fusion
 15 having the correct nucleotide sequence. A single such clone was selected and designated Amgen strain #4506.

The nucleotide and amino acid sequences (SEQ ID NOS: 1059 and 1060) of the fusion protein are shown in Figures 21A and 21B.

20 IL-1 antagonist-Fc. A DNA sequence coding for an IL-1 antagonist peptide fused in-frame to the Fc region of human IgG1 was constructed using standard PCR technology. The template for the PCR reaction was a plasmid containing an unrelated peptide fused via a five glycine linker to Fc. The nucleotides encoding the IL-1 antagonist peptide were provided by the sense PCR primer 2269-69, with primer 1200-54 serving as the
 25 antisense primer (SEQ ID NOS: 1119 and 407, respectively). The primer sequences are shown below:

30 2269-69 GAA TAA CAT ATG TTC GAA TGG ACC CCG GGT TAC TGG CAG CCG TAC GCT
 CTG CCG CTG GGT GGA GGC GGT GGG GAC AAA ACT
 1200-54 GTT ATT GCT CAG CGG TGG CA

The oligonucleotide 2269-69 overlaps the glycine linker and Fc portion of the template by 24 nucleotides, with the PCR resulting in the two genes being fused together in the correct reading frame.

5 The PCR gene product (the full length fusion gene) was digested with restriction endonucleases NdeI and BamHI, and then ligated into the vector pAMG21 and transformed into competent E. coli strain 2596 cells as described for EMP-Fc herein. Clones were screened for the ability to produce the recombinant protein product and to possess the gene fusion
10 having the correct nucleotide sequence. A single such clone was selected and designated Amgen strain #4505.

The nucleotide and amino acid sequences (SEQ ID NOS: 1061 and 1062) of the fusion protein are shown in Figures 22A and 22B. Expression and purification were carried out as in previous examples.

15 Characterization of Fc-IL-1 antagonist peptide and IL-1 antagonist peptide-Fc activity. IL-1 Receptor Binding competition between IL-1 β , IL-1RA and Fc-conjugated IL-1 peptide sequences was carried out using the IGEN system. Reactions contained 0.4 nM biotin-IL-1R + 15 nM IL-1-TAG + 3 uM competitor + 20 ug/ml streptavidin-conjugate beads, where
20 competitors were IL-1RA, Fc-IL-1 antagonist, IL-1 antagonist-Fc). Competition was assayed over a range of competitor concentrations from 3 uM to 1.5 pM. The results are shown in Table C below:

Table C—Results from IL-1 Receptor Binding Competition Assay

		<i>IL-1pep-Fc</i>	<i>Fc-IL-1pep</i>	<i>IL-1ra</i>
5	KI	281.5	59.58	1.405
	EC50	530.0	112.2	2.645
	95% Confidence Intervals			
10	EC50	280.2 to 1002	54.75 to 229.8	1.149 to 6.086
	KI	148.9 to 532.5	29.08 to 122.1	0.6106 to 3.233
15	Goodness of Fit			
	R²	0.9790	0.9687	0.9602

Example 6

VEGF-Antagonists

Fc-VEGF Antagonist. A DNA sequence coding for the Fc region of human IgG1 fused in-frame to a monomer of the VEGF mimetic peptide was constructed using standard PCR technology. The templates for the PCR reaction were the pFc-A3 plasmid and a synthetic VEGF mimetic peptide gene. The synthetic gene was assembled by annealing the following two oligonucleotides primer (SEQ ID NOS: 1110 and 1111, respectively):

2293-11 GTT GAA CCG AAC TGT GAC ATC CAT GTT ATG TGG GAA TGG GAA
TGT TTT GAA CGT CTG

2293-12 CAG ACG TTC AAA ACA TTC CCA TTC CCA CAT AAC ATG GAT GTC
ACA GTT CGG TTC AAC

The two oligonucleotides anneal to form the following duplex encoding an amino acid sequence shown below (SEQ ID NOS 1113 and 1114):

1 GTTGAACCGAACTGTGACATCCATGTTATGTGGGAATGGGAATGTTTTGAACGTCTG
CAACTTGGCTTGACACTGTAGGTACAATACACCCTTACCCTTACAAAACCTTGCAGAC

25 a V E P N C D I H V M W E W E C F E R L

This duplex was amplified in a PCR reaction using 2293-05 and 2293-06 as the sense and antisense primers (SEQ ID NOS. 1122 and 1123).

30 The Fc portion of the molecule was generated in a PCR reaction with the pFc-A3 plasmid using the primers 2293-03 and 2293-04 as the sense and antisense primers (SEQ ID NOS. 1120 and 1121, respectively). The full length fusion gene was obtained from a third PCR reaction using the outside primers 2293-03 and 2293-06. These primers are shown below:

2293-03 ATT TGA TTC TAG AAG GAG GAA TAA CAT ATG GAC AAA ACT CAC
ACA TGT

5 2293-04 GTC ACA GTT CGG TTC AAC ACC ACC ACC ACC ACC TTT ACC CGG
AGA CAG GGA

2293-05 TCC CTG TCT CCG GGT AAA GGT GGT GGT GGT GGT GTT GAA CCG
AAC TGT GAC ATC

10

2293-06 CCG CGG ATC CTC GAG TTA CAG ACG TTC AAA ACA TTC CCA

The PCR gene product (the full length fusion gene) was digested with restriction endonucleases NdeI and BamHI, and then ligated into the vector pAMG21 and transformed into competent E. coli strain 2596 cells as described for EMP-Fc herein. Clones were screened for the ability to produce the recombinant protein product and to possess the gene fusion having the correct nucleotide sequence. A single such clone was selected and designated Amgen strain #4523.

20 The nucleotide and amino acid sequences (SEQ ID NOS: 1063 and 1064) of the fusion protein are shown in Figures 23A and 23B.

VEGF antagonist -Fc. A DNA sequence coding for a VEGF mimetic peptide fused in-frame to the Fc region of human IgG1 was constructed using standard PCR technology. The templates for the PCR reaction were the pFc-A3 plasmid and the synthetic VEGF mimetic peptide gene described above. The synthetic duplex was amplified in a PCR reaction using 2293-07 and 2293-08 as the sense and antisense primers (SEQ ID NOS. 1124 and 1125, respectively).

30 The Fc portion of the molecule was generated in a PCR reaction with the pFc-A3 plasmid using the primers 2293-09 and 2293-10 as the sense and antisense primers (SEQ ID NOS. 1126 and 1127, respectively).

The full length fusion gene was obtained from a third PCR reaction using the outside primers 2293-07 and 2293-10. These primers are shown below:

5 2293-07 ATT TGA TTC TAG AAG GAG GAA TAA CAT ATG GTT GAA CCG AAC
 TGT GAC

2293-08 ACA TGT GTG AGT TTT GTC ACC ACC ACC ACC ACC CAG ACG TTC
 AAA ACA TTC

10 2293-09 GAA TGT TTT GAA CGT CTG GGT GGT GGT GGT GGT GAC AAA ACT
 CAC ACA TGT

2293-10 CCG CGG ATC CTC GAG TTA TTT ACC CGG AGA CAG GGA GAG

15 The PCR gene product (the full length fusion gene) was digested
with restriction endonucleases NdeI and BamHI, and then ligated into the
vector pAMG21 and transformed into competent E. coli strain 2596 cells as
described for EMP-Fc herein. Clones were screened for the ability to
produce the recombinant protein product and to possess the gene fusion
having the correct nucleotide sequence. A single such clone was selected
20 and designated Amgen strain #4524.

The nucleotide and amino acid sequences (SEQ ID NOS: 1065 and
1066) of the fusion protein are shown in Figures 24A and 24B. Expression
and purification were carried out as in previous examples.

25

Example 7

MMP Inhibitors

Fc-MMP inhibitor. A DNA sequence coding for the Fc region of
human IgG1 fused in-frame to a monomer of an MMP inhibitory peptide
was constructed using standard PCR technology. The Fc and 5 glycine
30 linker portion of the molecule was generated in a PCR reaction with DNA
from the Fc-TNF- α inhibitor fusion strain #4544 (see Example 4) using the
sense primer 1216-52 and the antisense primer 2308-67 (SEQ ID NOS: 369

and 1115 respectively). The nucleotides encoding the MMP inhibitor peptide were provided by the PCR primer 2308-67 shown below:

5 1216-52 AAC ATA AGT ACC TGT AGG ATC G
 2308-67 CCG CGG ATC CAT TAG CAC AGG GTG AAA CCC CAG TGG GTG GTG
 CAA CCA CCA CCT CCA CCT TTA CCC

10 The oligonucleotide 2308-67 overlaps the glycine linker and Fc portion of the template by 22 nucleotides, with the PCR resulting in the two genes being fused together in the correct reading frame.

15 The PCR gene product (the full length fusion gene) was digested with restriction endonucleases NdeI and BamHI, and then ligated into the vector pAMG21 and transformed into competent E. coli strain 2596 cells as described for EMP-Fc herein. Clones were screened for the ability to produce the recombinant protein product and to possess the gene fusion having the correct nucleotide sequence. A single such clone was selected and designated Amgen strain #4597.

20 The nucleotide and amino acid sequences (SEQ ID NOS: 1067 and 1068) of the fusion protein are shown in Figures 25A and 25B. Expression and purification were carried out as in previous examples.

25 MMP Inhibitor-Fc. A DNA sequence coding for an MMP inhibitory peptide fused in-frame to the Fc region of human IgG1 was constructed using standard PCR technology. The Fc and 5 glycine linker portion of the molecule was generated in a PCR reaction with DNA from the Fc-TNF- α inhibitor fusion strain #4543 (see Example 4). The nucleotides encoding the MMP inhibitory peptide were provided by the sense PCR primer 2308-66, with primer 1200-54 serving as the antisense primer (SEQ ID NOS: 1116 and 407, respectively). The primer sequences are shown below:

30
35 2308-66 GAA TAA CAT ATG TGC ACC ACC CAC TGG GGT TTC ACC CTG TGC
 GGT GGA GGC GGT GGG GAC AAA
 1200-54 GTT ATT GCT CAG CGG TGG CA

The oligonucleotide 2269-69 overlaps the glycine linker and Fc portion of the template by 24 nucleotides, with the PCR resulting in the two genes being fused together in the correct reading frame.

5 The PCR gene product (the full length fusion gene) was digested with restriction endonucleases NdeI and BamHI, and then ligated into the vector pAMG21 and transformed into competent E. coli strain 2596 cells as described for EMP-Fc herein. Clones were screened for the ability to produce the recombinant protein product and to possess the gene fusion
10 having the correct nucleotide sequence. A single such clone was selected and designated Amgen strain #4598.

The nucleotide and amino acid sequences (SEQ ID NOS: 1069 and 1070) of the fusion protein are shown in Figures 26A and 26B.

* * *

15 The invention now being fully described, it will be apparent to one
of ordinary skill in the art that many changes and modifications can be
made thereto, without departing from the spirit and scope of the invention
as set forth herein.

20 **Abbreviations**

Abbreviations used throughout this specification are as defined below, unless otherwise defined in specific circumstances.

Ac	acetyl (used to refer to acetylated residues)
AcBpa	acetylated p-benzoyl-L-phenylalanine
ADCC	antibody-dependent cellular cytotoxicity
Aib	aminoisobutyric acid
bA	beta-alanine
Bpa	p-benzoyl-L-phenylalanine
BrAc	bromoacetyl ($\text{BrCH}_2\text{C}(\text{O})$)

	BSA	Bovine serum albumin
	Bzl	Benzyl
	Cap	Caproic acid
	CTL	Cytotoxic T lymphocytes
5	CTLA4	Cytotoxic T lymphocyte antigen 4
	DARC	Duffy blood group antigen receptor
	DCC	Dicyclohexylcarbodiimide
	Dde	1-(4,4-dimethyl-2,6-dioxo-cyclohexylidene)ethyl
	EMP	Erythropoietin-mimetic peptide
10	ESI-MS	Electron spray ionization mass spectrometry
	EPO	Erythropoietin
	Fmoc	fluorenylmethoxycarbonyl
	G-CSF	Granulocyte colony stimulating factor
	GH	Growth hormone
15	HCT	hematocrit
	HGB	hemoglobin
	hGH	Human growth hormone
	HOBt	1-Hydroxybenzotriazole
	HPLC	high performance liquid chromatography
20	IL	interleukin
	IL-R	interleukin receptor
	IL-1R	interleukin-1 receptor
	IL-1ra	interleukin-1 receptor antagonist
	Lau	Lauric acid
25	LPS	lipopolysaccharide
	LYMPH	lymphocytes
	MALDI-MS	Matrix-assisted laser desorption ionization mass spectrometry
	Me	methyl

	MeO	methoxy
	MHC	major histocompatibility complex
	MMP	matrix metalloproteinase
	MMPI	matrix metalloproteinase inhibitor
5	1-Nap	1-naphthylalanine
	NEUT	neutrophils
	NGF	nerve growth factor
	Nle	norleucine
	NMP	N-methyl-2-pyrrolidinone
10	PAGE	polyacrylamide gel electrophoresis
	PBS	Phosphate-buffered saline
	Pbf	2,2,4,6,7-pendamethyldihydrobenzofuran-5-sulfonyl
	PCR	polymerase chain reaction
	Pec	pipecolic acid
15	PEG	Poly(ethylene glycol)
	pGlu	pyroglutamic acid
	Pic	picolinic acid
	PLT	platelets
	pY	phosphotyrosine
20	RBC	red blood cells
	RBS	ribosome binding site
	RT	room temperature (25 °C)
	Sar	sarcosine
	SDS	sodium dodecyl sulfate
25	STK	serine-threonine kinases
	t-Boc	tert-Butoxycarbonyl
	tBu	tert-Butyl
	TGF	tissue growth factor
	THF	thymic humoral factor

	TK	tyrosine kinase
	TMP	Thrombopoietin-mimetic peptide
	TNF	Tissue necrosis factor
	TPO	Thrombopoietin
5	TRAIL	TNF-related apoptosis-inducing ligand
	Trt	trityl
	UK	urokinase
	UKR	urokinase receptor
	VEGF	vascular endothelial cell growth factor
10	VIP	vasoactive intestinal peptide
	WBC	white blood cells

EDITORIAL NOTE

APPLICATION NUMBER - 12322/00

The following Sequence Listing pages 1 to 460 are part of the description. The claims pages follow on pages 129 to 134.

A-527 PCT.ST25.txt
SEQUENCE LISTING

<110> AMGEN INC.

<120> MODIFIED PEPTIDES AS THERAPEUTIC AGENTS

<130> A-527

<140> PCT/US 99/25044

<141> 1999-10-25

<150> US 09/428,082

<151> 1999-10-22

<150> US 60/105,371

<151> 1998-10-23

<160> 1133

••••• <170> PatentIn version 3.1

••••• <210> 1

••••• <211> 684

••••• <212> DNA

<213> HUMAN

<220>

••••• <221> CDS

••••• <222> (1)..(684)

••••• <223>

••••• <400> 1

atg gac aaa act cac aca tgt cca cct tgt cca gct ccg gaa ctc ctg
Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
1 5 10 15

48

ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc ctc
Page 1

96

[illegible]

<400> 2

A-527 PCT.ST25.txt

Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
1 5 10 15

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
20 25 30

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
35 40 45

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
50 55 60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
65 70 75 80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
85 90 95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
100 105 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
145 150 155 160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
180 185 190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
210 215 220

Ser Pro Gly Lys
225

<210> 3

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> SYNTHETIC SCHEME FOR PREPARATION OF PEGYLATED PEPTIDE

<220>

<221> misc_feature

<222> (18)..(18)

<223> Methoxy-polyethylene glycol (5000 Dalton)-sulfoacetyl group attached to the sidechain.

<400> 3

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30


Ala Ala Arg Ala
35

<210> 4

<211> 36

<212> PRT

<213> Artificial Sequence



<220>


<223> SYNTHETIC SCHEME FOR PREPARATION OF PEGYLATED PEPTIDE

<220>

<221> misc_feature

<222> (18)..(18)

<223> Methoxy-polyethylene glycol (5000 Dalton)-succinimidyl group attached to the sidechain.



<400> 4

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Cys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210>	5
<211>	794
<212>	DNA
<213>	Artificial Sequence

<220>
<223> FC-TMP
<220>
<221> CDS
<222> (39) .. (779)
<223>

<400> 5																
tctagatttg	ttttaactaa	ttaaaggagg	aataacat	atg	gac	aaa	act	cac	aca							56
				Met	Asp	Lys	Thr	His	Thr							
				1				5								
tgt	cca	cct	tgt	cca	gct	ccg	gaa	ctc	ctg	ggg	gga	ccg	tca	gtc	ttc	104
Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	
			10					15					20			
ctc	ttc	ccc	cca	aaa	ccc	aag	gac	acc	ctc	atg	atc	tcc	cgg	acc	cct	152
Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	
		25					30					35				
gag	gtc	aca	tgc	gtg	gtg	gtg	gac	gtg	agc	cac	gaa	gac	cct	gag	gtc	200
Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	
	40					45					50					
aag	ttc	aac	tgg	tac	gtg	gac	ggc	gtg	gag	gtg	cat	aat	gcc	aag	aca	248
Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	
55					60					65					70	
aag	ccg	cgg	gag	gag	cag	tac	aac	agc	acg	tac	cgt	gtg	gtc	agc	gtc	296
Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	
				75					80					85		
ctc	acc	gtc	ctg	cac	cag	gac	tgg	ctg	aat	ggc	aag	gag	tac	aag	tgc	344
Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	
			90					95					100			
aag	gtc	tcc	aac	aaa	gcc	ctc	cca	gcc	ccc	atc	gag	aaa	acc	atc	tcc	392
Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	
		105					110					115				
aaa	gcc	aaa	ggg	cag	ccc	cga	gaa	cca	cag	gtg	tac	acc	ctg	ccc	cca	440
Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	
	120					125					130					
tcc	cgg	gat	gag	ctg	acc	aag	aac	cag	gtc	agc	ctg	acc	tgc	ctg	gtc	488
Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	
135					140					145					150	
aaa	ggc	ttc	tat	ccc	agc	gac	atc	gcc	gtg	gag	tgg	gag	agc	aat	ggg	536

A-527 PCT.ST25.txt

Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	
				155					160					165		
cag	ccg	gag	aac	aac	tac	aag	acc	acg	cct	ccc	gtg	ctg	gac	tcc	gac	584
Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	
			170					175					180			
ggc	tcc	ttc	ttc	ctc	tac	agc	aag	ctc	acc	gtg	gac	aag	agc	agg	tgg	632
Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	
		185					190					195				
cag	cag	ggg	aac	gtc	ttc	tca	tgc	tcc	gtg	atg	cat	gag	gct	ctg	cac	680
Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	
	200					205					210					
aac	cac	tac	acg	cag	aag	agc	ctc	tcc	ctg	tct	ccg	ggt	aaa	ggt	gga	728
Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys	Gly	Gly	
215					220				225						230	
ggt	ggt	ggt	atc	gaa	ggt	ccg	act	ctg	cgt	cag	tgg	ctg	gct	gct	cgt	776
Gly	Gly	Gly	Ile	Glu	Gly	Pro	Thr	Leu	Arg	Gln	Trp	Leu	Ala	Ala	Arg	
			235					240						245		
gct	taatctcgag	gatcc														794
Ala																

<210> 6

<211> 247

<212> PRT

<213> Artificial Sequence

<220>

<223> FC-TMP

<400> 6

Met	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu
1				5					10					15	

Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu
		20					25					30			

Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser
		35					40					45			

His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu
	50					55					60				

Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr
65					70				75						80

Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn
				85					90					95	

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
 100 105 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
 115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
 130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
 145 150 155 160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
 165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
 180 185 190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
 195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
 210 215 220

Ser Pro Gly Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg
 225 230 235 240

Gln Trp Leu Ala Ala Arg Ala
 245

.
 <210> 7
 <211> 861
 <212> DNA
 <213> Artificial Sequence

<220>

<223> FC-TMP-TMP

. <220>
 <221> CDS
 <222> (39)..(842)
 <223>

.
 <400> 7

tctagatttg ttttaactaa ttaaaggagg aataacat atg gac aaa act cac aca
 Met Asp Lys Thr His Thr
 1 5

56

A-527 PCT.ST25.txt

	tgt	cca	cct	tgt	cca	gct	ccg	gaa	ctc	ctg	ggg	gga	ccg	tca	gtc	ttc	104
	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	
				10					15					20			
	ctc	ttc	ccc	cca	aaa	ccc	aag	gac	acc	ctc	atg	atc	tcc	cgg	acc	cct	152
	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	
			25					30					35				
	gag	gtc	aca	tgc	gtg	gtg	gtg	gac	gtg	agc	cac	gaa	gac	cct	gag	gtc	200
	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	
		40					45					50					
	aag	ttc	aac	tgg	tac	gtg	gac	ggc	gtg	gag	gtg	cat	aat	gcc	aag	aca	248
	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	
	55					60				65						70	
	aag	ccg	cgg	gag	gag	cag	tac	aac	agc	acg	tac	cgt	gtg	gtc	agc	gtc	296
	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	
					75					80					85		
	ctc	acc	gtc	ctg	cac	cag	gac	tgg	ctg	aat	ggc	aag	gag	tac	aag	tgc	344
	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	
				90					95					100			
	aag	gtc	tcc	aac	aaa	gcc	ctc	cca	gcc	ccc	atc	gag	aaa	acc	atc	tcc	392
	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	
			105					110					115				
	aaa	gcc	aaa	ggg	cag	ccc	cga	gaa	cca	cag	gtg	tac	acc	ctg	ccc	cca	440
	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	
		120					125					130					
	tcc	cgg	gat	gag	ctg	acc	aag	aac	cag	gtc	agc	ctg	acc	tgc	ctg	gtc	488
	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	
	135					140					145					150	
...	aaa	ggc	ttc	tat	ccc	agc	gac	atc	gcc	gtg	gag	tgg	gag	agc	aat	ggg	536
...	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	
...					155					160					165		
...	cag	ccg	gag	aac	aac	tac	aag	acc	acg	cct	ccc	gtg	ctg	gac	tcc	gac	584
...	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	
...				170						175				180			
...	ggc	tcc	ttc	ttc	ctc	tac	agc	aag	ctc	acc	gtg	gac	aag	agc	agg	tgg	632
...	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	
...			185					190					195				
	cag	cag	ggg	aac	gtc	ttc	tca	tgc	tcc	gtg	atg	cat	gag	gct	ctg	cac	680
	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	
		200					205					210					
...	aac	cac	tac	acg	cag	aag	agc	ctc	tcc	ctg	tct	ccg	ggt	aaa	ggt	gga	728
...	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys	Gly	Gly	
...	215					220					225					230	
...	ggt	ggt	ggt	atc	gaa	ggt	ccg	act	ctg	cgt	cag	tgg	ctg	gct	gct	cgt	776
...	Gly	Gly	Gly	Ile	Glu	Gly	Pro	Thr	Leu	Arg	Gln	Trp	Leu	Ala	Ala	Arg	
...					235					240					245		
...	gct	ggt	ggt	gga	ggt	ggc	ggc	gga	ggt	att	gag	ggc	cca	acc	ctt	cgc	824
...	Ala	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Ile	Glu	Gly	Pro	Thr	Leu	Arg	
...				250					255					260			
	caa	tgg	ctt	gca	gca	cgc	gcataatctc	gaggatccg									861
	Gln	Trp	Leu	Ala	Ala	Arg											
			265														

<210> 8
 <211> 268
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> FC-TMP-TMP
 <400> 8

Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
 1 5 10 15

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
 20 25 30

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
 35 40 45

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
 50 55 60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
 65 70 75 80

•••• Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
 85 90 95

•••• Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
 100 105 110

•••• Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
 115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
 130 135 140

•••• Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
 145 150 155 160

•••• Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
 165 170 175

•••• Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
 180 185 190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
 195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
 210 215 220

Ser Pro Gly Lys Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg
 225 230 235 240

Gln Trp Leu Ala Ala Arg Ala Gly Gly Gly Gly Gly Gly Gly Ile
 245 250 255

Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg
 260 265

<210> 9

<211> 855

<212> DNA

<213> Artificial Sequence

<220>

<223> TMP-TMP-Fc

<220>

<221> CDS

<222> (39)..(845)

<223>

<400> 9

tctagatttg ttttaactaa ttaaaggagg aataacat atg atc gaa ggt ccg act 56
 Met Ile Glu Gly Pro Thr
 1 5

ctg cgt cag tgg ctg gct gct cgt gct ggc ggt ggt ggc gga ggg ggt 104
 Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly Gly Gly Gly Gly Gly
 10 15 20

ggc att gag ggc cca acc ctt cgc caa tgg ctt gca gca cgc gca ggg 152
 Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly
 25 30 35

gga ggc ggt ggg gac aaa act cac aca tgt cca cct tgc cca gca cct 200
 Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Cys Pro Ala Pro
 40 45 50

gaa ctc ctg ggg gga ccg tca gtt ttc ctc ttc ccc cca aaa ccc aag 248
 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
 55 60 65 70

gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg 296
 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
 75 80 85

gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac 344
 Page 10

A-527 PCT.ST25.txt

Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp		
			90					95					100				
ggc	gtg	gag	gtg	cat	aat	gcc	aag	aca	aag	ccg	cgg	gag	gag	cag	tac	392	
Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr		
		105					110					115					
aac	agc	acg	tac	cgt	gtg	gtc	agc	gtc	ctc	acc	gtc	ctg	cac	cag	gac	440	
Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp		
	120					125					130						
tgg	ctg	aat	ggc	aag	gag	tac	aag	tgc	aag	gtc	tcc	aac	aaa	gcc	ctc	488	
Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu		
	135				140					145					150		
cca	gcc	ccc	atc	gag	aaa	acc	atc	tcc	aaa	gcc	aaa	ggg	cag	ccc	cga	536	
Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg		
				155					160					165			
gaa	cca	cag	gtg	tac	acc	ctg	ccc	cca	tcc	cgg	gat	gag	ctg	acc	aag	584	
Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys		
			170					175					180				
aac	cag	gtc	agc	ctg	acc	tgc	ctg	gtc	aaa	ggc	ttc	tat	ccc	agc	gac	632	
Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp		
		185					190					195					
atc	gcc	gtg	gag	tgg	gag	agc	aat	ggg	cag	ccg	gag	aac	aac	tac	aag	680	
Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys		
	200					205					210						
acc	acg	cct	ccc	gtg	ctg	gac	tcc	gac	ggc	tcc	ttc	ttc	ctc	tac	agc	728	
Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser		
	215				220				225						230		
aag	ctc	acc	gtg	gac	aag	agc	agg	tgg	cag	cag	ggg	aac	gtc	ttc	tca	776	
Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser		
				235					240					245			
tgc	tcc	gtg	atg	cat	gag	gct	ctg	cac	aac	cac	tac	acg	cag	aag	agc	824	
Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser		
			250					255					260				
ctc	tcc	ctg	tct	ccg	ggt	aaa	taatggatcc									855	
Leu	Ser	Leu	Ser	Pro	Gly	Lys											
		265															

<210> 10

<211> 269

<212> PRT

<213> Artificial Sequence

<220>

<223> TMP-TMP-FC

<400> 10

Met	Ile	Glu	Gly	Pro	Thr	Leu	Arg	Gln	Trp	Leu	Ala	Ala	Arg	Ala	Gly
1				5					10					15	

Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp
20 25 30

Leu Ala Ala Arg Ala Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys
35 40 45

Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
50 55 60

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
65 70 75 80

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
85 90 95

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
100 105 110

Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
115 120 125

Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
130 135 140

Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
145 150 155 160

Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
165 170 175

Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
180 185 190

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
195 200 205

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
210 215 220

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
225 230 235 240

Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
245 250 255

His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
260 265

<210> 11

<211> 789

<212> DNA

<213> Artificial Sequence

<220>

<223> TMP-FC

<220>

<221> CDS

<222> (39) .. (779)

<223>

<400> 11

tctagatttg ttttaactaa ttaaaggagg aataacat atg atc gaa ggt ccg act 56
Met Ile Glu Gly Pro Thr
1 5

ctg cgt cag tgg ctg gct gct cgt gct ggt gga ggc ggt ggg gac aaa 104
Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly Gly Gly Asp Lys
10 15 20

act cac aca tgt cca cct tgc cca gca cct gaa ctc ctg ggg gga ccg 152
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
25 30 35

tca gtt ttc ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc 200
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
40 45 50

••••• cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac 248
 ••••• Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
 ••••• 55 60 65 70

cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat 296
 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
 75 80 85

..... gcc aag aca aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg 344
 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
 90 95 100

gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag 392
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
105 110 115

:::: tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa 440
 :::: Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
 :::: 120 125 130

..... acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc 488
 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
 135 140 145 150

ctg ccc cca tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc 536
 Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
 155 160 165

tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag 584
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
170 175 180

A-527 PCT.ST25.txt

agc aat ggg cag ccg gag aac aac tac aag acc acg cct ccc gtg ctg	632
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu	
185 190 195	
gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag	680
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys	
200 205 210	
agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag	728
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu	
215 220 225 230	
gct ctg cac aac cac tac acg cag aag agc ctc tcc ctg tct ccg ggt	776
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly	
235 240 245	
aaa taatggatcc	789
Lys	

<210> 12

<211> 247

<212> PRT

<213> Artificial Sequence

<220>

<223> TMP-Fc

<400> 12

Met Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly
1 5 10 15
Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
20 25 30
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
35 40 45
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
50 55 60
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
65 70 75 80
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
85 90 95
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
100 105 110
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
115 120 125

Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
130 135 140

Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
145 150 155 160

Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
165 170 175

Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
180 185 190

Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
195 200 205

Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
210 215 220

Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
225 230 235 240

Leu Ser Leu Ser Pro Gly Lys
245

<210> 13

<211> 14

••••• <212> PRT

••••• <213> Artificial Sequence

•••••

••••• <220>

••••• <223> TMP

<400> 13

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
1 5 10

••••• <210> 14

••••• <211> 36

••••• <212> PRT

••••• <213> Artificial Sequence

•••••

••••• <220>

<223> TMP-TMP

<400> 14

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
 20 25 30

Ala Ala Arg Ala
 35

<210> 15

<211> 812

<212> DNA

<213> Artificial Sequence

<220>

<223> FC-EMP

<220>

<221> CDS

<222> (39)..(797)

<223>

```

<400> 15
tctagatttg ttttaactaa ttaaaggagg aataacat atg gac aaa act cac aca 56
                                         Met Asp Lys Thr His Thr
                                         1 5

tgt cca cct tgt cca gct ccg gaa ctc ctg ggg gga ccg tca gtc ttc 104
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
10 15 20

ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct 152
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
25 30 35

gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc 200
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
40 45 50

aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca 248
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
55 60 65 70

aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc 296
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
75 80 85


ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc 344
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
90 95 100

aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc 392

```

A-527 PCT.ST25.txt

Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	
		105					110					115				
aaa	gcc	aaa	ggg	cag	ccc	cga	gaa	cca	cag	gtg	tac	acc	ctg	ccc	cca	440
Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	
	120					125					130					
tcc	cgg	gat	gag	ctg	acc	aag	aac	cag	gtc	agc	ctg	acc	tgc	ctg	gtc	488
Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	
135					140					145					150	
aaa	ggc	ttc	tat	ccc	agc	gac	atc	gcc	gtg	gag	tgg	gag	agc	aat	ggg	536
Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	
				155					160					165		
cag	ccg	gag	aac	aac	tac	aag	acc	acg	cct	ccc	gtg	ctg	gac	tcc	gac	584
Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	
				170				175					180			
ggc	tcc	ttc	ttc	ctc	tac	agc	aag	ctc	acc	gtg	gac	aag	agc	agg	tgg	632
Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	
		185					190					195				
cag	cag	ggg	aac	gtc	ttc	tca	tgc	tcc	gtg	atg	cat	gag	gct	ctg	cac	680
Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	
	200					205					210					
aac	cac	tac	acg	cag	aag	agc	ctc	tcc	ctg	tct	ccg	ggt	aaa	ggt	gga	728
Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys	Gly	Gly	
215					220					225					230	
ggt	ggt	ggt	gga	ggt	act	tac	tct	tgc	cac	ttc	ggc	ccg	ctg	act	tgg	776
Gly	Gly	Gly	Gly	Gly	Thr	Tyr	Ser	Cys	His	Phe	Gly	Pro	Leu	Thr	Trp	
				235					240					245		
ggt	tgc	aaa	ccg	cag	ggt	ggt	taatctcgtg	gatcc								812
Val	Cys	Lys	Pro	Gln	Gly	Gly										
			250													




<210> 16
 <211> 253
 <212> PRT
 <213> Artificial Sequence

<220>

<223> FC-EMP

<400> 16



Met	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu
1				5					10					15	
Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu
			20					25					30		
Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser
		35					40					45			

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
50 55 60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
65 70 75 80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
85 90 95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
100 105 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
145 150 155 160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
180 185 190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
210 215 220

Ser Pro Gly Lys Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His
225 230 235 240

Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly
245 250

<210> 17

<211> 807

<212> DNA

<213> Artificial sequence

<220>

<223> EMP-Fc

<220>

<221> CDS

<222> (39)..(797)

<223>

<400> 17

tctagatttg ttttaactaa ttaaaggagg aataacat atg gga ggt act tac tct 56
 Met Gly Gly Thr Tyr Ser
 1 5

tgc cac ttc ggc ccg ctg act tgg gta tgt aag cca caa ggg ggt ggg 104
 Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly
 10 15 20

gga ggc ggg ggg gac aaa act cac aca tgt cca cct tgc cca gca cct 152
 Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
 25 30 35

gaa ctc ctg ggg gga ccg tca gtt ttc ctc ttc ccc cca aaa ccc aag 200
 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Lys Pro Lys
 40 45 50

gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg 248
 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
 55 60 65 70

gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac 296
 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
 75 80 85

ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac 344
 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
 90 95 100

aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac 392
 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
 105 110 115

tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc 440
 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
 120 125 130

cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga 488
 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
 135 140 145 150

gaa cca cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag 536
 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
 155 160 165

aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac 584
 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
 170 175 180

atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag 632
 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Tyr Lys
 185 190 195

acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc 680
 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
 200 205 210

aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca 728
 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
 215 220 225 230

A-527 PCT.ST25.txt

tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc 776
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
235 240 245

ctc tcc ctg tct ccg ggt aaa taatggatcc 807
Leu Ser Leu Ser Pro Gly Lys
250

<210> 18

<211> 253

<212> PRT

<213> Artificial Sequence

<220>

<223> EMP-Fc

<400> 18

Met Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys
1 5 10 15

Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys
20 25 30

Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
35 40 45

••••• Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
50 55 60

••••• Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
65 70 75 80

••••• Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
85 90 95

Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
100 105 110

••••• Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
115 120 125

••••• Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
130 135 140

••••• Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
145 150 155 160

Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
165 170 175

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
180 185 190

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
195 200 205

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
210 215 220

Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
225 230 235 240

His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
245 250

<210> 19

<211> 881

<212> DNA

<213> Artificial Sequence

<220>

<223> EMP-EMP-Fc

<220>

<221> CDS

<222> (41)..(871)

<223>

<400> 19

tctagatttg agttttaact tttagaagga ggaataaaat atg gga ggt act tac 55
Met Gly Gly Thr Tyr
1 5

tct tgc cac ttc ggc cca ctg act tgg gtt tgc aaa ccg cag ggt ggc 103
Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly
10 15 20

ggc ggc ggc ggc ggt ggt acc tat tcc tgt cat ttt ggc ccg ctg acc 151
Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr
25 30 35

tgg gta tgt aag cca caa ggg ggt ggg gga ggc ggg ggg gac aaa act 199
Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Asp Lys Thr
40 45 50

cac aca tgt cca cct tgc cca gca cct gaa ctc ctg ggg gga ccg tca 247
His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
55 60 65

ggt ttc ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg 295

A-527 PCT.ST25.txt

Val 70	Phe	Leu	Phe	Pro	Pro 75	Lys	Pro	Lys	Asp	Thr 80	Leu	Met	Ile	Ser	Arg 85	
acc Thr	cct Pro	gag Glu	gtc Val	aca Thr 90	tgc Cys	gtg Val	gtg Val	gtg Val	gac Asp 95	gtg Val	agc Ser	cac His	gaa Glu	gac Asp 100	cct Pro	343
gag Glu	gtc Val	aag Lys	ttc Phe 105	aac Asn	tgg Trp	tac Tyr	gtg Val	gac Asp 110	ggc Gly	gtg Val	gag Glu	gtg Val	cat His 115	aat Asn	gcc Ala	391
aag Lys	aca Thr	aag Lys 120	ccg Pro	cgg Arg	gag Glu	gag Glu	cag Gln 125	tac Tyr	aac Asn	agc Ser	acg Thr	tac Tyr 130	cgt Arg	gtg Val	gtc Val	439
agc Ser	gtc Val 135	ctc Leu	acc Thr	gtc Val	ctg Leu	cac His 140	cag Gln	gac Asp	tgg Trp	ctg Leu	aat Asn 145	ggc Gly	aag Lys	gag Glu	tac Tyr	487
aag Lys 150	tgc Cys	aag Lys	gtc Val	tcc Ser	aac Asn 155	aaa Lys	gcc Ala	ctc Leu	cca Pro	gcc Ala 160	ccc Pro	atc Ile	gag Glu	aaa Lys	acc Thr 165	535
atc Ile	tcc Ser	aaa Lys	gcc Ala	aaa Lys 170	ggg Gly	cag Gln	ccc Pro	cga Arg	gaa Glu 175	cca Pro	cag Gln	gtg Val	tac Tyr	acc Thr 180	ctg Leu	583
ccc Pro	cca Pro	tcc Ser	cgg Arg 185	gat Asp	gag Glu	ctg Leu	acc Thr	aag Lys 190	aac Asn	cag Gln	gtc Val	agc Ser	ctg Leu 195	acc Thr	tgc Cys	631
ctg Leu	gtc Val	aaa Lys 200	ggc Gly	ttc Phe	tat Tyr	ccc Pro	agc Ser 205	gac Asp	atc Ile	gcc Ala	gtg Val	gag Glu 210	tgg Trp	gag Glu	agc Ser	679
aat Asn 215	ggg Gly	cag Gln	ccg Pro	gag Glu	aac Asn	aac Asn 220	tac Tyr	aag Lys	acc Thr	acg Thr	cct Pro 225	ccc Pro	gtg Val	ctg Leu	gac Asp	727
tcc Ser 230	gac Asp	ggc Gly	tcc Ser	ttc Phe	ttc Phe 235	ctc Leu	tac Tyr	agc Ser	aag Lys	ctc Leu 240	acc Thr	gtg Val	gac Asp	aag Lys	agc Ser 245	775
agg Arg	tgg Trp	cag Gln	cag Gln	ggg Gly 250	aac Asn	gtc Val	ttc Phe	tca Ser	tgc Cys 255	tcc Ser	gtg Val	atg Met	cat His	gag Glu 260	gct Ala	823
ctg Leu	cac His	aac Asn	cac His 265	tac Tyr	acg Thr	cag Gln	aag Lys	agc Ser 270	ctc Leu	tcc Ser	ctg Leu	tct Ser	ccg Pro 275	ggg Gly	aaa Lys	871
taatggatcc															881	

<210> 20
 <211> 277
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> EMP-EMP-Fc

<400> 20

Met Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys
1 5 10 15

Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His
20 25 30

Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly
35 40 45

Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
50 55 60

Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
65 70 75 80

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
85 90 95

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
100 105 110

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
115 120 125

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
130 135 140

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
145 150 155 160

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
165 170 175

Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
180 185 190

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
195 200 205

Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
210 215 220

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
225 230 235 240

Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
245 250 255

Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
260 265 270

Leu Ser Pro Gly Lys
275

<210> 21

<211> 885

<212> DNA

<213> Artificial Sequence

<220>

<223> FC-EMP-EMP

<220>

<221> CDS

<222> (39)..(869)

<223>

<400> 21

tctagatttg ttttaactaa ttaaaggagg aataacat atg gac aaa act cac aca 56
Met Asp Lys Thr His Thr
1 5

tgt cca cct tgc cca gca cct gaa ctc ctg ggg gga ccg tca gtt ttc 104
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
10 15 20

ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct 152
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
25 30 35

gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc 200
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
40 45 50

aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca 248
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
55 60 65 70

aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc 296
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
75 80 85

ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc 344
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
90 95 100

aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc 392
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
105 110 115

aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg cct cca 440
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
120 125 130

tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc 488
Page 24

A-527 PCT.ST25.txt

Ser 135	Arg	Asp	Glu	Leu	Thr 140	Lys	Asn	Gln	Val	Ser 145	Leu	Thr	Cys	Leu	Val 150	
aaa Lys	ggc Gly	ttc Phe	tat Tyr	ccc Pro 155	agc Ser	gac Asp	atc Ile	gcc Ala	gtg Val 160	gag Glu	tgg Trp	gag Glu	agc Ser	aat Asn 165	ggg Gly	536
cag Gln	ccg Pro	gag Glu	aac Asn 170	aac Asn	tac Tyr	aag Lys	acc Thr	acg Thr 175	cct Pro	ccc Pro	gtg Val	ctg Leu	gac Asp 180	tcc Ser	gac Asp	584
ggc Gly	tcc Ser	ttc Phe 185	ttc Phe	ctc Leu	tac Tyr	agc Ser	aag Lys 190	ctc Leu	acc Thr	gtg Val	gac Asp	aag Lys 195	agc Ser	agg Arg	tgg Trp	632
cag Gln 200	cag Gln	ggg Gly	aac Asn	gtc Val	ttc Phe	tca Ser 205	tgc Cys	tcc Ser	gtg Val	atg Met	cat His 210	gag Glu	gct Ala	ctg Leu	cac His	680
aac Asn 215	cac His	tac Tyr	acg Thr	cag Gln	aag Lys 220	agc Ser	ctc Leu	tcc Ser	ctg Leu	tct Ser 225	ccg Pro	ggt Gly	aaa Lys	ggt Gly	gga Gly 230	728
ggt Gly	ggt Gly	ggc Gly	gga Gly 235	ggt Gly	act Thr	tac Tyr	tct Ser	tgc Cys	cac His 240	ttc Phe	ggc Gly	cca Pro	ctg Leu	act Thr 245	tgg Trp	776
gtt Val	tgc Cys	aaa Lys	ccg Pro 250	cag Gln	ggt Gly	ggc Gly	ggc Gly	ggc Gly 255	ggc Gly	ggc Gly	ggt Gly	ggt Gly	acc Thr 260	tat Tyr	tcc Ser	824
tgt Cys	cat His	ttt Phe 265	ggc Gly	ccg Pro	ctg Leu	acc Thr	tgg Trp 270	gta Val	tgt Cys	aag Lys	cca Pro	caa Gln 275	ggg Gly	ggt Gly		869
taatctcgcag gatcca															885	

<210> 22
 <211> 277
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> FC-EMP-EMP
 <400> 22

Met 1	Asp	Lys	Thr	His 5	Thr	Cys	Pro	Pro	Cys 10	Pro	Ala	Pro	Glu	Leu 15	Leu
Gly	Gly	Pro	Ser 20	Val	Phe	Leu	Phe	Pro 25	Pro	Lys	Pro	Lys	Asp 30	Thr	Leu
Met	Ile	Ser 35	Arg	Thr	Pro	Glu	Val 40	Thr	Cys	Val	Val	Val 45	Asp	Val	Ser
His 50	Glu	Asp	Pro	Glu	Val	Lys 55	Phe	Asn	Trp	Tyr	Val 60	Asp	Gly	Val	Glu

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
65 70 75 80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
85 90 95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
100 105 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
145 150 155 160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
180 185 190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
210 215 220

Ser Pro Gly Lys Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His
225 230 235 240

Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly
245 250 255

Gly Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys
260 265 270

Lys Pro Gln Gly Gly
275

<210> 23

<211> 1546

<212> DNA

<213> Artificial sequence

<220>

<223> pAMG21

<400> 23

gcgtaacgta tgcattggtct ccccatgcga gagtagggaa ctgccaggca tcaaataaaa	60
cgaaaggctc agtcgaaaga ctgggccttt cgttttatct gttgtttgtc ggtgaacgct	120
ctcctgagta ggacaaatcc gccgggagcg gatttgaacg ttgcgaagca acggcccgga	180
gggtggcggg caggacgccc gccataaact gccaggcatc aaattaagca gaaggccatc	240
ctgacggatg gcctttttgc gtttctacaa actcttttgt ttatttttct aaatacattc	300
aaatatggac gtcgtactta acttttaaag tatgggcaat caattgctcc tgttaaaatt	360
gctttagaaa tactttggca gcggtttggt gtattgagtt tcatttgcgc attggttaaa	420
tggaaagtga ccgtgcgctt actacagcct aatatttttg aaatatccca agagcttttt	480
ccttcgcatg cccacgctaa acattctttt tctcttttgg ttaaatacgtt gtttgattta	540
ttatttgcta tatttttttt tcgataatta tcaactagag aaggaacaat taatggtatg	600
ttcatacacg catgtaaaaa taaactatct atatagttgt ctttctctga atgtgcaaaa	660
ctaagcattc cgaagccatt attagcagta tgaataggga aactaaacc agtgataaga	720
cctgatgatt tcgcttcttt aattacattt ggagattttt tatttacagc attgttttca	780
aatatatcc aattaatcgg tgaatgattg gagttagaat aatctactat aggatcatat	840
tttattaaat tagcgtcatc ataattttgc ctccattttt tagggtaatt atccagaatt	900
gaaatatcag atttaaccat agaatgagga taaatgatcg cgagtaaata atattcacia	960
tgtaccattt tagtcatatc agataagcat tgattaatat cattattgct tctacaggct	1020
ttaattttat taattattct gtaagtgtcg tcggcattta tgtctttcat acccatctct	1080
ttatccttac ctattgtttg tcgcaagttt tgcgtgttat atatcattaa aacggtaata	1140
gattgacatt tgattctaata aaattggatt tttgtcacac tattatatcg cttgaaatac	1200
aattgtttta cataagtacc tgtaggatcg tacaggttta cgcaagaaaa tggtttggtta	1260
tagtcgatta atcgatttga ttctagattt gttttaacta attaaaggag gaataacata	1320
tggttaacgc gttggaattc gagctcacta gtgtcgacct gcagggtacc atggaagctt	1380
actcgaggat ccgcggaaag aagaagaaga agaagaaagc ccgaaaggaa gctgagttgg	1440
ctgctgccac cgctgagcaa taactagcat aacccttggt ggcctctaaa cgggtcttga	1500
gggggttttt gctgaaagga ggaaccgctc ttcacgctct tcacgc	1546

<210> 24

<211> 14

<212> PRT

<213> Artificial sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 24

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Lys Ala
1 5 10

<210> 25

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 25


Ile Glu Gly Pro Thr Leu Arg Glu Trp Leu Ala Ala Arg Ala
1 5 10

<210> 26

<211> 14

<212> PRT

<213> Artificial Sequence



<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (14)..(14)

<223> At position 14, amino acid linker to an identical sequence

<400> 26

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
1 5 10

<210> 27

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (14)..(14)

<223> At position 14, amino acid linker to an identical sequence

<400> 27

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Lys Ala
1 5 10

<210> 28

<211> 14

<212> PRT

<213> Artificial sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (9)..(9)

<223> At position 9 disulfide linkage to position 9 of an identical sequence

<220>

<221> misc_feature

<222> (14)..(14)

<223> At position 14, amino acid linker to an identical sequence

<400> 28

Ile Glu Gly Pro Thr Leu Arg Gln Cys Leu Ala Ala Arg Ala
1 5 10

<210> 29

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (16)..(16)

<223> Position 16 bromoacetyl group linked to sidechain

<220>

<221> misc_feature

<222> (14)..(14)

<223> At position 14, amino acid linker attached N-to-C to Lys and to a
nother linker and an identical sequence

<400> 29

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
1 5 10

<210> 30

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (16)..(16)

<223> Position 16 polyethylene glycol linked to sidechain

<220>

<221> misc_feature

<222> (14)..(14)

<223> At position 14, amino acid linker attached N-to-C to Lys and to a
nother linker and an identical sequence

<400> 30

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
1 5 10

<210> 31

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (9)..(9)

<223> Position 9 disulfide bond to residue 9 of a separate identical sequence

<220>

<221> misc_feature

••••• <222> (14)..(14)

••••• <223> At position 14, amino acid linker to an identical sequence

•••••

••••• <400> 31

••••• Ile Glu Gly Pro Thr Leu Arg Gln Cys Leu Ala Ala Arg Ala
1 5 10

<210> 32

<211> 14

••••• <212> PRT

••••• <213> Artificial Sequence

•••••

••••• <220>

••••• <223> TPO-MIMETIC PEPTIDE

•••••

<220>

<221> misc_feature

<222> (14)..(14)

<223> At position 14, amino acid linker attachment site

<400> 32

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
1 5 10

<210> 33

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO MIMETIC PEPTIDE

<220>


<221> misc_feature

<222> (6, 7 and)..(8)

<223> Xaa = any amino acid

<400> 33

Val Arg Asp Gln Ile Xaa Xaa Xaa Leu
1 5



<210> 34

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 34

Thr Leu Arg Glu Trp Leu
1 5



<210> 35

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 35

Gly Arg Val Arg Asp Gln Val Ala Gly Trp
1 5 10

<210> 36

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 36

Gly Arg Val Lys Asp Gln Ile Ala Gln Leu
1 5 10

<210> 37

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 37

Gly Val Arg Asp Gln Val Ser Trp Ala Leu
1 5 10

<210> 38

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 38

Glu Ser Val Arg Glu Gln Val Met Lys Tyr
 1 5 10

<210> 39

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 39

Ser Val Arg Ser Gln Ile Ser Ala Ser Leu
 1 5 10


<210> 40


<211> 10

<212> PRT

<213> Artificial Sequence

<220>


 <223> TPO-MIMETIC PEPTIDE


 <400> 40



Gly Val Arg Glu Thr Val Tyr Arg His Met
 1 5 10


 <210> 41

<211> 11

<212> PRT

<213> Artificial Sequence


 <220>


 <223> TPO-MIMETIC PEPTIDE


 <400> 41



Gly Val Arg Glu Val Ile Val Met His Met Leu
 1 5 10

<210> 42

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 42

Gly Arg Val Arg Asp Gln Ile Trp Ala Ala Leu
1 5 10

<210> 43

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 43

Ala Gly Val Arg Asp Gln Ile Leu Ile Trp Leu
1 5 10

<210> 44

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 44

Gly Arg Val Arg Asp Gln Ile Met Leu Ser Leu
1 5 10

<210> 45

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (8) .. (10)

<223> Xaa = any amino acid

<400> 45

Gly Arg Val Arg Asp Gln Ile Xaa Xaa Xaa Leu
1 5 10

<210> 46

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 46

Cys Thr Leu Arg Gln Trp Leu Gln Gly Cys
1 5 10

 $\langle 210 \rangle$ 47

$\langle 211 \rangle$ 10

∴ $\angle 212^\circ$ PRT

•••••<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

.. .. <400> 47

$\begin{array}{ccccccccc} \cdot & & & & & & & & \\ \cdot\cdot\cdot & \text{Cys} & \text{Thr} & \text{Leu} & \text{Gln} & \text{Glu} & \text{Phe} & \text{Leu} & \text{Glu} & \text{Gly} & \text{Cys} \\ \cdot\cdot\cdot & 1 & & & & 5 & & & & & 10 \end{array}$

310 48

••••• $\langle 210 \rangle$ 48

••••• $\langle 211 \rangle$ 10

 $\cdot \cdot \cdot \cdot <212>$ PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 48

Cys Thr Arg Thr Glu Trp Leu His Gly Cys
1 5 10

<210> 49

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 49

Cys Thr Leu Arg Glu Trp Leu His Gly Gly Phe Cys
1 5 10

<210> 50

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 50

Cys Thr Leu Arg Glu Trp Val Phe Ala Gly Leu Cys
1 5 10

<210> 51

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 51

Cys Thr Leu Arg Gln Trp Leu Ile Leu Leu Gly Met Cys
 1 5 10

<210> 52

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 52

Cys Thr Leu Ala Glu Phe Leu Ala Ser Gly Val Glu Gln Cys
 1 5 10

<210> 53

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 53

Cys Ser Leu Gln Glu Phe Leu Ser His Gly Gly Tyr Val Cys
 1 5 10

<210> 54

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 54

Cys Thr Leu Arg Glu Phe Leu Asp Pro Thr Thr Ala Val Cys
 1 5 10

<210> 55

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 55

Cys Thr Leu Lys Glu Trp Leu Val ser His Glu val Trp Cys
1 5 10

<210> 56

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (8)..(9)

<223> Xaa = any amino acid

• **<400>** 56

Cys Thr Leu Arg Glu Trp Leu Xaa Xaa Cys
1 5 10

• $\langle 210 \rangle$ 57

<211> 11

<212> PRT

<213> Artificial Sequence

• $\langle 220 \rangle$

•<223> TPO-MIMETIC PEPTIDE

• $\langle 220 \rangle$

- <221> misc_feature

$$\vdots_{\langle 222 \rangle} \quad (8) \dots (10)$$

<223> Xaa = any amino acid

<400> 57

Cys Thr Leu Arg Glu Trp Leu Xaa Xaa Xaa Cys
1 5 10

<210> 58

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (8)..(11)

<223> Xaa = any amino acid

<400> 58

Cys Thr Leu Arg Glu Trp Leu Xaa Xaa Xaa Xaa Cys
1 5 10

<210> 59

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (8)..(12)

<223> Xaa = any amino acid

<400> 59

Cys Thr Leu Arg Glu Trp Leu Xaa Xaa Xaa Xaa Xaa Cys
1 5 10

<210> 60

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (8)..(13)

<223> Xaa = any amino acid

<400> 60

Cys Thr Leu Arg Glu Trp Leu Xaa Xaa Xaa Xaa Xaa Xaa Cys
 1 5 10

<210> 61

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 61

Arg Glu Gly Pro Thr Leu Arg Gln Trp Met
 1 5 10

<210> 62

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 62

Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala
 1 5 10

<210> 63
 <211> 10
 <212> PRT
 <213> Artificial Sequence


<220>
 <223> TPO-MIMETIC PEPTIDE
 <400> 63

Glu Arg Gly Pro Phe Trp Ala Lys Ala Cys
 1 5 10

<210> 64
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE
 <400> 64

Arg Glu Gly Pro Arg Cys Val Met Trp Met
 1 5 10



<210> 65
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE
 <400> 65

Cys Gly Thr Glu Gly Pro Thr Leu Ser Thr Trp Leu Asp Cys
 1 5 10



<210> 66
 <211> 14
 <212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 66

Cys Glu Gln Asp Gly Pro Thr Leu Leu Glu Trp Leu Lys Cys
1 5 10

<210> 67

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 67

Cys Glu Leu Val Gly Pro Ser Leu Met Ser Trp Leu Thr Cys
1 5 10

<210> 68

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 68

Cys Leu Thr Gly Pro Phe Val Thr Gln Trp Leu Tyr Glu Cys
1 5 10

<210> 69

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 69

Cys Arg Ala Gly Pro Thr Leu Leu Glu Trp Leu Thr Leu Cys
1 5 10

<210> 70

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 70

Cys Ala Asp Gly Pro Thr Leu Arg Glu Trp Ile Ser Phe Cys
1 5 10

<210> 71


<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE



<220>


<221> misc_feature

<222> (2)..(12)

<223> Xaa = any amino acid

<400> 71

Cys Xaa Glu Gly Pro Thr Leu Arg Glu Trp Leu Xaa Cys
1 5 10



<210> 72

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (2, 3)..(13)

<223> Xaa = any amino acid

<400> 72

Cys Xaa Xaa Glu Gly Pro Thr Leu Arg Glu Trp Leu Xaa Cys
1 5 10

<210> 73

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (2, 12)..(13)

••••• <223> Xaa = any amino acid

•••••

••••• <400> 73

••••• Cys Xaa Glu Gly Pro Thr Leu Arg Glu Trp Leu Xaa Xaa Cys
••••• 1 5 10

<210> 74

<211> 15

<212> PRT

••••• <213> Artificial Sequence

•••••

••••• <220>

••••• <223> TPO-MIMETIC PEPTIDE

••••• <220>

••••• <221> misc_feature

<222> (2, 3, 13)..(14)

<223> Xaa = any amino acid

<400> 74

Cys Xaa Xaa Glu Gly Pro Thr Leu Arg Glu Trp Leu Xaa Xaa Cys
1 5 10 15

<210> 75

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 75


Gly Gly Cys Thr Leu Arg Glu Trp Leu His Gly Gly Phe Cys Gly Gly
1 5 10 15

<210> 76

<211> 18

<212> PRT

<213> Artificial Sequence



<220>

<223> TPO-MIMETIC PEPTIDE

<400> 76

Gly Gly Cys Ala Asp Gly Pro Thr Leu Arg Glu Trp Ile Ser Phe Cys
1 5 10 15

Gly Gly



<210> 77

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 77

Gly Asn Ala Asp Gly Pro Thr Leu Arg Gln Trp Leu Glu Gly Arg Arg
1 5 10 15

Pro Lys Asn

<210> 78

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 78

Leu Ala Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu His Gly Asn Gly
1 5 10 15

Arg Asp Thr

<210> 79

<211> 19

•••••<212> PRT

•••••<213> Artificial Sequence

•••••<220>

•••••<223> TPO-MIMETIC PEPTIDE

<400> 79

His Gly Arg Val Gly Pro Thr Leu Arg Glu Trp Lys Thr Gln Val Ala
1 5 10 15

•••••Thr Lys Lys

•••••<210> 80

•••••<211> 18

•••••<212> PRT

•••••<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 80

Thr Ile Lys Gly Pro Thr Leu Arg Gln Trp Leu Lys Ser Arg Glu His
1 5 10 15

Thr Ser

<210> 81

<211> 18

<212> PRT

<213> Artificial Sequence


<220>

<223> TPO-MIMETIC PEPTIDE

<400> 81

Ile Ser Asp Gly Pro Thr Leu Lys Glu Trp Leu Ser Val Thr Arg Gly
1 5 10 15

Ala Ser



<210> 82

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO MIMETIC PEPTIDE

<400> 82



Ser Ile Glu Gly Pro Thr Leu Arg Glu Trp Leu Thr Ser Arg Thr Pro
1 5 10 15

His Ser

<210> 83

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (2, 4, 5, 8, 11)..(13)

<223> Xaa = any amino acid

<400> 83

Tyr Xaa Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Pro
1 5 10

<210> 84


<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE



<220>

<221> misc_feature

<222> (2, 4, 5, 8, 11, 13, 16, 18, 19, 22, 25)..(27)

<223> Xaa = any amino acid

<400> 84

Tyr Xaa Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Pro Tyr Xaa
1 5 10 15



Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Pro
20 25

<210> 85

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (14)..(14)

<223> At position 14, amino acid linker to an identical sequence

<220>

<221> misc_feature

<222> (2, 4, 5, 8, 11)..(13)

<223> xaa = any amino acid

<400> 85

Tyr Xaa Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Pro
 1 5 10

<210> 86

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (2, 4, 5, 8, 11)..(13)

<223> xaa = any amino acid

<400> 86

Tyr Xaa Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Pro
 1 5 10

<210> 87

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 87

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln Gly Gly
20

<210> 88

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 88

Gly Gly Asp Tyr His Cys Arg Met Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Leu Gly Gly
20

<210> 89

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 89

Gly Gly Val Tyr Ala Cys Arg Met Gly Pro Ile Thr Trp Val Cys Ser
1 5 10 15

Pro Leu Gly Gly
20

<210> 90

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 90

Val Gly Asn Tyr Met Cys His Phe Gly Pro Ile Thr Trp Val Cys Arg
 1 5 10 15

Pro Gly Gly Gly
 20

<210> 91

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 91

Gly Gly Leu Tyr Leu Cys Arg Phe Gly Pro Val Thr Trp Asp Cys Gly
 1 5 10 15

Tyr Lys Gly Gly
 20

<210> 92

<211> 40

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 92

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
 1 5 10 15

Pro Gln Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr
 20 25 30

Trp Val Cys Lys Pro Gln Gly Gly
35 40

<210> 93

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<220>

<221> misc_feature


<222> (20)..(20)

<223> Position 20, amino acid linker to an identical sequence

<400> 93

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln Gly Gly
20



<210> 94

<211> 23


<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 94



Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln Gly Gly Ser Ser Lys
20

<210> 95

<211> 46

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 95

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln Gly Gly Ser Ser Lys Gly Gly Thr Tyr Ser Cys His Phe Gly
20 25 30

Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Ser Ser Lys
35 40 45

<210> 96

<211> 23


<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<220>



<221> misc_feature


<222> (23)..(23)

<223> Position 23, amino acid linker to an identical sequence

<400> 96

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln Gly Gly Ser Ser Lys
20



<210> 97

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (22)..(22)

<223> Position 22 linked through epsilon amine to lysyl, which is linked to a separate identical sequence through that sequence's alpha amine

<400> 97

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln Gly Gly Ser Ser
20

<210> 98

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (23)..(23)

<223> At position 23 biotin linked to the sidechain through a linker

<400> 98

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln Gly Gly Ser Ser Lys
20

<210> 99

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> G-CSF-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (4)..(4)

<223> At position 4 disulfide bond to residue 4 of a separate identical sequence

<400> 99

Glu Glu Asp Cys Lys
1 5

<210> 100

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> G-CSF-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (4)..(4)

<223> At position 4, Xaa is an isoteric ethylene spacer linked to a separate identical sequence

<400> 100

Glu Glu Asp Xaa Lys
1 5

<210> 101

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> G-CSF-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa is a pyroglutamic acid residue

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa is an isoteric ethylene spacer linked to a separate identical sequence.

<400> 101

Xaa Gly Glu Asp Xaa Lys
1 5

<210> 102

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> G-CSF-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa is a picolinic acid residue

<220>

<221> misc_feature

<222> (4)..(4)

<223> Position 4, Xaa is an isoteric ethylene spacer linked to a separate identical sequence.

<400> 102

Xaa Ser Asp Xaa Lys
1 5

<210> 103

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> G-CSF-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> At position 5, amino acid linker to an identical sequence

<400> 103


Glu Glu Asp Cys Lys
1 5

<210> 104

<211> 5

<212> PRT

<213> Artificial Sequence



<220>


<223> G-CSF-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> At position 5, amino acid linker to an identical sequence



<220>

<221> misc_feature

<222> (4)..(4)

<223> Xaa = any amino acid

<400> 104

Glu Glu Asp Xaa Lys
1 5

<210> 105

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIVIRAL (HBV)

<400> 105

Leu Leu Gly Arg Met Lys
1 5

<210> 106

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 106

Tyr Cys Phe Thr Ala Ser Glu Asn His Cys Tyr
1 5 10

<210> 107

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 107

Tyr Cys Phe Thr Asn Ser Glu Asn His Cys Tyr
1 5 10

<210> 108

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 108

Tyr Cys Phe Thr Arg Ser Glu Asn His Cys Tyr
1 5 10

<210> 109

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 109

Phe Cys Ala Ser Glu Asn His Cys Tyr
1 5

<210> 110

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 110

Tyr Cys Ala Ser Glu Asn His Cys Tyr
1 5

<210> 111

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 111

Phe Cys Asn Ser Glu Asn His Cys Tyr
1 5

<210> 112

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 112

Phe Cys Asn Ser Glu Asn Arg Cys Tyr
1 5

<210> 113

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 113

Phe Cys Asn Ser Val Glu Asn Arg Cys Tyr
1 5 10

<210> 114

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 114

Tyr Cys Ser Gln Ser Val Ser Asn Asp Cys Phe
1 5 10

<210> 115

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 115

Phe Cys Val Ser Asn Asp Arg Cys Tyr
 1 5

<210> 116

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 116

Tyr Cys Arg Lys Glu Leu Gly Gln Val Cys Tyr
 1 5 10

<210> 117

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 117

Tyr Cys Lys Glu Pro Gly Gln Cys Tyr
 1 5

<210> 118

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 118

Tyr Cys Arg Lys Glu Met Gly Cys Tyr
1 5

<210> 119

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 119

Phe Cys Arg Lys Glu Met Gly Cys Tyr
1 5

<210> 120

<211> 9

<212> PRT

<213> Artificial Sequence



<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 120

Tyr Cys Trp Ser Gln Asn Leu Cys Tyr
1 5

<210> 121

<211> 10

<212> PRT

<213> Artificial Sequence



<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 121

Tyr Cys Glu Leu Ser Gln Tyr Leu Cys Tyr
1 5 10

<210> 122

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 122

Tyr Cys Trp Ser Gln Asn Tyr Cys Tyr
1 5

<210> 123

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 123

Tyr Cys Trp Ser Gln Tyr Leu Cys Tyr
1 5

<210> 124

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Xaa (Pos1) can be C, A, a-amino-g-bromobutyric acid or Hoc.

<220>

<221> misc_feature

<222> (2)..(2)

<223> Xaa can be R, H, L or W.

<220>

<221> misc_feature

<222> (3)..(3)

<223> Xaa can be M, F or I.

<220>

<221> misc_feature

<222> (6)..(6)

<223> Xaa can be any one of the 20 L-amino acids or the stereoisomeric D-amino acids.

<220>

<221> misc_feature

<222> (9)..(9)

<223> Xaa can be D, E, I, L or V.

••••• <220>

••••• <221> misc_feature

••••• <222> (10)..(10)

••••• <223> Xaa can be a-amino-g-bromobutyric acid or Hoc, provided that either Xaa (Pos1) or Xaa (Pos10) is C or Hoc.

•••••

<400> 124

Xaa Xaa Xaa Gly Pro Xaa Thr Trp Xaa Xaa
1 5 10

••••• <210> 125

••••• <211> 15

••••• <212> PRT

••••• <213> Artificial Sequence

•••••

<220>

<223> CTLA4-MIMETIC

<400> 125

Gly Phe Val Cys Ser Gly Ile Phe Ala Val Gly Val Gly Arg Cys
1 5 10 15

<210> 126

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> CTLA4-MIMETIC

<400> 126

Ala Pro Gly Val Arg Leu Gly Cys Ala Val Leu Gly Arg Tyr Cys
1 5 10 15

<210> 127

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> C3B ANTAGONIST

<400> 127

Ile Cys Val Val Gln Asp Trp Gly His His Arg Cys Thr Ala Gly His
1 5 10 15

Met Ala Asn Leu Thr Ser His Ala Ser Ala Ile
20 25

<210> 128

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> C3B ANTAGONIST

<400> 128

Ile Cys Val Val Gln Asp Trp Gly His His Arg Cys Thr
1 5 10

<210> 129
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> C3B ANTAGONIST
 <400> 129

Cys val val Gln Asp Trp Gly His His Ala Cys
 1 5 10

<210> 130
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> MDM/HDM ANTAGONIST PEPTIDE

<400> 130
 Thr Phe Ser Asp Leu Trp
 1 5

<210> 131
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> MDM/HDM ANTAGONIST PEPTIDE

<400> 131
 Gln Glu Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro
 1 5 10

<210> 132
 <211> 12
 <212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 132

Gln Pro Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro
1 5 10

<210> 133

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 133

Gln Glu Thr Phe Ser Asp Tyr Trp Lys Leu Leu Pro
1 5 10

<210> 134

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 134

Gln Pro Thr Phe Ser Asp Tyr Trp Lys Leu Leu Pro
1 5 10

<210> 135

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 135

Met Pro Arg Phe Met Asp Tyr Trp Glu Gly Leu Asn
 1 5 10

<210> 136

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 136

Val Gln Asn Phe Ile Asp Tyr Trp Thr Gln Gln Phe
 1 5 10

<210> 137

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 137

Thr Gly Pro Ala Phe Thr His Tyr Trp Ala Thr Phe
 1 5 10

<210> 138

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 138

Ile Asp Arg Ala Pro Thr Phe Arg Asp His Trp Phe Ala Leu Val
 1 5 10 15

<210> 139

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 139

Pro Arg Pro Ala Leu Val Phe Ala Asp Tyr Trp Glu Thr Leu Tyr
 1 5 10 15

<210> 140

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 140

Pro Ala Phe Ser Arg Phe Trp Ser Asp Leu Ser Ala Gly Ala His
 1 5 10 15


 <210> 141

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 141



Pro Ala Phe Ser Arg Phe Trp Ser Lys Leu Ser Ala Gly Ala His
 1 5 10 15

<210> 142

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (2, 4, 8)..(9)

<223> Xaa = any amino acid

<400> 142

Pro	Xaa	Phe	Xaa	Asp	Tyr	Trp	Xaa	Xaa	Leu
1				5					10

<210> 143

<211> 12

<212> PRT


<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 143

Gln	Glu	Thr	Phe	Ser	Asp	Leu	Trp	Lys	Leu	Leu	Pro
1				5					10		



<210> 144

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 144

Gln	Pro	Thr	Phe	Ser	Asp	Leu	Trp	Lys	Leu	Leu	Pro
1				5					10		

<210> 145

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 145

Gln Glu Thr Phe Ser Asp Tyr Trp Lys Leu Leu Pro
1 5 10

<210> 146

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 146

Gln Pro Thr Phe Ser Asp Tyr Trp Lys Leu Leu Pro
1 5 10

<210> 147

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 147

Asp Ile Thr Trp Asp Gln Leu Trp Asp Leu Met Lys
1 5 10

<210> 148

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 148

Asp Ile Thr Trp Asp Glu Leu Trp Lys Ile Met Asn
 1 5 10

<210> 149

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 149

Asp Tyr Thr Trp Phe Glu Leu Trp Asp Met Met Gln
 1 5 10

<210> 150

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 150

Gln Ile Thr Trp Ala Gln Leu Trp Asn Met Met Lys
 1 5 10

<210> 151

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 151

Asp Met Thr Trp His Asp Leu Trp Thr Leu Met Ser
 1 5 10

<210> 152

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 152

Asp Tyr Ser Trp His Asp Leu Trp Glu Met Met Ser
 1 5 10

<210> 153

<211> 12

<212> PRT

<213> Artificial Sequence


<220>

<223> SELECTIN ANTAGONIST PEPTIDE


<400> 153

Glu Ile Thr Trp Asp Gln Leu Trp Glu Val Met Asn
 1 5 10

<210> 154


 <211> 12


 <212> PRT



 <213> Artificial Sequence



 <220>


<223> SELECTIN ANTAGONIST PEPTIDE

<400> 154

His Val Ser Trp Glu Gln Leu Trp Asp Ile Met Asn
 1 5 10


 <210> 155


 <211> 12


 <212> PRT


 <213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 155

His Ile Thr Trp Asp Gln Leu Trp Arg Ile Met Thr
1 5 10

<210> 156

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 156

Arg Asn Met Ser Trp Leu Glu Leu Trp Glu His Met Lys
1 5 10

<210> 157

<211> 18

<212> PRT

<213> Artificial Sequence

••••• <220>

••••• <223> SELECTIN ANTAGONIST PEPTIDE

••••• <400> 157

••••• Ala Glu Trp Thr Trp Asp Gln Leu Trp His Val Met Asn Pro Ala Glu
1 5 10 15

Ser Gln

<210> 158

••••• <211> 14

••••• <212> PRT

••••• <213> Artificial Sequence

••••• <220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 158

His Arg Ala Glu Trp Leu Ala Leu Trp Glu Gln Met Ser Pro
 1 5 10

<210> 159

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 159

Lys Lys Glu Asp Trp Leu Ala Leu Trp Arg Ile Met Ser Val
 1 5 10

<210> 160

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 160

Ile Thr Trp Asp Gln Leu Trp Asp Leu Met Lys
 1 5 10

<210> 161

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 161

Asp Ile Thr Trp Asp Gln Leu Trp Asp Leu Met Lys
 1 5 10

<210> 162

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 162

Asp Ile Thr Trp Asp Gln Leu Trp Asp Leu Met Lys
1 5 10

<210> 163

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 163

Asp Ile Thr Trp Asp Gln Leu Trp Asp Leu Met Lys
1 5 10

<210> 164

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 164

Ser Cys Val Lys Trp Gly Lys Lys Glu Phe Cys Gly Ser
1 5 10

<210> 165

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 165

Ser Cys Trp Lys Tyr Trp Gly Lys Glu Cys Gly Ser
1 5 10

<210> 166

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 166


Ser Cys Tyr Glu Trp Gly Lys Leu Arg Trp Cys Gly Ser
1 5 10

<210> 167

<211> 13

<212> PRT

<213> Artificial Sequence



<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 167


Ser Cys Leu Arg Trp Gly Lys Trp Ser Asn Cys Gly Ser
1 5 10

<210> 168

<211> 13

<212> PRT

<213> Artificial Sequence



<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 168

Ser Cys Trp Arg Trp Gly Lys Tyr Gln Ile Cys Gly Ser
1 5 10

<210> 169

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 169

Ser Cys Val Ser Trp Gly Ala Leu Lys Leu Cys Gly Ser
 1 5 10

<210> 170

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 170

Ser Cys Ile Arg Trp Gly Gln Asn Thr Phe Cys Gly Ser
 1 5 10

<210> 171

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 171

Ser Cys Trp Gln Trp Gly Asn Leu Lys Ile Cys Gly Ser
 1 5 10

<210> 172

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 172

Ser Cys Val Arg Trp Gly Gln Leu Ser Ile Cys Gly Ser
1 5 10

<210> 173

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 173

Leu Lys Lys Phe Asn Ala Arg Arg Lys Leu Lys Gly Ala Ile Leu Thr
1 5 10 15

Thr Met Leu Ala Lys
20

<210> 174

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 174

Arg Arg Trp Lys Lys Asn Phe Ile Ala Val Ser Ala Ala Asn Arg Phe
1 5 10 15

Lys Lys

<210> 175

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 175

Arg Lys Trp Gln Lys Thr Gly His Ala Val Arg Ala Ile Gly Arg Leu
1 5 10 15

Ser Ser

<210> 176

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 176

Ile Asn Leu Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu
1 5 10

<210> 177

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 177

Lys Ile Trp Ser Ile Leu Ala Pro Leu Gly Thr Thr Leu Val Lys Leu
1 5 10 15

Val Ala

<210> 178

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 178

Leu Lys Lys Leu Leu Lys Leu Leu Lys Lys Leu Leu Lys Leu
1 5 10

<210> 179

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 179

Leu Lys Trp Lys Lys Leu Leu Lys Leu Leu Lys Lys Leu Leu Lys Lys
1 5 10 15

Leu Leu

<210> 180

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 180

Ala Glu Trp Pro Ser Leu Thr Glu Ile Lys Thr Leu Ser His Phe Ser
1 5 10 15

Val

<210> 181

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 181

Ala Glu Trp Pro Ser Pro Thr Arg Val Ile Ser Thr Thr Tyr Phe Gly
1 5 10 15

Ser

<210> 182

<211> 17

<212> PRT

<213> Artificial Sequence


<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 182

Ala Glu Leu Ala His Trp Pro Pro Val Lys Thr Val Leu Arg Ser Phe
1 5 10 15

Thr



<210> 183

<211> 17

<212> PRT

<213> Artificial Sequence


<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 183

Ala Glu Gly Ser Trp Leu Gln Leu Leu Asn Leu Met Lys Gln Met Asn
1 5 10 15

Asn



<210> 184

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 184

Ala Glu Trp Pro Ser Leu Thr Glu Ile Lys
 1 5 10

<210> 185

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> VINCULIN-BINDING

<400> 185

Ser Thr Gly Gly Phe Asp Asp Val Tyr Asp Trp Ala Arg Gly Val Ser
 1 5 10 15

Ser Ala Leu Thr Thr Thr Leu Val Ala Thr Arg
 20 25

<210> 186

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> VINCULIN-BINDING

<400> 186

Ser Thr Gly Gly Phe Asp Asp Val Tyr Asp Trp Ala Arg Arg Val Ser
 1 5 10 15

Ser Ala Leu Thr Thr Thr Leu Val Ala Thr Arg
 20 25

<210> 187

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> VINCULIN-BINDING

<400> 187

Ser Arg Gly Val Asn Phe Ser Glu Trp Leu Tyr Asp Met Ser Ala Ala
1 5 10 15

Met Lys Glu Ala Ser Asn Val Phe Pro Ser Arg Arg Ser Arg
20 25 30

<210> 188

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> VINCULIN-BINDING

<400> 188

Ser Ser Gln Asn Trp Asp Met Glu Ala Gly Val Glu Asp Leu Thr Ala
1 5 10 15

Ala Met Leu Gly Leu Leu Ser Thr Ile His Ser Ser Ser Arg
20 25 30

<210> 189

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> VINCULIN-BINDING

<400> 189

Ser Ser Pro Ser Leu Tyr Thr Gln Phe Leu Val Asn Tyr Glu Ser Ala
1 5 10 15

Ala Thr Arg Ile Gln Asp Leu Leu Ile Ala Ser Arg Pro Ser Arg
20 25 30

<210> 190

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> VINCULIN-BINDING

<400> 190

Ser Ser Thr Gly Trp Val Asp Leu Leu Gly Ala Leu Gln Arg Ala Ala
 1 5 10 15

Asp Ala Thr Arg Thr Ser Ile Pro Pro Ser Leu Gln Asn Ser Arg
 20 25 30

<210> 191

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> VINCULIN-BINDING

<400> 191

Asp Val Tyr Thr Lys Lys Glu Leu Ile Glu Cys Ala Arg Arg Val Ser
 1 5 10 15

Glu Lys

<210> 192

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> C4BP-BINDING

<400> 192

Glu Lys Gly Ser Tyr Tyr Pro Gly Ser Gly Ile Ala Gln Phe His Ile
 1 5 10 15

Asp Tyr Asn Asn Val Ser
20

<210> 193
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> C4BP-BINDING
<400> 193

Ser Gly Ile Ala Gln Phe His Ile Asp Tyr Asn Asn Val Ser Ser Ala
1 5 10 15

Glu Gly Trp His Val Asn
20

<210> 194
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> C4BP-BINDING
<400> 194
Leu Val Thr Val Glu Lys Gly Ser Tyr Tyr Pro Gly Ser Gly Ile Ala
1 5 10 15

Gln Phe His Ile Asp Tyr Asn Asn Val Ser Ser Ala Glu Gly Trp His
20 25 30

Val Asn

<210> 195
<211> 14
<212> PRT
<213> Artificial Sequence

<220>

<223> C4BP-BINDING

<400> 195

Ser Gly Ile Ala Gln Phe His Ile Asp Tyr Asn Asn Val Ser
 1 5 10

<210> 196

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 196

Ala Glu Pro Met Pro His Ser Leu Asn Phe Ser Gln Tyr Leu Trp Tyr
 1 5 10 15

Thr

<210> 197

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 197

Ala Glu His Thr Tyr Ser Ser Leu Trp Asp Thr Tyr Ser Pro Leu Ala
 1 5 10 15

Phe

<210> 198

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 198

Ala	Glu	Leu	Asp	Leu	Trp	Met	Arg	His	Tyr	Pro	Leu	Ser	Phe	Ser	Asn
1				5					10					15	

Arg

<210> 199

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 199

Ala	Glu	Ser	Ser	Leu	Trp	Thr	Arg	Tyr	Ala	Trp	Pro	Ser	Met	Pro	Ser
1				5					10					15	

Tyr

<210> 200

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 200

Ala	Glu	Trp	His	Pro	Gly	Leu	Ser	Phe	Gly	Ser	Tyr	Leu	Trp	Ser	Lys
1				5					10					15	

Thr

<210> 201

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 201

Ala Glu Pro Ala Leu Leu Asn Trp Ser Phe Phe Phe Asn Pro Gly Leu
1 5 10 15

His

<210> 202

<211> 17

<212> PRT

<213> Artificial Sequence


<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 202

Ala Glu Trp Ser Phe Tyr Asn Leu His Leu Pro Glu Pro Gln Thr Ile
1 5 10 15

Phe



<210> 203

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 203

Ala Glu Pro Leu Asp Leu Trp Ser Leu Tyr Ser Leu Pro Pro Leu Ala
1 5 10 15

Met



<210> 204

<211> 17

<210> 207

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 207

Ala Glu Ser Ser Leu Trp Arg Ile Phe Ser Pro Ser Ala Leu Met Met
 1 5 10 15

Ser

<210> 208

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 208

Ala Glu Ser Leu Pro Thr Leu Thr Ser Ile Leu Trp Gly Lys Glu Ser
 1 5 10 15
 Val

<210> 209

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 209

Ala Glu Thr Leu Phe Met Asp Leu Trp His Asp Lys His Ile Leu Leu
 1 5 10 15

Thr

<210> 210

<211> 17

<212> PRT

<213> Artificial sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 210

Ala	Glu	Ile	Leu	Asn	Phe	Pro	Leu	Trp	His	Glu	Pro	Leu	Trp	Ser	Thr
1			5					10						15	

Glu

<210> 211

<211> 17

<212> PRT

<213> Artificial sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 211

Ala	Glu	Ser	Gln	Thr	Gly	Thr	Leu	Asn	Thr	Leu	Phe	Trp	Asn	Thr	Leu
1			5					10						15	

Arg

<210> 212

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Xaa is V, L, I, E, P, G, Y, M, T or D.

<220>

<221> misc_feature

<222> (2)..(2)

<223> Xaa is Y, W or F.

<220>

<221> misc_feature

<222> (3)..(3)

<223> Xaa is F, W or Y.


<220>

<221> misc_feature

<222> (5)..(5)

<223> Xaa is P or Azetidine.

<220>



<221> misc_feature

<222> (7)..(7)


<223> Xaa is S, A, V or L.

<220>

<221> misc_feature

<222> (8)..(8)

<223> Xaa is V, L, I or E.



<220>

<221> misc_feature

<222> (9)..(9)

<223> Xaa is Q or P.

<400> 212

Xaa Xaa Xaa Gln Xaa Tyr Xaa Xaa Xaa
 1 5

<210> 213

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 213

Thr Ala Asn Val Ser Ser Phe Glu Trp Thr Pro Tyr Tyr Trp Gln Pro
 1 5 10 15


Tyr Ala Leu Pro Leu
 20

<210> 214

<211> 18

<212> PRT

<213> Artificial Sequence




<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 214

Ser Trp Thr Asp Tyr Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Ile Ser
 1 5 10 15

Gly Leu



<210> 215

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 215

Glu Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 216

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 216

Glu Asn Thr Tyr Ser Pro Asn Trp Ala Asp Ser Met Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 217

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 217

Ser Val Gly Glu Asp His Asn Phe Trp Thr Ser Glu Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 218

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 218

Asp Gly Tyr Asp Arg Trp Arg Gln Ser Gly Glu Arg Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 219

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 219

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr
1 5 10

<210> 220

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 220

Phe Glu Trp Thr Pro Gly Tyr Trp Gln His Tyr
1 5 10

<210> 221

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 221

Phe	Glu	Trp	Thr	Pro	Gly	Trp	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 222

<211> 11

<212> PRT

<213> Artificial Sequence

<220>


<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, optionally acetlated at N terminus



<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 222

Phe	Glu	Trp	Thr	Pro	Gly	Trp	Tyr	Gln	Xaa	Tyr
1				5					10	



<210> 223

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11, Xaa = azetidine

<400> 223

Phe Glu Trp Thr Pro Gly Trp Pro Tyr Gln Xaa Tyr
1 5 10

<210> 224

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 224

Phe Ala Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 225

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 225

Phe Glu Trp Ala Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 226

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>


<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 226

Phe Glu Trp Val Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10



<210> 227

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine



<400> 227


Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 228
 <211> 11
 <212> PRT
 <213> Artificial sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1, optionally acetylated at N terminus

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa = azetidine

<400> 228
 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
 1 5 10



<210> 229
 <211> 11
 <212> PRT
 <213> Artificial sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (6)..(6)
 <223> Position 6, Xaa products = "MeGly"



<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 229

Phe Glu Trp Thr Pro Xaa Trp Tyr Gln Xaa Tyr
1 5 10

<210> 230

<211> 11

<212> PRT

<213> Artificial Sequence

<220>


<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, Xaa = MeGly



<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 230

Phe Glu Trp Thr Pro Xaa Trp Tyr Gln Xaa Tyr
1 5 10



<210> 231

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 231

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Tyr	Gln	Pro	Tyr
1				5					10	

<210> 232

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 232

Phe	Glu	Trp	Thr	Pro	Gly	Trp	Trp	Gln	Pro	Tyr
1				5					10	

<210> 233

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 233

Phe	Glu	Trp	Thr	Pro	Asn	Tyr	Trp	Gln	Pro	Tyr
1				5					10	

<210> 234

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa = pipecolic acid

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 234

Phe Glu Trp Thr Xaa Val Tyr Trp Gln Xaa Tyr
1 5 10

<210> 235

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

••••• <222> (5)..(5)

••••• <223> Position 5, Xaa = pipecolic acid

•••••
•••••
•••••
•••••
•••••

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

•••••
•••••
•••••
•••••
•••••
•••••
•••••
•••••
•••••
•••••

<400> 235

Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr
1 5 10

••••• <210> 236

••••• <211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, Xaa = Aib

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 236

Phe Glu Trp Thr Pro Xaa Tyr Trp Gln Xaa Tyr
1 5 10

<210> 237

<211> 11

••••• <212> PRT

••••• <213> Artificial Sequence

•••••
•••••
•••••
•••••
•••••

<220>

••••• <223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

••••• <223> Position 5, Xaa = MeGly

•••••
•••••
•••••
•••••
•••••
•••••

<220>

••••• <221> misc_feature

••••• <222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 237

Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 238

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11, amino group added at C terminus

<400> 238

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr
1 5 10

<210> 239

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11, amino group added at C-terminus

<400> 239

Phe Glu Trp Thr Pro Gly Tyr Trp Gln His Tyr
1 5 10


<210> 240

<211> 11
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue
 Position 11 amino group added at C-terminus


<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Position 11 amino group added at C-terminus

<400> 240
 Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr
 1 5 10



<210> 241
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1 optionally acetylated at N-terminus



<220>
 <221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 241

Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr
1 5 10

<210> 242

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

••••• <221> misc_feature

••••• <222> (8)..(8)

••••• <223> Position 8, Xaa is a phyosphotyrosyl residue

••••• <220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

••••• <220>

••••• <221> misc_feature

••••• <222> (11)..(11)

••••• <223> Position 11 amino group added at C-terminus

<400> 242

Phe Glu Trp Thr Pro Gly Trp Xaa Gln Xaa Tyr
 1 5 10

<210> 243

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

••••• <400> 243

••••• Phe Ala Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
 ••••• 1 5 10

••••• <210> 244

••••• <211> 11

<212> PRT

<213> Artificial Sequence

••••• <220>

••••• <223> IL-1 ANTAGONIST PEPTIDE

••••• <220>

••••• <221> misc_feature

••••• <222> (10)..(10)

••••• <223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 244

Phe Glu Trp Ala Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 245

<211> 11

<212> PRT

<213> Artificial sequence

<220>


<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue



<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 245

Phe Glu Trp Val Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10



<210> 246

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 246

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 247

<211> 11

<212> PRT

<213> Artificial Sequence

••••• <220>

••••• <223> IL-1 ANTAGONIST PEPTIDE

••••• <220>

••••• <221> misc_feature

••••• <222> (1)..(1)

••••• <223> Position 1 acetylated at N-terminus

<220>

••••• <221> misc_feature

••••• <222> (10)..(10)

••••• <223> Position 10, Xaa is an azetidine residue

••••• <220>

••••• <221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 247

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 248

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, D amino acid residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 248

Phe Glu Trp Thr Pro Ala Trp Tyr Gln Xaa Tyr
1 5 10

<210> 249

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, Xaa is a sarcosine residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 249


 Phe Glu Trp Thr Pro Xaa Trp Tyr Gln Xaa Tyr
 1 5 10


<210> 250

<211> 11

<212> PRT

<213> Artificial Sequence

<220>


 <223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 250

Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Pro Tyr
 1 5 10

<210> 251

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 251

Phe Glu Trp Thr Pro Gly Trp Trp Gln Pro Tyr
 1 5 10

<210> 252

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 252

Phe Glu Trp Thr Pro Asn Tyr Trp Gln Pro Tyr
 1 5 10

<210> 253

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, D amino acid residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 253

Phe	Glu	Trp	Thr	Pro	Val	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 254

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa is a pipecolic acid residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 254

Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 255

<211> 11

<212> PRT

<213> Artificial Sequence

••••• <220>

••••• <223> IL-1 ANTAGONIST PEPTIDE

••••• <220>

••••• <221> misc_feature

••••• <222> (6)..(6)

<223> Position 6, Xaa = pipecolic acid

<220>

••••• <221> misc_feature

••••• <222> (10)..(10)

••••• <223> Position 10, Xaa = azetidine

••••• <400> 255

••••• Phe Glu Trp Thr Pro Xaa Tyr Trp Gln Xaa Tyr
1 5 10

<210> 256
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (5)..(5)
 <223> Position 5, Xaa = MeGly

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa = azetidine

<400> 256
 Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr
 1 5 10

•••••
 ••••• <210> 257
 ••••• <211> 15
 ••••• <212> PRT
 ••••• <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

••••• <400> 257
 ••••• Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
 ••••• 1 5 10 15

••••• <210> 258
 ••••• <211> 11
 ••••• <212> PRT
 ••••• <213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa is a 1-naphthylalanine residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue


<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 258


 Xaa Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
 1 5 10

<210> 259

<211> 11

<212> PRT

<213> Artificial Sequence

<220>


 <223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature
 <222> (11)..(11)
 <223> Position 11 amino group added at C-terminus

<400> 259

Tyr Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
 1 5 10

<210> 260
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

⋮ <220>
 ⋮ <221> misc_feature
 ⋮ <222> (11)..(11)
 ⋮ <223> Position 11 amino group added at C-terminus
 ⋮

<400> 260

Phe Glu Trp Val Pro Gly Tyr Tyr Gln Xaa Tyr
 1 5 10

⋮ <210> 261
 ⋮ <211> 11
 ⋮ <212> PRT
 ⋮ <213> Artificial Sequence

⋮ <220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, D amino acid residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 261

Phe Glu Trp Thr Pro Ser Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 262

••••• <211> 11

••••• <212> PRT

••••• <213> Artificial Sequence

••••• <220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

••••• <222> (6)..(6)

••••• <223> Position 6, D amino acid residue

••••• <220>

••••• <221> misc_feature

••••• <222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 262

Phe Glu Trp Thr Pro Asn Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 263

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 263

Thr Lys Pro Arg
1

••••• <210> 264

••••• <211> 5

••••• <212> PRT

••••• <213> Artificial Sequence

•••••

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 264

••••• Arg Lys Ser Ser Lys
1 5

••••• <210> 265

••••• <211> 5

••••• <212> PRT

••••• <213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 265

Arg Lys Gln Asp Lys
1 5

<210> 266

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 266

Asn Arg Lys Gln Asp Lys
1 5

<210> 267

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 267

Arg Lys Gln Asp Lys Arg
1 5

<210> 268

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 268

Glu Asn Arg Lys Gln Asp Lys Arg Phe
1 5

<210> 269
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 269

Val Thr Lys Phe Tyr Phe
 1 5

<210> 270
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 270

Val Thr Lys Phe Tyr
 1 5

<210> 271
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 271

Val Thr Asp Phe Tyr
 1 5

<210> 272
 <211> 17
 <212> PRT

<213> Artificial Sequence

<220>

<223> MAST CELL ANTAGONISTS/ PROTEASE INHIBITOR PEPTIDE

<400> 272

Ser Gly Ser Gly Val Leu Lys Arg Pro Leu Pro Ile Leu Pro Val Thr
1 5 10 15

Arg

<210> 273

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> MAST CELL ANTAGONISTS/ PROTEASE INHIBITOR PEPTIDE

<400> 273

Arg Trp Leu Ser Ser Arg Pro Leu Pro Pro Leu Pro Leu Pro Pro Arg
1 5 10 15

Thr

<210> 274

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> MAST CELL ANTAGONISTS/ PROTEASE INHIBITOR PEPTIDE

<400> 274

Gly Ser Gly Ser Tyr Asp Thr Leu Ala Leu Pro Ser Leu Pro Leu His
1 5 10 15

Pro Met Ser Ser
20

<210> 275

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> MAST CELL ANTAGONISTS/ PROTEASE INHIBITOR PEPTIDE

<400> 275

Gly Ser Gly Ser Tyr Asp Thr Arg Ala Leu Pro Ser Leu Pro Leu His
1 5 10 15

Pro Met Ser Ser
20

<210> 276

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> MAST CELL ANTAGONISTS/ PROTEASE INHIBITOR PEPTIDE

<400> 276

Gly Ser Gly Ser Ser Gly Val Thr Met Tyr Pro Lys Leu Pro Pro His
1 5 10 15

Trp Ser Met Ala
20

<210> 277

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> MAST CELL ANTAGONISTS/ PROTEASE INHIBITOR PEPTIDE

<400> 277

Gly Ser Gly Ser Ser Gly Val Arg Met Tyr Pro Lys Leu Pro Pro His
1 5 10 15

Trp Ser Met Ala
20

<210> 278

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> MAST CELL ANTAGONISTS/ PROTEASE INHIBITOR PEPTIDE

<400> 278

Gly Ser Gly Ser Ser Ser Met Arg Met Val Pro Thr Ile Pro Gly Ser
1 5 10 15

Ala Lys His Gly
20

<210> 279

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTI-HBV

<400> 279

Leu Leu Gly Arg Met Lys
1 5

<210> 280

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTI-HBV

<400> 280

Ala Leu Leu Gly Arg Met Lys Gly
1 5

<210> 281

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTI-HBV

<400> 281

Leu Asp Pro Ala Phe Arg
 1 5

<210> 282

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 282

Arg Pro Leu Pro Pro Leu Pro
 1 5

<210> 283

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 283

Arg Glu Leu Pro Pro Leu Pro
 1 5

<210> 284

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 284

Ser Pro Leu Pro Pro Leu Pro
 1 5

<210> 285

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 285


Gly Pro Leu Pro Pro Leu Pro
 1 5

<210> 286

<211> 7

<212> PRT

<213> Artificial Sequence


 <220>
 <223> SH3 ANTAGONIST PEPTIDE
 <400> 286
 Arg Pro Leu Pro Ile Pro Pro
 1 5

<210> 287

<211> 7

<212> PRT

<213> Artificial Sequence


 <220>
 <223> SH3 ANTAGONIST PEPTIDE
 <400> 287

Arg Pro Leu Pro Ile Pro Pro
 1 5

<210> 288

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 288

Arg Arg Leu Pro Pro Thr Pro
1 5

<210> 289

<211> 7

<212> PRT


<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 289

Arg Gln Leu Pro Pro Thr Pro
1 5



<210> 290

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 290

Arg Pro Leu Pro Ser Arg Pro
1 5



<210> 291

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 291

Arg Pro Leu Pro Thr Arg Pro
1 5

<210> 292

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 292

Ser Arg Leu Pro Pro Leu Pro
1 5

<210> 293

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 293

Arg Ala Leu Pro Ser Pro Pro
1 5

<210> 294

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 294

Arg Arg Leu Pro Arg Thr Pro
1 5

<210> 295

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 295

Arg Pro Val Pro Pro Ile Thr
1 5

<210> 296

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 296

Ile Leu Ala Pro Pro Val Pro
1 5

<210> 297

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 297

Arg Pro Leu Pro Met Leu Pro
1 5

<210> 298

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 298

Arg Pro Leu Pro Ile Leu Pro
1 5

<210> 299

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 299

Arg Pro Leu Pro Ser Leu Pro
1 5

<210> 300

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 300

Arg Pro Leu Pro Ser Leu Pro
1 5

<210> 301

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 301

Arg Pro Leu Pro Met Ile Pro
1 5

<210> 302

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 302


Arg Pro Leu Pro Leu Ile Pro
1 5

<210> 303

<211> 7

<212> PRT

<213> Artificial Sequence



<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 303


Arg Pro Leu Pro Pro Thr Pro
1 5

<210> 304

<211> 7

<212> PRT

<213> Artificial Sequence



<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 304

Arg Ser Leu Pro Pro Leu Pro
1 5

<210> 305
 <211> 7
 <212> PRT
 <213> Artificial sequence

<220>
 <223> SH3 ANTAGONIST PEPTIDE
 <400> 305
 Arg Pro Gln Pro Pro Pro Pro
 1 5

<210> 306
 <211> 7
 <212> PRT
 <213> Artificial sequence

<220>
 <223> SH3 ANTAGONIST PEPTIDE
 <400> 306

Arg Gln Leu Pro Ile Pro Pro
 1 5

<210> 307
 <211> 12
 <212> PRT
 <213> Artificial sequence

<220>
 <223> SH3 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (1, 2, 3)..(11)
 <223> Xaa = any amino acid
 <400> 307

Xaa Xaa Xaa Arg Pro Leu Pro Pro Leu Pro Xaa Pro
 1 5 10

<210> 308

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1, 2, 3, 11)..(12)

<223> Xaa = any amino acid

<400> 308

Xaa Xaa Xaa Arg Pro Leu Pro Pro Ile Pro Xaa Xaa
 1 5 10

<210> 309

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1, 2, 3, 11,)..(12)

<223> Xaa = any amino acid

<400> 309

Xaa Xaa Xaa Arg Pro Leu Pro Pro Leu Pro Xaa Xaa
 1 5 10

<210> 310

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (2, 3, 10)..(11)

<223> Xaa = any amino acid

<400> 310

Arg	Xaa	Xaa	Arg	Pro	Leu	Pro	Pro	Leu	Pro	Xaa	Pro
1				5					10		

<210> 311

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (2)..(3)

<223> Xaa = any amino acid

<400> 311

Arg	Xaa	Xaa	Arg	Pro	Leu	Pro	Pro	Leu	Pro	Pro	Pro
1				5					10		

<210> 312

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (11)..(12)

<223> Xaa = any amino acid

<400> 312

Pro Pro Pro Tyr Pro Pro Pro Pro Ile Pro Xaa Xaa
1 5 10

<210> 313

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (11)..(12)

<223> Xaa = any amino acid

<400> 313

Pro Pro Pro Tyr Pro Pro Pro Pro Val Pro Xaa Xaa
1 5 10

<210> 314

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (2, 3)..(8)

<223> Xaa (Pos2, 3, 8) is any amino acid

<220>

<221> misc_feature

<222> (9)..(9)

<223> Xaa (Pos 9) represents an aliphatic amino acid residue

<400> 314

Leu Xaa Xaa Arg Pro Leu Pro Xaa Xaa Pro
1 5 10

<210> 315

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa is an aliphatic amino acid residue

<220>

<221> misc_feature

<222> (2, 3)..(8)

<223> Positions 2, 3 & 8, Xaa is any amino acid

<400> 315

Xaa Xaa Xaa Arg Pro Leu Pro Xaa Leu Pro
1 5 10

<210> 316

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (3)..(3)

<223> Position 3, Xaa is any amino acid residue

<220>

<221> misc_feature

<222> (4)..(4)

<223> Position 4, Xaa is an aromatic amino acid residue

<220>

<221> misc_feature

<222> (9)..(9)

<223> Position 9, Xaa is an aliphatic amino acid residue

<400> 316

Pro Pro Xaa Xaa Tyr Pro Pro Pro Xaa Pro
1 5 10

<210> 317

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa is a basic amino acid residue

<220>

<221> misc_feature

<222> (4)..(4)

<223> Position 4, Xaa is an aliphatic amino acid residue

<220>

<221> misc_feature

<222> (6)..(9)

<223> Positions 6 & 9, Xaa is any amino acid residue

<400> 317

Xaa Pro Pro Xaa Pro Xaa Lys Pro Xaa Trp Leu
1 5 10

<210> 318

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (3, 4)..(6)

<223> Positions 3, 4 & 6, Xaa is an aliphatic amino acid residue

<220>

<221> misc_feature

<222> (8)..(8)

<223> Position 8, Xaa is a basic amino acid residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is any amino acid residue

<400> 318

Arg Pro Xaa Xaa Pro Xaa Arg Xaa Ser Xaa Pro
1 5 10

<210> 319

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (8)..(9)

<223> Xaa = any amino acid

<400> 319

Pro Pro Val Pro Pro Arg Pro Xaa Xaa Thr Leu
1 5 10

<210> 320

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1, 3)..(6)

<223> Positions 1, 3 and 6, Xaa is an aliphatic amino acid residue

<400> 320

Xaa Pro Xaa Leu Pro Xaa Lys
1 5

<210> 321
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SH3 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1, Xaa is a basic amino acid residue

<220>
 <221> misc_feature
 <222> (2)..(2)
 <223> Position 2, Xaa is an aromatic amino acid residue

<220>
 <221> misc_feature
 <222> (4)..(8)
 <223> Positions 4 & 8, Xaa is any amino acid residue

<400> 321
 Xaa Xaa Asp Xaa Pro Leu Pro Xaa Leu Pro
 1 5 10

<210> 322
 <211> 7
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> INHIBITION OF PLATELET AGGREGATION
 <220>

<221> misc_feature
 <222> (2)..(3)
 <223> Xaa = any amino acid

<400> 322
 Cys Xaa Xaa Arg Gly Asp Cys
 1 5

<210> 323
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SRC ANTAGONIST
 <400> 323
 Arg Pro Leu Pro Pro Leu Pro
 1 5

<210> 324
 <211> 6
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> SRC ANTAGONIST
 <400> 324
 Pro Pro Val Pro Pro Arg
 1 5

<210> 325
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTI-CANCER (PARTICULARLY FOR SARCOMAS)
 Page 143

<220>

<221> misc_feature

<222> (1, 3, 5, 7, 8, 10)..(11)

<223> Xaa = any amino acid

<400> 325

Xaa Phe Xaa Asp Xaa Trp Xaa Xaa Leu Xaa Xaa
1 5 10

<210> 326

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> P16-MIMETIC

<400> 326

Lys Ala Cys Arg Arg Leu Phe Gly Pro Val Asp Ser Glu Gln Leu Ser
1 5 10 15

Arg Asp Cys Asp
20

<210> 327

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> P16-MIMETIC

<400> 327

Arg Glu Arg Trp Asn Phe Asp Phe Val Thr Glu Thr Pro Leu Glu Gly
1 5 10 15

Asp Phe Ala Trp
20

<210> 328

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> P16-MIMETIC

<400> 328

Lys Arg Arg Gln Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg
1 5 10 15

Leu Ile Phe Ser
20

<210> 329

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> P16-MIMETIC

<400> 329

Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg Leu Ile Phe Ser
1 5 10 15

Lys Arg Lys Pro
20

<210> 330

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> P16-MIMETIC

<400> 330

Arg Arg Leu Ile Phe
1 5

<210> 331

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> P16-MIMETIC

<400> 331

Lys Arg Arg Gln Thr Ser Ala Thr Asp Phe Tyr His Ser Lys Arg Arg
1 5 10 15

Leu Ile Phe Ser Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met
20 25 30

Lys Trp Lys Lys
35

<210> 332

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> P16-MIMETIC

<400> 332

Lys Arg Arg Leu Ile Phe Ser Lys Arg Gln Ile Lys Ile Trp Phe Gln
1 5 10 15
Asn Arg Arg Met Lys Trp Lys Lys
20

<210> 333

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> PREFERRED LINKER

<400> 333

Gly Gly Gly Lys Gly Gly Gly Gly
1 5

<210> 334
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> PREFERRED LINKER
 <400> 334

Gly Gly Gly Asn Gly Ser Gly Gly
 1 5

<210> 335
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> PREFERRED LINKER
 <400> 335

Gly Gly Gly Cys Gly Gly Gly Gly
 1 5

<210> 336
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> PREFERRED LINKER
 <400> 336

Gly Pro Asn Gly Gly
 1 5

<210> 337
 <211> 41
 <212> PRT
 <213> Artificial Sequence

<220>

<223> TPO-MIMETIC

<220>

<221> misc_feature

<222> (1)..(1)

<223> Fc domain attached at Position 1 of the N-terminus

<400> 337

Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala
1 5 10 15

Ala Arg Ala Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr
20 25 30

Leu Arg Gln Trp Leu Ala Ala Arg Ala
35 40

<210> 338

<211> 41

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC

<220>

<221> misc_feature

<222> (41)..(41)

<223> Fc domain attached at Position 41 of the C-terminus

<400> 338

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15


Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala Gly Gly Gly Gly Gly
35 40


<210> 339
 <211> 49
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC
 <220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Fc domain attached at Position 1 of the N-terminus

<400> 339
 Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu
 1 5 10 15
 Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Thr
 20 25 30
 Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly
 35 40 45



Gly
 <210> 340
 <211> 49
 <212> PRT
 <213> Artificial Sequence



<220>
 <223> EPO-MIMETIC
 <220>
 <221> misc_feature
 <222> (49)..(49)
 <223> Fc domain attached at Position 49 of the C-terminus

<400> 340

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe
20 25 30

Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly
35 40 45

Gly

<210> 341

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 341

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Ile Glu
1 5 10 15

Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25

<210> 342

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 342

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Ile
1 5 10 15

Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25

<210> 343

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 343

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25 30

<210> 344

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 344

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25 30

<210> 345

<211> 32

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 345

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25 30

<210> 346
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDES
 <400> 346

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15
 Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg
 20 25 30

Ala

<210> 347
 <211> 34
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDES
 <400> 347
 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15
 Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala
 20 25 30

Arg Ala

<210> 348
 <211> 35
 <212> PRT
 <213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 348

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala
20 25 30

Ala Arg Ala
35

<210> 349

<211> 36

<212> PRT

<213> Artificial sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 349

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 350

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 350

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp
20 25 30

Leu Ala Ala Arg Ala
35

<210> 351

<211> 38

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 351

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln
20 25 30

Trp Leu Ala Ala Arg Ala
35

<210> 352

<211> 42

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 352

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro
20 25 30

Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
35 40

<210> 353

<211> 32

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 353

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Pro
1 5 10 15

Asn Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25 30

<210> 354

<211> 36

<212> PRT

<213> Artificial sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 354

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 355

<211> 36

<212> PRT

<213> Artificial sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 355

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 356

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 356

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 357

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 357

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 358

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<220>

<221> misc_feature

<222> (19)..(19)

<223> Position 19, xaa = bromoacetyl

<400> 358

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Lys Xaa Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp
20 25 30


Leu Ala Ala Arg Ala
35

<210> 359

<211> 36

<212> PRT

<213> Artificial Sequence



<220>


<223> TPO-MIMETIC PEPTIDES

<400> 359

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Cys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35



<210> 360

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<220>

<221> misc_feature

<222> (19)..(19)

<223> Position 19, Xaa = Poly(ethylene glycol)

<400> 360

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15

Gly Lys Xaa Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp
 20 25 30


Leu Ala Ala Arg Ala
 35

<210> 361

<211> 37

<212> PRT

<213> Artificial Sequence



<220>


<223> TPO-MIMETIC PEPTIDES

<220>

<221> misc_feature

<222> (19)..(19)

<223> Position 19, Xaa = Poly(ethylene glycol)



<400> 361

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15

Gly Cys Xaa Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp
 20 25 30

Leu Ala Ala Arg Ala
 35

<210> 362

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 362

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15

Gly Asn Gly Ser Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
 20 25 30

Ala Ala Arg Ala
 35

<210> 363

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 363

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15

Gly Cys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
 20 25 30

Ala Ala Arg Ala
 35

<210> 364

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> Fc-TMP

<400> 364
 aaaaaaggat cctcgagatt aagcacgagc agccagccac tgacgcagag tcggacc 57

<210> 365

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Fc-TMP

<400> 365
 aaaggtggag gtggtggtat cgaaggtccg actctgcgt 39

<210> 366

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Fc-TMP

••••• <400> 366
 cagtggctgg ctgctcgtgc ttaatctcga ggatcctttt tt 42

•••••

•••••

•••••

•••••

•••••

<210> 367

<211> 81

<212> DNA

<213> Artificial Sequence

<220>

•••••

<223> Fc-TMP

•••••

<220>

•••••

<221> CDS

•••••

<222> (1)..(60)

•••••

•••••

<223>

•••••

•••••

<400> 367
 aaa ggt gga ggt ggt ggt atc gaa ggt ccg act ctg cgt cag tgg ctg 48
 Lys Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu

1 5 10 15 81
gct gct cgt gct taatctcgag gatccttttt t
Ala Ala Arg Ala
20

<210> 368
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Fc-TMP
<400> 368
Lys Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
1 5 10 15

Ala Ala Arg Ala
20
<210> 369
<211> 22
<212> DNA
<213> Artificial Sequence

•••••
•••••
•••••
•••••
•••••
<220>
<223> Fc-TMP
<400> 369
aacataagta cctgtaggat cg 22

<210> 370
<211> 52
<212> DNA
<213> Artificial Sequence
•••••
•••••
•••••
•••••
•••••
<220>
<223> Fc-TMP
<400> 370
ttcgatacca ccacctccac ctttaccgag agacagggag aggcctcttct gc 52

<210> 371

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> FC-TMP-TMP

<400> 371

aaaggtggag gtggtggtat cgaaggtccg actctgcgtc agtggctggc tgctcgtgct 60

<210> 372

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> FC-TMP-TMP

<400> 372

acctccacca ccagcacgag cagccagcca ctgacgcaga gtcggacc 48

<210> 373

<211> 66

<212> DNA

<213> Artificial Sequence

<220>

<223> FC-TMP-TMP

<400> 373

ggtaggtggag gtggcggcgg aggtattgag ggcccaaccc ttcgccaatg gcttgagca 60

cgcgca 66

<210> 374

<211> 76

<212> PRT

<213> Artificial Sequence

<220>

<223> FC-TMP-TMP

<400> 374

Ala Ala Ala Ala Ala Ala Ala Gly Gly Ala Thr Cys Cys Thr Cys Gly
 1 5 10 15

Ala Gly Ala Thr Thr Ala Thr Gly Cys Gly Cys Gly Thr Gly Cys Thr
 20 25 30

Gly Cys Ala Ala Gly Cys Cys Ala Thr Thr Gly Gly Cys Gly Ala Ala
 35 40 45

Gly Gly Gly Thr Thr Gly Gly Gly Cys Cys Cys Thr Cys Ala Ala Thr
 50 55 60

Ala Cys Cys Thr Cys Cys Gly Cys Cys Gly Cys Cys
 65 70 75

<210> 375

<211> 126

<212> DNA

<213> Artificial Sequence

<220>

<223> FC-TMP-TMP

<220>

<221> CDS

<222> (1)..(126)

<223>

<400> 375

aaa ggt gga ggt ggt ggt atc gaa ggt ccg act ctg cgt cag tgg ctg 48
 Lys Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
 1 5 10 15

gct gct cgt gct ggt ggt gga ggt ggc ggc gga ggt att gag ggc cca 96
 Ala Ala Arg Ala Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro
 20 25 30

acc ctt cgc caa tgg ctt gca gca cgc gca 126
 Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
 35 40

<210> 376

<211> 42

<212> PRT

<213> Artificial Sequence

<220>

<223> FC-TMP-TMP

<400> 376

Lys Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
1 5 10 15

Ala Ala Arg Ala Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro
20 25 30

Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
35 40

<210> 377

<211> 39

<212> PRT

<213> Artificial sequence

<220>

<223> TMP-TMP-FC

<400> 377

Thr Thr Thr Thr Thr Thr Cys Ala Thr Ala Thr Gly Ala Thr Cys Gly
1 5 10 15

Ala Ala Gly Gly Thr Cys Cys Gly Ala Cys Thr Cys Thr Gly Cys Gly
20 25 30

Thr Cys Ala Gly Thr Gly Gly
35

<210> 378

<211> 48

<212> PRT

<213> Artificial Sequence

<220>

<223> TMP-TMP-FC

<400> 378

Ala Gly Cys Ala Cys Gly Ala Gly Cys Ala Gly Cys Cys Ala Gly Cys
1 5 10 15

Cys Ala Cys Thr Gly Ala Cys Gly Cys Ala Gly Ala Gly Thr Cys Gly
 20 25 30

Gly Ala Cys Cys Thr Thr Cys Gly Ala Thr Cys Ala Thr Ala Thr Gly
 35 40 45

<210> 379

<211> 45

<212> DNA

<213> Artificial sequence

<220>

<223> TMP-TMP-Fc

<400> 379

ctggctgctc gtgctggtgg aggcggtggg gacaaaactc acaca 45

<210> 380

<211> 51

<212> DNA

<213> Artificial sequence

<220>

<223> TMP-TMP-Fc

<400> 380

ctggctgctc gtgctggcgg tggcggcgga gggggtggca ttgagggccc a 51

<210> 381

<211> 54

<212> DNA

<213> Artificial Sequence

<220>

<223> TMP-TMP-Fc

<400> 381

aagccattgg cgaagggttg ggcctcaat gccaccccct ccgccaccac cgcc 54

<210> 382

<211> 54

<212> DNA

<213> Artificial Sequence

<220>

<223> TMP-TMP-Fc

<400> 382
acccttcgcc aatggcttgc agcacgcgca gggggaggcg gtggggacaa aact 54

<210> 383

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> TMP-TMP-Fc

<400> 383
cccaccgcct cccctgcgc gtgctgc 27

<210> 384

<211> 189

<212> DNA

<213> Artificial Sequence

<220>

<223> TMP-TMP-Fc

<220>

<221> CDS

<222> (10)..(180)

<223>

<400> 384
ttttttcat atg atc gaa ggt ccg act ctg cgt cag tgg ctg gct gct cgt 51
Met Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg
1 5 10

gct ggc ggt ggt ggc gga ggg ggt ggc att gag ggc cca acc ctt cgc 99
Ala Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg
15 20 25 30

caa tgg ctg gct gct cgt gct ggt gga ggc ggt ggg gac aaa act ctg 147
Gln Trp Leu Ala Ala Arg Ala Gly Gly Gly Gly Gly Asp Lys Thr Leu
35 40 45

gct gct cgt gct ggt gga ggc ggt ggg gac aaa actcacaca
 Ala Ala Arg Ala Gly Gly Gly Gly Gly Gly Asp Lys
 50 55

189

<210> 385

<211> 57

<212> PRT

<213> Artificial Sequence

<220>

<223> TMP-TMP-Fc

<400> 385

Met Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly
 1 5 10 15

Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp
 20 25 30

Leu Ala Ala Arg Ala Gly Gly Gly Gly Gly Asp Lys Thr Leu Ala Ala
 35 40 45

Arg Ala Gly Gly Gly Gly Gly Asp Lys
 50 55

<210> 386

<211> 141

<212> DNA

<213> Artificial Sequence

<220>

<223> pAMG21

<400> 386

ctaattccgc tctcacctac caaacaatgc cccctgcaa aaaataaatt catataaaaa 60

acatacagat aaccatctgc ggtgataaat tatctctggc ggtgttgaca taaataccac 120

tggcggatgat actgagcaca t 141

<210> 387

<211> 55

<212> DNA

<213> Artificial Sequence

<220>

<223> pAMG21

<400> 387

cgatttgatt ctagaaggag gaataacata tggttaacgc gttggaattc ggtac 55

<210> 388

<211> 872

<212> DNA

<213> Artificial Sequence

<220>

<223> GM221

<400> 388

ttattttcgt gcggccgcac cattatcacc gccagaggta aactagtcaa cacgcacggt 60

gttagatatt tatcccttgc ggtgatagat tgagcacatc gatttgattc tagaaggagg 120

gataatatat gagcacaaaa aagaaacat taacacaaga gcagcttgag gacgcacgtc 180


gccttaaagc aatttatgaa aaaaagaaaa atgaacttgg cttatcccag gaatctgtcg 240


cagacaagat ggggatgggg cagtcaggcg ttggtgcttt atttaatggc atcaatgcat 300

taaatgctta taacgccgca ttgcttaca aaatttctca agttagcggt gaagaattta 360

gcccttcaat cgccagagaa tctacgagat gtatgaagcg gttagtatgc agccgtcact 420

tagaagtgag tatgagtacc ctgttttttc tcatgttcag gcagggatgt tctcacctaa 480


 gcttagaacc ttaccaaag gtgatgcgga gagatgggta agcacaacca aaaaagccag 540


 tgattctgca ttctggcttg aggttgaagg taattccatg accgcaccaa caggctccaa 600



 gccaaagcttt cctgacggaa tgtaattct cgttgaccct gagcaggctg ttgagccagg 660



 tgatttctgc atagccagac ttgggggtga tgagtttacc ttcaagaaac tgatcaggga 720


tagcggctcag gtgtttttac aaccactaaa cccacagtac ccaatgatcc catgcaatga 780


gagttgttcc gttgtgggga aagttatcgc tagtcagtgg cctgaagaga cgtttggtg 840

atagactagt ggatccacta gtgtttctgc cc 872


 <210> 389


 <211> 1197


 <212> DNA


 <213> Artificial Sequence


 <220>

<223> GM221

<400> 389
ggcggaaacc gacgtccatc gaatggtgca aaacctttcg cggatatggca tgatagcgcc 60
cggaagagag tcaattcagg gtggtgaatg tgaaccaggt aacgttatac gatgtcgag 120
agtatgccgg tgtctcttat cagaccgttt ccgcgctggt gaaccaggcc agccacgttt 180
ctgcaaaaac gcgggaaaaa gtcgaagcgg cgatggcgga gctgaattac attcccaacc 240
gcgtggcaca acaactggcg ggcaaacagt cgctcctgat tggcgttgcc acctccagtc 300
tggccctgca cgcgccgtcg caaattgtcg cggcgattaa atctcgcgcc gatcaactgg 360
gtgccagcgt ggtggtgtcg atggtagaac gaagcggcgt cgaagcctgt aaagcggcgg 420
tgcacaatct tctcgcgcaa cgcgtcagtg ggctgatcat taactatccg ctggatgacc 480
aggatgccat tgctgtggaa gctgcctgca ctaatgttcc ggcgttattt cttgatgtct 540
ctgaccagac acccatcaac agtattattt tctcccatga agacgggtacg cgactgggcg 600
tgagcatctt ggtcgcattg ggtcaccagc aaatcgcgct gttagcgggc ccattaagtt 660
ctgtctcggc gcgtctgctg ctggctggct ggcataaata tctcactcgc aatcaaattc 720
agccgatagc ggaacgggaa ggcgactgga gtgccatgtc cggttttcaa caaacatgc 780
aaatgctgaa tgagggcatc gttccactg cgatgctggt tgccaacgat cagatggcgc 840
tgggcgcaat gcgcgccatt accgagtccg ggctgcgcgt tggcgcggat atctcggtag 900
tgggatacga cgataccgaa gacagctcat gttatatccc gccgttaacc accatcaaac 960
aggattttcg cctgctgggg caaaccagcg tggaccgctt gctgcaactc tctcagggcc 1020
aggcggtgaa gggcaatcag ctgttgcccc tctcactggt gaaaagaaaa accaccctgg 1080
cgcccaatac gcaaaccgcc tctccccgcg cgttggccga ttcattaatg cagctggcac 1140
gacaggtttc ccgactggaa agcggacagt aagggtaccat aggatccagg cacagga 1197

<210> 390

<211> 61

<212> DNA

<213> Artificial Sequence

<220>

<223> FC-EMP

<400> 390
tatgaaaggt ggaggtggtg gtggaggtac ttactcttgc cacttcggcc cgctgacttg 60
g 61

<210> 391

<211> 72

<212> DNA

<213> Artificial Sequence

<220>

<223> FC-EMP

<400> 391
cggtttgcaa acccaagtca gcggggccgaa gtggcaagag taagtacctc caccaccacc 60
tccacctttc at 72

<210> 392

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> FC-EMP


<400> 392
gtttgcaaac cgcagggtgg cggcggcggc ggcggtggta cctattcctg tcatttt 57

<210> 393

<211> 60

<212> DNA

<213> Artificial Sequence



<220>

<223> FC-EMP

<400> 393
ccaggtcagc gggccaaaat gacaggaata ggtaccaccg ccgccgccgc cgccaccctg 60

<210> 394

<211> 118

<212> DNA

<213> Artificial Sequence



<220>

<223> FC-EMP

<220>

<221> CDS

<222> (2)..(118)

<223>

<400> 394

t	atg	aaa	ggt	gga	ggt	ggt	ggt	gga	ggt	act	tac	tct	tgc	cac	ttc	ggc	49
Met	Lys	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Thr	Tyr	Ser	Cys	His	Phe	Gly	
1				5						10					15		

ccg	ctg	act	tgg	gtt	tgc	aaa	ccg	cag	ggt	ggc	ggc	ggc	ggc	ggc	ggc	ggt	97
Pro	Leu	Thr	Trp	Val	Cys	Lys	Pro	Gln	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	
			20					25						30			

ggt	acc	tat	tcc	tgt	cat	ttt											118
Gly	Thr	Tyr	Ser	Cys	His	Phe											
		35															

<210> 395

<211> 39

<212> PRT

<213> Artificial Sequence

<220>

<223> Fc-EMP

<400> 395

Met	Lys	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Thr	Tyr	Ser	Cys	His	Phe	Gly	
1				5					10					15		

Pro	Leu	Thr	Trp	Val	Cys	Lys	Pro	Gln	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	
			20					25						30			

Gly	Thr	Tyr	Ser	Cys	His	Phe											
		35															

<210> 396

<211> 61

<212> DNA

<213> Artificial Sequence

<220>

<223> Fc-EMP

<400> 396

gcagaagagc	ctctccctgt	ctccgggtaa	aggtggaggt	ggtggtggag	gtacttactc	60
t						61

<210> 397

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> FC-EMP

<400> 397

ctaattggat ccacgagatt aaccaccctg cggtttgcaa

40

<210> 398

<211> 18

<212> PRT


<213> Artificial Sequence

<220>

<223> FC-EMP

<400> 398

Gly	Glu	Arg	Trp	Cys	Phe	Asp	Gly	Pro	Leu	Thr	Trp	Val	Cys	Gly	Glu
1				5					10					15	


 Glu Ser

<210> 399

<211> 61

<212> DNA

<213> Artificial Sequence

<220>

<223> FC-EMP

<400> 399

agagtaagta cctccaccac cacctccacc ttatcccgga gacagggaga ggctcttctg

60

c

61

<210> 400

<211> 61

<212> DNA

<213> Artificial Sequence

<220>

<223> EMP-Fc

<400> 400
ggcccgcgtga cctgggtatg taagccacaa ggggggtgggg gaggcggggg gtaatctcga 60
g 61

<210> 401

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> EMP-Fc

<400> 401
gatcctcgag attaccccc gctccccca ccccttgtg gcttacatac 50

<210> 402

<211> 118

<212> DNA

••••• <213> Artificial Sequence

•••••

••••• <220>

••••• <223> EMP-Fc

••••• <220>

<221> CDS

<222> (1)..(108)

<223>

•••••

••••• <400> 402
gtt tgc aaa ccg cag ggt ggc ggc ggc ggc ggc ggc ggt ggt acc tat tcc 48
Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser
1 5 10 15

••••• tgt cat ttt ggc ccg ctg acc tgg gta tgt aag cca caa ggg ggt ggg 96
Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly
20 25 30

gga ggc ggg ggg taatctcgag 118
Gly Gly Gly Gly

35

<210> 403

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> EMP-Fc

<400> 403

Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser
 1 5 10 15

Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly
 20 25 30


Gly Gly Gly Gly
 35

<210> 404

<211> 39

<212> DNA

<213> Artificial Sequence



<220>

<223> EMP-Fc

<400> 404

ttatttcata tgaaagggtgg taactattcc tgtcatttt


39

<210> 405

<211> 43

<212> DNA

<213> Artificial Sequence



<220>

<223> EMP-Fc

<400> 405

tggacatgtg tgagttttgt cccccccgcc tccccacccc cct

43

<210> 406

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> EMP-Fc

<400> 406

agggggtggg ggaggcgggg gggacaaaac tcacacatgt cca

43

<210> 407

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> EMP-Fc

<400> 407

gttattgctc agcgggtggca

20

<210> 408

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> EMP-EMP-Fc

<400> 408

ttttttatcg atttgattct agatttgagt ttttaactttt agaaggagga ataaaaatag

60

<210> 409

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> EMP-EMP-Fc

<400> 409

taaaagttaa aactcaaatc tagaatcaaa tcgataaaaa a 41

<210> 410

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<223> EMP-EMP-Fc

<400> 410
ggaggtactt actcttgcca cttcggcccg ctgacttggg ttgcaaacc g 51

<210> 411

<211> 55

<212> DNA

<213> Artificial Sequence

<220>

<223> EMP-EMP-Fc

<400> 411
agtcagcggg ccgaagtggc aagagtaagt acctcccata ttttattcct ccttc 55

••••• <210> 412

••••• <211> 60

••••• <212> DNA

••••• <213> Artificial Sequence

•••••

<220>

<223> EMP-EMP-Fc

<400> 412
caggggtggcg gcggcgggcg cggtggtacc tattcctgtc attttggccc gctgacctgg 60

•••••

••••• <210> 413

••••• <211> 60

••••• <212> DNA

••••• <213> Artificial Sequence

•••••

<220>

<223> EMP-EMP-Fc

<400> 413
 aaaatgacag gaataggtac caccgccgcc gccgccgcca ccctgcggtt tgcaaaccga 60

<210> 414

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> EMP-EMP-Fc

<400> 414
 gtatgtaagc cacaaggggg tgggggaggc gggggggaca aaactcacac atgtcca 57

<210> 415

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> EMP-EMP-Fc

••••• <400> 415
 agttttgtcc ccccgccctc cccaccccc ttgtggctta catacccagg tcagcggggc 60

••••• <210> 416

••••• <211> 228

••••• <212> DNA

<213> Artificial Sequence

<220>

••••• <223> EMP-EMP-Fc

••••• <220>

••••• <221> CDS

••••• <222> (58)..(228)

••••• <223>

<400> 416

```

ttttttatcg atttgattct agatttgagt tttaactttt agaaggagga ataaaat      57
atg gga ggt act tac tct tgc cac ttc ggc ccg ctg act tgg gtt tgc      105
Met Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys
1          5          10          15

aaa ccg cag ggt ggc ggc ggc ggc ggc ggt ggt acc tat tcc tgt cat      153
Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His
          20          25          30

ttt ggc ccg ctg acc tgg gta tgt aag cca caa ggg ggt ggg gga ggc      201
Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly
          35          40          45

ggg ggg gac aaa act cac aca tgt cca
Gly Gly Asp Lys Thr His Thr Cys Pro      228
50          55

```

<210> 417

<211> 57

<212> PRT

<213> Artificial Sequence

<220>

<223> EMP-EMP-Fc

<400> 417

```

Met Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys
1          5          10          15

```

```

. . . Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His
. . .          20          25          30
. . .
. . . Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly
. . .          35          40          45
. . .
. . . Gly Gly Asp Lys Thr His Thr Cys Pro
. . .          50          55

```

<210> 418

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Fc-EMP-EMP

<400> 418

```

ctaattggat cctcgagatt aaccccccttg tggcttacat

```

40

<210> 419

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (1, 3, 9, 14, 15)..(16)

<223> Xaa (Positions 1, 3, 9, 14, 15 & 16) can be any one of the 20 L-amino acids

<220>

<221> misc_feature

<222> (5)..(5)

<223> Xaa can be R, H, L or W

<220>

<221> misc_feature

••••• <222> (6)..(6)

••••• <223> Xaa can be M, F or I

•••••

•••••

••••• <220>

••••• <221> misc_feature

<222> (12)..(12)

<223> Xaa can be D, E, I, L or V

••••• <220>

••••• <221> misc_feature

••••• <222> (13)..(13)

••••• <223> Xaa can be C, A, α -amino- γ -bromobutyric acid or Hoc

•••••

•••••

<400> 419

Xaa Tyr Xaa Xaa Xaa Xaa Gly Pro Xaa Thr Trp Xaa Xaa Xaa Xaa Xaa
 1 5 10 15

<210> 420

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (1, 3, 5, 6, 9, 12, 14, 15)..(16)

<223> Xaa = any amino acid residue

<400> 420

Xaa Tyr Xaa Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Xaa Xaa
 1 5 10 15

<210> 421

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (2)..(2)

<223> Xaa can be R, H, L, or W

<220>

<221> misc_feature

<222> (3)..(3)

<223> Xaa can be M, F, or I

<220>

<221> misc_feature

<222> (6)..(6)

<223> xaa is independently selected from any one of the 20 genetically coded L-amino acids or the stereoisomeric D-amino acids

<220>

<221> misc_feature

<222> (9)..(9)

<223> Xaa can be D, E, I, L, or V.

<400> 421

Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys
1 5 10

<210> 422

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 422

Gly Gly Thr Tyr Ser Cys His Gly Pro Leu Thr Trp Val Cys Lys Pro
1 5 10 15

Gln Gly Gly

<210> 423

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 423

Val Gly Asn Tyr Met Ala His Met Gly Pro Ile Thr Trp Val Cys Arg
Page 181

1 5 10 15

Pro Gly Gly

<210> 424

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 424

Gly Gly Pro His His Val Tyr Ala Cys Arg Met Gly Pro Leu Thr Trp
1 5 10 15

Ile Cys

<210> 425

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 425

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln

<210> 426

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 426

Gly Gly Leu Tyr Ala Cys His Met Gly Pro Met Thr Trp Val Cys Gln
1 5 10 15

Pro Leu Arg Gly
20

<210> 427

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 427

Thr Ile Ala Gln Tyr Ile Cys Tyr Met Gly Pro Glu Thr Trp Glu Cys
1 5 10 15

Arg Pro Ser Pro Lys Ala
20

<210> 428

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 428

Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10

<210> 429

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 429

Tyr Cys His Phe Gly Pro Leu Thr Trp Val Cys
1 5 10

<210> 430

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 430

Ala Glu Pro Val Tyr Gln Tyr Glu Leu Asp Ser Tyr Leu Arg Ser Tyr
1 5 10 15

Tyr

<210> 431

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 431

Ala Glu Leu Asp Leu Ser Thr Phe Tyr Asp Ile Gln Tyr Leu Leu Arg
1 5 10 15

Thr

<210> 432

<211> 17

<212> PRT

<213> Artificial sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 432

Ala Glu Phe Phe Lys Leu Gly Pro Asn Gly Tyr Val Tyr Leu His Ser
1 5 10 15

Ala

<210> 433

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (4, 5)..(6)

<223> Xaa = any amino acid

<400> 433

Phe Lys Leu Xaa Xaa Xaa Gly Tyr Val Tyr Leu
1 5 10

<210> 434

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 434

Ala Glu Ser Thr Tyr His His Leu Ser Leu Gly Tyr Met Tyr Thr Leu
1 5 10 15

Asn

<210> 435

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (3, 5)..(6)

<223> Xaa = any amino acid

<400> 435

Tyr His Xaa Leu Xaa Xaa Gly Tyr Met Tyr Thr
1 5 10

<210> 436

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> MAST CELL ANTAGONISTS/PROTEASE INHIBITOR PEPTIDE

<400> 436

Arg Asn Arg Gln Lys Thr
1 5

<210> 437

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> MAST CELL ANTAGONISTS/PROTEASE INHIBITOR PEPTIDE

<400> 437

Arg Asn Arg Gln
1

<210> 438

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> MAST CELL ANTAGONISTS/PROTEASE INHIBITOR PEPTIDE

<400> 438

Arg Asn Arg Gln Lys
1 5

<210> 439

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> MAST CELL ANTAGONISTS/PROTEASE INHIBITOR PEPTIDE

<400> 439

Asn Arg Gln Lys Thr
1 5

•••••<210> 440

•••••<211> 4

•••••<212> PRT

•••••<213> Artificial Sequence

•••••

<220>

<223> MAST CELL ANTAGONISTS/PROTEASE INHIBITOR PEPTIDE

<400> 440

•••••Arg Gln Lys Thr
1

•••••<210> 441

•••••<211> 7

•••••<212> PRT

•••••<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<220>

<221> misc_feature

<222> (2, 5)..(7)

<223> Xaa = any amino acid

<400> 441

Arg Xaa Glu Thr Xaa Trp Xaa
1 5

<210> 442

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<220>

<221> misc_feature

<222> (2, 5)..(7)

<223> xaa = any amino acid

<400> 442

Arg Xaa Glu Thr Xaa Trp Xaa
1 5

<210> 443

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<220>

<221> misc_feature

<222> (5)..(6)

<223> Xaa = any amino acid

<400> 443

Arg Gly Asp Gly Xaa
1 5

<210> 444

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<220>

<221> misc_feature

<222> (6)..(6)

<223> Xaa = any amino acid

<400> 444

Cys Arg Gly Asp Gly Xaa Cys
1 5

<210> 445

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<220>

<221> misc_feature

<222> (2, 3, 4, 8, 9, 10, 11, 12, 13)..(14)

<223> Xaa = any amino acid

<400> 445

Cys Xaa Xaa Xaa Arg Leu Asp Xaa Xaa Xaa Xaa Xaa Xaa Cys
1 5 10 15

<210> 446

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 446

Cys Ala Arg Arg Leu Asp Ala Pro Cys
1 5

<210> 447

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

••••• <400> 447

••••• Cys Pro Ser Arg Leu Asp Ser Pro Cys
••••• 1 5

••••• <210> 448

••••• <211> 9

<212> PRT

<213> Artificial Sequence

••••• <220>

••••• <223> INTEGRIN-BINDING PEPTIDE

••••• <220>

••••• <221> misc_feature

••••• <222> (1, 2, 3, 7, 8)..(9)

••••• <223> Xaa are capable of forming a cyclizing bond

<220>

<221> misc_feature

<222> (2)..(5)

<223> Feature at 1, 5 is an amino acid capable of forming a cyclizing bond and attached to 1-5 amino acid linker

<400> 448

Xaa Xaa Xaa Arg Gly Asp Xaa Xaa Xaa
1 5

<210> 449

<211> 9

<212> PRT

<213> Artificial Sequence

<220>


<223> INTEGRIN-BINDING PEPTIDE

<220>

<221> misc_feature

<222> (2)..(8)

<223> xaa = any amino acid



<400> 449


Cys Xaa Cys Arg Gly Asp Cys Xaa Cys
1 5

<210> 450

<211> 9

<212> PRT

<213> Artificial Sequence



<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 450

Cys Asp Cys Arg Gly Asp Cys Phe Cys
1 5

<210> 451

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 451

Cys Asp Cys Arg Gly Asp Cys Leu Cys
 1 5

<210> 452

<211> 9

<212> PRT


<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 452

Cys Leu Cys Arg Gly Asp Cys Ile Cys
 1 5



<210> 453

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<220>

<221> misc_feature

<222> (1, 2, 5, 6, 7)..(8)

<223> Xaa = any amino acid

<400> 453

Xaa Xaa Asp Asp Xaa Xaa Xaa Xaa
 1 5

<210> 454
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> INTEGRIN-BINDING PEPTIDE
 <220>
 <221> misc_feature
 <222> (1, 2, 3, 6, 7, 8, 9)..(10)
 <223> Xaa = any amino acid

<400> 454
 Xaa Xaa Xaa Asp Asp Xaa Xaa Xaa Xaa Xaa
 1 5 10

<210> 455
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> INTEGRIN-BINDING PEPTIDE
 <400> 455
 Cys Trp Asp Asp Gly Trp Leu Cys
 1 5

<210> 456
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> INTEGRIN-BINDING PEPTIDE
 <400> 456

Cys Trp Asp Asp Leu Trp Trp Leu Cys
1 5

<210> 457

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 457

Cys Trp Asp Asp Gly Leu Met Cys
1 5

<210> 458

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 458

Cys Trp Asp Asp Gly Trp Met Cys
1 5

<210> 459

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 459

Cys Ser Trp Asp Asp Gly Trp Leu Cys
1 5

<210> 460

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 460

Cys Pro Asp Asp Leu Trp Trp Leu Cys
1 5

<210> 461

<211> 12

<212> PRT

<213> Artificial Sequence

<220>


<223> EPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (2)..(8)

<223> Xaa can be any of the 20 L-amino acids



<220>

<221> misc_feature

<222> (3)..(3)

<223> Xaa can be C, A, α-amino-γ-bromobutyric acid or Hoc

<220>

<221> misc_feature

<222> (4)..(4)

<223> Xaa can be R, H, L or W



<220>

<221> misc_feature

<222> (5)..(5)

<223> Xaa can be M, F or I; Xaa

<220>

<221> misc_feature

$\langle 222 \rangle$ (11) .. (11)

<223> Xaa can be D, E, I, L or V

<220>

```
<221> misc_feature
```

$\langle 222 \rangle \quad (12) \dots (12)$

<223> Xaa can be C, A, a-amino-γ-bromobutyric acid or Hoc; provided that Xaa (Pos3 or 12) is C or Hoc.

<400> 461

Tyr Xaa Xaa Xaa Xaa Gly Pro Xaa Thr Trp Xaa Xaa
1 5 10

<210> 462

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 462

Cys Gln Asn Arg Tyr Thr Asp Leu Val Ala Ile Gln Asn Lys Asn Glu
1 5 10 15

<210> 463

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 463

Ala Glu Asn Trp Ala Asp Asn Glu Pro Asn Asn Lys Arg Asn Asn Glu
1 5 10 15

Asp

<210> 464

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 464

Arg Lys Asn Asn Lys Thr Trp Thr Trp Val Gly Thr Lys Lys Ala Leu
 1 5 10 15

Thr Asn Glu

<210> 465

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 465

Lys Lys Ala Leu Thr Asn Glu Ala Glu Asn Trp Ala Asp
 1 5 10

<210> 466

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (3)..(15)

<223> Xaa = any amino acid

<400> 466

Cys Gln Xaa Arg Tyr Thr Asp Leu Val Ala Ile Gln Asn Lys Xaa Glu
1 5 10 15

<210> 467

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (3, 5, 6, 13)..(15)

<223> Xaa = any amino acid

<400> 467

Arg Lys Xaa Asn Xaa Xaa Trp Thr Trp Val Gly Thr Xaa Lys Xaa Leu
1 5 10 15

Thr Glu Glu

<210> 468

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (13)..(15)

<223> Xaa = any amino acid

<400> 468

Ala Glu Asn Trp Ala Asp Gly Glu Pro Asn Asn Lys Xaa Asn Xaa Glu
 1 5 10 15

Asp

<210> 469

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (2, 3, 4, 7)..(15)

<223> Xaa = any amino acid

<400> 469

Cys Xaa Xaa Xaa Tyr Thr Xaa Leu Val Ala Ile Gln Asn Lys Xaa Glu
 1 5 10 15

<210> 470

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (3, 4, 5, 6, 8, 13, 15)..(18)

<223> Xaa = any amino acid

<400> 470

Arg Lys Xaa Xaa Xaa Xaa Trp Xaa Trp Val Gly Thr Xaa Lys Xaa Leu
 Page 199

1 5 15

Thr Xaa Glu

<210> 471

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (2, 5, 6, 7, 12, 13)..(14)

<223> Xaa = any amino acid

<400> 471

Ala Xaa Asn Trp Xaa Xaa Xaa Glu Pro Asn Asn Xaa Xaa Xaa Glu Asp
1 5 10 15

<210> 472

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1, 3, 6, 9, 12)..(13)

<223> Xaa = any amino acid

<400> 472

Xaa Lys Xaa Lys Thr Xaa Glu Ala Xaa Asn Trp Xaa Xaa
1 5 10

<210> 473

<211> 12
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE
 <220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Xaa is Asp-Arg-Met-Pro-Cys, Arg-Met-Pro-Cys, Met-Pro-Cys, Pro-Cys
 or Cys

<220>
 <221> misc_feature
 <222> (2)..(2)
 <223> Xaa is Arg or Lys

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Xaa is Ser or Thr

 <220>
 <221> misc_feature
 <222> (12)..(12)
 <223> Xaa is Cys-Lys or Cys

<400> 473
 Xaa Xaa Asn Phe Phe Trp Lys Thr Phe Xaa Ser Xaa
 1 5 10

 <210> 474
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 474

Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
1 5 10 15

Lys

<210> 475

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 475

Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys
1 5 10 15

<210> 476

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 476

Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys
1 5 10

<210> 477

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<400> 477

<210> 478

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 478

<210> 479

<211> 12

<212> PRT

<213> Artificial Sequence



Diagram illustrating a dislocation line (indicated by a dashed line) and its Burgers vector, labeled $\langle 220 \rangle$.

••••• <223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

••••• <400> 479


Cys Arg Asn Phe phe Trp Lys Thr Phe Ser Ser Cys
1 5 10

<210> 480

<211> 16

<212> PRT

⋮⋮⋮ <213> Artificial Sequence



A diagram of a 2D lattice with a $\langle 220 \rangle$ direction indicated. The lattice consists of a grid of dots. A dashed line passes through the center of the lattice, and an arrow points along this line towards the top right, labeled $\langle 220 \rangle$.

 $\langle 223 \rangle$ SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

 $\langle 400 \rangle$ 480

Asp Arg Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
1 5 10 15

<210> 481

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 481

Met	Pro	Cys	Lys	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Ser	Ser	Cys	Lys
1				5					10					15

<210> 482

<211> 13

<212> PRT


<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 482

Cys	Lys	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Ser	Ser	Cys	Lys
1				5					10			



<210> 483

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 483

Asp	Arg	Met	Pro	Cys	Lys	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Ser	Ser	Cys
1				5					10					15	



<210> 484

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 484

Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
1 5 10

<210> 485

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 485

Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
1 5 10

<210> 486

<211> 17

<212> PRT

••••• <213> Artificial Sequence

•••••

•••••

<220>

•••••

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

•••••

<400> 486

Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
1 5 10 15

Lys

•••••

<210> 487

•••••

<211> 15

•••••

<212> PRT

•••••

<213> Artificial Sequence

•••••

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 487

Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys Lys
1 5 10 15

<210> 488

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 488

Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys Lys
1 5 10

<210> 489

<211> 16

<212> PRT

<213> Artificial Sequence

••••• <220>

••••• <223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

••••• <400> 489

••••• Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
1 5 10 15

<210> 490

<211> 14

<212> PRT

••••• <213> Artificial Sequence

•••••
•••••
•••••

<220>

••••• <223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

••••• <400> 490

••••• Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
1 5 10

<210> 491

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 491

Cys	Arg	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Thr	Ser	Cys
1				5					10		

<210> 492

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 492

Asp	Arg	Met	Pro	Cys	Lys	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Thr	Ser	Cys
1				5					10					15	

Lys

<210> 493

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 493

Met	Pro	Cys	Lys	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Thr	Ser	Cys	Lys
1				5					10					15

<210> 494

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 494

Cys	Lys	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Thr	Ser	Cys	Lys
1				5					10			

<210> 495

<211> 16

<212> PRT

<213> Artificial Sequence


<220>


<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE


<400> 495

Asp	Arg	Met	Pro	Cys	Lys	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Thr	Ser	Cys
1				5					10					15	

<210> 496


 <211> 14


 <212> PRT


 <213> Artificial Sequence


 <220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 496

Met	Pro	Cys	Lys	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Thr	Ser	Cys
1				5					10				


 <210> 497


 <211> 12


 <212> PRT


 <213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 497

Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
1 5 10

<210> 498

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> CAP37 MIMETIC/LPS BINDING

<400> 498

Asn Gln Gly Arg His Phe Cys Gly Gly Ala Leu Ile His Ala Arg Phe
1 5 10 15

Val Met Thr Ala Ala Ser Cys Phe Gln
20 25

<210> 499

<211> 20

<212> PRT

••••• <213> Artificial Sequence

•••••

•••••

•••••

•••••

•••••

<220>

<223> CAP37 MIMETIC/LPS BINDING

<400> 499

Arg His Phe Cys Gly Gly Ala Leu Ile His Ala Arg Phe Val Met Thr
1 5 10 15

Ala Ala Ser Cys
20

•••••

•••••

•••••

•••••

•••••

•••••

<210> 500

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> CAP37 MIMETIC/LPS BINDING

<400> 500

Gly Thr Arg Cys Gln Val Ala Gly Trp Gly Ser Gln Arg Ser Gly Gly
 1 5 10 15

Arg Leu Ser Arg Phe Pro Arg Phe Val Asn Val
 20 25

<210> 501

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> VEGF- ANTAGONIST

<400> 501

Gly Glu Arg Trp Cys Phe Asp Gly Pro Arg Ala Trp Val Cys Gly Trp
 1 5 10 15

Glu Ile

<210> 502

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> VEGF- ANTAGONIST

<400> 502

Glu Glu Leu Trp Cys Phe Asp Gly Pro Arg Ala Trp Val Cys Gly Tyr
 1 5 10 15

Val Lys

<210> 503

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 503

Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu Phe Lys
1 5 10 15

Thr Leu Leu Ser Ala Val Gly Ser Ala Leu Ser Ser Ser Gly Gly Gln
20 25 30

Gln

<210> 504

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

••••• <222> (7, 18,)..(19)

••••• <223> Positions 7, 18, and 19, D amino acid residue

•••••
•••••
•••••
•••••
•••••

<400> 504

Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu Phe Lys
1 5 10 15

Thr Leu Leu Ser Ala Val Gly Ser Ala Leu Ser Ser Ser Gly Gly Gln
20 25 30

••••• Glu

•••••
•••••
•••••
•••••
•••••
•••••
•••••

<210> 505

<211> 22

<212> PRT

<213> Artificial sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (18)..(19)

<223> Positions 18 and 19, D amino acid residues

<400> 505

Gly	Phe	Phe	Ala	Leu	Ile	Pro	Lys	Ile	Ile	Ser	Ser	Pro	Leu	Phe	Lys
1				5				10						15	

Thr	Leu	Leu	Ser	Ala	Val
			20		

<210> 506


<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE



<220>


<221> misc_feature

<222> (7, 18)..(19)

<223> Positions 7, 18 and 19, D amino acid residues

<400> 506

Gly	Phe	Phe	Ala	Leu	Ile	Pro	Lys	Ile	Ile	Ser	Ser	Pro	Leu	Phe	Lys
1				5				10						15	



Thr	Leu	Leu	Ser	Ala	Val
			20		

<210> 507

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (8, 19)..(20)

<223> Positions 8, 19 and 20, D amino acid residues

<400> 507

Lys Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu Phe
1 5 10 15

Lys Thr Leu Leu Ser Ala Val
20

<210> 508

<211> 24

<212> PRT

<213> Artificial sequence

<220>

••••• <223> ANTIPATHOGENIC PEPTIDE

••••• <220>

••••• <221> misc_feature

••••• <222> (9, 20)..(21)

••••• <223> Positions 9, 20 and 21, D amino acid residues

<400> 508

Lys Lys Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu
1 5 10 15

••••• Phe Lys Thr Leu Leu Ser Ala Val
20

••••• <210> 509

••••• <211> 24

••••• <212> PRT

<213> Artificial sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (9, 20)..(21)

<223> Positions 9, 20 and 21, D amino acid residues

<400> 509

Lys Lys Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu
1 5 10 15

Phe Lys Thr Leu Leu Ser Ala Val
20

<210> 510

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

••••• <223> ANTIPATHOGENIC PEPTIDE

••••• <220>

••••• <221> misc_feature

••••• <222> (7)..(7)

••••• <223> Position 7, D amino acid residue

<400> 510

Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser
1 5 10

••••• <210> 511

••••• <211> 26

••••• <212> PRT

••••• <213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 511

Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
 1 5 10 15

Ile Ser Trp Ile Lys Arg Lys Arg Gln Gln
 20 25

<210> 512

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (5, 8, 17)..(23)

<223> Positions 5, 8, 17 and 23, D amino acid residues

<400> 512

Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
 1 5 10 15

Ile Ser Trp Ile Lys Arg Lys Arg Gln Gln
 20 25

<210> 513

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (5, 18, 17)..(23)

<223> Positions 5, 18, 17 and 23, D amino acid residues

<400> 513

Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
 1 5 10 15

Ile Ser Trp Ile Lys Arg Lys Arg Gln Gln
 20 25

<210> 514

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (5, 8, 17)..(21)

<223> Positions 5, 8, 17 and 21, D amino acid residues

<400> 514

Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
 1 5 10 15

Ile Ser Trp Ile Lys Arg
 20

<210> 515

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (2, 5, 14)..(18)

<223> Positions 2, 5, 14 and 18, D amino acid residues

<400> 515

Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu Ile Ser Trp
 1 5 10 15

Ile Lys Arg

<210> 516

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (3, 4, 8)..(10)

<223> Positions 3, 4, 8 and 10, D amino acid residues

<400> 516

••••• Lys Leu Leu Leu Leu Leu Lys Leu Leu Leu Leu Lys
 ••••• 1 5 10

•••••
 ••••• <210> 517

••••• <211> 12

••••• <212> PRT

<213> Artificial Sequence

<220>

••••• <223> ANTIPATHOGENIC PEPTIDE

••••• <220>

••••• <221> misc_feature

••••• <222> (3, 4, 8)..(10)

••••• <223> Positions 3, 4, 8 and 10, D amino acid residues
 •••••

<400> 517

Lys Leu Leu Leu Lys Leu Leu Leu Lys Leu Leu Lys
 1 5 10

<210> 518

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (3, 4, 8)..(10)

<223> Positions 3, 4, 8 and 10, D amino acid residues

<400> 518

Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Leu Lys
1 5 10

<210> 519

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 519

Lys Lys Leu Leu Lys Leu Lys Leu Lys Leu Lys Lys
1 5 10

<210> 520

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 520

Lys Leu Leu Leu Lys Leu Leu Leu Lys Leu Leu Lys
 1 5 10

<210> 521

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 521

Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Leu Lys
 1 5 10

<210> 522

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

••••• <223> ANTIPATHOGENIC PEPTIDE

••••• <400> 522

••••• Lys Leu Leu Leu Leu Lys
 1 5

••••• <210> 523

<211> 8

<212> PRT

<213> Artificial Sequence

••••• <220>

••••• <223> ANTIPATHOGENIC PEPTIDE

••••• <400> 523

••••• Lys Leu Leu Leu Lys Leu Leu Lys
 1 5

<210> 524

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 524

Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Leu Lys
 1 5 10

<210> 525

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 525

Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Leu Lys
 1 5 10


 <210> 526


 <211> 12


 <212> PRT


 <213> Artificial Sequence



<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 526



Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Leu Lys
 1 5 10



 <210> 527


 <211> 12


 <212> PRT


 <213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 527

Lys Ala Ala Ala Lys Ala Ala Ala Lys Ala Ala Lys
 1 5 10

<210> 528

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 528

Lys Val Val Val Lys Val Val Val Lys Val Val Lys
 1 5 10

<210> 529

<211> 12

<212> PRT

<213> Artificial Sequence



<220>



<223> ANTIPATHOGENIC PEPTIDE



<400> 529



Lys Val Val Val Lys Val Lys Val Lys Val Val Lys
 1 5 10

<210> 530

<211> 11



<212> PRT



<213> Artificial Sequence



<220>



<223> ANTIPATHOGENIC PEPTIDE



<400> 530

Lys Val Val Val Lys Val Lys Val Lys Val Lys
 1 5 10

<210> 531

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 531

Lys Val Val Val Lys Val Lys Val Lys Val Val Lys
 1 5 10

<210> 532

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 532

Lys Leu Ile Leu Lys Leu
 1 5

<210> 533

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 533

Lys Val Leu His Leu Leu
 1 5

<210> 534

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 534

Leu Lys Leu Arg Leu Leu
1 5

<210> 535

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 535

Lys Pro Leu His Leu Leu
1 5

<210> 536

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 536

Lys Leu Ile Leu Lys Leu Val Arg
1 5

<210> 537

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 537

Lys Val Phe His Leu Leu His Leu
1 5

<210> 538

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 538

His Lys Phe Arg Ile Leu Lys Leu
1 5

<210> 539

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 539

Lys Pro Phe His Ile Leu His Leu
1 5

<210> 540

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 540

Lys Ile Ile Ile Lys Ile Lys Ile Lys Ile Ile Lys
1 5 10

<210> 541

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 541

Lys Ile Ile Ile Lys Ile Lys Ile Lys Ile Ile Lys
 1 5 10

<210> 542

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 542

Lys Ile Ile Ile Lys Ile Lys Ile Lys Ile Ile Lys
 1 5 10

<210> 543

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 543

Lys Ile Pro Ile Lys Ile Lys Ile Lys Ile Pro Lys
 1 5 10

<210> 544

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 544

Lys Ile Pro Ile Lys Ile Lys Ile Lys Ile Val Lys
 1 5 10

<210> 545

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 545

Arg Ile Ile Ile Arg Ile Arg Ile Arg Ile Ile Arg
 1 5 10

<210> 546

<211> 12

<212> PRT

<213> Artificial Sequence



<220>



<223> ANTIPATHOGENIC PEPTIDE



<400> 546



Arg Ile Ile Ile Arg Ile Arg Ile Arg Ile Ile Arg
 1 5 10

<210> 547

<211> 12



<212> PRT



<213> Artificial Sequence



<220>



<223> ANTIPATHOGENIC PEPTIDE



<400> 547

Arg Ile Ile Ile Arg Ile Arg Ile Arg Ile Ile Arg
 1 5 10

<210> 548

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 548

Arg Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg
 1 5 10

<210> 549

<211> 12

<212> PRT


<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 549

Arg Ile Ile Val Arg Ile Arg Leu Arg Ile Ile Arg
 1 5 10



<210> 550

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 550

Arg Ile Gly Ile Arg Leu Arg Val Arg Ile Ile Arg
 1 5 10



<210> 551

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 551

Lys Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg
1 5 10

<210> 552

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 552

Arg Ile Ala Val Lys Trp Arg Leu Arg Phe Ile Lys
1 5 10

<210> 553

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 553

Lys Ile Gly Trp Lys Leu Arg Val Arg Ile Ile Arg
1 5 10

<210> 554

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 554

Lys Lys Ile Gly Trp Leu Ile Ile Arg Val Arg Arg
 1 5 10

<210> 555

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 555

Arg Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg Ile Arg
 1 5 10

<210> 556

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 556

Arg Ile Ile Val Arg Ile Arg Leu Arg Ile Ile Arg Val Arg
 1 5 10

<210> 557

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 557

Arg Ile Gly Ile Arg Leu Arg Val Arg Ile Ile Arg Arg Val
 1 5 10

<210> 558

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 558

Lys Ile Val Ile Arg Ile Arg Ala Arg Leu Ile Arg Ile Arg Ile Arg
 1 5 10 15

<210> 559

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 559

Arg Ile Ile Val Lys Ile Arg Leu Arg Ile Ile Lys Lys Ile Arg Leu
 1 5 10 15

<210> 560

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 560

Lys Ile Gly Ile Lys Ala Arg Val Arg Ile Ile Arg Val Lys Ile Ile
 1 5 10 15

<210> 561

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 561

Arg Ile Ile Val His Ile Arg Leu Arg Ile Ile His His Ile Arg Leu
 1 5 10 15

<210> 562

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 562

His Ile Gly Ile Lys Ala His Val Arg Ile Ile Arg Val His Ile Ile
 1 5 10 15

<210> 563

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 563

Arg Ile Tyr Val Lys Ile His Leu Arg Tyr Ile Lys Lys Ile Arg Leu
 1 5 10 15

<210> 564

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 564

Lys Ile Gly His Lys Ala Arg Val His Ile Ile Arg Tyr Lys Ile Ile
 1 5 10 15

<210> 565

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 565

Arg Ile Tyr Val Lys Pro His Pro Arg Tyr Ile Lys Lys Ile Arg Leu
 1 5 10 15

<210> 566

<211> 16

<212> PRT


<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 566

Lys Pro Gly His Lys Ala Arg Pro His Ile Ile Arg Tyr Lys Ile Ile
 1 5 10 15


 <210> 567

<211> 19

<212> PRT

<213> Artificial Sequence



<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 567



Lys Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg Ile Arg Ile Arg
 1 5 10 15




Lys Ile Val



 <210> 568


 <211> 19

<210> 571

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 571

Arg Phe Ala Val Lys Ile Arg Leu Arg Ile Ile Lys Lys Ile Arg Leu
 1 5 10 15

Ile Lys Lys Ile Arg Lys Arg Val Ile Lys
 20 25

<210> 572

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 572

Lys Ala Gly Trp Lys Leu Arg Val Arg Ile Ile Arg Val Lys Ile Gly
 1 5 10 15

Arg Leu Arg Lys Ile Gly Trp Lys Lys Arg Val Arg Ile Lys
 20 25 30

<210> 573

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 573

Arg Ile Tyr Val Lys Pro His Pro Arg Tyr Ile Lys Lys Ile Arg Leu
 1 5 10 15

<210> 574

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 574

Lys Pro Gly His Lys Ala Arg Pro His Ile Ile Arg Tyr Lys Ile Ile
1 5 10 15

<210> 575

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 575

Lys Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg Ile Arg Ile Arg
1 5 10 15

Lys Ile Val

<210> 576

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 576

Arg Ile Ile Val Lys Ile Arg Leu Arg Ile Ile Lys Lys Ile Arg Leu
1 5 10 15

Ile Lys Lys

<210> 577

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 577

Arg Ile Tyr Val Ser Lys Ile Ser Ile Tyr Ile Lys Lys Ile Arg Leu
 1 5 10 15

<210> 578

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 578

Lys Ile Val Ile Phe Thr Arg Ile Arg Leu Thr Ser Ile Arg Ile Arg
 1 5 10 15


 Ser Ile Val

<210> 579

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 579

Lys Pro Ile His Lys Ala Arg Pro Thr Ile Ile Arg Tyr Lys Met Ile
 1 5 10 15

<210> 580

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, disulfide bond to position 26

<220>

<221> misc_feature

<222> (26)..(26)

<223> Position 26, disulfide bond to position 1

<400> 580

Xaa	Cys	Lys	Gly	Phe	Phe	Ala	Leu	Ile	Pro	Lys	Ile	Ile	Ser	Ser	Pro
1				5					10					15	

Leu	Phe	Lys	Thr	Leu	Leu	Ser	Ala	Val	Cys
			20					25	

<210> 581

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 581

Cys	Lys	Lys	Gly	Phe	Phe	Ala	Leu	Ile	Pro	Lys	Ile	Ile	Ser	Ser	Pro
1				5					10					15	

Leu	Phe	Lys	Thr	Leu	Leu	Ser	Ala	Val	Cys
			20					25	

<210> 582

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 582

Cys Lys Lys Lys Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser
1 5 10 15

Pro Leu Phe Lys Thr Leu Leu Ser Ala Val Cys
20 25

<210> 583

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, disulfide bond to position 17

<220>

<221> misc_feature

<222> (17)..(17)

<223> Position 17, disulfide bond to position 1

<400> 583

Xaa Cys Arg Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg Ile Arg
1 5 10 15

Cys

<210> 584

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (1) .. (1)

<223> Position 1, disulfide bond to position 19

<220>

<221> misc_feature

<222> (19) .. (19)

<223> Position 19, disulfide bond to position 1

<400> 584

Xaa Cys Lys Pro Gly His Lys Ala Arg Pro His Ile Ile Arg Tyr Lys
1 5 10 15

Ile Ile Cys

 $\langle 210 \rangle$ 585

$\langle 211 \rangle$ 29

∴ : <212> PRT

..... <213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

```
... <221> misc_feature
```

$\cdot\cdot\cdot\cdot$ $\langle 222 \rangle$ (1) ..(1)

.....<223> Position 1, disulfide bond to position 29

```
<221> misc_feature
```


<222> (29)..(29)

<223> Position 29, disulfide bond to position 1

<400> 585

Xaa Cys Arg Phe Ala Val Lys Ile Arg Leu Arg Ile Ile Lys Lys Ile
 1 5 10 15

Arg Leu Ile Lys Lys Ile Arg Lys Arg Val Ile Lys Cys
 20 25

<210> 586

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 586

Lys Leu Leu Leu Lys Leu Leu Leu Lys Leu Leu Lys Cys
 1 5 10

<210> 587

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 587

Lys Leu Leu Leu Lys Leu Leu Leu Lys Leu Leu Lys
 1 5 10

<210> 588

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 588

Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Leu Lys Cys
 1 5 10

<210> 589

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 589

Lys Leu Leu Leu Lys Leu Leu Leu Lys Leu Leu Lys
 1 5 10

<210> 590

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 590

His Ser Asp Ala Val Phe Tyr Asp Asn Tyr Thr Arg Leu Arg Lys Gln
 1 5 10 15

Met Ala Val Lys Lys Tyr Leu Asn Ser Ile Leu Asn
 20 25

<210> 591

<211> 28

<212> PRT

<213> Artificial sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 591

His Ser Asp Ala Val Phe Tyr Asp Asn Tyr Thr Arg Leu Arg Lys Gln
 1 5 10 15

Met Ala Val Lys Lys Tyr Leu Asn Ser Ile Leu Asn
 20 25

<210> 592

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa is L-Lys, D-Lys or an ornithinyl residue

<220>

<221> misc_feature

<222> (2)..(2)

<223> Position 2, Xaa is L-Tyr, D-Tyr, Phe, Trp or a p-aminophenylalany
 l residue

<220>

<221> misc_feature

<222> (3)..(3)

<223> Position 3 is a hydrophobic aliphatic amino acid residue, Positio
 n 3, optional attachment to Leu, norleucyl, D-Ala, Asn-Ser, Asn-S
 er-Ile-, Asn-Ser-Tyr, Ser-Ile-Leu, Asn-Ser-Tyr-Leu or Asn-Ser-Tyr
 -Leu-Asn

<400> 592

Xaa Xaa Xaa

1

<210> 593

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (1)..(3)

<223> Position 1, Xaa is either absent, a hydrophobic aliphatic residue (X5), X5-Asn, Tyr-X5, Lys-X5, Lys-X5-Asn, Lys-Tyr-X5, Lys-Tyr-X5-Asn, Lys-Lys-Tyr-X5, Lys-Lys-Tyr-X5-Asn, Val-Lys-Lys-Tyr-X5, Val-Ala-Lys-Lys-Tyr-X5-Asn, or Ala-Val-Lys-Lys-Tyr-X5-Asn

<400> 593

Xaa Ser Xaa Leu Asn
1 5

<210> 594

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

•••••<223> VIP-MIMETIC PEPTIDE

•••••<220>

•••••<221> misc_feature

•••••<222> (1, 5, 6)..(7)

•••••<223> Positions 1 and 6, xaa are cross-linked amino acid residues as defined in w097/40070

<220>

•••••<221> misc_feature

•••••<222> (5)..(5)

•••••<223> Position 5, Xaa is a hydrophobic aliphatic aminod acid residue

•••••<220>

•••••<221> misc_feature

•••••<222>

•••••<223> (7)..(7)

<223> Position 7, is a covalent bond or Asn, Ser, Ile, Tyr, Leu, Asn-Ser, Asn-Ser-Ile, Asn-Ser-Tyr, Asn-Ser-Ile-Leu, Asn-Ser-Tyr-Leu, Asn-Ser-Ile-Leu-Asn or Asn-Ser-Tyr-Leu-Asn.

<400> 594

Xaa Lys Lys Tyr Xaa Xaa Xaa
1 5

<210> 595

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 595

Lys Lys Tyr Leu
1

<210> 596

<211> 5

<212> PRT

<213> Artificial Sequence



<220>

<223> VIP-MIMETIC PEPTIDE

<400> 596

Asn Ser Ile Leu Asn
1 5

<210> 597

<211> 4

<212> PRT

<213> Artificial Sequence



<220>

<223> VIP-MIMETIC PEPTIDE

<400> 597

Lys Lys Tyr Leu
1

<210> 598
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE
<400> 598

Lys Lys Tyr Ala
1

<210> 599
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE
<400> 599

Ala Val Lys Lys Tyr Leu
1 5

<210> 600
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE
<400> 600

Ser Ile Leu Asn
1

<210> 601
<211> 4

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 601

Lys Lys Tyr Val
1

<210> 602

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (3) . . (3)

<223> Position 3, Xaa is a lauric acid residue

<400> 602

```

. . .
. . . <400> 602
. . . Ser Ile Xaa Asn
. . . 1

```

```

::: ser Ile Xaa Asn
::: 1

```

1

••••• $\langle 210 \rangle$ 603

<211> 5

<212> PRT

<213> Artificial Sequence



A diagram showing a 2D lattice of points. A dashed line passes through several points, labeled $\langle 220 \rangle$.

••••• : <223> VIP-MIMETIC PEPTIDE



$\langle 220 \rangle$

... <221> misc_feature

$$\begin{array}{c} \bullet \quad \bullet \quad \bullet \\ \bullet \quad \bullet \quad \bullet \end{array} \langle 222 \rangle \quad (5) \dots (5)$$

<223> Position 5, Xaa is a norleucyl residue

<400> 603

Lys Lys Tyr Leu Xaa
1 5

<210> 604

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 604

Asn Ser Tyr Leu Asn
1 5

<210> 605

<211> 5

<212> PRT

<213> Artificial Sequence

•••••<220>

•••••<223> VIP-MIMETIC PEPTIDE

•••••<400> 605

•••••Asn Ser Ile Tyr Asn
•••••1 5

<210> 606

<211> 11

<212> PRT

•••••<213> Artificial Sequence

•••••<220>

•••••<223>

•••••VIP-MIMETIC PEPTIDE

•••••<400> 606

•••••Lys Lys Tyr Leu Pro Pro Asn Ser Ile Leu Asn
•••••1 5 10

<210> 607
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE
 <220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1, Xaa is a lauric acid residue

<400> 607
 Xaa Lys Lys Tyr Leu
 1 5

<210> 608
 <211> 5
 <212> PRT
 <213> Artificial Sequence

•••••<220>
 •••••<223> VIP-MIMETIC PEPTIDE
 •••••<220>
 •••••<221> misc_feature
 •••••<222> (1)..(1)
 •••••<223> Position 1, Xaa is a caproic acid residue

•••••<400> 608
 •••••Xaa Lys Lys Tyr Leu
 •••••1 5
 •••••<210> 609
 •••••<211> 4
 •••••<212> PRT
 •••••<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (4)..(4)

<223> Position 4, Xaa is a norleucyl residue

<400> 609

Lys Lys Tyr Xaa
1

<210> 610

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 610

Val Lys Lys Tyr Leu
1 5

<210> 611

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 611

Leu Asn Ser Ile Leu Asn
1 5

<210> 612

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 612

Tyr Leu Asn Ser Ile Leu Asn
1 5

<210> 613

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 613

Lys Lys Tyr Leu Asn
1 5

<210> 614

<211> 6

••••• <212> PRT

••••• <213> Artificial Sequence

••••• <220>

••••• <223> VIP-MIMETIC PEPTIDE

<400> 614

Lys Lys Tyr Leu Asn Ser
1 5

••••• <210> 615

••••• <211> 7

••••• <212> PRT

••••• <213> Artificial Sequence

••••• <220>

<223> VIP-MIMETIC PEPTIDE

<400> 615

Lys Lys Tyr Leu Asn Ser Ile
1 5

<210> 616

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 616

Lys Lys Tyr Leu Asn Ser Ile Leu
1 5

<210> 617

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

••••• <223> VIP-MIMETIC PEPTIDE

••••• <400> 617

••••• Lys Lys Tyr Leu
1

••••• <210> 618

<211> 5

<212> PRT

<213> Artificial Sequence

•••••
••••• <220>

••••• <223> VIP-MIMETIC PEPTIDE

••••• <400> 618

••••• Lys Lys Tyr Asp Ala
1 5

<210> 619

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 619

Ala Val Lys Lys Tyr Leu
1 5

<210> 620

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 620

Asn Ser Ile Leu Asn
1 5

••••• <210> 621

••••• <211> 4

••••• <212> PRT

••••• <213> Artificial Sequence

•••••

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 621

••••• Lys Lys Tyr Val
1

•••••

••••• <210> 622

••••• <211> 4

••••• <212> PRT

••••• <213> Artificial Sequence

•••••

<220>

<223> VIP-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (1)..(3)

<223> Position 3, Xaa is a lauric acid residue

<400> 622

Xaa Ile Xaa Asn

1

<210> 623

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 623

Asn Ser Tyr Leu Asn

1

5

<210> 624

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 624

Asn Ser Ile Tyr Asn

1

5

<210> 625

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa is a norleucyl residue

<400> 625

Lys Lys Tyr Leu Xaa
1 5

<210> 626

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 626

Lys Lys Tyr Leu Pro Pro Asn Ser Ile Leu Asn
1 5 10

<210> 627

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 627

Lys Lys Tyr Leu
1

<210> 628

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 628

Lys Lys Tyr Asp Ala
1 5

<210> 629

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 629

Ala Val Lys Lys Tyr Leu
1 5

<210> 630

<211> 5

••••• <212> PRT

••••• <213> Artificial Sequence

••••• <220>

••••• <223> VIP-MIMETIC PEPTIDE

<400> 630

Asn Ser Ile Leu Asn
1 5

••••• <210> 631

••••• <211> 4

••••• <212> PRT

••••• <213> Artificial Sequence

••••• <220>

<223> VIP-MIMETIC PEPTIDE

<211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE
 <220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1, Xaa is a caproic acid residue

<400> 634
 Xaa Lys Lys Tyr Leu
 1 5

<210> 635
 <211> 4
 <212> PRT
 <213> Artificial Sequence

••••• <220>
 ••••• <223> VIP-MIMETIC PEPTIDE
 ••••• <220>
 ••••• <221> misc_feature
 ••••• <222> (4)..(4)
 <223> Position 4, Xaa is a norleucyl residue

<400> 635
 ••••• Lys Lys Tyr Xaa
 ••••• 1
 ••••• <210> 636
 ••••• <211> 5
 ••••• <212> PRT
 ••••• <213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 636

Val Lys Lys Tyr Leu
1 5

<210> 637

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 637


Leu Asn Ser Ile Leu Asn
1 5

<210> 638

<211> 7

<212> PRT

<213> Artificial Sequence



<220>

<223> VIP-MIMETIC PEPTIDE

<400> 638

Tyr Leu Asn Ser Ile Leu Asn
1 5

<210> 639

<211> 5

<212> PRT

<213> Artificial Sequence



<220>

<223> VIP-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa is a norleucyl residue

<400> 639

Lys Lys Tyr Leu Xaa
1 5

<210> 640

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 640

Lys Lys Tyr Leu Asn
1 5

<210> 641

<211> 6

<212> PRT

••••• <213> Artificial Sequence

••••• <220>

••••• <223> VIP-MIMETIC PEPTIDE

••••• <400> 641

Lys Lys Tyr Leu Asn Ser
1 5

<210> 642

••••• <211> 7

••••• <212> PRT

••••• <213> Artificial Sequence

••••• <220>

••••• <223> VIP-MIMETIC PEPTIDE

••••• <400> 642

Lys Lys Tyr Leu Asn Ser Ile
1 5

<210> 643

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 643

Lys Lys Tyr Leu Asn Ser Ile Leu
1 5

<210> 644

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 644

Lys Lys Lys Tyr Leu Asp
1 5

<210> 645

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Positions 1 and 6 disulfide cross-linked

<400> 645

Xaa Cys Lys Lys Tyr Leu Cys
1 5

<210> 646

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<220>

<221> misc_feature

<223> Positions 1 and 6 cross-linked by S-CH₂-CO

<400> 646

Cys Lys Lys Tyr Leu Lys
1 5

<210> 647

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<220>

<221> misc_feature

<223> Position 4, D amino acid residue

<400> 647

Lys Lys Tyr Ala
1

<210> 648

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 648

Trp Trp Thr Asp Thr Gly Leu Trp
1 5

<210> 649

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 649

Trp Trp Thr Asp Asp Gly Leu Trp
1 5

<210> 650

<211> 12

••••• <212> PRT

••••• <213> Artificial Sequence

•••••

••••• <220>

••••• <223> VIP-MIMETIC PEPTIDE

••••• <400> 650

Trp Trp Asp Thr Arg Gly Leu Trp Val Trp Thr Ile
1 5 10

••••• <210> 651

••••• <211> 12

••••• <212> PRT

••••• <213> Artificial Sequence

•••••

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 651

Phe Trp Gly Asn Asp Gly Ile Trp Leu Glu Ser Gly
 1 5 10

<210> 652

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 652

Asp Trp Asp Gln Phe Gly Leu Trp Arg Gly Ala Ala
 1 5 10


<210> 653

<211> 12


<212> PRT

<213> Artificial Sequence

<220>


 <223> VIP-MIMETIC PEPTIDE


 <400> 653



Arg Trp Asp Asp Asn Gly Leu Trp Val Val Val Leu
 1 5 10


 <210> 654

<211> 12

<212> PRT

<213> Artificial Sequence


 <220>


 <223> VIP-MIMETIC PEPTIDE


 <400> 654



Ser Gly Met Trp Ser His Tyr Gly Ile Trp Met Gly
 1 5 10

<210> 655

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 655

Gly Gly Arg Trp Asp Gln Ala Gly Leu Trp Val Ala
1 5 10

<210> 656

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 656

Lys Leu Trp Ser Glu Gln Gly Ile Trp Met Gly Glu
1 5 10

⋮⋮⋮<210> 657

⋮⋮⋮<211> 10

⋮⋮⋮<212> PRT

⋮⋮⋮<213> Artificial Sequence

⋮⋮⋮

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 657

⋮⋮⋮Cys Trp Ser Met His Gly Leu Trp Leu Cys
1 5 10

⋮⋮⋮

⋮⋮⋮<210> 658

⋮⋮⋮<211> 12

⋮⋮⋮<212> PRT

⋮⋮⋮<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 658

Gly Cys Trp Asp Asn Thr Gly Ile Trp Val Pro Cys
1 5 10

<210> 659

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 659

Asp Trp Asp Thr Arg Gly Leu Trp Val Tyr
1 5 10

<210> 660

<211> 10

<212> PRT

<213> Artificial Sequence

•••••
•••••

<220>

•••••
•••••

<223> VIP-MIMETIC PEPTIDE

•••••
•••••

<400> 660

•••••
•••••

Ser Leu Trp Asp Glu Asn Gly Ala Trp Ile
1 5 10

<210> 661

<211> 10

•••••
•••••

<212> PRT

•••••
•••••

<213> Artificial sequence

•••••
•••••

<220>

•••••
•••••

<223> VIP-MIMETIC PEPTIDE

•••••
•••••

<400> 661

Lys Trp Asp Asp Arg Gly Leu Trp Met His
1 5 10

<210> 662
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE
 <400> 662

Gln Ala Trp Asn Glu Arg Gly Leu Trp Thr
 1 5 10

<210> 663
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE
 <400> 663

...Gln Trp Asp Thr Arg Gly Leu Trp Val Ala
 ...1 5 10

...<210> 664
 ...<211> 9
 ...<212> PRT
 ...<213> Artificial Sequence

<220>
 ...<223> VIP-MIMETIC PEPTIDE
 ...<400> 664

...Trp Asn Val His Gly Ile Trp Gln Glu
 ...1 5

...<210> 665
 ...<211> 10
 ...<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 665

Ser Trp Asp Thr Arg Gly Leu Trp Val Glu
1 5 10

<210> 666

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 666

Asp Trp Asp Thr Arg Gly Leu Trp Val Ala
1 5 10

<210> 667

<211> 10

•••••<212> PRT

•••••<213> Artificial Sequence

•••••<220>

•••••<223> VIP-MIMETIC PEPTIDE

<400> 667

Ser Trp Gly Arg Asp Gly Leu Trp Ile Glu
1 5 10

•••••<210> 668

•••••<211> 10

•••••<212> PRT

•••••<213> Artificial Sequence

•••••<220>

<223> VIP-MIMETIC PEPTIDE

<400> 668

Glu Trp Thr Asp Asn Gly Leu Trp Ala Leu
 1 5 10

<210> 669

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 669

Ser Trp Asp Glu Lys Gly Leu Trp Ser Ala
 1 5 10

<210> 670

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

•••••<223> VIP-MIMETIC PEPTIDE

•••••<400> 670

•••••Ser Trp Asp Ser Ser Gly Leu Trp Met Asp
 •••••1 5 10

•••••<210> 671

<211> 11

<212> PRT

<213> Artificial Sequence

•••••<220>

•••••<223> IL-1 ANTAGONIST PEPTIDE

•••••<400> 671

•••••Ser His Leu Tyr Trp Gln Pro Tyr Ser Val Gln
 •••••1 5 10

<210> 672

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 672

Thr Leu Val Tyr Trp Gln Pro Tyr Ser Leu Gln Thr
 1 5 10

<210> 673

<211> 12

<212> PRT


<213> Artificial Sequence

<220>


<223> IL-1 ANTAGONIST PEPTIDE

<400> 673

Arg Gly Asp Tyr Trp Gln Pro Tyr Ser Val Gln Ser
 1 5 10


 <210> 674


 <211> 12



 <212> PRT


 <213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 674



Val His Val Tyr Trp Gln Pro Tyr Ser Val Gln Thr
 1 5 10


 <210> 675


 <211> 12


 <212> PRT


 <213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 675

Arg Leu Val Tyr Trp Gln Pro Tyr Ser Val Gln Thr
1 5 10

<210> 676

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 676


Ser Arg Val Trp Phe Gln Pro Tyr Ser Leu Gln Ser
1 5 10

<210> 677

<211> 12

<212> PRT

<213> Artificial Sequence



<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 677

Asn Met Val Tyr Trp Gln Pro Tyr Ser Ile Gln Thr
1 5 10

<210> 678

<211> 12



<212> PRT



<213> Artificial Sequence



<220>



<223> IL-1 ANTAGONIST PEPTIDE



<400> 678

Ser Val Val Phe Trp Gln Pro Tyr Ser Val Gln Thr
1 5 10

<210> 679
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 679

Thr Phe Val Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 680
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 680

Thr Leu Val Tyr Trp Gln Pro Tyr Ser Ile Gln Arg
 1 5 10

<210> 681
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 681

Arg Leu Val Tyr Trp Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 682
 <211> 12
 <212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 682

Ser Pro Val Phe Trp Gln Pro Tyr Ser Ile Gln Ile
1 5 10

<210> 683

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 683

Trp Ile Glu Trp Trp Gln Pro Tyr Ser Val Gln Ser
1 5 10

<210> 684

<211> 12

••••• <212> PRT

••••• <213> Artificial Sequence

••••• <220>

••••• <223> IL-1 ANTAGONIST PEPTIDE

<400> 684

Ser Leu Ile Tyr Trp Gln Pro Tyr Ser Leu Gln Met
1 5 10

••••• <210> 685

••••• <211> 12

••••• <212> PRT

••••• <213> Artificial Sequence

••••• <220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 685

Thr Arg Leu Tyr Trp Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 686

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 686

Arg Cys Asp Tyr Trp Gln Pro Tyr Ser Val Gln Thr
 1 5 10

<210> 687

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

••••• <223> IL-1 ANTAGONIST PEPTIDE

••••• <400> 687

••••• Met Arg Val Phe Trp Gln Pro Tyr Ser Val Gln Asn
 ••••• 1 5 10

••••• <210> 688

<211> 12

<212> PRT

<213> Artificial Sequence

•••••
 ••••• <220>

••••• <223> IL-1 ANTAGONIST PEPTIDE

••••• <400> 688

••••• Lys Ile Val Tyr Trp Gln Pro Tyr Ser Val Gln Thr
 ••••• 1 5 10

<210> 689

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 689

Arg His Leu Tyr Trp Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 690

<211> 12

<212> PRT


<213> Artificial Sequence


<220>


<223> IL-1 ANTAGONIST PEPTIDE

<400> 690

Ala Leu Val Trp Trp Gln Pro Tyr Ser Glu Gln Ile
 1 5 10


 <210> 691


 <211> 12


 <212> PRT


 <213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 691



Ser Arg Val Trp Phe Gln Pro Tyr Ser Leu Gln Ser
 1 5 10


 <210> 692


 <211> 10


 <212> PRT


 <213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 692

Trp Glu Gln Pro Tyr Ala Leu Pro Leu Glu
 1 5 10

<210> 693

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 693


Gln Leu Val Trp Trp Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 694

<211> 12

<212> PRT

<213> Artificial Sequence



<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 694


Asp Leu Arg Tyr Trp Gln Pro Tyr Ser Val Gln Val
 1 5 10

<210> 695

<211> 12

<212> PRT

<213> Artificial Sequence



<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 695

Glu Leu Val Trp Trp Gln Pro Tyr Ser Leu Gln Leu
 1 5 10

<210> 696

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 696

Asp	Leu	Val	Trp	Trp	Gln	Pro	Tyr	Ser	Val	Gln	Trp
1				5					10		

<210> 697

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 697

Asn	Gly	Asn	Tyr	Trp	Gln	Pro	Tyr	Ser	Phe	Gln	Val
1				5					10		

<210> 698

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

Asn	Gly	Asn	Tyr	Trp	Gln	Pro	Tyr	Ser	Phe	Gln	Val
1				5					10		

<400> 698

Glu	Leu	Val	Tyr	Trp	Gln	Pro	Tyr	Ser	Ile	Gln	Arg
1				5					10		

<210> 699

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 699

Glu Leu Met Tyr Trp Gln Pro Tyr Ser Val Gln Glu
1 5 10

<210> 700

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 700

Asn Leu Leu Tyr Trp Gln Pro Tyr Ser Met Gln Asp
1 5 10

<210> 701

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 701

Gly Tyr Glu Trp Tyr Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 702

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 702

Ser Arg Val Trp Tyr Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 703

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 703

Leu Ser Glu Gln Tyr Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 704

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 704

Gly Gly Gly Trp Trp Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 705

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 705

Val Gly Arg Trp Tyr Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 706

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 706

Val His Val Tyr Trp Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 707

<211> 12

<212> PRT


<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 707

Gln Ala Arg Trp Tyr Gln Pro Tyr Ser Val Gln Arg
 1 5 10


 <210> 708


 <211> 12


 <212> PRT


 <213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 708



Val His Val Tyr Trp Gln Pro Tyr Ser Val Gln Thr
 1 5 10


 <210> 709


 <211> 12


 <212> PRT


 <213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 709

Arg Ser Val Tyr Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 710

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 710

Thr Arg Val Trp Phe Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 711

<211> 12

<212> PRT

<213> Artificial Sequence

.....
.....
.....
.....
.....
.....

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 711

Gly Arg Ile Trp Phe Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 712

<211> 12

.....

<212> PRT

.....

<213> Artificial Sequence

.....

.....

.....

.....

.....

.....

.....

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 712

Gly Arg Val Trp Phe Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 713
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 713

Ala Arg Thr Trp Tyr Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 714
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 714

Ala Arg Val Trp Trp Gln Pro Tyr Ser Val Gln Met
 1 5 10

<210> 715
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 715

Arg Leu Met Phe Tyr Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 716
 <211> 12
 <212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 716

Glu Ser Met Trp Tyr Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 717

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 717

His Phe Gly Trp Trp Gln Pro Tyr Ser Val His Met
1 5 10

<210> 718

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 718

Ala Arg Phe Trp Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 719

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 719

Arg Leu Val Tyr Trp Gln Pro Tyr Ala Pro Ile Tyr
 1 5 10

<210> 720

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 720

Arg Leu Val Tyr Trp Gln Pro Tyr Ser Tyr Gln Thr
 1 5 10

<210> 721

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

•••••<223> IL-1 ANTAGONIST PEPTIDE
 •••••

•••••<400> 721
 •••••

•••••Arg Leu Val Tyr Trp Gln Pro Tyr Ser Leu Pro Ile
 •••••1 5 10
 •••••

<210> 722

<211> 12

<212> PRT

<213> Artificial Sequence

•••••<220>
 •••••<223> IL-1 ANTAGONIST PEPTIDE
 •••••

•••••<400> 722
 •••••

•••••Arg Leu Val Tyr Trp Gln Pro Tyr Ser Val Gln Ala
 •••••1 5 10

<210> 723

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 723

Ser Arg Val Trp Tyr Gln Pro Tyr Ala Lys Gly Leu
 1 5 10

<210> 724

<211> 12

<212> PRT

<213> Artificial Sequence


<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 724

Ser Arg Val Trp Tyr Gln Pro Tyr Ala Gln Gly Leu
 1 5 10


 <210> 725


 <211> 12


 <212> PRT


 <213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 725



Ser Arg Val Trp Tyr Gln Pro Tyr Ala Met Pro Leu
 1 5 10


 <210> 726


 <211> 12


 <212> PRT


 <213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 726

Ser	Arg	Val	Trp	Tyr	Gln	Pro	Tyr	Ser	Val	Gln	Ala
1				5					10		

<210> 727

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 727


Ser	Arg	Val	Trp	Tyr	Gln	Pro	Tyr	Ser	Leu	Gly	Leu
1				5					10		

<210> 728

<211> 12

<212> PRT

<213> Artificial Sequence



<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 728


Ser	Arg	Val	Trp	Tyr	Gln	Pro	Tyr	Ala	Arg	Glu	Leu
1				5					10		

<210> 729

<211> 12

<212> PRT

<213> Artificial Sequence



<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 729

Ser	Arg	Val	Trp	Tyr	Gln	Pro	Tyr	Ser	Arg	Gln	Pro
1				5					10		

<210> 730

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 730

Ser Arg Val Trp Tyr Gln Pro Tyr Phe Val Gln Pro
1 5 10

<210> 731

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 731

Glu Tyr Glu Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 732

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 732

Ile Pro Glu Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 733

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 733

Ser Arg Ile Trp Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 734

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 734

Asp Pro Leu Phe Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 735

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 735

Ser Arg Gln Trp Val Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 736

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 736

Ile Arg Ser Trp Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 737

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 737

Arg Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 738

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 738

Arg Leu Leu Trp Val Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 739

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 739

Glu Tyr Arg Trp Phe Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 740

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 740

Asp Ala Tyr Trp Val Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 741

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 741

Trp Ser Gly Tyr Phe Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

•••••<210> 742
 •••••<211> 12
 •••••<212> PRT
 •••••<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 742

•••••Asn Ile Glu Phe Trp Gln Pro Tyr Ala Leu Pro Leu
 •••••1 5 10

•••••<210> 743
 •••••<211> 12
 •••••<212> PRT
 •••••<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 743

Thr Arg Asp Trp Val Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 744

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 744


Asp Ser Ser Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 745

<211> 12

<212> PRT

<213> Artificial Sequence



<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 745

Ile Gly Asn Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 746

<211> 12

<212> PRT

<213> Artificial Sequence



<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 746

Asn Leu Arg Trp Asp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 747

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 747

Leu Pro Glu Phe Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 748

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 748

Asp Ser Tyr Trp Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 749

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 749

Arg Ser Gln Tyr Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 750

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 750

Ala Arg Phe Trp Leu Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 751

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 751

Asn Ser Tyr Phe Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 752

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 752

Arg Phe Met Tyr Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 753

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 753

Ala His Leu Phe Trp Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 754

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 754

Trp Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5

<210> 755

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 755

Tyr Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5

<210> 756

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 756

Tyr Phe Gln Pro Tyr Ala Leu Gly Leu
 1 5

<210> 757

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 757

Tyr	Trp	Tyr	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10

<210> 758

<211> 10

<212> PRT


<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 758

Arg	Trp	Trp	Gln	Pro	Tyr	Ala	Thr	Pro	Leu
1				5					10



<210> 759

<211> 10

<212> PRT


<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 759

Gly	Trp	Tyr	Gln	Pro	Tyr	Ala	Leu	Gly	Phe
1				5					10



<210> 760

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 760

Tyr Trp Tyr Gln Pro Tyr Ala Leu Gly Leu
 1 5 10

<210> 761

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 761

Ile Trp Tyr Gln Pro Tyr Ala Met Pro Leu
 1 5 10

<210> 762

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 762

Ser Asn Met Gln Pro Tyr Gln Arg Leu Ser
 1 5 10

<210> 763

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 763

Thr Phe Val Tyr Trp Gln Pro Tyr Ala Val Gly Leu Pro Ala Ala Glu
 1 5 10 15

Thr Ala Cys Asn
20

<210> 764

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 764

Thr Phe Val Tyr Trp Gln Pro Tyr Ser Val Gln Met Thr Ile Thr Gly
1 5 10 15

Lys Val Thr Met
20

<210> 765

<211> 20

<212> PRT

<213> Artificial Sequence



<220>


<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (12, 13)..(16)

<223> Xaa = any amino acid



<400> 765

Thr Phe Val Tyr Trp Gln Pro Tyr Ser Ser His Xaa Xaa Val Pro Xaa
1 5 10 15

Gly Phe Pro Leu
20

<210> 766

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 766

Thr Phe Val Tyr Trp Gln Pro Tyr Tyr Gly Asn Pro Gln Trp Ala Ile
 1 5 10 15

His Val Arg His
 20

<210> 767

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 767

Thr Phe Val Tyr Trp Gln Pro Tyr Val Leu Leu Glu Leu Pro Glu Gly
 1 5 10 15

Ala Val Arg Ala
 20

<210> 768

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 768

Thr Phe Val Tyr Trp Gln Pro Tyr Val Asp Tyr Val Trp Pro Ile Pro
 1 5 10 15

Ile Ala Gln Val
 20

<210> 769

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 769

Gly Trp Tyr Gln Pro Tyr Val Asp Gly Trp Arg
1 5 10

<210> 770

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 770

Arg Trp Glu Gln Pro Tyr Val Lys Asp Gly Trp Ser
1 5 10

•••••

<210> 771

•••••

<211> 12

•••••

<212> PRT

•••••

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

•••••

<400> 771

•••••

Glu Trp Tyr Gln Pro Tyr Ala Leu Gly Trp Ala Arg
1 5 10

•••••

<210> 772

•••••

<211> 10

•••••

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 772

Gly Trp Trp Gln Pro Tyr Ala Arg Gly Leu
1 5 10

<210> 773

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 773

Leu Phe Glu Gln Pro Tyr Ala Lys Ala Leu Gly Leu
1 5 10

<210> 774

<211> 12

<212> PRT

••••• <213> Artificial Sequence

•••••

••••• <220>

••••• <223> IL-1 ANTAGONIST PEPTIDE

••••• <400> 774

Gly Trp Glu Gln Pro Tyr Ala Arg Gly Leu Ala Gly
1 5 10

<210> 775

••••• <211> 12

••••• <212> PRT

••••• <213> Artificial Sequence

•••••

••••• <220>

••••• <223> IL-1 ANTAGONIST PEPTIDE

<400> 775

Ala Trp Val Gln Pro Tyr Ala Thr Pro Leu Asp Glu
 1 5 10

<210> 776

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 776

Met Trp Tyr Gln Pro Tyr Ser Ser Gln Pro Ala Glu
 1 5 10

<210> 777

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 777

Gly Trp Thr Gln Pro Tyr Ser Gln Gln Gly Glu Val
 1 5 10

<210> 778

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 778

Asp Trp Phe Gln Pro Tyr Ser Ile Gln Ser Asp Glu
 1 5 10

<210> 779

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 779

Pro	Trp	Ile	Gln	Pro	Tyr	Ala	Arg	Gly	Phe	Gly
1			5						10	

<210> 780

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 780

Arg	Pro	Leu	Tyr	Trp	Gln	Pro	Tyr	Ser	Val	Gln	Val
1				5					10		

<210> 781


 <211> 12


 <212> PRT


 <213> Artificial Sequence


 <220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 781

Thr	Leu	Ile	Tyr	Trp	Gln	Pro	Tyr	Ser	Val	Gln	Ile
1				5					10		


 <210> 782


 <211> 12


 <212> PRT


 <213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 782

Arg Phe Asp Tyr Trp Gln Pro Tyr Ser Asp Gln Thr
 1 5 10

<210> 783

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 783

Trp His Gln Phe Val Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 784

<211> 17

<212> PRT

<213> Artificial Sequence

 <220>

 <223> IL-1 ANTAGONIST PEPTIDE

 <400> 784



Glu Trp Asp Ser Val Tyr Trp Gln Pro Tyr Ser Val Gln Thr Leu Leu
 1 5 10 15

Arg

<210> 785

 <211> 17

 <212> PRT

 <213> Artificial Sequence

 <220>

 <223> IL-1 ANTAGONIST PEPTIDE

<400> 785

Trp Glu Gln Asn Val Tyr Trp Gln Pro Tyr Ser Val Gln Ser Phe Ala
 1 5 10 15

Asp

<210> 786

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 786

Ser Asp Val Val Tyr Trp Gln Pro Tyr Ser Val Gln Ser Leu Glu Met
 1 5 10 15

<210> 787

<211> 17

<212> PRT

<213> Artificial Sequence

••••• <220>

••••• <223> IL-1 ANTAGONIST PEPTIDE

••••• <400> 787

••••• Tyr Tyr Asp Gly Val Tyr Trp Gln Pro Tyr Ser Val Gln Val Met Pro
 1 5 10 15

Ala

<210> 788

••••• <211> 12

••••• <212> PRT

••••• <213> Artificial Sequence

••••• <220>

••••• <223> IL-1 ANTAGONIST PEPTIDE

<400> 788

Ser Asp Ile Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 789

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 789

Gln Arg Ile Trp Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 790

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 790

Ser Arg Ile Trp Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 791

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 791

Arg Ser Leu Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 792

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 792

Thr Ile Ile Trp Glu Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 793

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 793

Trp Glu Thr Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 794

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 794

Ser Tyr Asp Trp Glu Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 795

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 795

Ser Arg Ile Trp Cys Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 796

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 796

Glu Ile Met Phe Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 797

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 797

Asp Tyr Val Trp Gln Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 798

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 798

Met Asp Leu Leu Val Gln Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10 15

<210> 799

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 799

Gly Ser Lys Val Ile Leu Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 800

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 800

Arg Gln Gly Ala Asn Ile Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 801

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 801

Gly Gly Gly Asp Glu Pro Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 802

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 802

Ser Gln Leu Glu Arg Thr Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 803

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 803

Glu Thr Trp Val Arg Glu Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 804

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 804

Lys Lys Gly Ser Thr Gln Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 805

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 805

Leu Gln Ala Arg Met Asn Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10 15

<210> 806

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 806

Glu Pro Arg Ser Gln Lys Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10 15

<210> 807

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 807

Val Lys Gln Lys Trp Arg Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10 15

<210> 808

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 808

Leu Arg Arg His Asp Val Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10 15

<210> 809

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 809

Arg	Ser	Thr	Ala	Ser	Ile	Trp	Tyr	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5				10						15

<210> 810

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 810

Glu	Ser	Lys	Glu	Asp	Gln	Trp	Tyr	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1			5					10						15

<210> 811

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 811

Glu	Gly	Leu	Thr	Met	Lys	Trp	Tyr	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5				10						15

<210> 812

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 812

Glu	Gly	Ser	Arg	Glu	Gly	Trp	Tyr	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10					15

<210> 813

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 813

Val	Ile	Glu	Trp	Trp	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10		

<210> 814

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 814

Val	Trp	Tyr	Trp	Glu	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10		

<210> 815

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 815

Ala	Ser	Glu	Trp	Trp	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10		

<210> 816

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 816

Phe	Tyr	Glu	Trp	Trp	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10		

<210> 817

<211> 12

<212> PRT


<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 817

Glu	Gly	Trp	Trp	Val	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10		



<210> 818

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 818

Trp	Gly	Glu	Trp	Leu	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10		

<210> 819

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 819

Asp Tyr Val Trp Glu Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 820

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 820

Ala His Thr Trp Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 821

<211> 12

<212> PRT

••••• <213> Artificial Sequence

••••• <220>

••••• <223> IL-1 ANTAGONIST PEPTIDE

••••• <400> 821

Phe Ile Glu Trp Phe Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 822

••••• <211> 12

••••• <212> PRT

••••• <213> Artificial Sequence

••••• <220>

••••• <223> IL-1 ANTAGONIST PEPTIDE

<400> 822

Trp Leu Ala Trp Glu Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 823

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 823

Val Met Glu Trp Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 824

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

•••••<400> 824

•••••Glu Arg Met Trp Gln Pro Tyr Ala Leu Pro Leu
 •••••1 5 10

•••••<210> 825

•••••<211> 12

<212> PRT

<213> Artificial Sequence

•••••<220>

•••••<223> IL-1 ANTAGONIST PEPTIDE

•••••<220>

•••••<221> misc_feature

•••••<222> (2, 3, 5)..(6)

•••••<223> Xaa = any amino acid

<400> 825

Asn Xaa Xaa Trp Xaa Xaa Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 826

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 826

Trp Gly Asn Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 827

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

•••••<223> IL-1 ANTAGONIST PEPTIDE

•••••<400> 827

•••••Thr Leu Tyr Trp Glu Gln Pro Tyr Ala Leu Pro Leu
•••••1 5 10

•••••<210> 828

<211> 12

<212> PRT

<213> Artificial Sequence

•••••<220>

•••••<223> IL-1 ANTAGONIST PEPTIDE

•••••<400> 828

•••••Val Trp Arg Trp Glu Gln Pro Tyr Ala Leu Pro Leu
•••••1 5 10

<210> 829

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 829

Leu Leu Trp Thr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 830

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(6)

•••••<223> xaa = any amino acid
 •••••

•••••<400> 830
 •••••

•••••Ser Arg Ile Trp Xaa Xaa Pro Tyr Ala Leu Pro Leu
 •••••1 5 10

<210> 831

<211> 12

<212> PRT

•••••<213> Artificial Sequence
 •••••

•••••<220>
 •••••

•••••<223> IL-1 ANTAGONIST PEPTIDE
 •••••

•••••<400> 831
 •••••

Ser Asp Ile Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 832

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(6)

<223> Xaa = any amino acid

<400> 832


Trp Gly Tyr Tyr Xaa Xaa Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 833

<211> 12

<212> PRT

<213> Artificial Sequence



<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 833

Thr Ser Gly Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 834

<211> 12



<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(6)

<223> Xaa = any amino acid

<400> 834

Val His Pro Tyr Xaa Xaa Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 835

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 835

Glu His Ser Tyr Phe Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 836

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(2)

<223> Xaa = any amino acid

<400> 836

Xaa Xaa Ile Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 837

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 837

Ala Gln Leu His Ser Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 838

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 838

Trp Ala Asn Trp Phe Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 839

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 839

Ser Arg Leu Tyr Ser Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 840

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 840

Gly Val Thr Phe Ser Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 841

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 841

Ser Ile Val Trp Ser Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 842

<211> 12

<212> PRT

<213> Artificial Sequence

<220>


 <223> IL-1 ANTAGONIST PEPTIDE

<400> 842



Ser Arg Asp Leu Val Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 843

<211> 17

<212> PRT

<213> Artificial Sequence

<220>


 <223> IL-1 ANTAGONIST PEPTIDE

<400> 843



His Trp Gly His Val Tyr Trp Gln Pro Tyr Ser Val Gln Asp Asp Leu
 1 5 10 15

Gly

<210> 844

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 844

Ser Trp His Ser Val Tyr Trp Gln Pro Tyr Ser Val Gln Ser Val Pro
1 5 10 15

Glu

<210> 845

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

•••••<223> IL-1 ANTAGONIST PEPTIDE

•••••<400> 845

•••••Trp Arg Asp Ser Val Tyr Trp Gln Pro Tyr Ser Val Gln Pro Glu Ser
•••••1 5 10 15

•••••Ala

<210> 846

<211> 17

•••••<212> PRT

•••••<213> Artificial Sequence

•••••<220>

•••••<223> IL-1 ANTAGONIST PEPTIDE

•••••<400> 846

Thr Trp Asp Ala Val Tyr Trp Gln Pro Tyr Ser Val Gln Lys Trp Leu
1 5 10 15

Asp

<210> 847

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 847

Thr Pro Pro Trp Val Tyr Trp Gln Pro Tyr Ser Val Gln Ser Leu Asp
1 5 10 15


Pro

<210> 848

<211> 17

<212> PRT

<213> Artificial Sequence




<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 848

Tyr Trp Ser Ser Val Tyr Trp Gln Pro Tyr Ser Val Gln Ser Val His
1 5 10 15

Ser



<210> 849

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 849

Tyr	Trp	Tyr	Gln	Pro	Tyr	Ala	Leu	Gly	Leu
1				5					10

<210> 850

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 850

Tyr	Trp	Tyr	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10

<210> 851

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 851

Glu	Trp	Ile	Gln	Pro	Tyr	Ala	Thr	Gly	Leu
1				5					10

<210> 852

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 852

Asn	Trp	Glu	Gln	Pro	Tyr	Ala	Lys	Pro	Leu
1				5					10

<210> 853

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 853

Ala Phe Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 854

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 854

Phe Leu Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 855

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 855

Val Cys Lys Gln Pro Tyr Leu Glu Trp Cys
1 5 10

<210> 856

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 856

Glu Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 857

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 857

Gln Gly Trp Leu Thr Trp Gln Asp Ser Val Asp Met Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 858

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 858

Phe Ser Glu Ala Gly Tyr Thr Trp Pro Glu Asn Thr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 859

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 859

Thr Glu Ser Pro Gly Gly Leu Asp Trp Ala Lys Ile Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 860

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 860

Asp Gly Tyr Asp Arg Trp Arg Gln Ser Gly Glu Arg Tyr Trp Gln Pro
1 5 10 15

••••• Tyr Ala Leu Pro Leu
••••• 20

••••• <210> 861

••••• <211> 21

<212> PRT

<213> Artificial Sequence

••••• <220>

••••• <223> IL-1 ANTAGONIST PEPTIDE

••••• <400> 861

••••• Thr Ala Asn Val Ser Ser Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro
••••• 1 5 10 15

••••• Tyr Ala Leu Pro Leu
••••• 20

<210> 862

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 862

Ser Val Gly Glu Asp His Asn Phe Trp Thr Ser Glu Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 863

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 863

Met Asn Asp Gln Thr Ser Glu Val Ser Thr Phe Pro Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 864

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 864

Ser Trp Ser Glu Ala Phe Glu Gln Pro Arg Asn Leu Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 865

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 865

Gln Tyr Ala Glu Pro Ser Ala Leu Asn Asp Trp Gly Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 866

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 866

Asn Gly Asp Trp Ala Thr Ala Asp Trp Ser Asn Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 867

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 867

Thr His Asp Glu His Ile Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10 15

<210> 868
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 868

Met Leu Glu Lys Thr Tyr Thr Thr Trp Thr Pro Gly Tyr Trp Gln Pro
 1 5 10 15
 Tyr Ala Leu Pro Leu
 20

<210> 869
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 869

Trp Ser Asp Pro Leu Thr Arg Asp Ala Asp Leu Tyr Trp Gln Pro Tyr
 1 5 10 15
 Ala Leu Pro Leu
 20

<210> 870
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 870

Ser Asp Ala Phe Thr Thr Gln Asp Ser Gln Ala Met Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 871

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 871

Gly Asp Asp Ala Ala Trp Arg Thr Asp Ser Leu Thr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 872

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 872

Ala Ile Ile Arg Gln Leu Tyr Arg Trp Ser Glu Met Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 873

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 873

Glu Asn Thr Tyr Ser Pro Asn Trp Ala Asp Ser Met Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 874

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 874

Met Asn Asp Gln Thr Ser Glu Val Ser Thr Phe Pro Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 875

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 875

Ser Val Gly Glu Asp His Asn Phe Trp Thr Ser Glu Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 876

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 876

Gln Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 877

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 877

Glu Asn Pro Phe Thr Trp Gln Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

•••••
 •••••
 •••••
 •••••
 •••••
 •••••

<210> 878

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 878

Val Thr Pro Phe Thr Trp Glu Asp Ser Asn Val Phe Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

•••••
 •••••
 •••••

<210> 879

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 879

Gln Ile Pro Phe Thr Trp Glu Gln Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 880

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 880

Gln Ala Pro Leu Thr Trp Gln Glu Ser Ala Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 881

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 881

Glu Pro Thr Phe Thr Trp Glu Glu Ser Lys Ala Thr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 882

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 882

Thr Thr Thr Leu Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 883

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 883

•••••Glu Ser Pro Leu Thr Trp Glu Glu Ser Ser Ala Leu Tyr Trp Gln Pro
 •••••1 5 10 15

•••••Tyr Ala Leu Pro Leu
 •••••20

<210> 884

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 884

•••••Glu Thr Pro Leu Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
 •••••1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 885

<211> 21

<212> PRT

<213> Artificial sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 885

Glu Ala Thr Phe Thr Trp Ala Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 886

<211> 21

<212> PRT

<213> Artificial sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 886

Glu Ala Leu Phe Thr Trp Lys Glu Ser Thr Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 887

<211> 20

<212> PRT

<213> Artificial sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 887

Ser Thr Pro Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro Tyr
1 5 10 15

Ala Leu Pro Leu
20

<210> 888

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 888

Glu Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 889

<211> 21

<212> PRT

•••••<213> Artificial Sequence

•••••<220>

•••••<223> IL-1 ANTAGONIST PEPTIDE

•••••<400> 889

Lys Ala Pro Phe Thr Trp Glu Glu Ser Gln Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

•••••<210> 890

•••••<211> 21

•••••<212> PRT

•••••<213> Artificial Sequence

•••••<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 890

Ser Thr Ser Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 891

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 891

Asp Ser Thr Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 892

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 892

Tyr Ile Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 893

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 893

Gln Thr Ala Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 894

<211> 21

<212> PRT

<213> Artificial Sequence


<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 894

Glu Thr Leu Phe Thr Trp Glu Glu Ser Asn Ala Thr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20



<210> 895

<211> 21

<212> PRT

<213> Artificial Sequence


<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 895

Val Ser Ser Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20



<210> 896

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 896

Gln Pro Tyr Ala Leu Pro Leu
1 5

<210> 897

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa is a phosphotyrosyl residue

<220>

<221> misc_feature

<222> (2)..(2)

<223> Position 2, Xaa is a 1-naphthylalanyl residue

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, Xaa is an azetidine residue

<400> 897

Xaa Xaa Pro Tyr Gln Xaa Tyr Ala Leu Pro Leu
1 5 10

<210> 898

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 898

Thr Ala Asn Val Ser Ser Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 899

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

•••••<400> 899

•••••Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
•••••1 5 10 15

•••••<210> 900

•••••<211> 15

<212> PRT

<213> Artificial Sequence

•••••<220>

•••••<223> IL-1 ANTAGONIST PEPTIDE

•••••<220>

•••••<221> misc_feature

•••••<222> (10)..(10)

•••••<223> Position 10, Xaa is an azetidine residue

<400> 900

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr Ala Leu Pro Leu
Page 340

1 5 10 15

<210> 901

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 901

Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr Ala Leu Pro Leu
1 5 10 15

<210> 902

•••••<211> 21

•••••<212> PRT

•••••<213> Artificial Sequence

•••••<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 902

Glu Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

•••••Tyr Ala Leu Pro Leu
•••••20

•••••<210> 903

•••••<211> 18

•••••<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (13)..(13)

<223> Position 13, Xaa is an azetidine residue

<400> 903

Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Xaa Tyr Ala Leu
1 5 10 15

Pro Leu

<210> 904

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

•••••<223> IL-1 ANTAGONIST PEPTIDE

•••••<400> 904

•••••Ala Asp Val Leu Tyr Trp Gln Pro Tyr Ala Pro Val Thr Leu Trp Val
•••••1 5 10 15

•••••<210> 905

<211> 17

<212> PRT

<213> Artificial Sequence

•••••

•••••<220>

•••••<223> IL-1 ANTAGONIST

•••••<400> 905

•••••Gly Asp Val Ala Glu Tyr Trp Gln Pro Tyr Ala Leu Pro Leu Thr Ser
•••••1 5 10 15

Leu

<210> 906

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 906

Ser Trp Thr Asp Tyr Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Ile Ser
1 5 10 15

Gly Leu

<210> 907

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

•••••<223> IL-1 ANTAGONIST PEPTIDE

•••••<220>

•••••<221> misc_feature

•••••<222> (1, 2, 7)..(8)

•••••<223> Xaa is any amino acid

<220>

•••••<221> misc_feature

•••••<222> (4)..(4)

•••••<223> Position 4, Xaa is prolyl or an azetidine residue

•••••<220>

•••••<221> misc_feature

<222> (6)..(6)

<223> Position 6, Xaa is S, A, V or L

<400> 907

Xaa Xaa Gln Xaa Tyr Xaa Xaa Xaa
 1 5

<210> 908

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa is Y, W or F

<220>

<221> misc_feature


 <222> (2, 7)..(8)


 <223> Xaa is any amino acid


 <220>


 <221> misc_feature

<222> (4)..(4)

<223> Position 4, Xaa is prolyl or an azetidine residue


 <220>


 <221> misc_feature


 <222> (6)..(6)


 <223> Position 6, Xaa is S, A, V or L


 <400> 908

Xaa Xaa Gln Xaa Tyr Xaa Xaa Xaa
 1 5

<210> 909

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa is Y, W or F

<220>

<221> misc_feature

<222> (2)..(2)

<223> Position 2, Xaa is E, F, V, W or Y

<220>

•••••<221> misc_feature

•••••<222> (4)..(4)

•••••<223> Position 4, Xaa is prolyl or an azetidine residue

•••••<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, Xaa is S, A, V or L

•••••<220>

•••••<221> misc_feature

•••••<222> (7)..(7)

•••••<223> Position 7, Xaa is M, F, V, R, Q, K, T, S, D, L, I or E

•••••<220>

<220>

<221> misc_feature

<222> (8)..(8)

<223> Position 8, Xaa is E, L, W, V, H, I, G, A, D, L, Y, N, Q or P

<400> 909

Xaa Xaa Gly Xaa Tyr Xaa Xaa Xaa
1 5

<210> 910

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa is V, L, I, E, P, G, Y, M, T or D

⋮⋮⋮<220>

⋮⋮⋮<221> misc_feature

⋮⋮⋮<222> (2)..(2)

⋮⋮⋮<223> Position 2, Xaa is Y, W or F

⋮⋮⋮

<220>

<221> misc_feature

<222> (3)..(3)

⋮⋮⋮<223> Position 3, Xaa is E, F, V, W or Y

⋮⋮⋮

⋮⋮⋮<220>

⋮⋮⋮<221> misc_feature

⋮⋮⋮<222> (5)..(5)

⋮⋮⋮<223> Position 5, Xaa is prolyl or an azetidine residue;

⋮⋮⋮

<220>

<221> misc_feature

<222> (7) .. (7)

<223> Position 7, Xaa is S, A, V or L

<220>

<221> misc_feature

<222> (8) . . (8)

<223> Position 8, Xaa is M, F, V, R, Q, K, T, S, D, L, I or E;

<220>

<221> misc_feature

<222> (9) . . (9)

<223> Position 9, Xaa is E, L, W, V, H, I, G, A, D, L, Y, N, Q or P

<400> 910

Xaa Xaa Xaa Gln Xaa Tyr Xaa Xaa Xaa
1 5

<210> 911

 $\langle 211 \rangle$ 15

••••• $\langle 212 \rangle$ PRT

• • • • • $\langle 213 \rangle$ Artificial Sequence



A diagram of a 2D lattice with a $\langle 220 \rangle$ direction indicated. The lattice consists of a grid of points. A horizontal line of points is highlighted, and a vertical line of points is also highlighted, intersecting at a point. The label $\langle 220 \rangle$ is placed to the right of the vertical line.

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 911

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15


¹
 $\langle 210 \rangle$ 912

<210> 912

<211> 15

<212> PRT

 $\langle 213 \rangle$ Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Xaa = any amino acid

<400> 912

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr Ala Leu Pro Leu
1 5 10 15

<210> 913

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 913

Phe Glu Trp Thr Pro Gly Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 914

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 914

Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr Ala Leu Pro Leu
1 5 10 15

<210> 915

<211> 15

<212> PRT

<213> Artificial sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 915

Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 916

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 916

Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr Ala Leu Pro Leu
1 5 10 15

<210> 917

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa is A, D, E, F, G, K, Q, S, T, V or Y

<220>

<221> misc_feature

<222> (2)..(2)

<223> Position 2, Xaa is A, D, G, I, N, P, S, T, V or W

<220>

<221> misc_feature

<222> (3)..(3)

<223> Position 3, Xaa is A, D, G, L, N, P, S, T, W or Y

<220>

<221> misc_feature

<222> (4)..(4)

<223> Position 4, Xaa is A, D, E, F, L, N, R, V or Y

<220>

••••• <221> misc_feature

••••• <222> (5)..(5)

••••• <223> Position 5, Xaa is A, D, E, Q, R, S or T

•••••

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, Xaa is H, I, L, P, S, T or W

•••••

<220>

••••• <221> misc_feature

••••• <222> (7)..(7)

••••• <223> Position 7, Xaa is A, E, F, K, N, Q, R, S or Y;

•••••

<220>

<221> misc_feature

<222> (8)..(8)

<223> Position 8, Xaa is D, E, F, Q, R, T or W

<220>

<221> misc_feature

<222> (9)..(9)

<223> Position 9, Xaa is A, D, P, S, T or W

<220>

<221> misc_feature

<222> (10)..(10)


<223> Position 10, Xaa is A, D, G, K, N, Q, S or T

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11, Xaa is A, E, L, P, S, T, V or Y



<220>

<221> misc_feature

<222> (12)..(12)


<223> Position 12, Xaa is V, L, I, E, P, G, Y, M, T or D

<220>

<221> misc_feature

<222> (13)..(13)

<223> Position 13, Xaa is Y, W or F



<220>

<221> misc_feature

<222> (14)..(14)

<223> Position 14, Xaa is E, F, V, W or Y

<220>

<221> misc_feature

<222> (16)..(16)

<223> Position 16, Xaa is P or an azetidine residue;

<220>

<221> misc_feature

<222> (18)..(18)

<223> Position 18, Xaa is S, A, V or L

<220>

<221> misc_feature

<222> (19)..(19)

<223> Position 19, Xaa is M, F, V, R, Q, K, T, S, D, L, I or E

<220>

<221> misc_feature

<222> (20)..(20)

<223> Position 20, Xaa is Q or P.

<400> 917

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gln Xaa
1 5 10 15

Tyr Xaa Xaa Xaa Leu
20

<210> 918

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 918

Thr Ala Asn Val Ser Ser Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu

20

<210> 919

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 919

Ser Trp Thr Asp Tyr Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Ile Ser
 1 5 10 15

Gly Leu

<210> 920

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 920

Glu Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 921

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 921

Glu Asn Thr Tyr Ser Pro Asn Trp Ala Asp Ser Met Tyr Trp Gln Pro
 Page 353

1 5 15

Tyr Ala Leu Pro Leu
20

<210> 922

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 922

Ser Val Gly Glu Asp His Asn Phe Trp Thr Ser Glu Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 923

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 923

Asp Gly Tyr Asp Arg Trp Arg Gln Ser Gly Glu Arg Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 924

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 924

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 925

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 925

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr
1 5 10

<210> 926

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 926

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 927

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 927

Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr
1 5 10

<210> 928

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 928

••••• Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr
••••• 1 5 10
•••••

<210> 929

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

••••• <223> IL-1 ANTAGONIST PEPTIDE
•••••

<220>

••••• <221> misc_feature
•••••

••••• <222> (10)..(10)
•••••

••••• <223> Position 10, Xaa is an azetidine residue
•••••

<400> 929

Ala Glu Trp Thr pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 930
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE
<220>
<221> misc_feature
<222> (10)..(10)
<223> Position 10, Xaa is an azetidine residue

<400> 930
Phe Ala Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 931
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE
<220>
<221> misc_feature
<222> (10)..(10)
<223> Position 10, Xaa is an azetidine residue

<400> 931
Phe Glu Ala Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 932
<211> 11
<212> PRT
<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 932

Phe	Glu	Trp	Ala	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 933

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 933

Phe	Glu	Trp	Thr	Ala	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 934

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<400> 934
 Phe Glu Trp Thr Pro Ala Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 935
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

•••••<400> 935
 •••••Phe Glu Trp Thr Pro Gly Ala Trp Gln Xaa Tyr
 •••••1 5 10
 •••••
 •••••<210> 936
 •••••<211> 11
 •••••<212> PRT
 •••••<213> Artificial Sequence

•••••<220>
 •••••<223> IL-1 ANTAGONIST PEPTIDE
 •••••<220>
 •••••<221> misc_feature
 •••••<222> (10)..(10)
 •••••<223> Position 10, Xaa is an azetidine residue

<400> 936

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Ala	Gln	Xaa	Tyr
1				5					10	

<210> 937

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 937

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Xaa	Ala
1				5					10	

<210> 938

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 938

Phe	Glu	Trp	Thr	Gly	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 939

<211> 11
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 5, D amino acid residue
 Position 10, Xaa is an azetidine residue

<400> 939
 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 940
 <211> 11
 <212> PRT
 <213> Artificial Sequence

•••••<220>
 •••••<223> IL-1 ANTAGONIST PEPTIDE
 •••••<220>
 •••••<221> misc_feature
 •••••<222> (5)..(10)
 •••••<223> Position 10, xaa is an azetidine residue

<400> 940
 •••••Phe Glu Trp Thr xaa Gly Tyr Trp Gln Xaa Tyr
 •••••1 5 10
 •••••<210> 941
 •••••<211> 11
 •••••<212> PRT
 •••••<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa is a pipecolic acid residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 941


Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 942

<211> 11

<212> PRT

<213> Artificial Sequence



<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, Xaa is an aminoisobutyric acid residue



<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 942

Phe Glu Trp Thr Pro Xaa Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 943

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, Xaa is a sarcosine residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 943

Phe Glu Trp Thr Pro Xaa Trp Tyr Gln Xaa Tyr
 1 5 10

<210> 944

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa is a sarcosine residue

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<400> 944
 Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 945
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

•••••<400> 945
 •••••Phe Glu Trp Thr Pro Asn Tyr Trp Gln Xaa Tyr
 •••••1 5 10

•••••<210> 946
 •••••<211> 11
 •••••<212> PRT
 •••••<213> Artificial Sequence

•••••<220>
 •••••<223> IL-1 ANTAGONIST PEPTIDE
 •••••<220>
 •••••<221> misc_feature
 •••••<222> (10)..(10)
 •••••<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, D amino acid residue

<400> 946

Phe Glu Trp Thr Pro Val Tyr Trp Gln Xaa Tyr
1 5 10

<210> 947

<211> 11

<212> PRT

<213> Artificial Sequence

<220>


<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue



<400> 947


Phe Glu Trp Thr Val Pro Tyr Trp Gln Xaa Tyr
1 5 10

<210> 948

<211> 11

<212> PRT

<213> Artificial Sequence



<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, acetylated Phe

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 948

Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr
1 5 10

<210> 949

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

•••••<223> Position 1, acetylated Phe

•••••<220>

•••••<221> misc_feature

•••••<222> (10)..(10)

•••••<223> Position 10, Xaa is an azetidine residue

<400> 949

•••••Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
•••••1 5 10

•••••<210> 950

•••••<211> 11

•••••<212> PRT

•••••<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa = 1-naphthylalanine

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 950


Xaa Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 951

<211> 11

<212> PRT

<213> Artificial Sequence



<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, xaa is an azetidine residue



<400> 951

Tyr Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 952

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 952

Phe Glu Trp Val Pro Gly Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 953

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

•••••<221> misc_feature

•••••<222> (10)..(10)

•••••<223> Position 10, Xaa is an azetidine residue

•••••

<400> 953

phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 954

•••••<211> 11

•••••<212> PRT

•••••<213> Artificial Sequence

•••••

•••••<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 954

Phe	Glu	Trp	Thr	Pro	Ser	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 955

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

•••••	<400>	955									
•••••	Phe	Glu	Trp	Thr	Pro	Asn	Tyr	Tyr	Gln	Xaa	Tyr
•••••	1				5					10	

<210> 956

<211> 12

<212> PRT

<213> Artificial Sequence

•••••	<220>
•••••	<223> IL-1 ANTAGONIST PEPTIDE
•••••	<220>
•••••	<221> misc_feature
•••••	<222> (5)..(5)
•••••	<223> Position 5, Xaa = naphthylalanine

<400> 956

Ser His Leu Tyr Xaa Gln Pro Tyr Ser Val Gln Met
1 5 10

<210> 957

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa = naphthylalanine

<400> 957

Thr Leu Val Tyr Xaa Gln Pro Tyr Ser Leu Gln Thr
1 5 10

<210> 958

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa = naphthylalanine

<400> 958

Arg Gly Asp Tyr Xaa Gln Pro Tyr Ser Val Gln Ser
1 5 10

<210> 959

<211> 12

<212> PRT

<213> Artificial sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa = naphthylalanine

<400> 959

Asn Met Val Tyr Xaa Gln Pro Tyr Ser Ile Gln Thr
1 5 10

<210> 960

<211> 9

<212> PRT

<213> Artificial sequence

•••••<220>

•••••<223> IL-1 ANTAGONIST PEPTIDE

•••••<400> 960

•••••Val Tyr Trp Gln Pro Tyr Ser Val Gln
•••••1 5

<210> 961

<211> 9

<212> PRT

•••••<213> Artificial sequence

•••••<220>

•••••<223> IL-1 ANTAGONIST PEPTIDE

•••••<220>

•••••<221> misc_feature

<222> (3)..(3)

<223> Position 3, Xaa = naphthylalanine

<400> 961

Val Tyr Xaa Gln Pro Tyr Ser Val Gln
1 5

<210> 962

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>


<221> misc_feature

<222> (7)..(7)

<223> Position 7, Xaa is an azetidine residue

<400> 962

Thr Phe Val Tyr Trp Gln Xaa Tyr Ala Leu Pro Leu
1 5 10



<210> 963

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE



<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11, Xaa = p-benzoyl-L-phenylalanine

<400> 963

Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Xaa
1 5 10

<210> 964

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa = acetylated Phe

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11, Xaa = p-benzoyl-L-phenylalanine.

<400> 964

Xaa Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Xaa
1 5 10

<210> 965

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (8)..(10)

<223> Position 8, Xaa = p-benzoyl-L-phenylalanine
Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 965

Phe Glu Trp Thr Pro Gly Tyr Xaa Gln Xaa Tyr
1 5 10

<210> 966

•••••<211> 11

•••••<212> PRT

•••••<213> Artificial Sequence

•••••<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

•••••<222> (1)..(1)

•••••<223> Position 1, Xaa = acetylated Phe

•••••<220>

•••••<221> misc_feature

•••••<222> (8)..(8)

<223> Position 8, Xaa = p-benzoyl-L-phenylalanine

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue.

<400> 966

Phe Glu Trp Thr Pro Gly Tyr Xaa Gln Xaa Tyr
1 5 10

<210> 967

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (7)..(7)

•••••<223> Position 7, Xaa = p-benzoyl-L-phenylalanine

•••••<220>

•••••<221> misc_feature

•••••<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue.

<400> 967

•••••Phe Glu Trp Thr Pro Gly Xaa Tyr Gln Xaa Tyr
•••••1 5 10

•••••<210> 968

•••••<211> 11

•••••<212> PRT

•••••<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa = acetylated Phe

<220>

<221> misc_feature

<222> (7)..(7)

<223> Position 7, Xaa = p-benzoyl-L-phenylalanine

<220>


<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue.

<400> 968

Phe Glu Trp Thr Pro Gly Xaa Tyr Gln Xaa Tyr
1 5 10



<210> 969

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE



<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa = acetylated Phe

<220>

<221> misc_feature

<222> (3)..(3)

<223> Position 3, Xaa = p-benzoyl-L-phenylalanine

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue.

<400> 969

Phe Glu Xaa Thr Pro Gly Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 970

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

••••• <221> misc_feature

••••• <222> (1)..(1)

••••• <223> Position 1, Xaa = acetylated Phe

••••• <220>

<220>

<221> misc_feature

<222> (3)..(3)

<223> Position 3, Xaa = p-benzoyl-L-phenylalanine

••••• <220>

••••• <221> misc_feature

••••• <222> (10)..(10)

••••• <223> Position 10, Xaa is an azetidine residue.

••••• <220>

<400> 970

Phe Glu Xaa Thr Pro Gly Tyr Tyr Gln Xaa Tyr
 1 5 10

<210> 971

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa = p-benzoyl-L-phenylalanine

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue.

•••••<400> 971
 •••••Xaa Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
 •••••1 5 10

•••••<210> 972

•••••<211> 11

<212> PRT

<213> Artificial Sequence

•••••<220>

•••••<223> IL-1 ANTAGONIST PEPTIDE

•••••<220>

•••••<221> misc_feature

•••••<222> (1)..(1)

•••••<223> Position 1, Xaa = acetylated p-benzoyl-L-phenylalanine

<220>

<221> misc_feature

$\langle 222 \rangle$ (10) .. (10)

<223> Position 10, Xaa is an azetidine residue.

<400> 972

Xaa Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 973

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 973

Val Tyr Trp Gln Pro Tyr Ser Val Gln
1 5

<210> 974

 $\therefore \therefore \therefore \langle 211 \rangle \quad 12$

$\cdot \cdot \cdot$ $\langle 212 \rangle$ PRT

• • • • • <213> Artificial Sequence

• • $\langle 220 \rangle$

<223> IL-1 ANTAGONIST PEPTIDE

<400> 974

Arg Leu Val Tyr Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 975

 $\cdot \cdot \cdot : \langle 211 \rangle \quad 12$

... <212> PRT

Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa = naphthylalanine

<400> 975

Arg Leu Val Tyr Xaa Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 976

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 976

Arg Leu Asp Tyr Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

••••• <210> 977

••••• <211> 12

••••• <212> PRT

••••• <213> Artificial Sequence

•••••

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 977

••••• Arg Leu Val Trp Phe Gln Pro Tyr Ser Val Gln Arg
1 5 10

•••••

••••• <210> 978

••••• <211> 12

••••• <212> PRT

••••• <213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 978

Arg Leu Val Tyr Trp Gln Pro Tyr Ser Ile Gln Arg
1 5 10

<210> 979

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa = D or Y

<220>

<221> misc_feature

<222> (3)..(3)

<223> Position 3, Xaa = D or S

<220>

<220>

<221> misc_feature

<222> (4)..(4)

<223> Position 4, Xaa = S, T or A

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa = S or W

<220>

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, Xaa = S or Y

<220>

<221> misc_feature

<222> (7)..(7)

<223> Xaa is any amino acid

<220>

<221> misc_feature

<222> (8)..(8)

<223> Position 8, Xaa = N, S, K, H or W

<220>

<221> misc_feature

<222> (9)..(9)

<223> Position 9, Xaa = F or L

<220>

••••• <221> misc_feature

••••• <222> (10)..(10)

••••• <223> Position 10, Xaa = D, N, S or L

•••••
•••••
•••••
•••••
•••••

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11, Xaa = L, I, Q, M or A.

•••••
•••••
•••••
•••••
•••••

<400> 979

••••• Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
••••• 1 5 10

•••••
•••••
•••••
•••••
•••••

<210> 980

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 980

Asp Asn Ser Ser Trp Tyr Asp Ser Phe Leu Leu
1 5 10

<210> 981

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 981

Asp Asn Thr Ala Trp Tyr Glu Ser Phe Leu Ala
1 5 10

<210> 982

<211> 11

••••• <212> PRT

••••• <213> Artificial Sequence

•••••
•••••
•••••
•••••
•••••

<220>

••••• <223> IL-1 ANTAGONIST PEPTIDE

<400> 982

Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu
1 5 10

••••• <210> 983

••••• <211> 17

••••• <212> PRT

••••• <213> Artificial Sequence

•••••
•••••
•••••
•••••
•••••

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 983

Pro Ala Arg Glu Asp Asn Thr Ala Trp Tyr Asp Ser Phe Leu Ile Trp
1 5 10 15

Cys

<210> 984

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 984

Thr Ser Glu Tyr Asp Asn Thr Thr Trp Tyr Glu Lys Phe Leu Ala Ser
1 5 10 15

Gln

<210> 985

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 985

Ser Gln Ile Pro Asp Asn Thr Ala Trp Tyr Gln Ser Phe Leu Leu His
1 5 10 15

Gly

<210> 986

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 986

Ser Pro Phe Ile Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Thr
1 5 10 15

Tyr

<210> 987

<211> 17

<212> PRT

<213> Artificial Sequence


<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 987

Glu Gln Ile Tyr Asp Asn Thr Ala Trp Tyr Asp His Phe Leu Leu Ser
1 5 10 15

Tyr



<210> 988

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 988



Thr Pro Phe Ile Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Thr
1 5 10 15

Tyr

<210> 989

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 989

Thr Tyr Thr Tyr Asp Asn Thr Ala Trp Tyr Glu Arg Phe Leu Met Ser
1 5 10 15

Tyr

<210> 990

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 990

Thr Met Thr Gln Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Ser
1 5 10 15

•••••
••Tyr

•••••

••<210> 991

••<211> 17

<212> PRT

<213> Artificial Sequence

••<220>

••<223> IL-1 ANTAGONIST PEPTIDE

••<400> 991

••••• Ile Asp Asn Thr Ala Trp Tyr Ala Asn Leu Val Gln Thr Tyr Pro
1 5 10 15

•••••
••Gln

<210> 992

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 992

Thr Ile Asp Asn Thr Ala Trp Tyr Glu Arg Phe Leu Ala Gln Tyr Pro
1 5 10 15

Asp

<210> 993

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 993

His Ile Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Thr Tyr Thr
1 5 10 15
Pro

<210> 994

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 994

Ser Gln Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Ser Tyr Lys
1 5 10 15

Ala

<210> 995
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 995

Gln Ile Asp Asn Thr Ala Trp Tyr Glu Arg Phe Leu Leu Gln Tyr Asn
 1 5 10 15

Ala

<210> 996
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 996
 Asn Gln Asp Asn Thr Ala Trp Tyr Glu Ser Phe Leu Leu Gln Tyr Asn
 1 5 10 15

Thr

<210> 997
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 997

Thr Ile Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Asn His Asn

1 5 10 15

Leu

<210> 998

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 998

His Tyr Asp Asn Thr Ala Trp Tyr Glu Arg Phe Leu Gln Gln Gly Trp
1 5 10 15

His

<210> 999

<211> 21

<212> PRT

•••••<213> Artificial Sequence

•••••<220>

•••••<223> IL-1 ANTAGONIST PEPTIDE

•••••<400> 999

Glu Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

•••••<210> 1000

•••••<211> 21

•••••<212> PRT

•••••<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 1000

Tyr Ile Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 1001

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 1001

Asp Gly Tyr Asp Arg Trp Arg Gln Ser Gly Glu Arg Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 1002

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa = phosphotyrosine

<220>

<221> misc_feature

<222> (2)..(2)

<223> Position 2, Xaa = naphthylalanine

<220>

<221> misc_feature

<222> (3)..(3)

<223> Position 3, Xaa = phosphotyrosine

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, Xaa is an azetidine residue.

<400> 1002


Xaa	Xaa	Xaa	Gln	Gln	Xaa	Tyr	Ala	Leu	Pro	Leu
1			5						10	

<210> 1003

<211> 21

<212> PRT

<213> Artificial Sequence



<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 1003

Thr	Ala	Asn	Val	Ser	Ser	Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Pro
1				5					10					15	

Tyr	Ala	Leu	Pro	Leu
				20

<210> 1004

<211> 15

<212> PRT

<213> Artificial Sequence



<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 1004

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr Ala Leu Pro Leu
1 5 10 15

<210> 1005

<211> 17

<212> PRT

<213> Artificial Sequence


<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 1005

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu Ser
1 5 10 15

Asp



<210> 1006

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine



<400> 1006

Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr Ala Leu Pro Leu
1 5 10 15

<210> 1007

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 1007

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 1008

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1 is acetylated Phe

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 1008

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 1009
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 1 is acetylated Phe
 Position 10, Xaa = azetidine

<400> 1009
 Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr
 1 5 10

<210> 1010
 <211> 11
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (1)..(1)

<223> Position 1 is acetylated Phe
 <220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa = azetidine

<400> 1010

Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
 1 5 10

<210> 1011

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)


<223> Position 1 is acetylated Phe

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine



<400> 1011


Phe Glu Trp Thr Pro Ala Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 1012

<211> 11

<212> PRT

<213> Artificial Sequence



<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1 is acetylated Phe

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 1012

Phe	Glu	Trp	Thr	Pro	Ala	Trp	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 1013

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1 is acetylated Phe

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 1013

Phe	Glu	Trp	Thr	Pro	Ala	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 1014

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 1014

Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr Ala Leu Pro Leu
1 5 10 15

<210> 1015

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 1015

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr Ala Leu Pro Leu
1 5 10 15

<210> 1016

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 1016

Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr Ala Leu Pro Leu
1 5 10 15

<210> 1017

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 1017

Thr Ala Asn Val Ser Ser Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 1018

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1 is acetylated Phe

<400> 1018

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 1019

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1 is acetylated Phe

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 1019

Phe	Glu	Trp	Thr	Pro	Gly	Trp	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 1020

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1 is acetylated Phe

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 1020

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 1021

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1 is acetylated Phe

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, D amino acid residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine.

<400> 1021

Phe	Glu	Trp	Thr	Pro	Ala	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 1022

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1 is acetylated Phe

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, D amino acid residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine.

<400> 1022

Phe Glu Trp Thr Pro Ala Trp Tyr Gln Xaa Tyr
 1 5 10

<210> 1023

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1 is acetylated Phe

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, D amino acid residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine.

<400> 1023


Phe Glu Trp Thr Pro Ala Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 1024

<211> 20

<212> PRT

<213> Artificial Sequence



<220>

<223> EPO-MIMETIC PEPTIDE

<400> 1024

Gly Gly Leu Tyr Leu Cys Arg Phe Gly Pro Val Thr Trp Asp Cys Gly
1 5 10 15

Tyr Lys Gly Gly
20



<210> 1025

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 1025

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
 1 5 10 15

Pro Gln Gly Gly
 20

<210> 1026

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 1026

Gly Gly Asp Tyr His Cys Arg Met Gly Pro Leu Thr Trp Val Cys Lys
 1 5 10 15

Pro Leu Gly Gly
 20

<210> 1027

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> VEGF-ANTAGONIST

<400> 1027

Val Glu Pro Asn Cys Asp Ile His Val Met Trp Glu Trp Glu Cys Phe
 1 5 10 15

Glu Arg Leu

<210> 1028

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> MMP INHIBITOR

<400> 1028

Cys Thr Thr His Trp Gly Phe Thr Leu Cys
1 5 10

<210> 1029

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 1029

Val Gly Asn Tyr Met Cys His Phe Gly Pro Ile Thr Trp Val Cys Arg
1 5 10 15

Pro Gly Gly Gly
20

<210> 1030

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 1030

Gly Gly Val Tyr Ala Cys Arg Met Gly Pro Ile Thr Trp Val Cys Ser
1 5 10 15

Pro Leu Gly Gly
20

<210> 1031

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> VEGF- ANTAGONIST

<400> 1031

Arg Gly Trp Val Glu Ile Cys Ala Ala Asp Asp Tyr Gly Arg Cys Leu
1 5 10 15

Thr Glu Ala Gln
20

<210> 1032

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC

<220>

<221> misc_feature

<222> (1)..(1)

<223> Fc domain attached at Position 1 of the N-terminus

<400> 1032
Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala
1 5 10 15
Ala Arg Ala

<210> 1033

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC

<220>

<221> misc_feature

<222> (19)..(19)

<223> Fc domain attached at Position 19 of the C-terminus

<400> 1033

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15

Gly Gly Gly

<210> 1034

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC

<220>

<221> misc_feature

<222> (25)..(25)

<223> Fc domain attached at Position 25 of the C-terminus


 <400> 1034
 Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
 1 5 10 15
 Pro Gln Gly Gly Gly Gly Gly Gly Gly
 20 25

<210> 1035

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 1035

Val Gly Asn Tyr Met Ala His Met Gly Pro Ile Thr Trp Val Cys Arg
 1 5 10 15

Pro Gly Gly

<210> 1036

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 1036

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
 1 5 10 15

Pro Gln

<210> 1037

<211> 20

<212> PRT

<213> Artificial Sequence

•••••
 •••••
 •••••
 •••••
 •••••
 •••••

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 1037

••••• Gly Gly Leu Tyr Ala Cys His Met Gly Pro Met Thr Trp Val Cys Gln
 1 5 10 15

Pro Leu Arg Gly
20

•••••
 •••••
 •••••
 •••••
 •••••
 •••••
 •••••
 •••••

<210> 1038

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 1038

Thr Ile Ala Gln Tyr Ile Cys Tyr Met Gly Pro Glu Thr Trp Glu Cys
 1 5 10 15

Arg Pro Ser Pro Lys Ala
 20

<210> 1039

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 1039

Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
 1 5 10

<210> 1040

<211> 11

<212> PRT

<213> Artificial Sequence



<220>



<223> EPO-MIMETIC PEPTIDE



<400> 1040



Tyr Cys His Phe Gly Pro Leu Thr Trp Val Cys
 1 5 10

<210> 1041

<211> 12

<212> PRT

<213> Artificial Sequence



<220>



<223> EPO-MIMETIC PEPTIDE



<400> 1041

Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
 1 5 10

<210> 1042
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)

<223> Xaa (Pos1) can be any one of the 20 L-amino acids; except Xaa (Pos1) may/may not be Y and Xaa (Pos1) may be any non-naturally occurring aromatic acid analog when Xaa (Pos1) is Y.

<220>
 <221> misc_feature
 <222> (2)..(8)
 <223> Xaa (Pos2, 8) can be any one of the 20 L-amino acids

<220>
 <221> misc_feature
 <222> (3)..(3)
 <223> Xaa (Pos3) can be C, A, a-amino-γ-bromobutyric acid or Hoc;

<220>
 <221> misc_feature
 <222> (4)..(4)
 <223> Xaa (Pos4) can be R, H, L or W

<220>
 <221> misc_feature
 <222> (5)..(5)
 <223> Xaa (Pos5) can be M, F or I

<220>

<221> misc_feature

<222> (10)..(10)

<223> Xaa is any amino acid

<220>

<221> misc_feature

<222> (11)..(11)

<223> Xaa (Pos11) can be D, E, I, L or V

<220>

<221> misc_feature

<222> (12)..(12)

<223> Xaa (Pos12) can be C, A, a-amino-γ-bromobutyric acid or Hoc provided that either Xaa (Pos3, 12) is C or Hoc.

<400> 1042

Xaa	Xaa	Xaa	Xaa	Gly	Pro	Xaa	Thr	Trp	Xaa	Xaa
1				5					10	

<210> 1043

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<220>

<221> misc_feature

<222> (3)..(4)

<223> Xaa = any amino acid

<400> 1043

Asp	Leu	Xaa	Xaa	Leu
1				5

<210> 1044

<211> 12
 <212> PRT
 <213> Artificial Sequence


<220>
 <223> INTEGRIN-BINDING PEPTIDE
 <400> 1044

Arg Thr Asp Leu Asp Ser Leu Arg Thr Tyr Thr Leu
 1 5 10

<210> 1045
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TNF-ALPHA INHIBITOR
 <220>
 <221> misc_feature

<222> (1)..(1)
 <223> Fc domain attached at Position 1 of the N-terminus



<400> 1045
 Gly Gly Gly Gly Gly Asp Phe Leu Pro His Tyr Lys Asn Thr Ser Leu
 1 5 10 15

Gly His Arg Pro
 20

<210> 1046
 <211> 20
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> TNF-ALPHA INHIBITOR
 <220>

<221> misc_feature

<222> (20)..(20)

<223> Fc domain attached at Position 20 of the C-terminus

<400> 1046

Asp Phe Leu Pro His Tyr Lys Asn Thr Ser Leu Gly His Arg Pro Gly
1 5 10 15

Gly Gly Gly Gly
20

<210> 1047

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST

<220>

<221> misc_feature

<222> (1)..(1)

<223> Fc domain attached at Position 1 of the N-terminus

<400> 1047

Gly Gly Gly Gly Gly Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr
1 5 10 15

Ala Leu Pro Leu
20

<210> 1048

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST

<220>

<221> misc_feature

<222> (20)..(20)

<223> Fc domain attached at Position 20 of the C-terminus

<400> 1048

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu Gly
1 5 10 15

Gly Gly Gly Gly
20

<210> 1049

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> VEGF-ANTAGONIST

<220>

<221> misc_feature

<222> (1)..(1)

•••••<223> Fc domain attached at Position 1 of the N-terminus
•••••

•••••<400> 1049
•••••

•••••Gly Gly Gly Gly Gly Val Glu Pro Asn Cys Asp Ile His Val Met Trp
•••••1 5 10 15

Glu Trp Glu Cys Phe Glu Arg Leu
20

<210> 1050

•••••<211> 24
•••••

•••••<212> PRT
•••••

•••••<213> Artificial Sequence
•••••

•••••<220>
•••••

<223> VEGF-ANTAGONIST

<220>

<221> misc_feature

<222> (24)..(24)

<223> Fc domain attached at Position 24 of the C-terminus

<400> 1050

Val Glu Pro Asn Cys Asp Ile His Val Met Trp Glu Trp Glu Cys Phe
1 5 10 15

Glu Arg Leu Gly Gly Gly Gly Gly
20

<210> 1051

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> MMP INHIBITOR

<220>

<221> misc_feature

<222> (1)..(1)

•••••<223> Fc domain attached at Position 1 of the N-terminus
•••••

•••••<400> 1051
•••••

•••••Gly Gly Gly Gly Gly Cys Thr Thr His Trp Gly Phe Thr Leu Cys
•••••1 5 10 15

<210> 1052

<211> 15

<212> PRT

•••••<213> Artificial Sequence
•••••

•••••<220>
•••••

•••••<223> MMP INHIBITOR
•••••

•••••<220>
•••••

<221> misc_feature

<222> (15)..(15)

<223> Fc domain attached at Position 15 of the C-terminus

<400> 1052

Cys Thr Thr His Trp Gly Phe Thr Leu Cys Gly Gly Gly Gly Gly
1 5 10 15

<210> 1053

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1053

Arg Thr Asp Leu Asp Ser Leu Arg Thr Tyr
1 5 10

<210> 1054

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1054

Arg Thr Asp Leu Asp Ser Leu Arg Thr
1 5

<210> 1055

<211> 757

<212> DNA

<213> Artificial Sequence

<220>

<223> FC-TNF-ALPHA INHIBITORS

<220>

<221> CDS

<222> (4)..(747)

<223>

<400> 1055

cat	atg	gac	aaa	act	cac	aca	tgt	cca	cct	tgt	cca	gct	ccg	gaa	ctc	48
Met	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu		
1				5					10					15		
ctg	ggg	gga	ccg	tca	gtc	ttc	ctc	ttc	ccc	cca	aaa	ccc	aag	gac	acc	96
Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	
				20					25					30		
ctc	atg	atc	tcc	cgg	acc	cct	gag	gtc	aca	tgc	gtg	gtg	gtg	gac	gtg	144
Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	
			35					40					45			
agc	cac	gaa	gac	cct	gag	gtc	aag	ttc	aac	tgg	tac	gtg	gac	ggc	gtg	192
Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	
		50					55					60				
gag	gtg	cat	aat	gcc	aag	aca	aag	ccg	cgg	gag	gag	cag	tac	aac	agc	240
Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	
	65					70					75					
acg	tac	cgt	gtg	gtc	agc	gtc	ctc	acc	gtc	ctg	cac	cag	gac	tgg	ctg	288
Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	
					85					90					95	
aat	ggc	aag	gag	tac	aag	tgc	aag	gtc	tcc	aac	aaa	gcc	ctc	cca	gcc	336
Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	
				100					105					110		
ccc	atc	gag	aaa	acc	atc	tcc	aaa	gcc	aaa	ggg	cag	ccc	cga	gaa	cca	384
Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	
			115					120					125			
cag	gtg	tac	acc	ctg	ccc	cca	tcc	cgg	gat	gag	ctg	acc	aag	aac	cag	432
Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	
							135					140				
gtc	agc	ctg	acc	tgc	ctg	gtc	aaa	ggc	ttc	tat	ccc	agc	gac	atc	gcc	480
Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	
	145					150					155					
gtg	gag	tgg	gag	agc	aat	ggg	cag	ccg	gag	aac	aac	tac	aag	acc	acg	528
Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	
	160				165				170						175	
cct	ccc	gtg	ctg	gac	tcc	gac	ggc	tcc	ttc	ttc	ctc	tac	agc	aag	ctc	576
Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	
				180					185					190		
acc	gtg	gac	aag	agc	agg	tgg	cag	cag	ggg	aac	gtc	ttc	tca	tgc	tcc	624
Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	
			195					200					205			
gtg	atg	cat	gag	gct	ctg	cac	aac	cac	tac	acg	cag	aag	agc	ctc	tcc	672
Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	
		210					215					220				
ctg	tct	ccg	ggt	aaa	ggt	gga	ggt	ggt	ggt	gac	ttc	ctg	ccg	cac	tac	720
Leu	Ser	Pro	Gly	Lys	Gly	Gly	Gly	Gly	Gly	Asp	Phe	Leu	Pro	His	Tyr	
	225					230					235					

aaa aac acc tct ctg ggt cac cgt ccg taatggatcc
 Lys Asn Thr Ser Leu Gly His Arg Pro
 240 245

<210> 1056

<211> 248

<212> PRT

<213> Artificial Sequence

<220>

<223> FC-TNF-ALPHA INHIBITORS

<400> 1056

Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
 1 5 10 15

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
 20 25 30

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
 35 40 45

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
 50 55 60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
 65 70 75 80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
 85 90 95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
 100 105 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
 115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
 130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
 145 150 155 160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
 165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
 180 185 190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
 195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
 210 215 220

Ser Pro Gly Lys Gly Gly Gly Gly Gly Asp Phe Leu Pro His Tyr Lys
 225 230 235 240

Asn Thr Ser Leu Gly His Arg Pro
 245

<210> 1057

<211> 761

<212> DNA

<213> Artificial Sequence

<220>

<223> TNF-ALPHA INHIBITOR-Fc

<220>

<221> CDS

<222> (4)..(747)

<223>

<400> 1057

cat atg gac ttc ctg ccg cac tac aaa aac acc tct ctg ggt cac cgt 48
 Met Asp Phe Leu Pro His Tyr Lys Asn Thr Ser Leu Gly His Arg
 1 5 10 15

ccg ggt gga ggc ggt ggg gac aaa act cac aca tgt cca cct tgc cca 96
 Pro Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro
 20 25 30

gca cct gaa ctc ctg ggg gga ccg tca gtt ttc ctc ttc ccc cca aaa 144
 Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
 35 40 45

ccc aag gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg 192
 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
 50 55 60

gtg gtg gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac 240
 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
 65 70 75

gtg gac ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag 288
 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
 80 85 90 95

cag tac aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac 336
 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His

A-527 PCT.ST25.txt

100	105	110		
cag gac tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys	115	120	125	384
gcc ctc cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln	130	135	140	432
ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu	145	150	155	480
acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro	160	165	170	528
agc gac atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn	180	185	190	576
tac aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu	195	200	205	624
tac agc aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val	210	215	220	672
ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln	225	230	235	720
aag agc ctc tcc ctg tct ccg ggt aaa taatggatcc gcgg Lys Ser Leu Ser Leu Ser Pro Gly Lys	240	245		761

<210> 1058
 <211> 248
 <212> PRT
 <213> Artificial Sequence

<220>

<223> TNF-ALPHA INHIBITOR-Fc

<400> 1058

Met Asp Phe Leu Pro His Tyr Lys Asn Thr Ser Leu Gly His Arg Pro	1	5	10	15
Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala	20	25	30	
Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro	35	40	45	

Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
 Page 419

50

55

Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
65 70 75 80

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
85 90 95

Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
100 105 110

Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
115 120 125

Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
130 135 140

Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr
145 150 155 160

Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
165 170 175

Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
180 185 190

Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
195 200 205


 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
210 215 220


 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
225 230 235 240

Ser Leu Ser Leu Ser Pro Gly Lys
245

<210> 1059

<211> 763

<212> DNA

<213> Artificial Sequence

<220>

<223> FC-IL-1 ANTAGONIST

<220>

<221> CDS

<222> (4)..(747)

<223>

<400> 1059

cat	atg	gac	aaa	act	cac	aca	tgt	cca	cct	tgt	cca	gct	ccg	gaa	ctc	48
	Met	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	
	1				5					10				15		
ctg	ggg	gga	ccg	tca	gtc	ttc	ctc	ttc	ccc	cca	aaa	ccc	aag	gac	acc	96
Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	
				20					25					30		
ctc	atg	atc	tcc	cgg	acc	cct	gag	gtc	aca	tgc	gtg	gtg	gtg	gac	gtg	144
Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	
			35					40					45			
agc	cac	gaa	gac	cct	gag	gtc	aag	ttc	aac	tgg	tac	gtg	gac	ggc	gtg	192
Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	
		50					55					60				
gag	gtg	cat	aat	gcc	aag	aca	aag	ccg	cgg	gag	gag	cag	tac	aac	agc	240
Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	
	65					70					75					
acg	tac	cgt	gtg	gtc	agc	gtc	ctc	acc	gtc	ctg	cac	cag	gac	tgg	ctg	288
Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	
					85					90					95	
aat	ggc	aag	gag	tac	aag	tgc	aag	gtc	tcc	aac	aaa	gcc	ctc	cca	gcc	336
Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	
				100					105					110		
ccc	atc	gag	aaa	acc	atc	tcc	aaa	gcc	aaa	ggg	cag	ccc	cga	gaa	cca	384
Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	
			115					120					125			
cag	gtg	tac	acc	ctg	ccc	cca	tcc	cgg	gat	gag	ctg	acc	aag	aac	cag	432
Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	
							135					140				
gtc	agc	ctg	acc	tgc	ctg	gtc	aaa	ggc	ttc	tat	ccc	agc	gac	atc	gcc	480
Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	
						150					155					
gtg	gag	tgg	gag	agc	aat	ggg	cag	ccg	gag	aac	aac	tac	aag	acc	acg	528
Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	
					165					170					175	
cct	ccc	gtg	ctg	gac	tcc	gac	ggc	tcc	ttc	ttc	ctc	tac	agc	aag	ctc	576
Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	
				180					185					190		
acc	gtg	gac	aag	agc	agg	tgg	cag	cag	ggg	aac	gtc	ttc	tca	tgc	tcc	624
Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	
			195					200					205			
gtg	atg	cat	gag	gct	ctg	cac	aac	cac	tac	acg	cag	aag	agc	ctc	tcc	672
Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	
					210		215					220				
ctg	tct	ccg	ggt	aaa	ggt	gga	ggt	ggt	ggt	ttc	gaa	tgg	acc	ccg	ggt	720
Leu	Ser	Pro	Gly	Lys	Gly	Gly	Gly	Gly	Gly	Phe	Glu	Trp	Thr	Pro	Gly	
						230					235					

tac tgg cag ccg tac gct ctg ccg ctg taatggatcc ctcgag
 Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
 240 245

<210> 1060

<211> 248

<212> PRT

<213> Artificial Sequence

<220>

<223> FC-IL-1 ANTAGONIST

<400> 1060

Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
 1 5 10 15

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
 20 25 30

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
 35 40 45

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
 50 55 60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
 65 70 75 80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
 85 90 95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
 100 105 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
 115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
 130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
 145 150 155 160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
 165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
 180 185 190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
210 215 220

Ser Pro Gly Lys Gly Gly Gly Gly Gly Phe Glu Trp Thr Pro Gly Tyr
225 230 235 240

Trp Gln Pro Tyr Ala Leu Pro Leu
245

<210> 1061

<211> 757

<212> DNA

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST-FC

<220>

<221> CDS

<222> (4)..(747)

<223>

<400> 1061

cat atg ttc gaa tgg acc ccg ggt tac tgg cag ccg tac gct ctg ccg 48
Met Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro
1 5 10 15

ctg ggt gga ggc ggt ggg gac aaa act cac aca tgt cca cct tgc cca 96
Leu Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro
20 25 30

gca cct gaa ctc ctg ggg gga ccg tca gtt ttc ctc ttc ccc cca aaa 144
Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
35 40 45

ccc aag gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg 192
Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
50 55 60

gtg gtg gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac 240
Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
65 70 75

gtg gac ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag 288
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
80 85 90 95

cag tac aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac 336
Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
423

A-527 PCT.ST25.txt

100

105

110

```

cag gac tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa 384
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
115 120 125

gcc ctc cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag 432
Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
130 135 140

ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg 480
Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
145 150 155

acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc 528
Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
160 165 170 175

agc gac atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac 576
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
180 185 190

tac aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc 624
Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
195 200 205

tac agc aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc 672
Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
210 215 220

ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag 720
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
225 230 235

aag agc ctc tcc ctg tct ccg ggt aaa taatggatcc 757
Lys Ser Leu Ser Leu Ser Pro Gly Lys
240 245

```

```

: : :
: : : <210> 1062
: : :
: : : <211> 248
: : :
: : : <212> PRT
: : :
: : : <213> Artificial Sequence

```

<220>

<223> IL-1 ANTAGONIST-FC

```

: : : <400> 1062
: : : Met Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
: : : 1 5 10
: : :
: : : Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
: : : 20 25 30
: : :
: : : Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
: : : 35 40 45

```

```

Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
Page 424

```

50

55

Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
65 70 75 80

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
85 90 95

Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
100 105 110

Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
115 120 125

Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
130 135 140

Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr
145 150 155 160

Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
165 170 175

Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
180 185 190

Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
195 200 205

Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
210 215 220

Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
225 230 235 240

Ser Leu Ser Leu Ser Pro Gly Lys
245

<210> 1063

<211> 773

<212> DNA

<213> Artificial Sequence

<220>

<223> FC-VEGF ANTAGONIST

<220>

<221> CDS

<222> (4)..(759)

<223>

<400> 1063

cat	atg	gac	aaa	act	cac	aca	tgt	cca	ccg	tgc	cca	gca	cct	gaa	ctc	48
	Met	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	
	1				5					10				15		

ctg	ggg	gga	ccg	tca	gtt	ttc	ctc	ttc	ccc	cca	aaa	ccc	aag	gac	acc	96
Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	
				20					25					30		

ctc	atg	atc	tcc	cgg	acc	cct	gag	gtc	aca	tgc	gtg	gtg	gtg	gac	gtg	144
Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	
			35					40					45			

agc	cac	gaa	gac	cct	gag	gtc	aag	ttc	aac	tgg	tac	gtg	gac	ggc	gtg	192
Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	
		50					55					60				

gag	gtg	cat	aat	gcc	aag	aca	aag	ccg	cgg	gag	gag	cag	tac	aac	agc	240
Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	
	65					70					75					

acg	tac	cgt	gtg	gtc	agc	gtc	ctc	acc	gtc	ctg	cac	cag	gac	tgg	ctg	288
Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	
	80				85					90					95	

aat	ggc	aag	gag	tac	aag	tgc	aag	gtc	tcc	aac	aaa	gcc	ctc	cca	gcc	336
Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	
				100					105					110		

ccc	atc	gag	aaa	acc	atc	tcc	aaa	gcc	aaa	ggg	cag	ccc	cga	gaa	cca	384
Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	
			115					120					125			

cag	gtg	tac	acc	ctg	ccc	cca	tcc	cgg	gat	gag	ctg	acc	aag	aac	cag	432
Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	
		130					135					140				

gtc	agc	ctg	acc	tgc	ctg	gtc	aaa	ggc	ttc	tat	ccc	agc	gac	atc	gcc	480
Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	
	145					150					155					

gtg	gag	tgg	gag	agc	aat	ggg	cag	ccg	gag	aac	aac	tac	aag	acc	acg	528
Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	
	160				165					170					175	

cct	ccc	gtg	ctg	gac	tcc	gac	ggc	tcc	ttc	ttc	ctc	tac	agc	aag	ctc	576
Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	
				180					185					190		

acc	gtg	gac	aag	agc	agg	tgg	cag	cag	ggg	aac	gtc	ttc	tca	tgc	tcc	624
Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	
			195					200					205			

gtg	atg	cat	gag	gct	ctg	cac	aac	cac	tac	acg	cag	aag	agc	ctc	tcc	672
Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	
		210					215					220				

ctg	tct	ccg	ggg	aaa	ggg	ggg	ggg	ggg	ggg	ggt	gaa	ccg	aac	tgt	gac	720
Leu	Ser	Pro	Gly	Lys	Gly	Gly	Gly	Gly	Gly	Val	Glu	Pro	Asn	Cys	Asp	
	225					230					235					

atc cat gtt atg tgg gaa tgg gaa tgt ttt gaa cgt ctg taactcgagg 769
 ile His Val Met Trp Glu Trp Glu Cys Phe Glu Arg Leu
 240 245 250

atcc 773

<210> 1064

<211> 252

<212> PRT

<213> Artificial Sequence

<220>

<223> FC-VEGF ANTAGONIST

<400> 1064

Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
 1 5 10 15

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
 20 25 30

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
 35 40 45

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
 50 55 60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
 65 70 75 80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
 85 90 95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
 100 105 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
 115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
 130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
 145 150 155 160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
 165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr

180

185

190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
 195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
 210 215 220

Ser Pro Gly Lys Gly Gly Gly Gly Gly Val Glu Pro Asn Cys Asp Ile
 225 230 235 240

His Val Met Trp Glu Trp Glu Cys Phe Glu Arg Leu
 245 250

<210> 1065

<211> 773

<212> DNA

<213> Artificial Sequence

<220>

<223> VEGF ANTAGONIST-Fc

<220>

<221> CDS

••••• <222> (4)..(759)

••••• <223>

•••••

•••••

•••••

•••••

•••••

•••••

•••••

•••••

•••••

•••••

•••••

•••••

•••••

•••••

•••••

•••••

•••••

•••••

•••••

•••••

•••••

•••••

<400> 1065
 cat atg gtt gaa ccg aac tgt gac atc cat gtt atg tgg gaa tgg gaa 48
 Met Val Glu Pro Asn Cys Asp Ile His Val Met Trp Glu Trp Glu 15

tgt ttt gaa cgt ctg ggt ggt ggt ggt ggt gac aaa act cac aca tgt 96
 Cys Phe Glu Arg Leu Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys 20 25 30

cca ccg tgc cca gca cct gaa ctc ctg ggg gga ccg tca gtt ttc ctc 144
 Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 35 40 45

ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct gag 192
 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 50 55 60

gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc aag 240
 Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 65 70 75

ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca aag 288
 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 80 85 90 95

A-527 PCT.ST25.txt

ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc ctc 336
Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
100 105 110

acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc aag 384
Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
115 120 125

gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc aaa 432
Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
130 135 140

gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc 480
Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
145 150 155

cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa 528
Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
160 165 170 175

ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg cag 576
Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
180 185 190

ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac ggc 624
Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
195 200 205

tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg cag 672
Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
210 215 220

cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac aac 720
Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
225 230 235

cac tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa taactcgagg 769
His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
240 245 250

atcc 773

<210> 1066

<211> 252

<212> PRT

<213> Artificial Sequence

<220>

<223> VEGF ANTAGONIST-Fc

<400> 1066

Met Val Glu Pro Asn Cys Asp Ile His Val Met Trp Glu Trp Glu Cys
1 5 10 15

Phe Glu Arg Leu Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro
20 25 30

Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe
Page 429

35

40

45

Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
 50 55 60

Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe
 65 70 75 80

Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
 85 90 95

Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
 100 105 110

Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
 115 120 125

Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
 130 135 140

Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
 145 150 155 160

Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
 165 170 175

Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
 180 185 190

Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
 195 200 205

Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
 210 215 220

Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
 225 230 235 240

Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 245 250

<210> 1067

<211> 748

<212> DNA

<213> Artificial Sequence

<220>

<223> FC MMP INHIBITOR

<220>

<221> CDS

<222> (4)..(732)

<223>

<400> 1067

cat	atg	gac	aaa	act	cac	aca	tgt	cca	cct	tgt	cca	gct	ccg	gaa	ctc	48
Met	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	15	
1				5					10							
ctg	ggg	gga	ccg	tca	gtc	ttc	ctc	ttc	ccc	cca	aaa	ccc	aag	gac	acc	96
Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	
				20					25					30		
ctc	atg	atc	tcc	cgg	acc	cct	gag	gtc	aca	tgc	gtg	gtg	gtg	gac	gtg	144
Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	
			35					40					45			
agc	cac	gaa	gac	cct	gag	gtc	aag	ttc	aac	tgg	tac	gtg	gac	ggc	gtg	192
Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	
		50					55					60				
gag	gtg	cat	aat	gcc	aag	aca	aag	ccg	cgg	gag	gag	cag	tac	aac	agc	240
Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	
	65					70					75					
acg	tac	cgt	gtg	gtc	agc	gtc	ctc	acc	gtc	ctg	cac	cag	gac	tgg	ctg	288
Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	
					85					90					95	
aat	ggc	aag	gag	tac	aag	tgc	aag	gtc	tcc	aac	aaa	gcc	ctc	cca	gcc	336
Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	
				100					105					110		
ccc	atc	gag	aaa	acc	atc	tcc	aaa	gcc	aaa	ggg	cag	ccc	cga	gaa	cca	384
Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	
			115					120					125			
cag	gtg	tac	acc	ctg	ccc	cca	tcc	cgg	gat	gag	ctg	acc	aag	aac	cag	432
Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	
			130				135					140				
gtc	agc	ctg	acc	tgc	ctg	gtc	aaa	ggc	ttc	tat	ccc	agc	gac	atc	gcc	480
Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	
	145					150					155					
gtg	gag	tgg	gag	agc	aat	ggg	cag	ccg	gag	aac	aac	tac	aag	acc	acg	528
Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	
	160				165					170					175	
cct	ccc	gtg	ctg	gac	tcc	gac	ggc	tcc	ttc	ttc	ctc	tac	agc	aag	ctc	576
Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	
				180					185					190		
acc	gtg	gac	aag	agc	agg	tgg	cag	cag	ggg	aac	gtc	ttc	tca	tgc	tcc	624
Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	
			195					200					205			
gtg	atg	cat	gag	gct	ctg	cac	aac	cac	tac	acg	cag	aag	agc	ctc	tcc	672
Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	
		210					215					220				

ctg tct ccg ggt aaa ggt gga ggt ggt ggt tgc acc acc cac tgg ggt 720
 Leu Ser Pro Gly Lys Gly Gly Gly Gly Gly Cys Thr Thr His Trp Gly
 225 230 235

ttc acc ctg tgc taatggatcc ctcgag 748
 Phe Thr Leu Cys
 240

<210> 1068

<211> 243

<212> PRT

<213> Artificial Sequence

<220>

<223> FC MMP INHIBITOR

<400> 1068

Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
 1 5 10 15

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
 20 25 30

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
 35 40 45

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
 50 55 60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
 65 70 75 80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
 85 90 95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
 100 105 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
 115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
 130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
 145 150 155 160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
 165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
 180 185 190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
 195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
 210 215 220

Ser Pro Gly Lys Gly Gly Gly Gly Gly Cys Thr Thr His Trp Gly Phe
 225 230 235 240

Thr Leu Cys

<210> 1069

<211> 763

<212> DNA

<213> Artificial Sequence

<220>

<223> MMP INHIBITOR-Fc

<220>

••••• <221> CDS

••••• <222> (4)..(753)

••••• <223>

•••••

•••••

<400> 1069
 cat atg tgc acc acc cac tgg ggt ttc acc ctg tgc ggt gga ggc ggt 48
 Met Cys Thr Thr His Trp Gly Phe Thr Leu Cys Gly Gly Gly Gly
 1 5 10 15

ggg gac aaa ggt gga ggc ggt ggg gac aaa act cac aca tgt cca cct 96
 Gly Asp Lys Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro
 20 25 30

••••• tgc cca gca cct gaa ctc ctg ggg gga ccg tca gtt ttc ctc ttc ccc 144
 ••••• Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro
 ••••• 35 40 45

••••• cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct gag gtc aca 192
 ••••• Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr
 ••••• 50 55 60

••••• tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc aag ttc aac 240
 ••••• Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn
 ••••• 65 70 75

tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg 288
 Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
 433

80	85	90	95	
gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc				336
Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val	100	105	110	
ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc				384
Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser	115	120	125	
aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa				432
Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys	130	135	140	
ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc cgg gat				480
Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp	145	150	155	
gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc				528
Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe	160	165	170	175
tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg cag ccg gag				576
Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu	180	185	190	
aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc				624
Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe	195	200	205	
ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg cag cag ggg				672
Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly	210	215	220	
aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac tac				720
Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr	225	230	235	
acg cag aag agc ctc tcc ctg tct ccg ggt aaa taatggatcc				763
Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys	240	245	250	
<210> 1070				
<211> 250				
<212> PRT				
<213> Artificial Sequence				

<220>

<223> MMP INHIBITOR-Fc

<400> 1070

Met	Cys	Thr	Thr	His	Trp	Gly	Phe	Thr	Leu	Cys	Gly	Gly	Gly	Gly	Gly
1				5					10					15	
Asp	Lys	Gly	Gly	Gly	Gly	Gly	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys
		20						25					30		

Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro

Page 434

35

40

A-527 PCT.ST25.txt

45

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 50 55 60

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 65 70 75 80

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 85 90 95

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 100 105 110

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 115 120 125

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 130 135 140

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
 145 150 155 160

Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 165 170 175

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
 180 185 190

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 195 200 205

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
 210 215 220

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 225 230 235 240

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 245 250

<210> 1071

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1071

Cys Gly Arg Glu Cys Pro Arg Leu Cys Gln Ser Ser Cys
1 5 10

<210> 1072

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1072

Cys Asn Gly Arg Cys Val Ser Gly Cys Ala Gly Arg Cys
1 5 10

<210> 1073

<211> 8

<212> PRT

<213> Artificial Sequence

••••• <220>

••••• <223> INTEGRIN-BINDING PEPTIDE

••••• <400> 1073

••••• Cys Leu Ser Gly Ser Leu Ser Cys
1 5

••••• <210> 1074

••••• <211> 6

••••• <212> PRT

••••• <213> Artificial Sequence

••••• <220>

••••• <223> INTEGRIN-BINDING PEPTIDE

••••• <400> 1074

••••• Asn Gly Arg Ala His Ala
1 5

<210> 1075

<211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> INTEGRIN-BINDING PEPTIDE
 <400> 1075

Cys Asn Gly Arg Cys
 1 5

<210> 1076
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> INTEGRIN-BINDING PEPTIDE
 <400> 1076

Cys Asp Cys Arg Gly Asp Cys Phe Cys
 1 5

•••••<210> 1077
 •••••<211> 7
 •••••<212> PRT
 •••••<213> Artificial Sequence

<220>
 <223> INTEGRIN-BINDING PEPTIDE

•••••<400> 1077
 •••••Cys Gly Ser Leu Val Arg Cys
 1 5

•••••<210> 1078
 •••••<211> 8
 •••••<212> PRT
 <213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1078

Arg Thr Asp Leu Asp Ser Leu Arg
1 5

<210> 1079

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1079

Gly Asp Leu Asp Leu Leu Lys Leu Arg Leu Thr Leu
1 5 10

<210> 1080

<211> 12

<212> PRT

<213> Artificial Sequence



<220>



<223> INTEGRIN-BINDING PEPTIDE



<400> 1080



Gly Asp Leu His Ser Leu Arg Gln Leu Leu Ser Arg
1 5 10

<210> 1081

<211> 12

<212> PRT

<213> Artificial Sequence



<220>



<223> INTEGRIN-BINDING PEPTIDE



<400> 1081

Arg Asp Asp Leu His Met Leu Arg Leu Gln Leu Trp
Page 438

1

5

10

<210> 1082

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1082

Ser Ser Asp Leu His Ala Leu Lys Lys Arg Tyr Gly
 1 5 10

<210> 1083

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1083

Arg Gly Asp Leu Lys Gln Leu Ser Glu Leu Thr Trp
 1 5 10

<210> 1084

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1084

Arg Gly Asp Leu Ala Ala Leu Ser Ala Pro Pro Val
 1 5 10

<210> 1085

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> VEGF-ANTAGONIST

<400> 1085

Arg Gly Trp Val Glu Ile Cys Val Ala Asp Asp Asn Gly Met Cys Val
1 5 10 15

Thr Glu Ala Gln
20

<210> 1086

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> VEGF-ANTAGONIST

<400> 1086

Gly Trp Asp Glu Cys Asp Val Ala Arg Met Trp Glu Trp Glu Cys Phe
1 5 10 15

Ala Gly Val

<210> 1087

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> VEGF-ANTAGONIST

<400> 1087

Arg Gly Trp Val Glu Ile Cys Glu Ser Asp Val Trp Gly Arg Cys Leu
1 5 10 15

<210> 1088

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> VEGF-ANTAGONIST

<400> 1088

Arg Gly Trp Val Glu Ile Cys Glu Ser Asp Val Trp Gly Arg Cys Leu
1 5 10 15

<210> 1089

<211> 19

<212> PRT

<213> Artificial Sequence


<220>

<223> VEGF-ANTAGONIST

<400> 1089

Gly Gly Asn Glu Cys Asp Ile Ala Arg Met Trp Glu Trp Glu Cys Phe
1 5 10 15

Glu Arg Leu



<210> 1090

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> VEGF-ANTAGONIST

<400> 1090



Arg Gly Trp Val Glu Ile Cys Ala Ala Asp Asp Tyr Gly Arg Cys Leu
1 5 10 15

<210> 1091

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> MMP INHIBITOR

<220>

<221> misc_feature

<222> (6)..(6)

<223> Xaa = any amino acid

<400> 1091

Cys Leu Arg Ser Gly Xaa Gly Cys
1 5

<210> 1092

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> MMP INHIBITOR

<220>

<221> misc_feature

⋮⋮⋮<222> (2, 3, 8)..(9)

⋮⋮⋮<223> Xaa = any amino acid.

⋮⋮⋮<400> 1092

⋮⋮⋮Cys Xaa Xaa His Trp Gly Phe Xaa Xaa Cys
1 5 10

<210> 1093

<211> 5

⋮⋮⋮<212> PRT

⋮⋮⋮<213> Artificial Sequence

⋮⋮⋮<220>

⋮⋮⋮<223> MMP INHIBITOR

⋮⋮⋮<220>

<221> misc_feature

<222> (2)..(4)

<223> xaa = any amino acid

<400> 1093

Cys Xaa Pro Xaa Cys
1 5

<210> 1094

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> MMP INHIBITOR

<400> 1094

Cys Arg Arg His Trp Gly Phe Glu Phe Cys
1 5 10

<210> 1095

<211> 10

<212> PRT

•••••<213> Artificial Sequence

•••••
•••••
•••••
•••••
•••••

<220>

<223> MMP INHIBITOR

<400> 1095

Ser Thr Thr His Trp Gly Phe Thr Leu Ser
1 5 10

<210> 1096

•••••
•••••
•••••
•••••
•••••

<211> 10

<212> PRT

<213> Artificial Sequence

•••••
•••••
•••••

<220>

<223> CTLA4-MIMETIC

<400> 1096

Cys Ser Leu His Trp Gly Phe Trp Trp Cys
1 5 10

<210> 1097
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> CARBOHYDRATE (GD1 ALPHA) MIMETIC
<400> 1097

Trp His Trp Arg His Arg Ile Pro Leu Gln Leu Ala Ala Gly Arg
1 5 10 15

<210> 1098
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> BETA2GPI AB BINDING

•••••<400> 1098
•••••Leu Lys Thr Pro Arg Val
•••••1 5

•••••<210> 1099
•••••<211> 8
•••••<212> PRT
•••••<213> Artificial Sequence

•••••<220>
•••••<223> BETA2GPI AB BINDING
•••••<400> 1099
•••••Asn Thr Leu Lys Thr Pro Arg Val
•••••1 5

<210> 1100
<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> BETA2GPI AB BINDING

<400> 1100

Asn Thr Leu Lys Thr Pro Arg Val Gly Gly Cys
1 5 10

<210> 1101

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> BETA2GPI AB BINDING

<400> 1101

Lys Asp Lys Ala Thr Phe
1 5

<210> 1102

•••••<211> 10

•••••<212> PRT

•••••<213> Artificial Sequence

•••••<220>

<223> BETA2GPI AB BINDING

<400> 1102

Lys Asp Lys Ala Thr Phe Gly Cys His Asp
1 5 10

•••••<210> 1103

•••••<211> 12

•••••<212> PRT

•••••<213> Artificial Sequence

<220>

<223> BETA2GPI AB BINDING

<400> 1103

Lys Asp Lys Ala Thr Phe Gly Cys His Asp Gly Cys
 1 5 10

<210> 1104

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> BETA2GPI AB BINDING

<400> 1104

Thr Leu Arg Val Tyr Lys
 1 5

<210> 1105

<211> 9

<212> PRT

<213> Artificial Sequence

•••••<220>

•••••<223> BETA2GPI AB BINDING

•••••<400> 1105

•••••Ala Thr Leu Arg Val Tyr Lys Gly Gly
 •••••1 5

<210> 1106

<211> 10

<212> PRT

•••••<213> Artificial Sequence

•••••<220>

•••••<223> BETA2GPI AB BINDING

•••••<400> 1106

•••••Cys Ala Thr Leu Arg Val Tyr Lys Gly Gly
 •••••1 5 10

<210> 1107

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> MEMBRANE-TRANSPORTING

<400> 1107

Ile Asn Leu Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu
1 5 10

<210> 1108

<211> 12

<212> PRT


<213> Artificial Sequence

<220>

<223> MEMBRANE-TRANSPORTING

<400> 1108

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly
1 5 10



<210> 1109

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> MEMBRANE-TRANSPORTING

<400> 1109

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Lys Ile Asn Leu
1 5 10 15

Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu
20 25

<210> 1110

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> Fc VEGF ANTAGONIST

<400> 1110

gttgaaccga actgtgacat ccatgttatg tgggaatggg aatgttttga acgtctg 57

<210> 1111

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> Fc VEGF ANTAGONIST

<400> 1111

cagacgttca aaacattccc attcccacat aacatggatg tcacagttcg gttcaac 57

<210> 1112

<211> 81

<212> DNA

<213> Artificial Sequence

<220>

<223> Fc-TNA-ALPHA INHIBITORS

<400> 1112

ccgcggatcc attacggacg gtgaccaga gaggtgtttt tgtagtgcg caggaagtca 60

ccaccacctc cacctttacc c 81

<210> 1113

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> Fc VEGF ANTAGONIST

<220>

<221> CDS

<222> (1)..(57)

<223>

<400> 1113

gtt	gaa	ccg	aac	tgt	gac	atc	cat	gtt	atg	tgg	gaa	tgg	gaa	tgt	ttt	48
Val	Glu	Pro	Asn	Cys	Asp	Ile	His	Val	Met	Trp	Glu	Trp	Glu	Cys	Phe	
1				5					10					15		

gaa	cgt	ctg														57
Glu	Arg	Leu														

<210> 1114

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Fc VEGF ANTAGONIST

<400> 1114

Val	Glu	Pro	Asn	Cys	Asp	Ile	His	Val	Met	Trp	Glu	Trp	Glu	Cys	Phe
1				5					10					15	

•••••	Glu	Arg	Leu

•••••			

•••••	<210>	1115

•••••	<211>	66

•••••	<212>	DNA

<213> Artificial Sequence

<220>

•••••	<223>	Fc MMP INHIBITOR

•••••	<400>	1115	
•••••	ccgcggatcc	attagcacag ggtgaaaccc cagtgggtgg tgcaaccacc acctccacct	60

•••••	ttaccc		66

•••••	<210>	1116

•••••	<211>	63

•••••	<212>	DNA

<213> Artificial Sequence

<220>

<223> MMP INHIBITOR Fc

<400> 1116
gaataacata tgtgcaccac ccactggggt ttcaccctgt gcggtggagg cggtggggac 60
aaa 63

<210> 1117

<211> 81

<212> DNA

<213> Artificial Sequence

<220>

<223> TNF-ALPHA INHIBITOR Fc

<400> 1117
gaataacata tggacttcct gccgcactac aaaaacacct ctctgggtca ccgtccgggt 60
ggaggcggtg gggacaaaac t 81

<210> 1118

<211> 81

<212> DNA

<213> Artificial Sequence

<220>

<223> Fc IL-1 ANTAGONIST

<400> 1118
ccgcggatcc attacagcgg cagagcgtag ggctgccagt aacccgggggt ccattcgaaa 60
ccaccacctc cacctttacc c 81

<210> 1119

<211> 81

<212> DNA

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST Fc

<400> 1119
gaataacata tgttcgaatg gaccccggt tactggcagc cgtacgctct gccgctgggt 60
ggaggcggtg gggacaaaac t 81

<210> 1120
<211> 48
<212> DNA
<213> Artificial Sequence

<220>
<223> Fc VEGF ANTAGONIST
<400> 1120
atttgattct agaaggagga ataacatatg gacaaaactc acacatgt 48

<210> 1121
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> Fc VEGF ANTAGONIST
<400> 1121
gtcacagtgc ggttcaacac caccaccacc acctttaccc ggagacaggg a 51

<210> 1122
<211> 54
<212> DNA
<213> Artificial Sequence

<220>
<223> Fc VEGF ANTAGONIST
<400> 1122
tccctgtctc cgggtaaagg tggtggtggt ggtgttgaac cgaactgtga catc 54

<210> 1123
<211> 39
<212> DNA
<213> Artificial Sequence

<220>

<223> Fc VEGF ANTAGONIST

<400> 1123

ccgcggatcc tcgagttaca gacgttcaaa acattccca

39

<210> 1124

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> VEGF ANTAGONIST Fc

<400> 1124

atttgattct agaaggagga ataacatatg gttgaaccga actgtgac

48

<210> 1125

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<223> VEGF ANTAGONIST Fc

<220>

<221> misc_feature

<222> (2)..(2)

<223> Position 2, Xaa is L-lys, D-lys, or an ornithyl residue

<220>

<221> misc_feature

<222> (3)..(3)

<223> Position 3, Xaa is L-tyr, D-tyr, phe, trp, or a p-aminophenylalan
yl residue

<220>

<221> misc_feature

<222> (4)..(4)

<223> Position 4, Xaa is a hydrophobic aliphatic amino acid residue

<220>

<221> misc_feature

<222> (4)..(4)

<223> Position 4, optional attachment to leu, norleucyl, D-ala, Asn-Ser, asn-ser-ile, asn-ser-tyr, asn-ser-ile-leu, asn-ser-tyr-leu, or asn-ser-tyr-leu-asn

<400> 1125

acatgtgtga gttttgtcac caccaccacc acccagacgt tcaaaacatt c

51

<210> 1126

<211> 51

<212> DNA

<213> Artificial Sequence


<220>

<223> VEGF ANTAGONIST Fc

<400> 1126

gaatgttttg aacgtctggg tggtggtggt ggtgacaaaa ctcacacatg t

51



<210> 1127

<211> 39

<212> DNA

<213> Artificial Sequence


<220>

<223> VEGF ANTAGONIST Fc

<400> 1127

ccgcggatcc tcgagttatt tacccggaga caggagag

39



<210> 1128

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> SYNTHETIC SCHEME FOR PREPARATION OF PEGYLATED PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Butoxycarbonyl group attached to the amino terminus.

<220>

<221> misc_feature

<222> (2, 5, 24 and)..(27)

<223> Tert-butyl group attached to the sidechain.

<220>

<221> misc_feature

<222> (7, 13, 29 and)..(35)

<223> 2,2,4,6,7-pendamethyldihydrobenzofuran-5-sulfonyl group attached to the sidechain.

<220>

<221> misc_feature

<222> (8 and)..(30)

<223> Trityl group attached to the sidechain.

<220>

<221> misc_feature

<222> (9 and)..(31)

<223> Butoxycarbonyl group attached to the sidechain.

<220>

<221> misc_feature

<222> (18)..(18)

<223> 1-(4,4-dimethyl-2,6-dioxo-cyclohexylidene)ethyl group attached to the sidechain.

<220>

<221> misc_feature

<222> (36)..(36)

<223> Methoxy resin attached to the carboxyl terminus.

<400> 1128

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Lys Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 1129

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> SYNTHETIC SCHEME FOR PREPARATION OF PEGYLATED PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Butoxycarbonyl group attached to the amino terminus.

<220>

<221> misc_feature

<222> (2, 5, 24 and)..(27)

<223> Tert-butyl group attached to the sidechain.

<220>

<221> misc_feature

<222> (7, 12, 29 and)..(35)

<223> 2,2,4,6,7-pendamethyldihydrobenzofuran-5-sulfonyl group attached to the sidechain.

<220>

<221> misc_feature

<222> (8 and)..(30)

<223> Trityl group attached to the sidechain.

<220>

<221> misc_feature

<222> (9 and)..(31)

<223> Butoxycarbonyl group attached to the sidechain.

<220>

<221> misc_feature

<222> (36)..(36)

<223> Methoxy resin attached to the carboxyl terminus.

<400> 1129

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15

Gly Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
 20 25 30

Ala Ala Arg Ala
 35

<210> 1130

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> SYNTHETIC SCHEME FOR PREPARATION OF PEGYLATED PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Butoxycarbonyl group attached to the amino terminus.

<220>

<221> misc_feature

<222> (2, 5, 24 and)..(27)

<223> Tert-butyl group attached to the sidechain.

<220>

<221> misc_feature

<222> (7, 13, 29 and)..(35)

<223> 2,2,4,6,7-pendamethyldihydrobenzofuran-5-sulfonyl group attached to the sidechain.

<220>

<221> misc_feature

<222> (8 and)..(30)

<223> Trityl group attached to the sidechain.

<220>

<221> misc_feature

<222> (9 and)..(31)

<223> Butoxycarbonyl group attached to the sidechain.

<220>

<221> misc_feature

<222> (18)..(18)

<223> Bromoacetyl group attached to the sidechain.

<220>

<221> misc_feature

<222> (36)..(36)

<223> Methoxy resin attached to the carboxyl terminus.

<400> 1130

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 1131

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> SYNTHETIC SCHEME FOR PREPARATION OF PEGYLATED PEPTIDE

<220>

<221> misc_feature

<222> (18)..(18)

<223> Bromoacetyl group attached to the sidechain.

<400> 1131

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 1132

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> SYNTHETIC SCHEME FOR PREPARATION OF PEGYLATED PEPTIDE

<220>

<221> misc_feature

<222> (2, 5, 24 and)..(27)

<223> Tert-butyl group attached to the sidechain.

<220>

<221> misc_feature

<222> (7, 13, 29 and)..(35)

<223> 2,2,4,6,7-pendamethyldihydrobenzofuran-5-sulfonyl group attached to the sidechain.

<220>

<221> misc_feature

<222> (8, 18 and)..(30)

<223> Trityl group attached to the sidechain.

<220>

<221> misc_feature

<222> (9 and)..(31)

<223> Butoxycarbonyl group attached to the sidechain.

<220>

<221> misc_feature

<222> (36)..(36)

<223> Methoxy resin attached to the carboxyl terminus.

<400> 1132

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Cys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 1133

<211> 36

<212> PRT

<213> Artificial Sequence

<220>


<223> SYNTHETIC SCHEME FOR PREPARATION OF PEGYLATED PEPTIDE

<400> 1133

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Cys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35




- 129 -

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:-

5

1. A composition of matter of the formula



and multimers thereof, wherein:

F^1 is an Fc domain;

10

X^1 and X^2 are each independently selected from $-(L^1)_c-P^1$, $-(L^1)_c-P^1-(L^2)_d$, $-P^2$, $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3$, and $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3-(L^4)_f-P^4$

P^1 , P^2 , P^3 , and P^4 are each independently randomized sequences of pharmacologically active peptides;

L^1 , L^2 , L^3 , and L^4 are each independently linkers; and

15

a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1 and wherein neither X^1 nor X^2 is a native protein.

2. The composition of matter of Claim 1 of the formulae




or


20



3. The composition of matter of Claim 1 of the formula



4. The composition of matter of Claim 1 of the formula



25

5. The composition of matter of Claim 1 wherein F^1 is an IgG Fc domain.

6. The composition of matter of Claim 1 wherein F^1 is an IgG1 Fc domain.

7. The composition of matter of Claim 1 wherein F^1 comprises the sequence of SEQ ID NO: 2.

30

8. The composition of matter of Claim 1 wherein X^1 and X^2 comprise an IL-1 antagonist peptide sequence.

9. The composition of matter of Claim 8 wherein the IL-1 antagonist peptide sequence is selected from SEQ ID NOS: 212, 907, 908, 909, 910, 917, and 979.
10. The composition of matter of Claim 8 wherein the IL-1 antagonist peptide sequence is selected from SEQ ID NOS: 213 to 271, 671 to 906, 911 to 916, and 918 to 1023.
11. The composition of matter of Claim 8 wherein F¹ comprises the sequence of SEQ ID NO: 2.
12. The composition of matter of Claim 1 wherein X¹ and X² comprise an EPO-mimetic peptide sequence.
13. The composition of matter of Claim 12 wherein the EPO-mimetic peptide sequence is selected from Table 5.
14. The composition of matter of Claim 12 wherein F¹ comprises the sequence of SEQ ID NO: 2.
15. 15. The composition of matter of Claim 12 comprising a sequence selected from SEQ ID NOS: 83, 84, 85, 124, 419, 420, 421, and 461. .
16. The composition of matter of claim 12 comprising a sequence selected from SEQ ID NOS: 339 and 340.
17. The composition of matter of Claim 12 comprising a sequence selected from SEQ ID NOS: 20 and 22.
18. The composition of matter of Claim 3 wherein P¹ is a TPO-mimetic peptide sequence.
19. The composition of matter of Claim 18 wherein P¹ is a TPO-mimetic peptide sequence selected from Table 6.
20. 20. The composition of matter of Claim 18 wherein F¹ comprises the sequence of SEQ ID NO: 2.
21. The composition of matter of Claim 18 having a sequence selected from SEQ ID NOS: 6 and 12.
22. A DNA encoding a composition of matter of any of Claims 1 to 21.

23. An expression vector comprising the DNA of Claim 22.
24. A host cell comprising the expression vector of Claim 23.
25. The cell of Claim 24, wherein the cell is an E. coli cell.
26. A process for preparing a pharmacologically active compound,
5 which comprises
- a) selecting at least one randomized peptide that modulates the activity of a protein of interest; and
- b) preparing a pharmacologic agent comprising at least one Fc domain covalently linked to at least one amino acid sequence
10 of the selected peptide or peptides.
27. The process of Claim 26, wherein the peptide is selected in a process comprising screening of a phage display library, an E. coli display library, a ribosomal library, or a chemical peptide library.
28. The process of Claim 26, wherein the preparation of the
15 pharmacologic agent is carried out by:
- a) preparing a gene construct comprising a nucleic acid sequence encoding the selected peptide and a nucleic acid sequence encoding an Fc domain; and
- b) expressing the gene construct.
- 20 29. The process of Claim 26, wherein the gene construct is expressed in an E. coli cell.
30. The process of Claim 26, wherein the protein of interest is a cell surface receptor.
31. The process of Claim 26, wherein the protein of interest has a linear
25 epitope.
32. The process of Claim 26, wherein the protein of interest is a cytokine receptor.
33. The process of Claim 26, wherein the peptide is an EPO-mimetic peptide.

34. The process of Claim 26, wherein the peptide is a TPO-mimetic peptide.
35. The process of Claim 26, wherein the peptide is an IL-1 antagonist peptide.
- 5 36. The process of Claim 26, wherein the peptide is an MMP inhibitor peptide or a VEGF antagonist peptide.
37. The process of Claim 26, wherein the peptide is a TNF-antagonist peptide.
38. The process of Claim 26, wherein the peptide is a CTLA4-mimetic peptide.
- 10 39. The process of Claim 26, wherein the peptide is selected from Tables 4 to 20.
40. The process of Claim 26, wherein the selection of the peptide is carried out by a process comprising:
- 15 a) preparing a gene construct comprising a nucleic acid sequence encoding a first selected peptide and a nucleic acid sequence encoding an Fc domain;
- b) conducting a polymerase chain reaction using the gene construct and mutagenic primers, wherein
- 20 i) a first mutagenic primer comprises a nucleic acid sequence complementary to a sequence at or near the 5' end of a coding strand of the gene construct, and
- ii) a second mutagenic primer comprises a nucleic acid sequence complementary to the 3' end of the noncoding strand of the gene construct.
- 25 41. The process of Claim 26, wherein the compound is derivatized.
42. The process of Claim 26, wherein the derivatized compound comprises a cyclic portion, a cross-linking site, a non-peptidyl

linkage, an N-terminal replacement, a C-terminal replacement, or a modified amino acid moiety.

43. The process of Claim 26 wherein the Fc domain is an IgG Fc domain.

5 44. The process of Claim 26, wherein the vehicle is an IgG1 Fc domain.

45. The process of Claim 26, wherein the vehicle comprises the sequence of SEQ ID NO: 2.

46. The process of Claim 26, wherein the compound prepared is of the formula



and multimers thereof, wherein:

F^1 is an Fc domain;

X^1 and X^2 are each independently selected from $-(L^1)_c-P^1$, $-(L^1)_c-P^1-(L^2)_d-P^2$, $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3$, and $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3-(L^4)_f-P^4$

15

P^1 , P^2 , P^3 , and P^4 are each independently sequences of pharmacologically active peptides;

L^1 , L^2 , L^3 , and L^4 are each independently linkers; and

a , b , c , d , e , and f are each independently 0 or 1, provided

20


that at least one of a and b is 1.

47. The process of Claim 46, wherein the compound prepared is of the formulae




or

25




48. The process of Claim 46, wherein the compound prepared is of the formulae



- 134 -

or



49. The process of Claim 46, wherein F^1 is an IgG Fc domain.
50. The process of Claim 46, wherein F^1 is an IgG1 Fc domain.
51. The process of Claim 46, wherein F^1 comprises the sequence of SEQ ID NO:2.
52. A pharmacologically active compound when prepared by a process according to any one of claims 26 to 51.
53. A pharmaceutical composition comprising a composition according to any one of claims 1 to 21 and a pharmaceutically acceptable carrier.
54. A method of treatment comprising administering a therapeutically effective amount of a composition according to any one of claims 1 to 21 to a subject in need thereof.
55. Use of a composition according to any one of claims 1 to 21 in the manufacture of a medicament.
56. A composition of matter according to any one of claims 1 to 21 and substantially as herein described with reference to any one of the examples but excluding comparative examples.
57. A process for preparing a pharmacologically active compound according to any one of claims 26 to 51 and substantially as herein described with reference to any one of the examples but excluding comparative examples.
58. A pharmaceutical composition according to claim 53 and substantially as herein described with reference to any one of the examples but excluding comparative examples.
59. A method of treatment according to claim 54 and substantially as herein described with reference to any one of the examples but excluding comparative examples.
60. Use of a composition according to claim 55 and substantially as herein described with reference to any one of the examples but excluding comparative examples.
61. The composition of matter of claim 8 wherein the IL-1 antagonist peptide sequences are selected from Table 4.
62. The composition of matter of claim 8 wherein C is 1.

DATED this 24th day of September 2003
BALDWIN SHELSTON WATERS
Attorneys for: AMGEN, INC.

FIG. 1




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D




FIG. 2E




FIG. 2F




FIG. 3A




FIG. 3B





FIG. 3C



SUBSTITUTE SHEET (RULE 26)

FIG. 5




FIG. 6




FIG. 7

FIG. 7

XbaI
|
TCTAGATTTGTTTTAACTAATTAAAGGAGGAATAACATATGGACAAAACACTCACACATGTC
1+.....+.....+.....+.....+.....+.....+.....60
AGATCTAAACAAAAATTGATTAATTCCTCCTTATTGTATACCTGTTTTGAGTGTTACAG
 M D K T H T C P -

CACCTTGTCAGCTCCGGAACCTCGGGGGACCCTGAGTCTTCCTCTTCCCCCAAAC
61+.....+.....+.....+.....+.....+.....+.....120
GTGGAACAGGTCGAGGCCTTAGGACCCCCCTGGCAGTCAAGAAGAGAAGGGGGTTTTG
P C P A P E L L G G P S V F L F P P K P -

CCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTACATGCCGTGGTGGTGGACGTGA
121+.....+.....+.....+.....+.....+.....+.....180
GGTTCCTGTGGGAGTACTAGAGGCCTGGGGACTCCAGTGTACGCACCACCACCTGCACST
K D T L M I S R T P E V T C V V V V D V S -

GCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATG
181+.....+.....+.....+.....+.....+.....+.....240
CGGTGCTTCTGGGACTCCAGTTCAAGTTGACCATGCACCTGCCGACCTCCACGTATTAC
H E D P E V K F N W Y V D G V E V H N A -

CCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCA
241+.....+.....+.....+.....+.....+.....+.....300
GGTTCGTGTTTCGGCGCCCTCCTCGTCATGTTGTGCTGCATGGCACACCAGTCGCAGGAGT
K T K P R E E Q Y N S T Y R V V S V L T -

CCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGAAGGTCTCCAACAAAG
301+.....+.....+.....+.....+.....+.....+.....360
GGCAGGACGTGGTCTTGACCGACTTACCGTTCCCTCATGTTACGTTCCAGAGGTTGTTTC
V L H Q D W L N G K E Y K C K V S N K A -

CCCTCCCAGCCCCCATCGAGAAAACCATCTCAAAGCCAAAGGGCAGCCCCGAGAACCAC
361+.....+.....+.....+.....+.....+.....+.....420
GGGAGGGTGGGGGTAGCTCTTTTGGTAGAGGTTTCGGTTTCCCGTCGGGGCTCTTGGTG
L P A P I E K T I S K A K G Q P R E P Q -

AGGTGTACACCCTGCCCCCATCCCGGATGAGCTGACCAAGAACCAGGTACGCCTGACCT
421+.....+.....+.....+.....+.....+.....+.....480
TCCACATGTGGGACGGGGGTAGGGCCCTACTCGACTGGTTCCTTGGTCCAGTCGGACTGGA
V Y T L P P S R D E L T K N Q V S L T C -

GCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGC
481+.....+.....+.....+.....+.....+.....+.....540
CGGACCAGTTTCCGAAGATAGGGTCGCTGTAGCGGCACCTCACCCCTCTCGTTACCCGTG
L V K G F Y P S D I A V E W E S N G Q P -

CGGAGAACAACCTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCT
541+.....+.....+.....+.....+.....+.....+.....600
GCCTCTTGTTGATGTTCTGGTGGGAGGACGACCTGAGGCTGCCGAGGAAGAAGGAGA
E N N Y K T T P P V L D S D G S F F L Y -

ACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCG
601+.....+.....+.....+.....+.....+.....+.....660
TGTCGTTTCGAGTGGCACCTGTTCTCGTCCACCGTCGTCCCCTTGCAAGAGTACGAGGC
S K L T V D K S R W Q Q G N V F S C S V -

TGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTA
661+.....+.....+.....+.....+.....+.....+.....720
ACTACGTACTCCGAGACGTGTTGGTGTGTGCGTCTTCTCGGAGAGGGACAGAGGCCCAT
M H E A L H N H Y T Q K S L S L S P G K -

AAGGTGGAGGTGGTGGTATCGAAGGTCCGACTCTGCGTCAGTGGCTGGCTGCTCGTGCTT
721+.....+.....+.....+.....+.....+.....+.....780
TTCCACCTCCACCACCATAGCTTCCAGGCTGAGACGCAGTCAACCGACCGACGAGCACGAA
G G G G G I E G P T L R Q W L A A R A * -

BamHI
|
AATCTCGAGGATCC
781+..... 794
TTAGAGCTCCTAGG

FIG. 8

FIG. 8

XbaI
|

1 TCTAGATTGTGTTTAACTAATTAAGGAGGAATAACATATGGACAAAACTCACACATGTC 60
-----+-----+-----+-----+-----+
AGATCTAAACAAATGATTAATTTCTCCTTATTGTATACCTGTTTTGAGTGTGTACAG
M D K T H T C P

61 CACCTTGTCAGCTCCGGAACCTCTGGGGGACCGTCAGTCTTCCTCTTCCCCCAAAAC 120
-----+-----+-----+-----+-----+
GTGGAACAGGTTCGAGGCCTTGAGGACCCCCCTGGCAGTCAGAAGGAGAAGGGGGGTTTTG
P C P A P E L L G G P S V F L F P P K P

121 CCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTACATGCGTGGTGGTGGACGTGA 180
-----+-----+-----+-----+-----+
GGTTCTGTGGGAGTACTAGAGGGCCTGGGGACTCCAGTGTACGCACCACCACCTGCCT
K D T L M I S R T P E V T C V V V D V S

181 GCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATG 240
-----+-----+-----+-----+-----+
CGGTGCTTCTGGGACTCCAGTTCAAGTTGACCATGCACCTGCCGCACCTCCACGTATTAC
H E D P E V K F N W Y V D G V E V H N A

241 CCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCTCTCA 300
-----+-----+-----+-----+-----+
GGTTCTGTGTTTCGGCGCCCTCCTCGTCATGTTGTCGTGCATGGCACACCAGTCGCAGGAGT
K T K P R E E Q Y N S T Y R V V S V L T

301 CCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAG 360
-----+-----+-----+-----+-----+
GGCAGGACGTGGTTCCTGACCGACTTACCGTTCTCATGTTACGTTCCAGAGGTTGTTTC
V L H Q D W L N G K E Y K C K V S N K A

361 CCCTCCCAGCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCAC 420
-----+-----+-----+-----+-----+
GGGAGGGTCGGGGGTAGCTCTTTTGGTAGAGGTTTCGGTTTCCCGTCGGGGCTCTTGGTG
L P A P I E K T I S K A K G Q P R E P Q

421 AGGTGTACACCCTGCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCT 480
-----+-----+-----+-----+-----+
TCCACATGTGGGACGGGGTAGGGCCCTACTCGACTGGTCTTGGTCCAGTCGGACTGGA
V Y T L P P S R D E L T K N Q V S L T C

481 GCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGC 540
-----+-----+-----+-----+-----+
CGGACCAGTTTCCGAAGATAGGGTCGCTGTAGCGGCACCTCACCTCTCGTTACCCGTCG
L V K G F Y P S D I A V E W E S N G Q P

541 CGGAGAACAACACTACAAGACCACGCCTCCCGTCTGGACTCCGACGGCTCCTTCTCTCTCT 600
-----+-----+-----+-----+-----+
GCCTCTTGTGATGTTCTGGTGGGAGGGCACGACCTGAGGCTGCCGAGGAAGAAGGAGA
E N N Y K T T P P V L D S D G S F F L Y

601 ACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGCTTCTCATGCTCCG 660
-----+-----+-----+-----+-----+
TGTCGTTCGAGTGGCACCTGTCTCGTCCACCGTCGTCCCCTTGCAGAAGAGTACGAGGC
S K L T V D K S R W Q Q G N V F S C S V

661 TGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTA 720
-----+-----+-----+-----+-----+
ACTACGTACTCCGAGACGTGTTGGTGATGTGCGTCTTCTCGGAGAGGGACAGAGGCCCAT
M H E A L H N H Y T Q K S L S L S P G K

721 AAGGTGGAGGTGGTGGTATCGAAGGTCCGACTCTGCGTCAGTGGCTGGCTGCTCGTGCTG 780
-----+-----+-----+-----+-----+
TTCCACCTCCACCACCATAGCTTCCAGGCTGAGACGCAGTCACCGACCGACGAGCACGAC
G G G G G I E G P T L R Q W L A A R A G

781 GTGGTGGAGGTGGCGGGCGAGGTATTGAGGGCCCAACCTTCGCCAATGGCTTGCAGCAC 840
-----+-----+-----+-----+-----+
CACCACCTCCACCGCCGCTCCATAACTCCCGGGTTGGGAAGCGGTTACCGAACGTCGTG
G G G G G G I E G P T L R Q W L A A R

BamHI
|

841 GCGCATAATCTCGAGGATCCG 861
-----+-----+
CGCGTATTAGAGCTCCTAGGC

BATHI

841 GCGCATAATCTCGAGGATCCG 861
- - - - - + - - - - - + -
CGCGTATTAGAGCTCCTAGGC

C

A * -

Xba I

BamHI

GTAAATAATGGATCC

841 855

CATTATTACCTAGG

К ★

FIG. 10

[illegible]

FIG.11




FIG.12




FIG. 14

[illegible]

FIG. 15

TCTAGATTTGAGTTTTAAC TTTTAGAAGGAGGAATAAAATATGGGAGGTACTTACTCTTG
+ + + + +
AGATCTAAACTCAAAATTGAAAATCTTCCTCCTTATTTTATACCCTCCATGAATGAGAAC 60
M G G T Y S C -

61 CCACTTCGGCCCACTGACTTGGGTTTGCAAACCGCAGGGTGGCGGC GGCGGCCGGGTGG
 ++++++
 GGTGAAGCCGGGTGACTGAACCCAAACGTTTGGCGTCCCACC GCCCGCCGCCGCCACC
 H F G P L T W V C K P Q G G G G G G G -

121 TACCTATTCTGTCAATTTGGCCCCGCTGACCTGGGTATGTAAGCCACAAGGGGGTGGGG 180
+.....+.....+.....+.....+.....+.....+.....+.....+
 ATGGATAAGGACAGTAAACCGGGCGACTGGACCATACATTCGGTGTTCCCCCACCCCC
 T Y S C H E G P L T W V C K P O G G G G .

[illegible]

241 ACCGTCAGTTTTCCTCTTCCCCCAAACCCAAGGACACCCTCATGATCTCCCGGACCCC 300
+.....+.....+.....+.....+.....+.....+.....+.....
 TGGCAGTCAAAAGGAGAAGGGGGGTTTGGGTTCCTGTGGGAGTACTAGAGGGCCTGGGG
 P S V E L F P P K P K D T L M I S R T P

301 TGAGGTCACATGCCGTGGTGGTGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTG 360
-----+-----+-----+-----+-----+
ACTCCAGTGTACGCACCACCACCTGCACTCGGTGCTTCTGGGACTCCAGTTCAAGTTGAC
E V T C V V V D V S H E D P E V K F N W .

361 GTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAA 420
 ---+---+---+---+---+---+---+---+---+---+---+---+---+---+---+---+
 CATGCACCTGCCGCACCTCCACGTATTACGGTCTCTGTTTCGGCGCCCTCCTCGTCATGTT
 Y V D G V E V H N A K T K P R E E O Y N -

421 CAGCACGTACCGTGTGGTCAGCGTCCTACCGTCCTGCACCAGGACTGGCTGAATGGCAA 480
-----+-----+-----+-----+-----+-----+-----+
GTCGTGCATGGCACACCAGTCGCAGGAGTGGCAGGACGTGGTCCTGACCGACTTACCGTT
S T Y R V V S V L T V L H Q D W L N G K .

481 GGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCATCGAGAAAACCATCTC 540
+.....+.....+.....+.....+.....+.....+.....+.....+
 CCTCATGTTTCACGTTCCAGAGGTTGTTTCGGGAGGGTCGGGGGTAGCTCTTTTGGTAGAG
 E Y K C K V S N K A L P A P I E K T I S -

CAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCATCCCGGGATGA
541+.....+.....+.....+.....+.....+.....+.....600
GTTTCGGTTTTCCCGTCGGGCTCTTGGTGTCACATGTGGGACGGGGTAGGGCCCTACT
K A K G O P R E P Q V Y T L P P S R D E -

601 GCTGACCAAGAACAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAGCGACAT 660
-----+-----+-----+-----+-----+-----+
CGACTGGTTCTTGGTCCAGTCGGACTGGACGGACCAGTTTCCGAAGATAGGGTCGCTGTA
L T K N O V S L T C L V K G F Y P S D I -

CGCCGTGGAGTGGGAGACAAATGGGCAGCCGGAGAACAAC TACAAGACCACGCCTCCCGT
661+.....+.....+.....+.....+.....+.....+ 720
GCGGCACCTCACCTCTCGTTACCCGTCGGCTCTTGTTGATGTTCTGGTGCGGAGGGCA
A V E W E S N G O P E N N Y K T T P P V .

[illegible]

781 GCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACAC 840
-----+-----+-----+-----+-----+-----+-----+
CGTCGTCCTCCCTTGCAGAAGAGTACGAGGCACTACGTACTCCGAGACGTGTTGGTGATGTG
O O G N V F S C S V M H E A L H N H Y T -

BamHI

GCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATAATGGATCC
841 -----+-----+-----+-----+ 881
CGTCTTCTCGGAGAGGGACAGAGGCCCATTTATTACCTAGG
O K S L S L S P G K *

FIG. 16

XbaI
|
1 TCTAGATTGTTTTAACTAATTAAGGAGGAATAACATATGGACAAAACCTCACACATGTC
+-----+-----+-----+-----+-----+-----+ 60
AGATCTAAACAAAATTGATTAATTTCTCTTATTGTATACCTGTTTTGAGTGTGTACAG
c M D K T H T C P -

61 CACCTTGCCCAGCACCTGAACCTCTGGGGGACCGTCAGTTTCTCTTCCCCCAAAAC
+-----+-----+-----+-----+-----+-----+ 120
GTGGAACGGGTCTGTGACTTGAGGACCCCCCTGGCAGTCAAAGGAGAAGGGGGTTTTG
c P C P A P E L L G G P S V F L P P P K P -

121 CCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTACATGCGTGGTGGTGGACGTGA
+-----+-----+-----+-----+-----+-----+ 180
GGTTCCTGTGGGAGTACTAGAGGGCCTGGGGACTCCAGTGTACGCACCACCACCTGCACT
c K D T L M I S R T P E V T C V V V D V S -

181 GCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATG
+-----+-----+-----+-----+-----+-----+ 240
CGGTGCTTCTGGGACTCCAGTTCAAGTTGACCATGCACCTGCCGCACCTCCACGTATTAC
c H E D P E V K F N W Y V D G V E V H N A -

241 CCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAAGCTCCTCA
+-----+-----+-----+-----+-----+-----+ 300
GGTTCGTGTTTCGGCGCCCTCCTCGTCATGTTGTCGTGCATGGCACACCAAGTCGAGGAGT
c K T K P R E E Q Y N S T Y R V V S V L T -

301 CCGTCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAG
+-----+-----+-----+-----+-----+-----+ 360
GGCAGGACGTGGTCTGACCGACTTACCGTTCTCTCATGTTACGTTCCAGAGGTTGTTTC
c V L H Q D W L N G K E Y K C K V S N K A -

361 CCCTCCCAGCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCAC
+-----+-----+-----+-----+-----+-----+ 420
GGGAGGGTCGGGGTAGCTCTTTGGTAGAGGTTTCGGTTTCCCGTCGGGCTCTTGGTG
c L P A P I E K T I S K A K G Q P R E P Q -

421 AGGTGTACACCCTGCCTCCATCCCGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCT
+-----+-----+-----+-----+-----+-----+ 480
TCCACATGTGGGACGGAGGTAGGGCCCTACTCGACTGGTTCTTGGTCCAGTCGGACTGGA
c V Y T L P P S R D E L T K N Q V S L T C -

481 GCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGC
+-----+-----+-----+-----+-----+-----+ 540
CGGACCAGTTTCCGAAGATAGGGTCGCTGTAGCGGCACCTCACCTCTCGTTACCCGTCG
c L V K G F Y P S D I A V E W E S N G Q P -

541 CGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCTCT
+-----+-----+-----+-----+-----+-----+ 600
GCCTCTTGTGATGTTCTGGTGCGGAGGGCACGACCTGAGGCTGCCGAGGAAGAAGGAGA
c E N N Y K T T P P V L D S D G S F F L Y -

601 ACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCG
+-----+-----+-----+-----+-----+-----+ 660
TGTCGTTTCGAGTGGCACCTGTTCTCGTCCACCGTCGTCCTTGCAGAAGAGTACGAGGC
c S K L T V D K S R W Q Q G N V F S C S V -

661 TGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTA
+-----+-----+-----+-----+-----+-----+ 720
ACTACGTACTCCGAGACGTGTTGGTGATGTGCGTCTTCTCGGAGAGGGACAGAGGCCCAT
c M H E A L H N H Y T Q K S L S L S P G R -

721 AAGGTGGAGGTGGTGGCGGAGGTAATCTCTTGCCACTTCGGCCCACTGACTTGGGTTT
+-----+-----+-----+-----+-----+-----+ 780
TTCCACCTCCACCACCGCCTCCATGAATGAGAACGGTGAAGCCGGGTGACTGAACCCAAA
c G G G G G G G T Y S C H F G P L T W V C -

781 GCAAACCGCAGGTGGCGGGCGGGCGGGCGGTGGTACCTATTCCTGTCAATTTGGCCCCG
+-----+-----+-----+-----+-----+-----+ 840
CGTTTGGCGTCCCACCGCGCGCGCGCGCCACCATGGATAAGGACAGTAAACCGGGCG
c K P Q G G G G G G G T Y S C H F G P L -

BamHI
|
841 TGACCTGGGTATGTAAGCCACAAGGGGGTTAATCTCGAGGATCC
+-----+-----+-----+-----+-----+-----+ 884
ACTGGACCCATACATTCGGTGTTCCTCCCAATTAGAGCTCCTAGG
c T W V C K P Q G G *

FIG. 17A

[AatII sticky end] 5' GCGTAACGTATGCATGGTCTCC-
(position #4358 in pAMG21) 3' TGCACGCATTGCATACGTACCAGAGG-

- CCATGCGAGAGTAGGGAAGTCCAGGCATCAAATAAAACGAAAGGCTCAGTCGAAAGACT-
- GGTACGCTCTCATCCCTTGACGGTCCGTAGTTTATTTTGGCTTTCCGAGTCAGCTTTCTGA-

- GGGCCTTTCGTTTTATCTGTTGTTTGTGCGGTGAACGCTCTCCTGAGTAGGACAAATCCGC-
- CCCGAAAGCAAAATAGACAACAAACAGCCACTTGCGAGAGGACTCATCCTGTTTAGGCG-

- CGGGAGCGGATTTGAACGTTGCGAAGCAACGGCCCCGAGGGTGGCGGGCAGGACGCCCCG-
- GCCCTCGCCTAAACTTGCAACGTTTGGTTGCCGGGCTCCACC GCCCGTCTGCGGGCG-

- CATAAACTGCCAGGCATCAAATTAAGCAGAAGGCCATCCTGACGGATGGCCTTTTGGCGT-
- GTATTTGACGGTCCGTAGTTTAATTTCGTCTTCCGGTAGGACTGCCTACCGGAAAAACGCA-

AatII

- TTCTACAACTCTTTTGTATTATTTTCTAAATACATTCAAATATGGACGTCGTACTTAAC-
- AAGATGTTTGAGAAAACAAATAAAAAGATTTATGTAAGTTTATACCTGCAGCATGAATTG-

- TTTTAAAGTATGGGCAATCAATTGCTCCTGTAAAATTGCTTTAGAAATACTTTGGCAGC-
- AAAATTCATACCCGTTAGTTAACGAGGACAATTTAACGAAATCTTTATGAAACCGTCG-

- GGTTTGTGTTGATTGAGTTTCATTTGCGCATTGGTTAAATGGAAAGTGACCGTGCCTTAC-
- CCAAACAACATAACTCAAAGTAAACGCGTAACCAATTTACCTTCACTGGCACCGCAATG-

- TACAGCCTAATATTTTGAATATCCCAAGAGCTTTTTCCTTCGCATGCCACGCTAAAC-
- ATGTCGGATTATAAAAACCTTTATAGGGTTCTCGAAAAAGGAAGCGTACGGGTGCGATTTG-

- ATTCTTTTCTCTTTTGGTTAAATCGTTGTTTGATTTATTATTTGCTATATTTATTTTTC-
- TAAGAAAAAGAGAAAACCAATTTAGCAACAACTAAATAATAAACGATATAAATAAAAAG-

- GATAATTATCAACTAGAGAAGGAACAATTAATGGTATGTTTCATACACGCATGTAAAAATA-
- CTATTAATAGTTGATCTCTTCTTGTAAATTACCATACAAGTATGTGCGTACATTTTTAT-

- AACTATCTATATAGTTGTCTTCTCTGAATGTGCAAACTAAGCATTCCGAAGCCATTAT-
- TTGATAGATATATCAACAGAAAGAGACTTACACGTTTTGATTTCGTAAGGCTTCGGTAATA-

- TAGCAGTATGAATAGGGAACATAACCCAGTGATAAGACCTGATGATTTTCGCTTCTTTAA-
- ATCGTCATACTTATCCCTTTGATTTGGGTCACTATTCTGGACTACTAAAGCGAAGAAATT-

- TTACATTTGGAGATTTTTTATTTACAGCATTGTTTTCAAATATATTCCAATTAATCGGTG-
- AATGTAAACCTCTAAAAATAAATGTCGTAACAAAAGTTTATATAAGGTTAATTAGCCAC-

- AATGATTGGAGTTAGAATAATCTACTATAGGATCATATTTTATTAAATTAGCGTCATCAT-
- TTACTAACCTCAATCTTATTAGATGATATCCTAGTATAAAATAATTTAATCGCAGTAGTA-

- AATATTGCCTCCATTTTTTAGGGTAATTATCCAGAATTGAAATATCAGATTTAACCATAG-
- TTATAACGGAGGTAAAAAATCCCATTAATAGGTCTTAACCTTATAGTCTAAATTGGTATC-

- AATGAGGATAAATGATCGCGAGTAAATAATATTCACAATGTACCATTTTAGTCATATCAG-
- TTACTCCTATTTACTAGCGCTCATTTATTATAAGTGTTACATGGTAAATCAGTATAGTC-

- ATAAGCATTGATTAATATCATTATTGCTTCTACAGGCTTTAATTTTATTAATTATTCTGT-
- TATTCGTAACCTAATTATAGTAATAACGAAGATGTCCGAAATTAAATAATTAATAAGACA-

- AAGTGTGCTCGGCATTTATGTCTTTCATACCCATCTCTTTATCCTTACCTATTGTTTGTG-
- TTCACAGCAGCGTAAATACAGAAAGTATGGGTAGAGAAATAGGAATGGATAACAAACAG-

- GCAAGTTTTGCGTGTTATATATCATTTAAACGGTAATAGATTGACATTTGATTCTAATAA-
- CGTTCAAAACGCACAATATATAGTAATTTTGCATTATCTAACTGTAAACTAAGATTATT-

FIG. 17B

- ATTGGATTTTGTGCACACTATTATATCGCTTGAAATACAATTGTTTAACATAAGTACCTG -
- TAACCTAAAAACAGTGTGATAATATAGCGAACTTTATGTTAACAAATTGTATTCATGGAC -

- TAGGATCGTACAGGTTTACGCAAGAAAATGGTTTGTATAGTCGATTAATCGATTTGATT -
- ATCCTAGCATGTCCAAATGCGTTCCTTTACCAAACAATATCAGCTAATTAGCTAAACTAA -

- CTAGATTTGTTTTAACTAATTAAAGGAGGAATAACATATGGTTAACGCGTTGGAATTCGA -
- GATCTAAACAAAATTGATTAATTCCTCCTTATTGTATACCAATTGCGCAACCTTAAGCT -

- GCTCACTAGTGTGCGACCTGCAGGGTACCATGGAAGCTTACTCGAGGATCCGCGGAAAGAA -
- CGAGTGATCACAGCTGGACGTCCCATGGTACCTTCGAATGAGCTCCTAGGCGCCTTTCTT -

- GAAGAAGAAGAAGAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATA -
- CTTCTTCTTCTTCTTTCGGGCTTTCCTTCGACTCAACCGACGACGGTGGCGACTCGTTAT -

- ACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTTGCTGAAAGGAGG -
- TGATCGTATTGGGGAACCCCGGAGATTTGCCCAGAACTCCCCAAAAACGACTTTCCTCC -

- AACCGCTCTTCACGCTCTTCACGC 3' [SacII sticky end]
- TTGGCGAGAAGTGCGAGAAGTG 5' (position #5904 in pAMG21)

19/37

FIG.18A - 1




FIG.18A - 2




FIG.18A - 3




FIG.18B - 1




FIG.18B - 2




FIG.18B - 3




FIG. 19A

NdeI

```

1 CATATGGACAAAACCTCACACATGTCCACCTTGTCAGCTCCGGAACCTCCTGGGGGGACCG
  -----+-----+-----+-----+-----+-----+-----+
a      M D K T H T C P P C P A P E L L G G P
61 TCAGTCTTCCTCTTCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAG
  -----+-----+-----+-----+-----+-----+-----+
a      S V F L F P P K P K D T L M I S R T P E
121 AGTCAGAAGGAGAAGGGGGGTTTGGGTTCCTGTGGGAGTACTAGAGGGCCTGGGGACTC
  -----+-----+-----+-----+-----+-----+-----+
a      V T C V V V D V S H E D P E V K F N W Y
181 GTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTAC
  -----+-----+-----+-----+-----+-----+-----+
a      V D G V E V H N A K T K P R E E Q Y N S
241 CAGTGTACGCACCACCACCTGCACTCGGTGCTTCTGGGACTCCAGTTCAAGTTGACCATG
  -----+-----+-----+-----+-----+-----+-----+
a      T Y R V V S V L T V L H Q D W L N G K E
301 GTCATGGCACACCAGTCGCAGGAGTGGCAGGACGTGGTCCTGACCGACTTACCGTTCCTC
  -----+-----+-----+-----+-----+-----+-----+
a      Y K C K V S N K A L P A P I E K T I S K
361 TACAAGTGCAAGGTCTCCAACAAAGCCCTCCAGCCCCCATCGAGAAAACCATCTCCAAA
  -----+-----+-----+-----+-----+-----+-----+
a      GCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTG
  -----+-----+-----+-----+-----+-----+-----+
a      A K G Q P R E P Q V Y T L P P S R D E L
421 CGGTTTCCCGTCGGGGCTCTTGGTGTCCACATGTGGGACGGGGGTAGGGCCCTACTCGAC
  -----+-----+-----+-----+-----+-----+-----+
a      ACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCC
  -----+-----+-----+-----+-----+-----+-----+
a      T K N Q V S L T C L V K G F Y P S D I A
481 TGGTCTTGGTCCAGTCGGACTGGACGGACAGTTTCCGAAGATAGGGTCGCTGTAGCGG
  -----+-----+-----+-----+-----+-----+-----+
a      GTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACCTACAAGACCACGCCTCCCGTGCTG
  -----+-----+-----+-----+-----+-----+-----+
a      V E W E S N G Q P E N N Y K T T P P V L
541 CACCTCACCTCTCGTTACCCGTGCGCCTCTTGTGATGTTCTGGTGGGAGGGGCACGAC
  -----+-----+-----+-----+-----+-----+-----+
a      GACTCCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAG
  -----+-----+-----+-----+-----+-----+-----+
a      D S D G S F F L Y S K L T V D K S R W Q
600 CTGAGGCTGCCGAGGAAGAAGGAGATGTCGTTTCGAGTGGCACCTGTTCTCGTCCACCGTC
  -----+-----+-----+-----+-----+-----+-----+

```

FIG. 19B

```
601 CAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAG
-----+-----+-----+-----+-----+-----+-----+ 660
GTCCCCCTTGCAGAAGAGTACGAGGCACTACGTACTCCGAGACGTGTTGGTGATGTGCGTC

a   Q   G   N   V   F   S   C   S   V   M   H   E   A   L   H   N   H   Y   T   Q   -

661 AAGAGCCTCTCCCTGTCTCCGGGTAAAGGTGGAGGTGGTGGTGACTTCCTGCCGCACTAC
-----+-----+-----+-----+-----+-----+ 720
TTCTCGGAGAGGGACAGAGGCCCATTTCCACCTCCACCACCACTGAAGGACGGCGTGATG

a   K   S   L   S   L   S   P   G   K   G   G   G   G   G   D   F   L   P   H   Y   -

                                     BamHI
                                     |
721 AAAAAACACCTCTCTGGGTCACCGTCCGTAATGGATCC
-----+-----+-----+-----+-----+ 757
TTTTTGTGGAGAGACCCAGTGGCAGGCATTACCTAGG

a   K   N   T   S   L   G   H   R   P   *
```

FIG. 20A

NdeI
|
CATATGGA¹CTTCCTGCCGCACTACAAAAACACCTCTCTGGGTCACCGTCCGGGTGGAGGC
-----+-----+-----+-----+-----+ 60
GTATACCTGAAGGACGGCGTGATGTTTTTGTGGAGAGACCCAGTGGCAGGCCACCTCCG

a M D F L P H Y K N T S L G H R P G G G -

GGTGGGGACAAACTCACACATGTCCACCTTGCCCAGCACCTGAACTCCTGGGGGGACCG
61 -----+-----+-----+-----+-----+ 120
CCACCCCTGTTTTGAGTGTGTACAGGTGGAACGGGTCGTGGACTTGAGGACCCCTGGC

a G G D K T H T C P P C P A P E L L G G P -

TCAGTTTTCTCTTCCCCCAAAACCCAAGGACACCTCATGATCTCCCGGACCCCTGAG
121 -----+-----+-----+-----+-----+ 180
AGTCAAAAGGAGAAGGGGGGTTTTGGGTTCCTGTGGGAGTACTAGAGGGCCTGGGGACTC

a S V F L F P P K P K D T L M I S R T P E -

GTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTAC
181 -----+-----+-----+-----+-----+ 240
CAGTGTAACGCACCACCACCTGCACTCGGTGCTTCTGGGACTCCAGTTCAAGTTGACCATG

a V T C V V V D V S H E D P E V K F N W Y -

GTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGC
241 -----+-----+-----+-----+-----+ 300
CACCTGCCGCACCTCCACGTATTACGGTTCGTTCGCGGCCCTCCTCGTCATGTTGTGCG

a V D G V E V H N A K T K P R E E Q Y N S -

ACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAG
301 -----+-----+-----+-----+-----+ 360
TGCATGGCACACCAGTCGCAGGAGTGGCAGGACGTGGTCCTGACCGACTTACCGTTCCTC

a T Y R V V S V L T V L H Q D W L N G K E -

TACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCATCGAGAAAACCATCTCCAAA
361 -----+-----+-----+-----+-----+ 420
ATGTTACAGTTCAGAGGTTGTTTCGGGAGGGTCGGGGGTAGCTCTTTTGGTAGAGGTTT

a Y K C K V S N K A L P A P I E K T I S K -

GCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTG
421 -----+-----+-----+-----+-----+ 480
CGGTTTCCCGTCGGGGCTCTTGGTGTCCACATGTGGGACGGGGGTAGGGCCCTACTCGAC

a A K G Q P R E P Q V Y T L P P S R D E L -

ACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCC
481 -----+-----+-----+-----+-----+ 540
TGGTTCCTTGGTCCAGTCGGACTGGACGGACAGTTTCCGAAGATAGGGTCGCTGTAGCGG

a T K N Q V S L T C L V K G F Y P S D I A -

GTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCTCCCGTGCTG
541 -----+-----+-----+-----+-----+ 600
CACCTCACCTCTCGTTACCCGTGCGCCTCTTGTGTGATGTTCTGGTGCGGAGGGCACGAC

a V E W E S N G Q P E N N Y K T T P P V L -

FIG. 20B

601 GACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAG 660
-----+-----+-----+-----+-----+
CTGAGGCTGCCGAGGAAGAAGGAGATGTCGTTTCGAGTGGCACCTGTTCTCGTCCACCGTC
a D S D G S F F L Y S K L T V D K S R W Q -
CAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAG
661 -----+-----+-----+-----+-----+ 720
GTCCCCTTGCAAGAGTACGAGGCACTACGTACTCCGAGACGTGTTGGTGATGTGCGTC
a Q G N V F S C S V M H E A L H N H Y T Q -
BamHI
|
AAGAGCCTCTCCCTGTCTCCGGGTAAATAATGGATCCGCGG
721 -----+-----+-----+-----+ 761
TTCTCGGAGAGGGACAGAGGCCCATTTATTACCTAGGCGCC
a K S L S L S P G K *

FIG. 21A

NdeI
|
CATATGGACAAACTCACACATGTCCACCTTGTCCAGCTCCGGAACCTCTGGGGGGACCG
1 -----+-----+-----+-----+-----+-----+-----+ 60
GTATACCTGTTTTGAGTGTGTACAGGTGGAACAGGTTCGAGGCCTTGAGGACCCCCCTGGC

a M D K T H T C P P C P A P E L L G G P -

TCAGTCTTCCTCTTCCCCCAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAG
61 -----+-----+-----+-----+-----+-----+-----+ 120
AGTCAGAAGGAGAAGGGGGGTTTTGGGTTCTGTGGGAGTACTAGAGGGCCTGGGGACTC

a S V F L F P P K P K D T L M I S R T P E -

GTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTAC
121 -----+-----+-----+-----+-----+-----+-----+ 180
CAGTGTACGCACCACCACCTGCACTCGGTGCTTCTGGGACTCCAGTTCAAGTTGACCATG

a V T C V V V D V S H E D P E V K F N W Y -

GTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGC
181 -----+-----+-----+-----+-----+-----+-----+ 240
CACCTGCCGCACCTCCACGTATTACGGTTCTGTTTCGGCGCCCTCCTCGTCATGTTGTCTG

a V D G V E V H N A K T K P R E E Q Y N S -

ACGTACCGTGTGGTCAGCGTCCTCACCCTCCTGCACCAGGACTGGCTGAATGGCAAGGAG
241 -----+-----+-----+-----+-----+-----+-----+ 300
TGCATGGCACACCAGTCGCAGGAGTGGCAGGACGTGGTCTGACCGACTTACCGTTCCTC

a T Y R V V S V L T V L H Q D W L N G K E -

TACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAA
301 -----+-----+-----+-----+-----+-----+-----+ 360
ATGTTACAGTTCCAGAGGTTGTTTCGGGAGGGTCGGGGGTAGCTCTTTTGGTAGAGGTTT

a Y K C K V S N K A L P A P I E K T I S K -

GCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCATCCCGGGATGAGCTG
361 -----+-----+-----+-----+-----+-----+-----+ 420
CGGTTTCCCGTCGGGGCTCTTGGTGTCCACATGTGGGACGGGGGTAGGGCCCTACTCGAC

a A K G Q P R E P Q V Y T L P P S R D E L -

ACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCC
421 -----+-----+-----+-----+-----+-----+-----+ 480
TGGTTCTTGGTCCAGTCGGACTGGACGGACCAGTTTCGAAGATAGGGTCGCTGTAGCGG

a T K N Q V S L T C L V K G F Y P S D I A -

GTGGAGTGGGAGAGCAATGGGCAGCCGAGAACAACTACAAGACCACGCCTCCCGTGCTG
481 -----+-----+-----+-----+-----+-----+-----+ 540
CACCTCACCTCTCGTTACCCGTCGGCCTCTGTTGATGTTCTGGTGCAGGAGGGCACGAC

a V E W E S N G Q P E N N Y K T T P P V L -

GACTCCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAG
541 -----+-----+-----+-----+-----+-----+-----+ 600
CTGAGGCTGCCGAGGAAGAAGGAGATGTCGTTTCGAGTGGCACCTGTTCTCGTCCACCGTC

a D S D G S F F L Y S K L T V D K S R W Q -

FIG. 21B

```

601 CAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAG
-----+-----+-----+-----+-----+-----+-----+ 660
GTCCCCCTTGCAGAAGAGTACGAGGCACTACGTACTCCGAGACGTGTTGGTGATGTGCGTC

a   Q   G   N   V   F   S   C   S   V   M   H   E   A   L   H   N   H   Y   T   Q   .

AAGAGCCTCTCCCTGTCTCCGGGTAAAGGTGGAGGTGGTGGTTTCGAATGGACCCCGGGT
661 -----+-----+-----+-----+-----+-----+ 720
TTCTCGGAGAGGGACAGAGGCCCATTTCCACCTCCACCACCAAAGCTTACCTGGGGCCCA

a   K   S   L   S   L   S   P   G   K   G   G   G   G   G   F   E   W   T   P   G   .

                                     BamHI
                                     |
TACTGGCAGCCGTACGCTCTGCCGCTGTAATGGATCCCTCGAG
721 -----+-----+-----+-----+-----+ 763
ATGACCGTCGGCATGCGAGACGGCGACATTACCTAGGGAGCTC

a   Y   W   Q   P   Y   A   L   P   L   *

```

FIG. 22A

NdeI
 |
 1 CATATGTTTGAATGGACCCCGGGTTACTGGCAGCCGTACGCTCTGCCGCTGGGTGGAGGC 60
 -----+-----+-----+-----+-----+-----+-----+
 GTATACAAGCTTACCTGGGGCCCAATGACCGTCGGCATGCGAGACGGCGACCCACCTCCG
 a M F E W T P G Y W Q P Y A L P L G G G -
 GGTGGGGACAAAACCTCACACATGTCCACCTTGCCCAGCACCTGAACTCCTGGGGGGACCG
 61 -----+-----+-----+-----+-----+-----+-----+ 120
 CCACCCCTGTTTTGAGTGTGTACAGGTGGAACGGGTCGTGGACTTGAGGACCCCCCTGGC
 a G G D K T H T C P P C P A P E L L G G P -
 TCAGTTTTCTCTTCCCCCAAAACCAAGGACACCCTCATGATCTCCCGGACCCCTGAG
 121 -----+-----+-----+-----+-----+-----+-----+ 180
 AGTCAAAGGAGAAGGGGGGTTTTGGGTTCTGTGGGAGTACTAGAGGGCCTGGGGACTC
 a S V F L F P P K P K D T L M I S R T P E -
 GTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTAC
 181 -----+-----+-----+-----+-----+-----+-----+ 240
 CAGTGTACGCACCACCACCTGCACTCGGTGCTTCTGGGACTCCAGTTCAAGTTGACCATG
 a V T C V V V D V S H E D P E V K F N W Y -
 GTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGC
 241 -----+-----+-----+-----+-----+-----+-----+ 300
 CACCTGCCGCACCTCCACGTATTACGGTTCTGTTTCGGCGCCCTCCTCGTCATGTTGTCG
 a V D G V E V H N A K T K P R E E Q Y N S -
 ACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAG
 301 -----+-----+-----+-----+-----+-----+-----+ 360
 TGCATGGCACACCAGTCGCAGGAGTGGCAGGACGTGGTCCTGACCGACTTACCGTTCCCTC
 a T Y R V V S V L T V L H Q D W L N G K E -
 TACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCATCGAGAAAACCATCTCCAAA
 361 -----+-----+-----+-----+-----+-----+-----+ 420
 ATGTTACAGTTCCAGAGGTTGTTTCGGGAGGGTCGGGGGTAGCTCTTTTGGTAGAGGTTT
 a Y K C K V S N K A L P A P I E K T I S K -
 GCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCATCCCGGGATGAGCTG
 421 -----+-----+-----+-----+-----+-----+-----+ 480
 CGGTTTCCCGTCGGGGCTCTTGGTGTCCACATGTGGGACGGGGTAGGGCCCTACTCGAC
 a A K G Q P R E P Q V Y T L P P S R D E L -
 ACCAAGAACCAGGTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCC
 481 -----+-----+-----+-----+-----+-----+-----+ 540
 TGTTCTTGGTCCAGTCGGACTGGACGGACCAGTTTCCGAAGATAGGGTCGCTGTAGCGG
 a T K N Q V S L T C L V K G F Y P S D I A -
 GTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCTCCCGTGCTG
 541 -----+-----+-----+-----+-----+-----+-----+ 600
 CACCTCACCTCTCGTTACCCGTCGGCCTCTTGTGATGTTCTGGTGGGAGGGGCACGAC
 a V E W E S N G Q P E N N Y K T T P P V L -

FIG. 22B

```

601  GACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACC GTGGACAAGAGCAGGTGGCAG
-----+-----+-----+-----+-----+-----+-----+ 660
CTGAGGCTGCCGAGGAAGAAGGAGATGTCGTTGAGTGGCACCTGTTCTCGTCCACCGTC

a    D  S  D  G  S  F  F  L  Y  S  K  L  T  V  D  K  S  R  W  Q  -

661  CAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAG
-----+-----+-----+-----+-----+-----+-----+ 720
GTCCCCCTTGAGAAGAGTACGAGGCACTACGTACTCCGAGACGTGTTGGTGATGTGCGTC

a    Q  G  N  V  F  S  C  S  V  M  H  E  A  L  H  N  H  Y  T  Q  -

                                BamHI
                                |
721  AAGAGCCTCTCCCTGTCTCCGGGTAAATAATGGATCC
-----+-----+-----+-----+-----+-----+ 757
TTCTCGGAGAGGGACAGAGGCCCATTTATTACCTAGG

a    K  S  L  S  L  S  P  G  K  *
```


FIG. 23A

NdeI
|
CATATGGACAAACTCACACATGTCCACCGTGCCAGCACCTGAACTCCTGGGGGGACCG
1+.....+.....+.....+.....+.....+.....+ 60
GTATACCTGTTTTGAGTGTGTACAGGTGGCACGGGTCGTGGACTTGAGGACCCCCCTGGC

a M D K T H T C P P C P A P E L L G G P -

TCAGTTTTCCTCTTCCCCCAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAG
61+.....+.....+.....+.....+.....+.....+ 120
AGTCAAAAGGAGAAGGGGGTTTTGGGTTCTGTGGGAGTACTAGAGGGCCTGGGGACTC

a S V F L F P P K P K D T L M I S R T P E -

GTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTAC
121+.....+.....+.....+.....+.....+.....+ 180
CAGTGTACGCACCACCACCTGCACTCGGTGCTTCTGGGACTCCAGTTCAAGTTGACCATG

a V T C V V V D V S H E D P E V K F N W Y -

GTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGC
181+.....+.....+.....+.....+.....+.....+ 240
CACCTGCCGCACCTCCACGTATTACGGTTCTGTTTCGGCGCCCTCCTCGTCATGTTGTG

a V D G V E V H N A K T K P R E E Q Y N S -

ACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAG
241+.....+.....+.....+.....+.....+.....+ 300
TGCATGGCACACCAGTCGCAGGAGTGGCAGGACGTGGTCTGACCGACTTACCGTTCCTC

a T Y R V V S V L T V L H Q D W L N G K E -

TACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCATCGAGAAAACCATCTCCAAA
301+.....+.....+.....+.....+.....+.....+ 360
ATGTTACAGTTCCAGAGGTTGTTTCGGGAGGGTGGGGGTAGCTCTTTTGGTAGAGGTTT

a Y K C K V S N K A L P A P I E K T I S K -

GCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCATCCCGGGATGAGCTG
361+.....+.....+.....+.....+.....+.....+ 420
CGGTTTCCCGTCGGGGCTCTTGGTGTCCACATGTGGGACGGGGGTAGGGCCCTACTCGAC

a A K G Q P R E P Q V Y T L P P S R D E L -

ACCAAGAACCAGGTGAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCC
421+.....+.....+.....+.....+.....+.....+ 480
TGGTTCTTGGTCCAGTCGGACTGGACGGACCAGTTTCCGAAGATAGGGTCGCTGTAGCGG

a T K N Q V S L T C L V K G F Y P S D I A -

GTGGAGTGGGAGAGCAATGGGCAGCCGGAACAACCTACAAGACCACGCCTCCCGTGCTG
481+.....+.....+.....+.....+.....+.....+ 540
CACCTCACCTCTCGTTACCCGTCGGCCTCTTGTGATGTTCTGGTGCAGGAGGCACGAC

a V E W E S N G Q P E N N Y K T T P P V L -

GACTCCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAG
541+.....+.....+.....+.....+.....+.....+ 600
CTGAGGCTGCCGAGGAAGAAGGAGATGTCGTTGAGTGGCACCTGTTCTCGTCCACCGTC

a D S D G S F F L Y S K L T V D K S R W Q -

FIG. 23B

```

601 CAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAG
-----+-----+-----+-----+-----+-----+ 660
GTCCCCCTTGCAGAAGAGTACGAGGCACTACGTACTCCGAGACGTGTTGGTGATGTGCGTC

a   Q   G   N   V   F   S   C   S   V   M   H   E   A   L   H   N   H   Y   T   Q   -

661 AAGAGCCTCTCCCTGTCTCCGGGTAAAGGTGGTGGTGGTGGTGGTGAACCGAACTGTGAC
-----+-----+-----+-----+-----+-----+ 720
TTCTCGGAGAGGGACAGAGGCCCATTTCCACCACCACCACCACAACCTGGCTTGACACTG

a   K   S   L   S   L   S   P   G   K   G   G   G   G   G   V   E   P   N   C   D   -

                                     BamHI
                                     |
721 ATCCATGTTATGTGGGAATGGGAATGTTTGAACGTCTGTAACCTCGAGGATCC
-----+-----+-----+-----+-----+-----+ 773
TAGGTACAATACACCCTTACCCTTACAAAACCTGCAGACATTGAGCTCCTAGG

a   I   H   V   M   W   E   W   E   C   F   E   R   L   *
```

FIG. 24A

NdeI
|
CATATGGTTGAACCGAACTGTGACATCCATGTTATGTGGGAATGGGAATGTTTTGAACGT
1 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 60
GTATACCAACTTGGCTTGACACTGTAGGTACAATACACCCTTACCCTTACAAAACCTTGCA
a M V E P N C D I H V M W E W E C F E R -
CTGGGTGGTGGTGGTGGTGACAAAACCTCACACATGTCCACCGTGCCCAGCACCTGAACTC
61 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 120
GACCCACCACCACCACCACTGTTTTGAGTGTGTACAGGTGGCACGGGTCGTGGACTTGAG
a L G G G G G D K T H T C P P C P A P E -
CTGGGGGGACCGTCAGTTTTCTCTTCCCCCAAAACCCAAGGACACCCCTCATGATCTCC
121 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 180
GACCCCCCTGGCAGTCAAAAGGAGAAGGGGGGTTTTGGGTTCTGTGGGAGTACTAGAGG
a L G G P S V F L F P P K P K D T L M I S -
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAG
181 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 240
GCCTGGGGACTCCAGTGTACGCACCACCACCTGCACTCGGTGCTTCTGGGACTCCAGTTC
a R T P E V T C V V V D V S H E D P E V K -
TTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAG
241 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 300
AAGTTGACCATGCACCTGCCGCACCTCCACGTATTACGGTTCTGTTTCGGCGCCCTCCTC
a F N W Y V D G V E V H N A K T K P R E E -
CAGTACAACAGCACGTACCGTGTGGTCAGCGTCCCTCACCGTCCTGCACCAGGACTGGCTG
301 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 360
GTCATGTTGTCTGTCATGGCACACCAGTCGCAGGAGTGGCAGGACGTGGTCCTGACCGAC
a Q Y N S T Y R V V S V L T V L H Q D W L -
AATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAA
361 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 420
TTACCGTTCCTCATGTTACGTTCCAGAGGTTGTTTCGGGAGGGTCGGGGGTAGCTCTTT
a N G K E Y K C K V S N K A L P A P I E K -
ACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCC
421 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 480
TGGTAGAGGTTTCGGTTTCCCGTCGGGGCTCTGGTGTCCACATGTGGGACGGGGGTAGG
a T I S K A K G Q P R E P Q V Y T L P P S -
CGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCC
481 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 540
GCCCTACTCGACTGGTTCTTGGTCCAGTCGGACTGGACGGACAGTTTCCGAAGATAGGG
a R D E L T K N Q V S L T C L V K G F Y P -
AGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACCTACAAGACCACG
541 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 600
TCGCTGTAGCGGCACCTCACCTCTCGTTACCCGTCGGCCTCTTGTGTGATGTTCTGGTGC
a S D I A V E W E S N G Q P E N N Y K T T -

SUBSTITUTE SHEET (RULE 26)

FIG. 24B

```

601 CCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAG
-----+-----+-----+-----+-----+-----+ 660
GGAGGGCACGACCTGAGGCTGCCGAGGAAGAAGGAGATGTCGTTTCGAGTGGCACCTGTTC
a   P P V L D S D G S F F L Y S K L T V D K -

AGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAAC
661 -----+-----+-----+-----+-----+-----+ 720
TCGTCCACCGTCGTCCCCCTTG CAGAAGAGTACGAGGCACTACGTACTCCGAGACGTGTTG
a   S R W Q Q G N V F S C S V M H E A L H N -

                                     BamHI
                                     |
721 CACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATAACTCGAGGATCC
-----+-----+-----+-----+-----+-----+ 773
GTGATGTGCGTCTTCTCGGAGAGGGACAGAGGCCCATTTATTGAGCTCCTAGG
a   H Y T Q K S L S L S P G K *
```

FIG. 25A

NdeI
|
CATATGGACAAACTCACACATGTCCACCTTGTCCAGCTCCGGAACCTCTGGGGGGACCG
1 -----+-----+-----+-----+-----+-----+-----+ 60
GTATACCTGTTTTGAGTGTGTACAGGTGGAACAGGTCGAGGCCTTGAGGACCCCCCTGGC

a M D K T H T C P P C P A P E L L G G P -

TCAGTCTTCCTCTTCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAG
61 -----+-----+-----+-----+-----+-----+-----+ 120
AGTCAGAAGGAGAAGGGGGGTTTTGGGTTCCTGTGGGAGTACTAGAGGGCCTGGGGACTC

a S V F L F P P K P K D T L M I S R T P E -

GTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTAC
121 -----+-----+-----+-----+-----+-----+-----+ 180
CAGTGTACGCACCACCACCTGCACTCGGTGCTTCTGGGACTCCAGTTCAAGTTGACCATG

a V T C V V V D V S H E D P E V K F N W Y -

GTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGC
181 -----+-----+-----+-----+-----+-----+-----+ 240
CACCTGCCGCACCTCCACGTATTACGGTTCGTTCGGCGCCCTCCTCGTCATGTTGTCTG

a V D G V E V H N A K T K P R E E Q Y N S -

ACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAG
241 -----+-----+-----+-----+-----+-----+-----+ 300
TGCATGGCACACCAGTCGCAGGAGTGGCAGGACGTGGTCCTGACCGACTTACCGTTCCTC

a T Y R V V S V L T V L H Q D W L N G K E -

TACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCATCGAGAAAACCATCTCCAAA
301 -----+-----+-----+-----+-----+-----+-----+ 360
ATGTTACAGTTCAGAGGTTGTTTCGGGAGGGTCGGGGGTAGCTCTTTTGGTAGAGGTTT

a Y K C K V S N K A L P A P I E K T I S K -

GCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCATCCCGGGATGAGCTG
361 -----+-----+-----+-----+-----+-----+-----+ 420
CGGTTTCCCGTCGGGGCTCTTGGTGTCCACATGTGGGACGGGGGTAGGGCCCTACTCGAC

a A K G Q P R E P Q V Y T L P P S R D E L -

ACCAAGAACCAGGTGAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAGCGACATCGCC
421 -----+-----+-----+-----+-----+-----+-----+ 480
TGGTTCTTGGTCCAGTCGGACTGGACGGACAGTTTCCGAAGATAGGGTCGCTGTAGCGG

a T K N Q V S L T C L V K G F Y P S D I A -

GTGGAGTGGGAGAGCAATGGGCAGCCGAGAACAACCTACAAGACCACGCCTCCCGTGCTG
481 -----+-----+-----+-----+-----+-----+-----+ 540
CACCTCACCTCTCGTTACCCGTCGGCCTCTTGTGATGTTCTGGTGCGGAGGGCACGAC

a V E W E S N G Q P E N N Y K T T P P V L -

GACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAG
541 -----+-----+-----+-----+-----+-----+-----+ 600
CTGAGGCTGCCGAGGAAGAAGGAGATGTCGTTGAGTGGCACCTGTTCTCGTCCACCGTC

a D S D G S F F L Y S K L T V D K S R W Q -

FIG. 25B

```

601 CAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAG
-----+-----+-----+-----+-----+-----+ 660
GTCCCCCTTGCAAGAGTACGAGGCACTACGTACTCCGAGACGTGTTGGTGATGTGCGTC

a      Q  G  N  V  F  S  C  S  V  M  H  E  A  L  H  N  H  Y  T  Q  -

661 AAGAGCCTCTCCCTGTCTCCGGGTAAAGGTGGAGGTGGTGGTTGCACCACCCACTGGGGT
-----+-----+-----+-----+-----+-----+ 720
TTCTCGGAGAGGGACAGAGGCCCATTTCCACCTCCACCACCAACGTGGTGGGTGACCCCA

A      K  S  L  S  L  S  P  G  K  G  G  G  G  G  C  T  T  H  W  G  -

          BamHI
          |
721 TTCACCCTGTGCTAATGGATCCCTCGAG
-----+-----+-----+-----+ 748
AAGTGGGACACGATTACCTAGGGAGCTC

a      F  T  L  C  *
```

FIG. 26A

NdeI
|
CATATGTGCACCACCCACTGGGGTTTCACCCTGTGCGGTGGAGGCGGTGGGGACAAAGGT
1 -----+-----+-----+-----+-----+-----+-----+ 60
GTATACACGTGGTGGGTGACCCCAAAGTGGGACACGCCACCTCCGCCACCCCTGTTTCCA
a M C T T H W G F T L C G G G G G D K G -
GGAGGCGGTGGGGACAAACTCACACATGTCCACCTTGCCAGCACCTGAACTCCTGGGG
61 -----+-----+-----+-----+-----+-----+-----+ 120
CCTCCGCCACCCCTGTTTTGAGTGTGTACAGGTGGAACGGGTCGTGGACTTGAGGACCCC
a G G G G D K T H T C P P C P A P E L L G -
GGACCGTCAGTTTTCTTCTCCCCCAAACCCAAGGACACCCCTCATGATCTCCCGGACC
121 -----+-----+-----+-----+-----+-----+-----+ 180
CCTGGCAGTCAAAGGAGAAGGGGGTTTTGGGTTCTGTGGGAGTACTAGAGGGCCTGG
a G P S V F L F P P K P K D T L M I S R T -
CCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCCTGAGGTCAAGTTCAAC
181 -----+-----+-----+-----+-----+-----+-----+ 240
GGACTCCAGTGTACGCACCACCACCTGCACTCGGTGCTTCTGGGACTCCAGTTCAAGTTG
a P E V T C V V V D V S H E D P E V K F N -
TGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTAC
241 -----+-----+-----+-----+-----+-----+-----+ 300
ACCATGCACCTGCCGCACCTCCACGTATTACGGTTCTGTTTCGGCGCCCTCCTCGTCATG
a W Y V D G V E V H N A K T K P R E E Q Y -
AACAGCACGTACCGTGTGGTCAGCGTCCTCACCCTGCTGCACCAGGACTGGCTGAATGGC
301 -----+-----+-----+-----+-----+-----+-----+ 360
TTGTCGTGCATGGCACACCAGTCGCAGGAGTGGCAGGACGTGGTCCTGACCGACTTACCG
a N S T Y R V V S V L T V L H Q D W L N G -
AAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCATCGAGAAAACCATC
361 -----+-----+-----+-----+-----+-----+-----+ 420
TTCTCATGTTTCACGTTCCAGAGGTTGTTTCGGGAGGGTTCGGGGTAGCTCTTTTGGTAG
a K E Y K C K V S N K A L P A P I E K T I -
TCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCATCCCGGGAT
421 -----+-----+-----+-----+-----+-----+-----+ 480
AGGTTTCGGTTTCCCGTCGGGGCTCTTGGTGTCCACATGTGGGACGGGGTAGGGCCCTA
a S K A K G Q P R E P Q V Y T L P P S R D -
GAGCTGACCAAGAACCAGGTGACCTGACCTGGTCAAAGGCTTCTATCCCAGCGAC
481 -----+-----+-----+-----+-----+-----+-----+ 540
CTCGACTGGTTCTTGGTCCAGTCGGACTGGACGGACCAGTTTCCGAAGATAGGGTCGCTG
a E L T K N Q V S L T C L V K G F Y P S D -
ATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGAGAACTACAAGACCACGCCTCCC
541 -----+-----+-----+-----+-----+-----+-----+ 600
TAGCGGCACCTCACCTCTCGTTACCCGTCGGCCTCTTGTGATGTTCTGGTGGGAGGG
a I A V E W E S N G Q P E N N Y K T T P P -

FIG. 26B

```

601 GTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGG
-----+-----+-----+-----+-----+-----+ 660
CACGACCTGAGGCTGCCGAGGAAGAAGGAGATGTCGTTGAGTGGCACCTGTTCTCGTCC
a   V L D S D G S F F L Y S K L T V D K S R -
    TGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTAC
661 -----+-----+-----+-----+-----+-----+ 720
ACCGTCGTCCCCTTGCAGAAGAGTACGAGGCACTACGTACTCCGAGACGTGTTGGTGATG
a   W Q Q G N V F S C S V M H E A L H N H Y -
                                BamHI
                                |
    ACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATAATGGATCC
721 -----+-----+-----+-----+-----+ 763
TGCCTCTTCTCGGAGAGGGACAGAGGCCCATTTATTACCTAGG
a   T Q K S L S L S P G K *
```